var title_f33_29_34256="Diphenhydramine: Pediatric drug information";
var content_f33_29_34256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenhydramine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/48/19207?source=see_link\">",
"       Diphenhydramine (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/51/13108?source=see_link\">",
"       Diphenhydramine (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13236 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34256=[""].join("\n");
var outline_f33_29_34256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/48/19207?source=related_link\">",
"      Diphenhydramine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/51/13108?source=related_link\">",
"      Diphenhydramine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_29_34257="CT axial dilated sm bowel";
var content_f33_29_34257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel obstruction CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel obstruction seen on CT scan showing dilated, fluid-filled loops of small bowel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Hodin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34257=[""].join("\n");
var outline_f33_29_34257=null;
var title_f33_29_34258="Dorsal penile nerve block";
var content_f33_29_34258=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dorsal penile nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dorsal penile nerves are located beneath Buck's fascia at the one- and 11-o'clock positions (A). The sites for injection in dorsal penile nerve block are at the two- and 10-o'clock positions with the needle directed medially as indicated in (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34258=[""].join("\n");
var outline_f33_29_34258=null;
var title_f33_29_34259="Leg MRI in ECD";
var content_f33_29_34259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging of the leg in Erdheim-Chester disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) T1.",
"    <br/>",
"    (B) T2.",
"    <br/>",
"    Magnetic resonance imaging of the left leg in a 48-year-old male with Erdheim-Chester disease shows abnormal signaling in the distal tibia with surrounding soft tissue edema. There is a heterogeneous signal in the bone marrow on T1 and T2 with areas of patchy enhancement post-gadolinium. The bone marrow signal abnormality extends more proximally than the lesion itself. There is a mild periosteal reaction, but no overt abnormality of true tumor extending out from the bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34259=[""].join("\n");
var outline_f33_29_34259=null;
var title_f33_29_34260="Metaproterenol: Patient drug information";
var content_f33_29_34260=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metaproterenol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19812?source=see_link\">",
"     see \"Metaproterenol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/9/1172?source=see_link\">",
"     see \"Metaproterenol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3149994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Orciprenaline&reg;;",
"     </li>",
"     <li>",
"      ratio-Orciprenaline&reg;;",
"     </li>",
"     <li>",
"      Tanta-Orciprenaline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13319008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702480",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metaproterenol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10846 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34260=[""].join("\n");
var outline_f33_29_34260=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3149994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319008\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014513\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014512\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014517\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014518\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014520\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014515\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014516\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014521\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014522\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19812?source=related_link\">",
"      Metaproterenol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/9/1172?source=related_link\">",
"      Metaproterenol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_29_34261="Pipelle and Vabra instruments";
var content_f33_29_34261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Office endometrial biopsy instruments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Pipelle endometrial suction curette. (B) Vabra aspirator.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34261=[""].join("\n");
var outline_f33_29_34261=null;
var title_f33_29_34262="Magnesium sulfate: Pediatric drug information";
var content_f33_29_34262=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium sulfate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"    see \"Magnesium sulfate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/3/13365?source=see_link\">",
"    see \"Magnesium sulfate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1023184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Magnesium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     1 g of magnesium sulfate = 98.6 mg",
"     <b>",
"      elemental",
"     </b>",
"     magnesium = 8.12 mEq magnesium; treatment depends on severity and clinical status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypomagnesemia: I.V.: 25-50 mg magnesium sulfate/kg/dose (equal to 0.2-0.4 mEq magnesium/kg/dose) every 8-12 hours for 2-3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Daily maintenance magnesium: I.V.: 0.25-0.5 mEq magnesium/kg/day  (",
"     <b>",
"      Note:",
"     </b>",
"     mEq denotes amount of magnesium ion only not the total salt form.)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1023211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"      see \"Magnesium sulfate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypomagnesemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: I.M., I.V.: 25-50 mg magnesium sulfate/kg/dose (equal to 0.2-0.4 mEq magnesium/kg/dose) every 4-6 hours for 3-4 doses; maximum single dose: 2000 mg magnesium sulfate (equal to 16 mEq magnesium)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: I.M., I.V.: 1 g magnesium sulfate every 6 hours for 4 doses, or 250 mg magnesium sulfate/kg over a 4-hour period; for severe hypomagnesemia: 8-12 g magnesium sulfate/day in divided doses has been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Daily maintenance magnesium: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     mEq denotes amount of magnesium ion only not the total salt form",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &le;45 kg: 0.25-0.5 mEq magnesium/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &gt;45 kg and Adults: 0.2-0.5 mEq magnesium/kg/day or 3-10 mEq magnesium/1000 kcal/day (maximum: 8-24 mEq magnesium/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Management of seizures and hypertension: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 20-100 mg magnesium sulfate/kg/dose every 4-6 hours as needed; in severe cases, doses as high as 200 mg magnesium sulfate/kg/dose have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1 g magnesium sulfate every 6 hours for 4 doses as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prevention of premature labor: I.V.: Adolescents and Adults: Initial loading dose: 4-6 g magnesium sulfate followed by a continuous infusion of 2-3 g/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment and prevention of seizures in severe pre-eclampsia or eclampsia: I.V.: Adolescents and Adults: 4-6 g magnesium sulfate over 15-20 minutes; followed by a 1-2 g magnesium sulfate/hour continuous infusion; or may follow with I.M. doses of 4-5 g magnesium sulfate in each buttock every 4 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Initial infusion may be given over 3-4 minutes if eclampsia is severe, maximum: 40 g magnesium/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of torsade de pointes VT: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children: 25-50 mg magnesium sulfate/kg/dose; not to exceed 2 g magnesium sulfate/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1-2 g magnesium sulfate/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bronchodilation (adjunctive treatment in severe acute asthma for patients who have life-threatening exacerbations and in those whose exacerbations remain in the severe category after 1 hour of intensive conventional therapy, NIH Guidelines, 2007): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 25-75 mg magnesium sulfate/kg/dose (maximum dose: 2 g) as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 2 g magnesium sulfate as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Literature evaluating magnesium sulfate's efficacy in the relief of bronchospasm has utilized single dosages in patients with acute symptomatology who have received aerosol &beta;-agonist therapy with inconsistent results. A recent study (Ciarallo, 2000) showed significant improvement in pulmonary function in children who received a single dose of 40 mg/kg magnesium sulfate vs. placebo; pulmonary index scores after magnesium sulfate 75 mg/kg (maximum: 2.5 g) vs. placebo were not statistically different in 54 children between 1-18 years of age (Scarfone, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute receiving magnesium should have serum magnesium levels monitored.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 10 mg/mL (100 mL) [equivalent to elemental magnesium 0.99 mg (0.08 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in water for injection: 40 mg/mL (50 mL, 100 mL, 500 mL, 1000 mL) [equivalent to elemental magnesium 3.94 mg (0.32 mEq)/mL]; 80 mg/mL (50 mL) [equivalent to elemental magnesium 7.89 mg (0.65 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 500 mg/mL (20 mL) [equivalent to elemental magnesium 49.3 mg (4.06 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 500 mg/mL (2 mL, 10 mL, 20 mL, 50 mL) [equivalent to elemental magnesium 49.3 mg (4.06 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral/topical: USP: 100% (227 g, 454 g, 1810 g, 2720 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1023217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intermittent infusion: Dilute to a concentration of 0.5 mEq/mL (60 mg/mL of",
"     <b>",
"      magnesium sulfate",
"     </b>",
"     ) (maximum concentration: 1.6 mEq/mL, 200 mg/mL of magnesium sulfate) and infuse over 2-4 hours; do not exceed 1 mEq/kg/hour (125 mg/kg/hour of magnesium sulfate); in severe circumstances, half of the dosage to be administered may be infused over the first 15-20 minutes; in medical emergencies (eg, prevention of seizures in pre-eclampsia), the loading dose (4-6 g) may be infused over 15-20 minutes (smaller doses, eg, treatment of torsade de pointes, may be infused over 5-20 minutes).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     For I.M. administration, dilute magnesium sulfate to a maximum concentration of 200 mg/mL prior to injection",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1023203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS; not stable in fat emulsion 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, amifostine, amikacin, ampicillin, aztreonam, cefamandole, cefazolin, cefoperazone, cefotaxime, cefoxitin, chloramphenicol, cisatracurium, clindamycin, dobutamine, docetaxel, doxorubicin liposome, doxycycline, enalaprilat, erythromycin lactobionate, esmolol, etoposide, famotidine, fludarabine, gatifloxacin, gentamicin, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, idarubicin, insulin (regular), kanamycin, labetalol, linezolid, meperidine, metronidazole, milrinone, minocycline, morphine, nafcillin, ondansetron, oxacillin, paclitaxel, penicillin G potassium, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, sargramostim, thiotepa, ticarcillin, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Alatrofloxacin, amphotericin B cholesteryl sulfate complex, cefepime.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ciprofloxacin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Metoclopramide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Hydrocortisone sodium succinate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility when admixed: Compatible:",
"     </b>",
"     Calcium gluconate, chloramphenicol, cisplatin, heparin, hydrocortisone sodium succinate, isoproterenol, meropenem, methyldopate, norepinephrine, penicillin G potassium, potassium phosphates, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, clindamycin, cyclosporine, dobutamine, polymyxin B sulfate, procaine, sodium bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1023185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of hypomagnesemia, treatment of hypertension, torsade de pointes, and encephalopathy and seizures associated with acute nephritis; prevention and treatment of seizures in severe pre-eclampsia or eclampsia; prevention of premature labor; adjunctive treatment for bronchodilation in moderate to severe acute asthma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F191104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Magnesium sulfate may be confused with manganese sulfate, morphine sulfate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MgSO",
"       <sub>",
"        4",
"       </sub>",
"       is an error-prone abbreviation (mistaken as morphine sulfate)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects on neuromuscular function may occur at lower concentrations in patients with neuromuscular disease (eg, myasthenia gravis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing (I.V.; dose related), hypotension (I.V.; rate related), vasodilation (I.V.; rate related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1023187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to magnesium salt(s) or any component; serious renal impairment, myocardial damage, heart block; patients with colostomy or ileostomy, intestinal obstruction, impaction, or perforation, appendicitis, abdominal pain",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3416835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function (accumulation of magnesium may lead to magnesium intoxication)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1023188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of magnesium exist; close attention must be paid to the salt form when ordering and administering magnesium;",
"     <b>",
"      incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: Magnesium Sulfate may enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A/C (manufacturer dependent) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3013521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted; however, studies in pregnant women have not shown an increased risk of fetal abnormalities. Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama, 1998; Osada, 2002). Magnesium sulfate is used for the prevention and treatment of seizures in pregnant women with severe pre-eclampsia or eclampsia (ACOG, 2002). Magnesium sulfate may also be used prior to early preterm delivery to reduce the risk of cerebral palsy (ACOG, 2010; Reeves, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1023220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum magnesium, deep tendon reflexes, respiratory rate, renal function, blood pressure, stool output (laxative use)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1023206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neonates and Infants: 1.5-2.3 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 1.5-2.0 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 1.4-2.0 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1023204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body. There are at least 300 enzymes which are dependent upon magnesium for normal functioning. Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol. Magnesium is necessary for the maintaining of serum potassium and calcium levels due to its effect on the renal tubule. In the heart, magnesium acts as a calcium channel blocker. It also activates sodium potassium ATPase in the cell membrane to promote resting polarization and produce arrhythmias. Magnesium prevents premature labor by inhibiting myometrial contractions. In the CNS, magnesium prevents or controls seizures by blocking neuromuscular transmission and decreasing the amount of acetylcholine liberated at the end-plate by the motor nerve impulse. It also has a depressant effect on the CNS.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F3416836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anticonvulsant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Immediately",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Laxative: Oral: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Anticonvulsant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1023207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Elimination: Renal with unabsorbed drug excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3426605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium sulfate 500 mg = 49.3 mg",
"     <b>",
"      elemental",
"     </b>",
"     magnesium = 4.1 mEq magnesium. Nebulized magnesium sulfate in varying concentrations/dosages has been used successfully with and without beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonists in the treatment of acute asthma (Blitz, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     1 g of magnesium sulfate = 98.6 mg",
"     <b>",
"      elemental",
"     </b>",
"     magnesium = 8.12 mEq magnesium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Magnesium Content of Magnesium Salts",
"     </caption>",
"     <col align=\"left\" width=\"190\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/500 mg salt)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/500 mg salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         27",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium L-aspartate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium oxide",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         302",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse effects associated with elevated serum magnesium concentrations may include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;3 mg/dL: Blocked peripheral neuromuscular transmission leading to anticonvulsant effects, depressed CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;5 mg/dL: Depressed deep tendon reflexes, flushing, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;12 mg/dL: Complete heart block, respiratory paralysis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;2005 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) of Pediatric and Neonatal Patients: Pediatric Advanced Life Support,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):1005-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/16651281/pubmed\" id=\"16651281\" target=\"_blank\">",
"        16651281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blitz M, Blitz S, Beasely R, et al, \"Inhaled Magnesium Sulfate in the Treatment of Acute Asthma,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2005, 19(4):CD003898.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/16235345 /pubmed\" id=\"16235345 \" target=\"_blank\">",
"        16235345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Briggs GG and Wan SR, \"Drug Therapy During Labor and Delivery, Part 2,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(12):1131-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/16754739/pubmed\" id=\"16754739\" target=\"_blank\">",
"        16754739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bloch H, Silverman R, Mancherje N, et al, &ldquo;Intravenous Magnesium Sulfate as an Adjunct in the Treatment of Acute Asthma,&rdquo;",
"      <i>",
"       Chest,",
"      </i>",
"      1995, 107(6):1576-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/7781349/pubmed\" id=\"7781349\" target=\"_blank\">",
"        7781349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chernow B, Smith J, Rainey TG, et al, &ldquo;Hypomagnesemia: Implications for the Critical Care Specialist,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1982, 10(3):193-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/7037303/pubmed\" id=\"7037303\" target=\"_blank\">",
"        7037303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheuk DK, Chau TC, and Lee SL, \"A Meta-analysis on Intravenous Magnesium Sulphate for Treating Acute Asthma,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2005, 90(1):74-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/15613519 /pubmed\" id=\"15613519 \" target=\"_blank\">",
"        15613519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ciarallo L, Brousseau D, and Reinert S, &ldquo;Higher-Dose Intravenous Magnesium Therapy for Children With Moderate to Severe Acute Asthma,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2000, 154(10):979-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/11030848/pubmed\" id=\"11030848\" target=\"_blank\">",
"        11030848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ciarallo L, Sauer AH, and Shannon MW, &ldquo;Intravenous Magnesium Therapy for Moderate to Severe Pediatric Asthma: Results of a Randomized, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 129(6):809-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/8969721 /pubmed\" id=\"8969721 \" target=\"_blank\">",
"        8969721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Diagnosis and Management of Asthma. NAEPP Expert Panel Report 3,&rdquo; August 2007, www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scarfone RJ, Loiselle JM, Joffe MD, et al, &ldquo;A Randomized Trial of Magnesium in the Emergency Department Treatment of Children With Asthma,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2000, 36(6):572-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/29/34262/abstract-text/11097697/pubmed\" id=\"11097697\" target=\"_blank\">",
"        11097697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12982 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34262=[""].join("\n");
var outline_f33_29_34262=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023184\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443860\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023211\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191066\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191050\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023217\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023203\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023185\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191104\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191101\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023187\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416835\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023188\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299640\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191059\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191062\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013521\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023220\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023206\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023204\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416836\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023207\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426605\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12982|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=related_link\">",
"      Magnesium sulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/3/13365?source=related_link\">",
"      Magnesium sulfate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_29_34263="Delayed surgical management of the disrupted anal sphincter";
var content_f33_29_34263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Delayed surgical management of the disrupted anal sphincter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34263/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34263/contributors\">",
"     Liliana Bordeianou, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34263/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34263/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34263/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34263/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/29/34263/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3235929\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal incontinence is the involuntary loss of flatus or feces. Data are conflicting as to whether the rate is higher in women than in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Fecal incontinence affects 9 percent of women aged 40 to 59 years old and as many as 21 percent of women aged over 80 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/3\">",
"     3",
"    </a>",
"    ]. Unfortunately, it is often unrecognized by clinicians because patients do not report their symptoms. The emotional, psychological, and social problems created by fecal incontinence can be devastating, debilitating, and costly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22458?source=see_link&amp;anchor=H2#H2\">",
"     \"Fecal incontinence in adults\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common cause of fecal incontinence in healthy women is obstetric trauma, which can result in mechanical disruption of the anal sphincter muscles or damage to the nerves that innervate these muscles. The injury may be occult and symptoms may not occur until many years after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A rectovaginal fistula is another cause of fecal incontinence; it may occur after breakdown of a repair of third or fourth degree lacerations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9097?source=see_link\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to episiotomy\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32951?source=see_link\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed repair of anal sphincter disruption will be reviewed here. The anatomy and physiology of the anal sphincter, pathogenesis of anal sphincter dysfunction, and evaluation of patients with fecal incontinence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .) Primary surgical repair of anal sphincter injury related to childbirth is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3433?source=see_link\">",
"     \"Repair of episiotomy and perineal lacerations associated with childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic third and fourth degree lacerations occur from unrecognized obstetric trauma or breakdown of a primary perineal repair after childbirth. Women who suffer from chronic third or fourth degree lacerations typically complain of fecal urgency, and can have incontinence to gas, mucus, liquid, and even solid feces. The severity of symptoms is, at least in part, dependent on the size of the tear, but also on the amount and functionality of the residual muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3235936\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with chronic fourth degree lacerations frequently have complete disruption of the perineal body, as well as the external and internal anal sphincter. Disruption of the sphincter complex occurs anteriorly, and in many patients, the tear is easily identifiable on examination. Occasionally, the tear is less obvious: physical examination alone can miss a tear in as many as 25 percent of women who present with fecal incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/8\">",
"     8",
"    </a>",
"    ]. Therefore, endoanal ultrasound should always be obtained as part of the evaluation of fecal incontinence and prior to any surgical repair. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Preoperative diagnostic studies'",
"    </a>",
"    below.) In addition, the rectovaginal septum is often attenuated. The anal mucosa usually is in direct proximity to the distal vaginal epithelium; however, in some women, a thin bridge of perineal skin is present between the vaginal and anal epithelium.",
"   </p>",
"   <p>",
"    In contrast to most fourth degree lacerations, women with chronic third degree lacerations have a thinned, but intact, perineal body. The radial skin creases of the anal verge are noticeably absent anteriorly, corresponding to the anterior sphincter defect. This appearance is called the \"dovetail\" sign and indicates the external anal sphincter is not intact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The woman should be asked to contract her anal sphincter as part of the examination. Upon voluntary contraction, constriction of the separated end of the external anal sphincter will create dimpling in the perianal skin. The location of the dimpling suggests the location of the snapped sphincter complex. Absence of this dimpling may be due to significant neurologic injury to the sphincter and should alert the clinician that simple anastomosis may not completely cure the incontinence.",
"   </p>",
"   <p>",
"    After the external examination, an internal rectovaginal examination is essential. The examiner inserts an index finger into the anal canal while the thumb is inserted into the distal vagina. The presence or absence of intact muscle between the two fingers is assessed using a \"pinch and drag\" maneuver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREOPERATIVE DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of preoperative diagnostic studies in patients with disrupted anal sphincter is to confirm the diagnosis (if appropriate) and determine anatomic features important both to surgical planning and prognostic counseling. Appropriate patient selection for sphincter repairs is guided by preoperative endoanal ultrasound, anorectal physiology testing with anorectal manometry, and pudendal nerve terminal motor latency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276282179\">",
"    <span class=\"h2\">",
"     Endoanal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoanal ultrasound is by far the most useful clinical tool for the diagnosis of anal sphincter disruption. Both the external and internal anal sphincter are easily visualized by this modality, which can be used to confirm anal sphincter disruption and help the surgeon identify the location of the snapped ends of the anal sphincter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76163 \" href=\"mobipreview.htm?19/14/19687\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21735?source=see_link\">",
"     \"Endorectal endoscopic ultrasound in the evaluation of fecal incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276282186\">",
"    <span class=\"h2\">",
"     Anorectal physiology tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of anorectal physiology testing in predicting outcomes is controversial and poorly studied. At our institution, all patients with fecal incontinence are tested with both anorectal manometry and pudendal nerve testing at the time of their initial surgical consultation. The results of these tests are then used to educate the patients considering sphincteroplasty about their potential functional outcomes after surgery. However, given that data on the ability of anorectal physiology testing to predict outcomes are mostly retrospective, no individual test result in isolation is ever used to deny patients the opportunity for a sphincteroplasty as long as they understand that their testing results, when worrisome, mean there is an increased risk that surgery may not lead to an improvement in function.",
"   </p>",
"   <p>",
"    Anorectal physiology testing is performed with either an air or water charged catheter system. Anal resting and squeeze pressures are calculated at each centimeter starting at 6 cm from the anal verge. The high pressure zone is identified and then mean resting pressure, maximum resting pressure, and maximum Squeeze pressure are calculated using the definitions of the American Society of Colon and Rectal Surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mean resting pressure is the mean of the resting pressures recorded within the high-pressure zone.",
"     </li>",
"     <li>",
"      Maximum resting pressure is the highest resting pressure recorded.",
"     </li>",
"     <li>",
"      Maximum squeeze pressure is the highest pressure recorded above the baseline (zero) at any level of the anal canal during maximum squeeze effort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with low pressures on anorectal manometry are informed that retrospective studies show that patients with low preoperative mean resting and squeeze pressures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a short anal canal showed more improvement in these measurements postoperatively than those with higher preoperative pressures and a longer anal canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/11\">",
"     11",
"    </a>",
"    ]. They are also told that this postoperative improvement in pressures does not necessarily result in a better functional outcome, as measured by patient questionnaires. Patients who have high anal pressures on anorectal manometry are generally discouraged from undergoing sphincter repair without considering alternative treatment approaches first, such as sensitivity retraining, biofeedback, and dietary modification. We feel that surgical repair is less likely to be successful in significantly augmenting sphincter function in this situation.",
"   </p>",
"   <p>",
"    Pudendal nerve testing is performed by gently inserting a digital electrode into the rectum to stimulate the pudendal nerve. The time from pudendal nerve stimulation to the first contraction of the external sphincter is electronically recorded (",
"    <a class=\"graphic graphic_figure graphicRef51112 \" href=\"mobipreview.htm?14/24/14729\">",
"     figure 1",
"    </a>",
"    ). Patients who have unilateral or bilateral pudendal neuropathy are informed that some studies show that they may have a lower chance of a successful functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. An observational study found that patients with bilateral normal pudendal nerve function have a 60 percent success rate after surgery, whereas patients with unilateral or no pudendal nerve function have only a 17 percent chance of a satisfactory functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276282982\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients considering sphincteroplasty should be thoroughly informed about their chances for a successful functional outcome after surgery. In the absence of anorectal physiology testing and pudendal nerve terminal motor latency testing, they should understand that this procedure is most effective in women with moderate fecal incontinence (weekly loss of partial or complete solid bowel movements) or severe fecal incontinence (daily loss of complete solid bowel movements). Mild flatal incontinence, loss of liquid bowel movements, and occasional staining are less likely to improve with surgery. In fact, a repair can lead to worsening symptoms if a surgical complication occurs.",
"   </p>",
"   <p>",
"    An ideal candidate for surgery is less than 50 years old, has symptoms of weekly loss of solid bowel movements, and tests results showing low anorectal manometry pressures with good pudendal nerve conduction. Unfortunately, even in this highly selected group of patients, complete functional success only occurs in approximately 60 percent of patients, and the long-term success rate drops to 25 percent at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, unilateral or absent pudendal nerve function lowers success rates from 60 percent to 17 percent at a median of two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, setting realistic short- and long-term expectations is an important part of the preoperative counseling that needs to be offered to these patients, and we find anorectal physiology testing results helpful during this discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREOPERATIVE MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no evidence-based guideline for a preoperative bowel regimen before anal surgery, common practice is a bowel prep before sphincter repair to diminish bacterial contamination of the perineal wound. For example, Nulytely or Golytely the night before surgery can be used as a mechanical bowel preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;An antibiotic regimen that covers skin and enteric flora should be administered preoperatively. Appropriate regimens for patients with and without beta-lactam allergy, as well as the evidence behind these recommendations, can be found separately (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"mobipreview.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Repeat dosing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=see_link\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;General anesthesia without paralysis (eg, laryngeal mask anesthesia) facilitates identification of the sphincter muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Foley catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Foley catheter is placed before the procedure. The Foley catheter is typically left in overnight and removed the morning after surgery because pain from the anal surgery often inhibits spontaneous voiding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may be positioned in either the dorsal lithotomy or a jack knife prone position for the repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgical goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of sphincter repair is reconstruction of a cylindrical anal canal utilizing both external sphincter muscle and perineal body scar to allow circumferential contraction of the anal musculature when the patient attempts to defer defecation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3235943\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perineal body is incised transversely in the plane that separates the rectum from the vagina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3235950\">",
"    <span class=\"h2\">",
"     Dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vaginal and rectal walls are separated from each other by dissection to the levator ani complex, with care to avoid injuring the rectum, which could lead to a rectovaginal fistula postoperatively. The snapped ends of the external anal sphincter muscle are identified where they connect to the anterior perineal body scar created by the injury. The scar and the external sphincter muscles are carefully freed from the internal sphincter to allow the left and right external sphincter and scar complexes to overlap anteriorly. The scar connection to the muscle should not be trimmed off, as it is utilized in the repair. During this dissection, care should be taken not to extend the original incision and the final dissection laterally beyond the 180 degree circumference of the anus, as this may injure the pudendal nerves and thus compromise functional outcomes.",
"   </p>",
"   <p>",
"    In situations where the internal anal sphincter is also injured anteriorly, both internal and external sphincters are mobilized en block to create the overlapping repair. Although some surgeons advocate separate dissection of the internal and external sphincters, we and others believe that this extra step is difficult to perform and does not necessarily translate in better function postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3235957\">",
"    <span class=\"h2\">",
"     Repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following mobilization of the external (and, if injured, the internal) anal sphincter, some surgeons, including myself, perform a levatorplasty to lengthen the anal canal, believing that this added maneuver may improve functional outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/18\">",
"     18",
"    </a>",
"    ]. This can be accomplished with one or two interrupted nonabsorbable prolene sutures.",
"   </p>",
"   <p>",
"    We use an overlap technique to attach the snapped ends of the external anal sphincter and the perineal body scar, which are sutured to each other with a nonabsorbable horizontal mattress stitch. These sutures should be placed in the scar, since the sutures are more likely to hold if placed in fibrous tissue. The goal is to create an overlap that forms a circumferential functioning muscular tunnel that surrounds the anal canal. Preservation of scar minimizes the lateral dissection necessary to create this tunnel and thus decreases the risk of injury to the pudendal nerves, which run laterally to the anal sphincter. Retrospective data suggest that preservation and utilization of scar in the overlap repair may improve short-term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/19\">",
"     19",
"    </a>",
"    ] and long-term functional outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/20\">",
"     20",
"    </a>",
"    ]. However, no data from randomized trials are available to support this recommendation.",
"   </p>",
"   <p>",
"    For acute repair of obstetric anal sphincter tears, where no scar is present to allow for an overlapping repair, the advantages of an overlapping sphincteroplasty as opposed to an end-to-end anastomosis are less clear. Though an overlapping repair has been advocated by some experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], most randomized trials have not demonstrated statistical or clinical superiority of this technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/23-27\">",
"     23-27",
"    </a>",
"    ], with one exception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/28\">",
"     28",
"    </a>",
"    ]. A meta-analysis concluded the overlap technique might be associated with lower risks of fecal urgency and overall anal incontinence at 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/29\">",
"     29",
"    </a>",
"    ], but these results were confined to this one small trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/28\">",
"     28",
"    </a>",
"    ]. Limitations of these studies were the inclusion of multiparous women and women with partial tears, and differences in measurement of outcomes and surgical experience.",
"   </p>",
"   <p>",
"    Imbrication of the external anal sphincter provides an alternative in patients who have attenuation of the sphincter with incomplete disruptions and patients with wide lateral retraction of the muscle edges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lastly, the subcutaneous tissue and the skin are loosely closed with interrupted absorbable sutures. This allows drainage, which is important given the high risk of postoperative wound infections in these patients.",
"   </p>",
"   <p>",
"    Diverting colostomy does not improve functional results or healing following repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. We typically reserve colostomy for selected patients who present particularly challenging cases, such as some patients with Crohn&rsquo;s disease or recurrent sphincter repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3235964\">",
"    <span class=\"h2\">",
"     Alternative techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small number of surgical trials for treatment of fecal incontinence (all causes), their small sample sizes, and methodological weaknesses make it impossible to identify clinically important differences among alternative surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14616580\">",
"    <span class=\"h3\">",
"     Sacral nerve stimulator",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sacral nerve stimulator improves fecal continence in patients with disrupted anal sphincters, including those with previously failed overlapping sphincteroplasty. Over 80 percent of patients achieve a &ge;50 percent reduction from baseline in incontinent episodes per week, with sustained long-term results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This approach is a reasonable option for patients who are not good candidates for an overlapping sphincteroplasty or who failed a sphincteroplasty. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22458?source=see_link&amp;anchor=H31#H31\">",
"     \"Fecal incontinence in adults\", section on 'Sacral nerve stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14616587\">",
"    <span class=\"h3\">",
"     Artificial sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion of an artificial bowel sphincter is effective in motivated patients who understand its high risks for wound infection and device malfunction and who have enough tissue between the rectum and the vagina to allow device placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22458?source=see_link&amp;anchor=H30#H30\">",
"     \"Fecal incontinence in adults\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients stay overnight in the hospital, and are given a clear liquid diet. Expert opinions differ on whether a high fiber or low residue diet should be prescribed for the first month postoperatively. In general, immediately after surgery, we prescribe an oral laxative, such as milk of magnesia or polyethylene glycol, which can be given for the first few weeks to avoid constipation and to ensure that the patient is having loose stools. Two or three weeks later, we switch to a high fiber supplement such as Benefiber&reg; or Metamucil&reg;. A trial of women undergoing primary repair of third degree anal sphincter tears randomly assigned them to bowel confinement (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    phosphate 60 mg orally three times daily) or laxatives (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    10 mL orally three times daily) for the first three postoperative days and found no difference between groups in continence scores, anal manometry, and endoanal ultrasound findings three months after the repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/38\">",
"     38",
"    </a>",
"    ]. However, patients in the laxative group had significantly earlier and less painful bowel motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound breakdown is the most frequent complication: the reported infection rate ranges from 10 to 80 percent. Bowel confinement with narcotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/38\">",
"     38",
"    </a>",
"    ], prolonged antibiotic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/39\">",
"     39",
"    </a>",
"    ], and diverting colostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/31-33\">",
"     31-33",
"    </a>",
"    ] do not decrease the rate of postoperative infections and are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADJUVANT NONSURGICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary treatment for obstetric and traumatic causes of fecal incontinence is surgical repair. However, mechanical injury to the continence mechanism is often associated with nonreversible neurologic injury that may become progressive with age and menopause.",
"   </p>",
"   <p>",
"    Patients treated surgically also benefit from adjuvant treatments such as dietary manipulation, pharmacologic management, and behavioral and biofeedback techniques. As an example, biofeedback has been used to improve functional outcomes in patients with persistent fecal incontinence despite successful anatomical reapproximation of the anal sphincter complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34263/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22458?source=see_link&amp;anchor=H27#H27\">",
"     \"Fecal incontinence in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FUTURE OBSTETRICAL DELIVERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have a secondary repair of an anal sphincter rupture should be thoroughly counseled regarding future pregnancy and deliveries. Experts recommend that a woman with persistent fecal incontinence and a poorly functioning anal sphincter despite secondary repair be offered a planned cesarean for subsequent deliveries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9097?source=see_link&amp;anchor=H22#H22\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\", section on 'Recurrence with subsequent vaginal delivery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9097?source=see_link&amp;anchor=H25#H25\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\", section on 'Approach to obstetric management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common cause of fecal incontinence in healthy women is obstetric trauma that results in mechanical disruption to the anal sphincter muscles, damage to the nerves that innervate these muscles,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      formation of a rectovaginal fistula. (See",
"      <a class=\"local\" href=\"#H3235929\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of sphincter repair is reconstruction of a muscular cylinder to surround the anal canal and allow for circumferential muscular contraction upon attempts to defer defecation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest an overlapping technique rather than an end-to-end technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Implantation of a sacral nerve stimulator is a reasonable option for patients who are not good candidates for sphincteroplasty or who failed sphincteroplasty. (See",
"      <a class=\"local\" href=\"#H14616580\">",
"       'Sacral nerve stimulator'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/1\">",
"      Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/2\">",
"      Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology 2009; 137:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/3\">",
"      Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA 2008; 300:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/4\">",
"      Sung VW, Rogers ML, Myers DL, et al. National trends and costs of surgical treatment for female fecal incontinence. Am J Obstet Gynecol 2007; 197:652.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/5\">",
"      Sultan AH, Kamm MA, Hudson CN, Bartram CI. Third degree obstetric anal sphincter tears: risk factors and outcome of primary repair. BMJ 1994; 308:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/6\">",
"      Dudding TC, Vaizey CJ, Kamm MA. Obstetric anal sphincter injury: incidence, risk factors, and management. Ann Surg 2008; 247:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/7\">",
"      Bordeianou L, Lee KY, Rockwood T, et al. Anal resting pressures at manometry correlate with the Fecal Incontinence Severity Index and with presence of sphincter defects on ultrasound. Dis Colon Rectum 2008; 51:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/8\">",
"      Keating JP, Stewart PJ, Eyers AA, et al. Are special investigations of value in the management of patients with fecal incontinence? Dis Colon Rectum 1997; 40:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/9\">",
"      Toglia MR, DeLancey JO. Anal incontinence and the obstetrician-gynecologist. Obstet Gynecol 1994; 84:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/10\">",
"      Lowry AC, Simmang CL, Boulos P, et al. Consensus statement of definitions for anorectal physiology and rectal cancer: report of the Tripartite Consensus Conference on Definitions for Anorectal Physiology and Rectal Cancer, Washington, D.C., May 1, 1999. Dis Colon Rectum 2001; 44:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/11\">",
"      Gearhart S, Hull T, Floruta C, et al. Anal manometric parameters: predictors of outcome following anal sphincter repair? J Gastrointest Surg 2005; 9:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/12\">",
"      Ricciardi R, Mellgren AF, Madoff RD, et al. The utility of pudendal nerve terminal motor latencies in idiopathic incontinence. Dis Colon Rectum 2006; 49:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/13\">",
"      Gilliland R, Altomare DF, Moreira H Jr, et al. Pudendal neuropathy is predictive of failure following anterior overlapping sphincteroplasty. Dis Colon Rectum 1998; 41:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/14\">",
"      Barisi G, Krivokapi Z, Markovi V, et al. The role of overlapping sphincteroplasty in traumatic fecal incontinence. Acta Chir Iugosl 2000; 47:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/15\">",
"      Bravo Gutierrez A, Madoff RD, Lowry AC, et al. Long-term results of anterior sphincteroplasty. Dis Colon Rectum 2004; 47:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/16\">",
"      Oberwalder M, Dinnewitzer A, Baig MK, et al. Do internal anal sphincter defects decrease the success rate of anal sphincter repair? Tech Coloproctol 2006; 10:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/17\">",
"      Wexner SD, Marchetti F, Jagelman DG. The role of sphincteroplasty for fecal incontinence reevaluated: a prospective physiologic and functional review. Dis Colon Rectum 1991; 34:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/18\">",
"      Aitola P, Hiltunen KM, Matikainen M. Functional results of anterior levatorplasty and external sphincter plication for faecal incontinence. Ann Chir Gynaecol 2000; 89:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/19\">",
"      Moscovitz I, Rotholtz NA, Baig MK, et al. Overlapping sphincteroplasty: does preservation of the scar influence immediate outcome? Colorectal Dis 2002; 4:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/20\">",
"      Fang DT, Nivatvongs S, Vermeulen FD, et al. Overlapping sphincteroplasty for acquired anal incontinence. Dis Colon Rectum 1984; 27:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/21\">",
"      Goetz LH, Lowry AC. Overlapping sphincteroplasty: is it the standard of care? Clin Colon Rectal Surg 2005; 18:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/22\">",
"      Sultan AH, Monga AK, Kumar D, Stanton SL. Primary repair of obstetric anal sphincter rupture using the overlap technique. Br J Obstet Gynaecol 1999; 106:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/23\">",
"      Tjandra JJ, Han WR, Goh J, et al. Direct repair vs. overlapping sphincter repair: a randomized, controlled trial. Dis Colon Rectum 2003; 46:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/24\">",
"      Garcia V, Rogers RG, Kim SS, et al. Primary repair of obstetric anal sphincter laceration: a randomized trial of two surgical techniques. Am J Obstet Gynecol 2005; 192:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/25\">",
"      Fitzpatrick M, Behan M, O'Connell PR, O'Herlihy C. A randomized clinical trial comparing primary overlap with approximation repair of third-degree obstetric tears. Am J Obstet Gynecol 2000; 183:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/26\">",
"      Williams A, Adams EJ, Tincello DG, et al. How to repair an anal sphincter injury after vaginal delivery: results of a randomised controlled trial. BJOG 2006; 113:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/27\">",
"      Farrell SA, Gilmour D, Turnbull GK, et al. Overlapping compared with end-to-end repair of third- and fourth-degree obstetric anal sphincter tears: a randomized controlled trial. Obstet Gynecol 2010; 116:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/28\">",
"      Fernando RJ, Sultan AH, Kettle C, et al. Repair techniques for obstetric anal sphincter injuries: a randomized controlled trial. Obstet Gynecol 2006; 107:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/29\">",
"      Fernando R, Sultan AH, Kettle C, et al. Methods of repair for obstetric anal sphincter injury. Cochrane Database Syst Rev 2006; :CD002866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/30\">",
"      Delancey JO, Toglia MR, Perucchini D. Internal and external anal sphincter anatomy as it relates to midline obstetric lacerations. Obstet Gynecol 1997; 90:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/31\">",
"      Arnaud A, Sarles JC, Sielezneff I, et al. Sphincter repair without overlapping for fecal incontinence. Dis Colon Rectum 1991; 34:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/32\">",
"      Schoetz DJ Jr. Operative therapy for anal incontinence. Surg Clin North Am 1985; 65:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/33\">",
"      Hasegawa H, Yoshioka K, Keighley MR. Randomized trial of fecal diversion for sphincter repair. Dis Colon Rectum 2000; 43:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/34\">",
"      Brown SR, Wadhawan H, Nelson RL. Surgery for faecal incontinence in adults. Cochrane Database Syst Rev 2010; :CD001757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/35\">",
"      Matzel KE, Lux P, Heuer S, et al. Sacral nerve stimulation for faecal incontinence: long-term outcome. Colorectal Dis 2009; 11:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/36\">",
"      Wexner SD, Coller JA, Devroede G, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg 2010; 251:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/37\">",
"      Wong WD, Congliosi SM, Spencer MP, et al. The safety and efficacy of the artificial bowel sphincter for fecal incontinence: results from a multicenter cohort study. Dis Colon Rectum 2002; 45:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/38\">",
"      Mahony R, Behan M, O'Herlihy C, O'Connell PR. Randomized, clinical trial of bowel confinement vs. laxative use after primary repair of a third-degree obstetric anal sphincter tear. Dis Colon Rectum 2004; 47:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/39\">",
"      McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. Aust N Z J Surg 1998; 68:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34263/abstract/40\">",
"      Jensen LL, Lowry AC. Biofeedback improves functional outcome after sphincteroplasty. Dis Colon Rectum 1997; 40:197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3270 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34263=[""].join("\n");
var outline_f33_29_34263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3235929\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3235936\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREOPERATIVE DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276282179\">",
"      Endoanal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276282186\">",
"      Anorectal physiology tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276282982\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Foley catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgical goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3235943\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3235950\">",
"      Dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3235957\">",
"      Repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3235964\">",
"      Alternative techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14616580\">",
"      - Sacral nerve stimulator",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14616587\">",
"      - Artificial sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADJUVANT NONSURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FUTURE OBSTETRICAL DELIVERIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3270|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/14/19687\" title=\"diagnostic image 1\">",
"      Retracted internal anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3270|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/24/14729\" title=\"figure 1\">",
"      Pudendal nerve terminal motor latency test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3270|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21735?source=related_link\">",
"      Endorectal endoscopic ultrasound in the evaluation of fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3433?source=related_link\">",
"      Repair of episiotomy and perineal lacerations associated with childbirth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_29_34264="Transcatheter aortic valve replacement";
var content_f33_29_34264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transcatheter aortic valve replacement",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     Stephen JD Brecker, MD, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34264/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/29/34264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22200542\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve replacement is the mainstay of treatment of symptomatic aortic stenosis (AS). In properly selected patients, this surgical procedure offers substantial improvements in symptoms and life expectancy.",
"   </p>",
"   <p>",
"    However, aortic valve surgery entails substantial risks for some patients with severe comorbidities, and for some considered at &ldquo;extreme&rdquo; risk, surgery is not appropriate. In others, technical limitations, eg, porcelain aorta, may mean that surgery is not feasible. Percutaneous aortic valvotomy was developed as a less invasive means to treat AS but has important limitations. Subsequently developed catheter-based techniques for aortic valve implantation may provide an alternative method for treating AS in patients with unacceptably high estimated surgical risks. A multidisciplinary team approach is recommended in approaching patients with symptomatic AS. &nbsp;",
"   </p>",
"   <p>",
"    This topic will review transcatheter aortic valve implantation, which has been termed transcatheter aortic valve replacement (TAVR). Indications for aortic valve replacement, surgical aortic valve replacement, estimating the risk of aortic valve surgery, medical therapy of symptomatic AS, and percutaneous aortic valvuloplasty are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11865?source=see_link\">",
"     \"Surgical valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/43/41654?source=see_link\">",
"     \"Medical management of symptomatic aortic stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39411?source=see_link\">",
"     \"Percutaneous aortic valvotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201028\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcatheter aortic valve replacement has been developed for the treatment of patients with severe symptomatic AS who have an unacceptably high estimated surgical risk, or in whom TAVR is preferred due to technical issues with surgery, eg, a porcelain aorta or prior significant mediastinal radiation, prior pericardiectomy with dense adhesions or prior sternal infection with complex reconstruction, or a patent left internal mammary graft lying beneath the sternum (as identified by computed tomography angiography).",
"   </p>",
"   <p>",
"    Thus, accurate estimation of the risk of surgical aortic valve replacement performed by an experienced cardiothoracic surgeon and multidisciplinary valve team is vital to appropriate evaluation of potential candidates for this emerging experimental procedure. Risk calculators are available to estimate the risk of valvular surgery. However, risk estimates are subject to inaccuracies (eg, the logistic EuroSCORE appears to overestimate mortality risk in patients undergoing high-risk aortic valve replacement) and the models do not account for some clinical characteristics (eg, porcelain aorta, severe pulmonary hypertension, or RV dysfunction) that may impact surgical mortality. In patients undergoing aortic valve replacement, the Society of Thoracic Surgeons (STS) model may provide more accurate risk stratification than the logistic EuroSCORE or the Ambler risk score. The logistic EuroSCORE has been replaced by the EuroSCORE II. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link&amp;anchor=H3#H3\">",
"     \"Estimating the mortality risk of valvular surgery\", section on 'Risk stratification models'",
"    </a>",
"    .) Of note, these scoring systems are only applicable to patients undergoing surgery and are not validated nor considered accurate in a TAVR eligible cohort of patients. More appropriate scoring systems are not currently available, although they are being developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13148008\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient selection criteria for TAVR are evolving. Selected patients who have indications for aortic valve replacement for calcific aortic stenosis are candidates for TAVR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .) The 2012 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Association for Thoracic",
"    <span class=\"nowrap\">",
"     Surgery/Society",
"    </span>",
"    for Cardiovascular Angiography and",
"    <span class=\"nowrap\">",
"     Interventions/Society",
"    </span>",
"    of Thoracic Surgeons",
"    <span class=\"nowrap\">",
"     (ACCF/AATS/SCAI/STS)",
"    </span>",
"    expert consensus document on TAVR lists the following criteria based upon those used in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcific aortic valve stenosis with the following echocardiographic criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severely calcified valve leaflets with reduced systolic motion",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mean gradient &gt;40 mm Hg or jet velocity &gt;4.0",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    Aortic valve area of &lt;1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    or indexed effective orifice area &lt;0.5",
"    <span class=\"nowrap\">",
"     cm",
"     <sup>",
"      2",
"     </sup>",
"     /m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the setting of LV systolic dysfunction, severe AS is present when the leaflets are calcified, with reduced systolic motion, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography shows an aortic velocity of &gt;4.0",
"      <span class=\"nowrap\">",
"       m/s",
"      </span>",
"      <strong>",
"       OR",
"      </strong>",
"      mean gradient &gt;40 mm Hg with a valve area &lt;1.0 cm",
"      <sup>",
"       2",
"      </sup>",
"      <strong>",
"       OR",
"      </strong>",
"      AV index &lt;0.6",
"      <span class=\"nowrap\">",
"       cm",
"       <sup>",
"        2",
"       </sup>",
"       /m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      at any flow rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are symptomatic (NYHA functional class II or greater) from aortic valve stenosis, rather than from symptoms related to comorbid conditions.",
"     </li>",
"     <li>",
"      A cardiac interventionalist and two experienced cardiothoracic surgeons agree that surgical aortic valve replacement is either precluded or high risk, based on a conclusion that the probability of death or serious irreversible morbidity exceeds the probability of meaningful improvement. At least one of the cardiac surgeon assessors must have physically evaluated the patient. The surgeon&rsquo;s consult notes should specify the medical or anatomic factors leading to this conclusion and should include a printout of the calculation of the STS score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The expert consensus document lists numerous exclusion criteria, including the following criteria related to the aortic valve:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bicuspid or unicuspid or noncalcified aortic valve",
"     </li>",
"     <li>",
"      Severe aortic regurgitation (&gt;3+)",
"     </li>",
"     <li>",
"      Native aortic annulus size as measured by echocardiography &lt;18 mm or &gt;the largest annulus size for which a TAVR device is available (eg, 29 mm for the largest Medtronic CoreValve). Of note, this criterion is subject to change as the range of available device sizes changes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other exclusion criteria may include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence (CK plus CK-MB elevation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      troponin elevation) of an acute myocardial infarction within one month before the intended treatment.",
"     </li>",
"     <li>",
"      Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days of screening evaluation.",
"     </li>",
"     <li>",
"      Need for emergency surgery.",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy with or without obstruction.",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction &lt;20 percent.",
"     </li>",
"     <li>",
"      Severe pulmonary hypertension and right ventricular dysfunction.",
"     </li>",
"     <li>",
"      A known contraindication or hypersensitivity to all anticoagulation regimens or inability to be anticoagulated for the study procedure.",
"     </li>",
"     <li>",
"      Renal insufficiency (eg, creatinine &gt;3.0",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      end-stage renal disease requiring chronic dialysis.",
"     </li>",
"     <li>",
"      Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.",
"     </li>",
"     <li>",
"      MRI confirmed CVA or TIA within six months (180 days) of the procedure.",
"     </li>",
"     <li>",
"      Severe incapacitating dementia.",
"     </li>",
"     <li>",
"      Estimated life expectancy &lt;12 months due to noncardiac comorbid conditions.",
"     </li>",
"     <li>",
"      Severe mitral regurgitation.",
"     </li>",
"     <li>",
"      Significant aortic disease including the following abnormalities may preclude a transfemoral approach: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thoracic or abdominal aortic aneurysm (luminal diameter &ge;5 cm), marked tortuosity (hyperacute bend)",
"     </li>",
"     <li>",
"      Aortic arch atheroma (especially if &gt;5 mm thick, protruding, or ulcerated)",
"     </li>",
"     <li>",
"      Narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta",
"     </li>",
"     <li>",
"      Marked tortuosity (hyperacute bend) of the aorta or severe &ldquo;unfolding&rdquo; of the thoracic aorta",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201035\">",
"    <span class=\"h1\">",
"     DELIVERY TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major catheter-based techniques for replacing the aortic valve have been investigated: retrograde percutaneous implantation and direct apical puncture. In addition, there is rapidly growing use of direct aortic access via either ministernotomy or right anterior thoracotomy.",
"   </p>",
"   <p>",
"    An antegrade transseptal approach has also been studied but adoption has been limited due to procedural complexity and associated risks (eg, development of acute mitral regurgitation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201049\">",
"    <span class=\"h2\">",
"     Retrograde approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrograde femoral arterial approach via the aortic arch and through the stenotic valve is an alternative to the antegrade approach, and devices were designed to overcome some of the limitations seen with transseptal antegrade delivery. Two stent-valve devices with different designs have been successfully implanted in humans using the retrograde femoral approach: a balloon-expandable valve (Edwards SAPIEN, which has replaced the Cribier-Edwards valve) and a self-expanding valve (Medtronic CoreValve) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/3\">",
"     3",
"    </a>",
"    ]. The Medtronic CoreValve had also been delivered in a retrograde fashion from the",
"    <span class=\"nowrap\">",
"     subclavian/axillary",
"    </span>",
"    artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/4\">",
"     4",
"    </a>",
"    ] and via direct aortic access via either ministernotomy or right anterior thoracotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201056\">",
"    <span class=\"h2\">",
"     Transapical antegrade approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternate catheter-based approach consists of direct left ventricular apical puncture and antegrade aortic valve implantation via a small anterolateral thoracotomy without cardiopulmonary bypass or sternotomy. This approach is particularly suited to patients with severe peripheral artery disease and heavily calcified ascending aorta and arch (porcelain aorta) who have an increased risk of stroke and other embolic events using other approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24148856\">",
"    <span class=\"h1\">",
"     PERIPROCEDURAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24148864\">",
"    <span class=\"h2\">",
"     Preprocedural considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidates for TAVR should be evaluated for potential risk factors such as depressed left ventricular ejection fraction, coronary artery disease, and kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1\">",
"     1",
"    </a>",
"    ]. For patients at risk of hemodynamic decompensation, preparations should include availability of rapid institution of cardiopulmonary bypass (and rarely elective bypass may be instituted).",
"   </p>",
"   <p>",
"    The expert consensus document recommends routine antibiotic prophylaxis for all patients undergoing TAVR prior to surgical incision or vascular access to prophylax against wound infection and endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24148896\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing TAVR generally receive general anesthesia, a temporary pacing lead, at least one large bore intravenous line, warming to avoid hypothermia, and monitoring by arterial line, pulmonary artery catheter, and transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some transfemoral procedures are performed with local anesthesia and conscious sedation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is administered after placement of standard sheaths and prior to placement of the large sheath.",
"   </p>",
"   <p>",
"    Management includes early identification and treatment of volume depletion, positive inotropic agents in patients with low cardiac output or greater than moderate pulmonary hypertension, and treatment of severe pulmonary hypertension and right ventricular failure with inhaled nitric oxide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures to avoid prolonged hypotension include maintenance of mean arterial pressure of &gt;75 mmHg prior to initiation of rapid ventricular pacing (required during valve placement of prostheses other than the CoreValve) with cautious use of intravenous vasopressor (norepinephrine, epinephrine, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    ) therapy as needed while avoiding hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201070\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcatheter aortic valve replacement (TAVR) techniques are rapidly evolving, and results of published trials suggest that TAVR is emerging as the standard of care in certain patient subsets, and a viable alternative to surgery in others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201077\">",
"    <span class=\"h2\">",
"     Comparison to medical therapy in inoperable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of a benefit of TAVR compared to standard medical care was provided by the PARTNER multicenter trial (cohort B) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The investigators randomly assigned 358 patients with aortic stenosis who were not considered surgical candidates to either standard therapy including balloon aortic valvotomy (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39411?source=see_link\">",
"     \"Percutaneous aortic valvotomy\"",
"    </a>",
"    ) or TAVR with an Edwards SAPIEN valve via transfemoral approach. The two treatment groups were similar, although the logistic EuroSCORE was slightly lower in the TAVR group (mean 26.4 versus 30.4). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one year, the mortality rate was reduced with TAVR compared to medical therapy including balloon aortic valvotomy (30.7 versus 50.7 percent). The rate of the composite end point of death or repeat hospitalization was also reduced with TAVR (42.5 versus 71.6 percent).",
"     </li>",
"     <li>",
"      At two years, the mortality rate was 43.4 percent with TAVR compared to 68 percent for medical therapy.",
"     </li>",
"     <li>",
"      Among survivors at one and two years, functional class was better with TAVR versus medical therapy (75 versus 42 percent in NYHA functional class I or II at one year).",
"     </li>",
"     <li>",
"      The stroke rate was significantly higher in the TAVR group than in the medical therapy group at 30 days (6.7 versus 1.7 percent) and at two years (13.8 versus 5.5 percent).",
"     </li>",
"     <li>",
"      In the medical therapy group, balloon aortic valvotomy was performed in 82.3 percent at one year and in 85.3 percent at two years. Moderate or severe transvalvular aortic regurgitation was observed in 16.9 percent at 30 days and 15.2 percent at one year. &nbsp;",
"     </li>",
"     <li>",
"      In the TAVR group, moderate or severe paravalvular aortic regurgitation was identified in 11.8 percent at 30 days and in 10.5 percent at one year. Moderate or severe transvalvular aortic regurgitation was observed in 1.3 percent at 30 days and 4.2 percent at one year.",
"     </li>",
"     <li>",
"      Of note, TAVR improved survival in patients with an STS score of &lt;15 percent but not in those with an STS score &ge;15 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201084\">",
"    <span class=\"h2\">",
"     Comparison to surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 699 patients in cohort A of the PARTNER trial were randomly assigned to undergo either TAVR (by transfemoral or transapical approach) or surgical aortic valve replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality rates in the TAVR and surgical group were similar at 30 days (3.4 and 6.5 percent, p = 0.07), one year (24.3 and 26.8 percent), and two years (33.9 and 35.0 percent).",
"     </li>",
"     <li>",
"      Combined strokes or transient ischemic attacks were more frequent after TAVR than after surgical aortic valve replacement at 30 days (5.5 versus 2.4 percent, p = 0.04) and at one year (8.7 versus 4.3 percent, p = 0.04) with a borderline significant difference at two years (11.2 versus 6.5 percent, p = 0.05).",
"     </li>",
"     <li>",
"      More patients undergoing TAVR reported symptom improvement at 30 days, but at one year symptom improvement was similar in the two groups.",
"     </li>",
"     <li>",
"      Differences in other 30-day adverse event rates were also observed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TAVR was associated with more frequent major vascular complications (11.0 versus 3.2 percent).",
"     </li>",
"     <li>",
"      Surgical aortic valve replacement was associated with more frequent major bleeding (19.5 versus 9.3 percent) and new-onset atrial fibrillation (16.0 versus 8.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate or severe paravalvular aortic regurgitation was more frequent after TAVR than after surgery at 30 days, one and two years (6.9 versus 0.9 percent at two years). The presence of paravalvular aortic regurgitation was associated with increased late mortality as discussed below. (See",
"      <a class=\"local\" href=\"#H702258\">",
"       'Paravalvular regurgitation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25554830\">",
"    <span class=\"h2\">",
"     Observational data",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201091\">",
"    <span class=\"h3\">",
"     Early outcomes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201099\">",
"    <span class=\"h4\">",
"     For retrograde approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early outcomes were reported following retrograde replacement of the Edwards SAPIEN valve between November 2007 and January 2009 in 463 patients (mean age 82 years) with high estimated surgical risk (mean logistic EuroSCORE 26) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link&amp;anchor=H3#H3\">",
"     \"Estimating the mortality risk of valvular surgery\", section on 'Risk stratification models'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procedural success was 95 percent.",
"     </li>",
"     <li>",
"      Procedural outcomes included conversion to open aortic valve replacement surgery in 1.7 percent, valve-in-valve replacement (a SAPIEN valve placed within a SAPIEN valve) due to malposition or",
"      <span class=\"nowrap\">",
"       moderate/severe",
"      </span>",
"      aortic regurgitation after placement of the first SAPIEN valve in 0.6 percent, greater than moderate (2+) aortic regurgitation in 1.6 percent, coronary obstruction in 0.7 percent, and transfusion was required in 9.9 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Major complications at 30 days included death (6.3 percent), stroke (2.4 percent), renal failure requiring dialysis (1.3 percent), and heart block resulting in permanent pacemaker implantation (6.7 percent). Vascular complications included access-related complications (17.9 percent), aortic dissection (1.9 percent), and non-access-related complications (1.1 percent).",
"   </p>",
"   <p>",
"    In an echocardiographic study of 88 patients undergoing retrograde Cribier-Edwards or Edwards SAPIEN valve implantation, the mean transaortic valve gradient fell from a preprocedure baseline of 39&plusmn;14 mmHg to 9&plusmn;3 mmHg one day after the procedure and was 11&plusmn;4 two years later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were found in a multicenter study of retrograde implantation of a self-expanding stent valve (CoreValve) in 646 patients (mean age 81) with a mean logistic EuroSCORE of 23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procedure success was 97 percent and the mean transaortic valve gradient decreased from 49 to 3 mmHg.",
"     </li>",
"     <li>",
"      Procedural outcomes included death in 1.5 percent, conversion to open aortic valve replacement surgery in 0.5 percent, and implantation of a second valve (including valve-in-valve) in 2.6 percent. Paravalvular regurgitation was common but usually mild and not more than moderate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At 30 days, mortality was 8 percent, heart block was treated with permanent pacemaker implantation in 9.3 percent, myocardial infarction occurred in 0.6 percent, and stroke occurred in 1.9 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201106\">",
"    <span class=\"h4\">",
"     For transapical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following early outcomes were reported following transapical implantation of the Edwards SAPIEN valve in 575 patients (mean age 81 years) with logistic EuroSCORE of 29 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link&amp;anchor=H3#H3\">",
"     \"Estimating the mortality risk of valvular surgery\", section on 'Risk stratification models'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The valve prosthesis was implanted successfully in 93 percent with a 3.5 percent rate of conversion to open surgery. The early incidence of greater than moderate (2+) aortic regurgitation was 2.3 percent.",
"     </li>",
"     <li>",
"      At 30 days, major complications included death (10.3 percent), stroke (2.6 percent), major vascular complication (2.4 percent), myocardial infarction (0.7 percent), need for dialysis (7.1 percent), pacemaker implantation (7.3 percent), and bleeding requiring reoperation (2.1 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link\">",
"       \"Estimating the mortality risk of valvular surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Outcomes for 100 patients undergoing transapical aortic valve implantation (mean age 83, mean logistic EuroSCORE 29) were comparable to those for 100 propensity-matched controls undergoing conventional aortic valve replacement (mean age 82, mean EuroSCORE 30) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/13\">",
"     13",
"    </a>",
"    ]. Transapical aortic valve implantation was successful in 97 patients, and three patients required conversion to open surgery. There were no strokes in the transapical group and two strokes in the conventional group. The mortality rates for the transapical and conventional surgery groups were similar: 10 and 15 percent at 30 days and 27 and 31 percent at one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201113\">",
"    <span class=\"h4\">",
"     For combination of approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a Canadian multicenter study of 339 adults with severe AS and high surgical risk, the Edwards Sapien valve was implanted by either the retrograde transfemoral approach or the antegrade transapical approach. The procedural success rate was 93 percent. Mortality at 30 days was 10.4 percent (9.5 percent for transfemoral and 11.3 for transapical approach). At one year, mortality was 25 and 22 percent in those treated with the transfemoral versus transapical approach. Predictors of cumulative late mortality were sepsis, need for hemodynamic support, pulmonary hypertension, chronic obstructive pulmonary disease, and chronic kidney disease. Compared to the rest of the cohort, outcomes were no different in adults with a heavily calcified proximal aorta (porcelain aorta) and those with frailty, conditions that were postulated to indicate higher risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608011\">",
"    <span class=\"h4\">",
"     Valve-in-valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;A valve-in-valve procedure involves catheter-based valve implantation inside an already implanted bioprosthetic valve. This approach may provide an alternative to replacement of a degenerated surgically-implanted valve, or a means of salvaging suboptimal implantation of a catheter-based valve during the initial implantation procedure.",
"   </p>",
"   <p>",
"    Preliminary reports have demonstrated the feasibility of transcatheter placement of a prosthetic valve within a degenerated bioprosthetic valve. As an example, valve-in-valve implantation was performed on 24 high-risk patients with aortic (n = 10), mitral (n = 7), pulmonary (n = 6), or tricuspid (n = 1) failed (stenotic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regurgitant) bioprostheses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/15\">",
"     15",
"    </a>",
"    ]. Implantation was unsuccessful for one (mitral) case. There were no deaths during the procedure. There was one stroke and one death in 30 days; the death was related to attempted transseptal mitral positioning. The NYHA functional class improved from 88 percent in class III or IV (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) at baseline to 88 percent in class I or II at last follow-up.",
"   </p>",
"   <p>",
"    Valve-in-valve implantation has been used to salvage suboptimal initial transcatheter aortic valve implantation and significant paravalvular aortic regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. In a series using Edwards SAPIEN valves, valve-in-valve implantation was performed in 0.6 percent of 463 retrograde procedures and 3.3 percent of 575 transapical antegrade procedures. In a series of 646 retrograde CoreValve procedures, moderate to severe aortic regurgitation during the implantation procedure was treated with balloon re-dilatation (in 21.2 percent of procedures)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    valve-in-valve placement (in 2.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/11\">",
"     11",
"    </a>",
"    ]. None of the 628 patients with successful CoreValve implantation had greater than moderate aortic regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201120\">",
"    <span class=\"h2\">",
"     One and two year outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longer term outcomes are illustrated by the following reports from multicenter registries:",
"   </p>",
"   <p>",
"    One year outcomes were reported for 1038 patients from 32 centers in the European Edwards SAPIEN registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients treated with the transapical approach (n = 575) have greater frequency of comorbidities and higher logistic EuroSCORE (29 versus 25.8 percent) compared to those treated with the transfemoral approach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One year mortality rates were 27.9 and 18.9 percent for transapical and transfemoral patients, respectively.",
"     </li>",
"     <li>",
"      Multivariable analysis identified logistic EuroSCORE, renal disease, liver disease, and smoking as the variables with the highest hazard ratios for one year mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early and two-year outcomes were reported for a multicenter cohort of 126 patients with symptomatic severe aortic stenosis who received the CoreValve between 2006 and 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/17\">",
"     17",
"    </a>",
"    ]. The mean logistic EuroSCORE was 23 percent. The cohort was retrospectively classified into moderate surgical risk (54 patients), high-risk operable (51 patients), and high-risk inoperable (21 patients) groups.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The technical success rate was 83.1 percent. Thirty-day mortality was 15.2 percent without significant differences in the subgroups. Of note, this study started enrollment before other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/9,11,18\">",
"       9,11,18",
"      </a>",
"      ] and the lower observed technical success rate as well as higher early mortality rate are likely largely due to learning curve issues.",
"     </li>",
"     <li>",
"      At two years, mortality was 38.1 percent with a significantly higher mortality in the combined high-risk groups as compared to the moderate-risk group (45.8 versus 27.8 percent).",
"     </li>",
"     <li>",
"      Functional class improved in 80 percent of patients and remained stable at two-year follow-up. The mean aortic valve gradient was unchanged at two-year follow-up (8.5 at 30 days and 9.0 at two years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The United Kingdom registry reported outcomes of two years for 870 patients undergoing 877 TAVR procedures (with a CoreValve or SAPIEN valve) from 2007 through 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/18\">",
"     18",
"    </a>",
"    ]. The mean logistic EuroSCORE was 18.5 percent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The procedural success rate was 97 percent. Thirty-day mortality was 7.1 percent. The in-hospital stroke risk was 4.1 percent.",
"     </li>",
"     <li>",
"      Mortality was 21.4 percent at one year and 26.3 percent at two years. There was no difference in mortality between the CoreValve and SAPIEN groups.",
"     </li>",
"     <li>",
"      In a multivariate model, the independent predictors of mortality were left ventricular ejection fraction &lt;30 percent, the presence of moderate to severe aortic regurgitation, and chronic obstructive pulmonary disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201127\">",
"    <span class=\"h2\">",
"     Predictors of mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for early and late mortality were identified in a study of 663 patients undergoing TAVR with a CoreValve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/19\">",
"     19",
"    </a>",
"    ]. Intraprocedural mortality was 0.9 percent. Mortality was 5.4 percent at 30 days and 15 percent at one year. Independent predictors of mortality at 30 days included certain procedural complications (conversion to open heart surgery, cardiac tamponade, major vascular or access site complications) as well as baseline characteristics (left ventricular ejection fraction &lt;40 percent, prior balloon valvuloplasty, and diabetes mellitus). Independent predictors of mortality between 30 days and one year included prior stroke, postprocedural paravalvular leak &ge;2+, prior acute pulmonary edema, and chronic kidney disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25554569\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of TAVR include shock and low cardiac output during and following deployment, annular rupture, vascular complications, heart block, paravalvular aortic regurgitation, and stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702154\">",
"    <span class=\"h2\">",
"     Low cardiac output",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock and low cardiac output during or immediately following TAVR may be triggered by anesthesia, volume depletion, rapid pacing, ischemia, and interruption in cardiac output during valve implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1\">",
"     1",
"    </a>",
"    ]. Management includes support of systemic blood pressure, inotropic support as needed, ventilatory support with intra-aortic balloon pump support as needed. Elective cardiopulmonary bypass is an option for patients at severe risk for hemodynamic instability. &nbsp;",
"   </p>",
"   <p>",
"    A rare cause of ischemia is coronary ostia occlusion, which may be treated by percutaneous coronary intervention or coronary artery bypass graft surgery. &ldquo;Suicide&rdquo; left ventricle is a rare complication in which left ventricular outflow tract or intracavitary obstruction is precipitated by volume depletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positive inotropic agents and is treated by administration of volume and a beta adrenergic receptor blocking agent. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702177\">",
"    <span class=\"h2\">",
"     Annular rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic annular rupture is a rare life-threatening complication of TAVR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1,20,21\">",
"     1,20,21",
"    </a>",
"    ]. Risk factors include smaller annular size or sinotubular junction, bulky calcification, and aggressive balloon predilation. Management options range from emergent conversion to an open procedure with aortic root replacement to pericardial drainage and autotransfusion of small leaks to comfort care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702408\">",
"    <span class=\"h2\">",
"     Vascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular complications are a frequent early complication of TAVR. For example, in cohort B of the PARTNER trial, vascular complications were significantly more common in the TAVR group than in the standard therapy (including percutaneous valvotomy) group (30.7 versus 5.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/5\">",
"     5",
"    </a>",
"    ] and in cohort A, vascular complications were more common in the TAVR group than in the surgical group (17.0 versus 3.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702465\">",
"    <span class=\"h2\">",
"     Heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for development of heart block with need for permanent pacemaker implantation include pre-existing right bundle branch block and use of a CoreValve (versus Sapien valve) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. In patients receiving the Sapien valve, the risk of this complication (1.8 to 8.5 percent) is similar to that observed following balloon aortic valvotomy or surgical aortic valve replacement. For example, in cohort B of the PARTNER trial, the rate of new pacemaker requirement at 30 days was similar in the TAVR and standard therapy (including balloon valvotomy) groups (3.4 and 5.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/5\">",
"     5",
"    </a>",
"    ] and in cohort A was also similar in the TAVR and surgical groups (3.8 versus 3.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/7\">",
"     7",
"    </a>",
"    ]. The risk of requiring a permanent pacemaker is higher (ranging from 19.2 to 42.5 percent) in patients receiving the CoreValve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702243\">",
"    <span class=\"h2\">",
"     Post-TAVR aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-TAVR aortic regurgitation includes paravalvular and central (valvular) jets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702258\">",
"    <span class=\"h3\">",
"     Paravalvular regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paravalvular aortic regurgitation is common, occurring in about 85 percent immediately post-TAVR. It is caused by incomplete apposition of the prosthesis with the aortic annulus due to inadequate inflation of the prosthesis or calcific deposits that prevent proper valve seating. Causes of paravalvular aortic regurgitation include a heavily calcified annulus, an undersized prosthesis, and an inadequate balloon aortic valvuloplasty prior to deployment of a self-expanding valve, &nbsp;",
"   </p>",
"   <p>",
"    Paravalvular regurgitation is associated with adverse outcomes. In patients undergoing TAVR in cohort A of the PARTNER trial, at least mild aortic regurgitation was present in about 40 percent of patients and moderate or severe paravalvular aortic regurgitation was identified in approximately 10 percent during follow-up to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/8\">",
"     8",
"    </a>",
"    ]. The presence of more than trace aortic regurgitation was associated with increased risk of late mortality (hazard ratio 2.11; 95% CI, 1.43 to 3.10). However, it remains unclear if mild or moderate aortic regurgitation itself leads to adverse outcomes or whether this finding identifies a higher risk patient subgroup.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702287\">",
"    <span class=\"h3\">",
"     Central regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central regurgitation may be caused by improper valve sizing or deployment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1\">",
"     1",
"    </a>",
"    ]. Minor valve displacement may resolve gentle probing of the leaflets but severe leaks are an indication for valve-in-valve deployment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201134\">",
"    <span class=\"h2\">",
"     Brain infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported 30-day risk of stroke following TAVR in observational studies and clinical trials is 2 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. Observational data have shown similar rates of stroke following transfemoral and transapical TAVR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/9,14,24,25\">",
"     9,14,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the randomized cohort A of the PARTNER trial showed that rates of strokes or transient ischemic attack were significantly higher after TAVR than after surgical AVR at 30 days (5.5 versus 2.4 percent) and at one year (8.7 versus 4.3 percent), and there was a borderline significant trend at two years (11.2 versus 6.5 percent, p = 0.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22201084\">",
"     'Comparison to surgical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Subclinical brain injury may be substantially more frequent than stroke as suggested by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A diffusion-weighted magnetic resonance imaging (MRI) study that compared 32 patients who underwent TAVR to 21 historical controls treated with surgical aortic valve replacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/26\">",
"       26",
"      </a>",
"      ]. New clinically silent cerebral foci of restricted diffusion were significantly more frequent in patients who had undergone retrograde aortic valve implantation than in those who had undergone surgical aortic valve replacement (84 versus 48 percent).",
"     </li>",
"     <li>",
"      Similarly high rates of new cerebral ischemic lesions detected by diffusion-weighted MRI were found in a study comparing transfemoral versus transapical TAVR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/27\">",
"       27",
"      </a>",
"      ]. Similar frequencies of new lesions were found in 19 of 29 (66 percent) patients in the transfemoral group and in 22 of 31 (71 percent) patients in the transapical group. Of note, the patients in the transapical group had a higher frequency of peripheral vascular disease than in the transfemoral group (45 versus 17 percent), although the frequency of aortic plaque &ge;4 mm was similar (29 and 28 percent). Most patients (76 percent) with new lesions had multiple lesions (median 3, range 1 to 31). The lesions were largely clinically silent, though one patient in each group had a clinically-evident stroke within 24 hours after the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is required to determine the clinical significance of these observations. Although most of the new lesions were clinically silent, there is concern that silent cerebral infarcts are associated with subtle cognitive change and with an increased risk of subsequent dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical diagnosis of stroke subtypes\", section on 'Silent brain infarcts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24148734\">",
"    <span class=\"h1\">",
"     POST-PROCEDURAL CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24148727\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receive intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    during valve implantation and chronic antithrombotic therapy after implantation. Following implantation of the SAPIEN valve, the following antithrombotic regimen is recommended: dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    75 or 100 mg daily plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    300 mg loading dose followed by 75 mg daily) for six months; and after six months, aspirin 75 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201163\">",
"    <span class=\"h1\">",
"     REGULATORY STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter-based aortic valves (Medtronic CoreValve, Edwards SAPIEN valve) have CE mark approval in Europe for patients with high or prohibitive risk for surgical valve replacement. In the United States, the Food and Drug Administration approved the Edwards SAPIEN valve for transfemoral implantation in patients with severe symptomatic native AS who have been determined by a cardiac surgeon to be inoperable for surgical aortic valve replacement and in whom existing co-morbidities would not preclude clinical benefit from correction of the AS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34264/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22201191\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic valve replacement is the mainstay of treatment of symptomatic aortic stenosis (AS). Aortic valve replacement offers substantial improvements in symptoms and life expectancy. (See",
"      <a class=\"local\" href=\"#H22200542\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TAVR has been developed as a treatment for patients with severe symptomatic AS with unacceptably high risk for surgical aortic valve replacement. (See",
"      <a class=\"local\" href=\"#H22201070\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In appropriately screened patients with inoperable severe symptomatic AS, TAVR provides better outcomes compared to medical therapy including percutaneous valvotomy. (See",
"      <a class=\"local\" href=\"#H22201077\">",
"       'Comparison to medical therapy in inoperable patients'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, TAVR offered no survival benefit compared to standard therapy in patients with an STS score of &ge;15 percent because of the high degree of comorbid conditions in these patients. (See",
"      <a class=\"local\" href=\"#H22201077\">",
"       'Comparison to medical therapy in inoperable patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In appropriately screened patients with severe symptomatic AS, TAVR and surgical aortic valve replacement are associated with similar rates of one-year survival. However, stroke or TIA and vascular complications are more frequent with TAVR, and major bleeding and atrial fibrillation are more common after surgical valve replacement. (See",
"      <a class=\"local\" href=\"#H22201084\">",
"       'Comparison to surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multidisciplinary team approach is recommended in approaching high-risk patients with symptomatic AS. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/1\">",
"      Holmes DR Jr, Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012; 59:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/2\">",
"      Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J Am Coll Cardiol 2006; 47:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/3\">",
"      Zajarias A, Cribier AG. Outcomes and safety of percutaneous aortic valve replacement. J Am Coll Cardiol 2009; 53:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/4\">",
"      Petronio AS, De Carlo M, Bedogni F, et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ Cardiovasc Interv 2010; 3:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/5\">",
"      Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/6\">",
"      Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012; 366:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/7\">",
"      Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/8\">",
"      Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/9\">",
"      Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010; 122:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/10\">",
"      Bauer F, Lemercier M, Zajarias A, et al. Immediate and long-term echocardiographic findings after transcatheter aortic valve implantation for the treatment of aortic stenosis: the Cribier-Edwards/Edwards-Sapien valve experience. J Am Soc Echocardiogr 2010; 23:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/11\">",
"      Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention 2008; 4:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/12\">",
"      Wendler O, Walther T, Nataf P, et al. Trans-apical aortic valve implantation: univariate and multivariate analyses of the early results from the SOURCE registry. Eur J Cardiothorac Surg 2010; 38:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/13\">",
"      Walther T, Schuler G, Borger MA, et al. Transapical aortic valve implantation in 100 consecutive patients: comparison to propensity-matched conventional aortic valve replacement. Eur Heart J 2010; 31:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/14\">",
"      Rod&eacute;s-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010; 55:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/15\">",
"      Webb JG, Wood DA, Ye J, et al. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation 2010; 121:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/16\">",
"      Thomas M, Schymik G, Walther T, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2011; 124:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/17\">",
"      Buellesfeld L, Gerckens U, Schuler G, et al. 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. J Am Coll Cardiol 2011; 57:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/18\">",
"      Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol 2011; 58:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/19\">",
"      Tamburino C, Capodanno D, Ramondo A, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 2011; 123:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/20\">",
"      Aminian A, Lalmand J, Dolatabadi D. Late contained aortic root rupture and ventricular septal defect after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2013; 81:E72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/21\">",
"      Eker A, Sozzi FB, Civaia F, Bourlon F. Aortic annulus rupture during transcatheter aortic valve implantation: safe aortic root replacement. Eur J Cardiothorac Surg 2012; 41:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/22\">",
"      Koos R, Mahnken AH, Aktug O, et al. Electrocardiographic and imaging predictors for permanent pacemaker requirement after transcatheter aortic valve implantation. J Heart Valve Dis 2011; 20:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/23\">",
"      Daneault B, Kirtane AJ, Kodali SK, et al. Stroke associated with surgical and transcatheter treatment of aortic stenosis: a comprehensive review. J Am Coll Cardiol 2011; 58:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/24\">",
"      Himbert D, Descoutures F, Al-Attar N, et al. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J Am Coll Cardiol 2009; 54:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/25\">",
"      Ewe SH, Delgado V, Ng AC, et al. Outcomes after transcatheter aortic valve implantation: transfemoral versus transapical approach. Ann Thorac Surg 2011; 92:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/26\">",
"      Kahlert P, Knipp SC, Schlamann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 2010; 121:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34264/abstract/27\">",
"      Rod&eacute;s-Cabau J, Dumont E, Boone RH, et al. Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J Am Coll Cardiol 2011; 57:18.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/cdrh_docs/pdf10/P100041c.pdf (Accessed on December 01, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83110 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34264=[""].join("\n");
var outline_f33_29_34264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22201191\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22200542\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22201028\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13148008\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22201035\">",
"      DELIVERY TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22201049\">",
"      Retrograde approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22201056\">",
"      Transapical antegrade approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24148856\">",
"      PERIPROCEDURAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24148864\">",
"      Preprocedural considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24148896\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22201070\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22201077\">",
"      Comparison to medical therapy in inoperable patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22201084\">",
"      Comparison to surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25554830\">",
"      Observational data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22201091\">",
"      - Early outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22201099\">",
"      For retrograde approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22201106\">",
"      For transapical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22201113\">",
"      For combination of approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H608011\">",
"      Valve-in-valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22201120\">",
"      One and two year outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22201127\">",
"      Predictors of mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25554569\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702154\">",
"      Low cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702177\">",
"      Annular rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702408\">",
"      Vascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702465\">",
"      Heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702243\">",
"      Post-TAVR aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H702258\">",
"      - Paravalvular regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H702287\">",
"      - Central regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22201134\">",
"      Brain infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24148734\">",
"      POST-PROCEDURAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24148727\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22201163\">",
"      REGULATORY STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22201191\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/83110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/83110|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=related_link\">",
"      Estimating the mortality risk of valvular surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/43/41654?source=related_link\">",
"      Medical management of symptomatic aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39411?source=related_link\">",
"      Percutaneous aortic valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11865?source=related_link\">",
"      Surgical valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_29_34265="Insertion and removal of an intrauterine contraceptive device";
var content_f33_29_34265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Insertion and removal of an intrauterine contraceptive device",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34265/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34265/contributors\">",
"     Daniela A Carusi, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34265/contributors\">",
"     Alisa B Goldberg, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34265/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/29/34265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/29/34265/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/29/34265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion of intrauterine contraception is an office procedure requiring specific patient preparation and technical skills. Training may be obtained in the clinical setting or may be provided by the manufacturers of these devices. This review is not intended as a substitute for training.",
"   </p>",
"   <p>",
"    Several terms are used to describe intrauterine contraception, including intrauterine device (IUD) and intrauterine contraceptive (IUC); the progestin-containing device is also referred to as an intrauterine system (IUS). In this topic, we use the term IUD for all types of intrauterine contraception.",
"   </p>",
"   <p>",
"    This topic will address technical issues regarding the insertion procedure for the intrauterine contraceptives available in the United States: a copper IUD (TCu380A, Paragard&reg;) and two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUDs (LNg20 andLNg14). Other aspects of intrauterine contraception are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link\">",
"     \"Management of problems related to intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREPROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Candidates for and selection of an IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate candidates for intrauterine contraception, types of IUDs, and the advantages and disadvantages of the various devices are discussed in detail separately. Nulliparous women, adolescents, women who are postpartum or postabortion, and women desiring emergency contraception or sterilization should be included among those considered appropriate candidates for intrauterine contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The provider should ensure that the patient has no absolute contraindications to IUD use (",
"    <a class=\"graphic graphic_table graphicRef63636 \" href=\"mobipreview.htm?21/8/21643\">",
"     table 1",
"    </a>",
"    ). If relative contraindications are present (",
"    <a class=\"graphic graphic_table graphicRef56428 \" href=\"mobipreview.htm?12/30/12779\">",
"     table 2",
"    </a>",
"    ), these should be discussed and then the provider and patient can decide together whether the overall benefits of IUD use outweigh potential patient-specific risks.",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) has published comprehensive tables of medical conditions and personal characteristics that may affect contraceptive choice (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 3",
"    </a>",
"    ). The World Health Organization (WHO) has published similar tables, which can be found separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Counseling and consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience has shown that much of the patient dissatisfaction that results from contraceptive method-related side effects, especially bleeding disturbances, can be averted by a thorough discussion of contraceptive methods prior to initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/2\">",
"     2",
"    </a>",
"    ]. Manufacturers of IUDs provide informational brochures for patients in the package inserts that accompany their products. These brochures are intended as a starting point for counseling. Areas addressed include a description of the product, its purpose and mechanism of action, effectiveness, benefits, risks, side effects, complications, warnings, and directions for use.",
"   </p>",
"   <p>",
"    Each patient should be given and asked to read the manufacturer's patient information brochure for the type of IUD she plans to use. In addition to being informative, it may help her identify concerns and contraindications that she may not have thought to disclose. The provider should go over the written material with the patient to make sure she has a clear understanding, answer any questions that arise, and highlight the most important points in the brochure. Training in counseling about IUD use may enhance patient selection of this method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/3\">",
"     3",
"    </a>",
"    ]. Alternative methods of contraception, their risks and benefits, should also be discussed as part of the counseling and consent process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient is then asked to sign a written consent for IUD insertion with the provider who will insert the IUD. The signed consent is placed in the patient's medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Timing of insertion and pregnancy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IUD may be inserted at any time during the menstrual cycle if the patient meets any of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      She is consistently using a reliable contraceptive method.",
"     </li>",
"     <li>",
"      She has been abstinent since her last menses.",
"     </li>",
"     <li>",
"      She is within five days of a single act of unprotected intercourse and would like emergency contraception with a copper IUD. Although not an approved indication, copper IUDs appear to be effective for emergency contraception. The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      -releasing IUDs have not been evaluated for this indication. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=see_link\">",
"       \"Emergency contraception\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Documentation of a negative pregnancy test is recommended for women with lactational amenorrhea, irregular intervals between menses (unclear timing of ovulation), or questionable compliance with contraception. To increase reliability, the pregnancy test should be obtained two or more weeks after her last episode of unprotected intercourse.",
"   </p>",
"   <p>",
"    Insertion during the late follicular phase (cycle day 5 to 10) probably represents the ideal time for insertion because of the lower risk of expulsion after menses have been completed and the lower risk of",
"    <span class=\"nowrap\">",
"     discomfort/side",
"    </span>",
"    effects with insertion before the luteal phase. In a large observational study, the rate of expulsion with insertion during the first five days of the menstrual cycle was 5 percent, significantly higher than the 2 percent risk of expulsion with luteal phase insertion, and significantly more women with luteal phase insertions had their IUD removed due to pain or bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/4\">",
"     4",
"    </a>",
"    ]. While insertion during menses has the theoretical advantage of reducing the risk of concurrent pregnancy, this study did not observe a significant difference in pregnancy rates with insertion at that time.",
"   </p>",
"   <p>",
"    A protocol that includes counseling, screening, and insertion of the IUD in one visit results in more IUD placements than when two visits are required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18272372\">",
"    <span class=\"h3\">",
"     Women who are switching from another method",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women switching from a hormonal method of contraception to an IUD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the IUD before discontinuing the previous method. The following table provides a simplified approach to overlapping contraceptive methods so there is no need for back up contraception (",
"      <a class=\"graphic graphic_table graphicRef77410 \" href=\"mobipreview.htm?4/46/4846\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the woman cannot, or chooses not, to overlap contraceptive methods as described in the table (",
"      <a class=\"graphic graphic_table graphicRef77410 \" href=\"mobipreview.htm?4/46/4846\">",
"       table 4",
"      </a>",
"      ), then back-up contraception (eg, male condom) should be used for the first seven days after the IUD is inserted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prevention of infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Screening for STDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In new IUD users, the first 20 days after IUD insertion is the period of greatest risk for developing pelvic inflammatory disease (PID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/6\">",
"     6",
"    </a>",
"    ], which suggests the pathogenesis of PID in new IUD users involves the introduction of bacterial pathogens when the device is placed. For this reason, it is important to look for signs of cervicitis (mucopurulent cervical drainage) or vaginitis (vaginal discharge) before inserting an IUD. However, the overall risk of PID with a new IUD insertion is low: 0.54 percent in a retrospective cohort study including over 57,000 IUD insertions between 2005 and 2009 at Kaiser Permanente Northern California [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of cervicitis should prompt testing for gonorrhea and chlamydia. If either infection is identified, it should be treated and IUD insertion should be delayed. A test of cure is not necessary since cure rates are generally high (&gt;95 percent) in compliant, nonpregnant patients who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , but recently infected persons should have repeat testing for C. trachomatis infection three months after treatment to exclude reinfection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/8\">",
"     8",
"    </a>",
"    ]. The IUD can be inserted at this time if this test is negative.",
"   </p>",
"   <p>",
"    No large studies have evaluated the outcome of IUD insertion in the presence of bacterial vaginosis (BV) or trichomonas. In one small prospective study, five women with documented BV had an IUD inserted without complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/9\">",
"     9",
"    </a>",
"    ]. If a suspicious vaginal discharge is identified, the device manufacturers recommend diagnostic testing and treatment of infection, but there is no evidence to support routine vaginitis screening in asymptomatic patients.",
"   </p>",
"   <p>",
"    Whether routine screening for gonorrhea and chlamydia is required is controversial. In systematic reviews, women with asymptomatic chlamydia or gonorrhea infections at the time of IUD insertion had a low risk of developing PID and their risk was similar to that of infected women not having an IUD inserted, but higher than the risk of developing PID in the absence of these pathogens (0 to 5 percent versus 0 to 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. For this reason, many clinicians screen for gonorrhea and chlamydia prior to IUD insertion. However, the cost of universal bacteriologic screening is prohibitive in many settings, and no studies have evaluated the cost-effectiveness of routine screening in areas of low STD-prevalence. Furthermore, awaiting results of STD screening tests could delay device insertion in noninfected, low risk patients, thereby potentially leading to unintended pregnancy.",
"   </p>",
"   <p>",
"    An alternative approach to universal screening is selective screening of women at high risk of having an STD. The manufacturers of the TCu380A and LNg20 IUDs both take this approach and recommend gonorrhea and chlamydia testing \"as indicated\" depending on risk status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. As a public health measure, the Centers for Disease Control and Prevention (CDC) and the United States Preventive Services Task Force (USPSTF) recommend testing for these infections in all sexually active women &le;25 years of age, as well as older women who have risk factors for STD acquisition (eg, a new partner or more than one sexual partner) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/8,14\">",
"     8,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Applying these general guidelines to define the indications for pre-IUD insertion screening may still miss a substantial number of infected women in areas of high disease prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. We feel the decision for universal or selective screening pre-IUD insertion should be based upon infection prevalence estimates for the patient population in the provider's clinical setting. Given that the CDC recommends screening all women under age 25, and that this age group has an approximately 3 percent prevalence of chlamydia, providers should consider screening their patients if the prevalence rate for their population is 3 percent or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/17\">",
"     17",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists has stated that for women at high risk of STDs (eg, aged 25 years or younger or having multiple sex partners), it is reasonable to screen for STDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/18\">",
"     18",
"    </a>",
"    ]; adolescents should be screened for both gonorrhea and chlamydia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/19\">",
"     19",
"    </a>",
"    ]. The IUD can be inserted on the same day as STD screening or insertion can be delayed until the test results are available; however, the latter approach may increase the possibility of unplanned pregnancy.",
"   </p>",
"   <p>",
"    If screening at the time of IUD insertion is reported as positive after insertion, the woman and her partner(s) can be treated without removal of the IUD. We recommend a retest after three months to confirm the absence of reinfection. We also repeat the bimanual examination to ensure the absence of cervical motion tenderness, uterine tenderness or other evidence of upper genital tract infection. If the retest is positive, suitability for continued IUD use should be evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis provides no benefit to women without sexually transmitted infections. Given the high costs of universal STD testing, the use of routine prophylactic antibiotics for the prevention of IUD complications has been investigated in four large randomized trials. A meta-analysis of these trials found that prophylactic antibiotics (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) decreased the frequency of unscheduled visits post-IUD insertion (OR 0.82, 95% CI 0.70-0.98), but there was no significant decrease in occurrence of PID (OR 0.89, 95% CI 0.53-1.51) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/20\">",
"     20",
"    </a>",
"    ]. Based on these data, routine antibiotic prophylaxis is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     SBE prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Heart Association does not recommend endocarditis prophylaxis for IUD insertion in the absence of a pelvic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This recommendation was based on the finding of a zero percent incidence of bacteremia following IUD insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22413030\">",
"    <span class=\"h3\">",
"     NSAID with or without misoprostal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral preprocedural analgesia with a nonsteroidal antiinflammatory drug (NSAID) does not appear to significantly reduce pain during or after insertion, although data are limited. This was illustrated in a systematic review of four randomized controlled trials (n = 2204 women) of treatments to",
"    <span class=\"nowrap\">",
"     prevent/reduce",
"    </span>",
"    IUD-insertion related pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/24\">",
"     24",
"    </a>",
"    ]. In three placebo-controlled trials, nonsteroidal antiinflammatory drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    400 or 600 mg or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    300 mg) primarily administered 60 to 90 minutes before insertion did not significantly reduce pain during the procedure.",
"   </p>",
"   <p>",
"    A fourth trial compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    400 mcg sublingually plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    one hour prior to IUD insertion with diclofenac alone and found that combined therapy did not reduce insertion-related pain; however, use of misoprostol facilitated insertion, and reduced the number of difficult and failed attempts at insertion in women with a narrow cervical canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14673762\">",
"     'Difficult insertion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Only two trials evaluated post-insertion pain: one observed a significant decrease in pain two hours post insertion of a Dalkon Shield in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    group. The Dalkon Shield was a large IUD and is no longer available. In the other trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    600 mg taken before IUD insertion did not reduce pain four to six hours after insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22413037\">",
"    <span class=\"h3\">",
"     Paracervical block",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paracervical block (10 to 20 mL of 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    injected to a depth of approximately 1 cm (",
"    <a class=\"graphic graphic_figure graphicRef64237 \" href=\"mobipreview.htm?16/0/16385\">",
"     figure 1",
"    </a>",
"    )) can be considered for patients at risk for significant insertional pain, such as nulliparas, those requiring cervical dilation, and women with a history of prior painful IUD insertion. Patients at risk of a vasovagal reaction by prior history can also benefit from paracervical block. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=see_link\">",
"     \"Pudendal and paracervical block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on effectiveness for relieving IUD insertion pain are limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of paracervical block versus no local anesthesia for IUD insertion in 50 women reported a lower median visual analogue score (VAS) among women who received local anesthesia (24 mm versus 62 mm on a 100 mm scale), but the range of scores in each group was wide and overlapping and the difference between groups did not achieve statistical significance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/26\">",
"       26",
"      </a>",
"      ]. Performance of the paracervical block itself was painful (median VAS 40 mm).",
"     </li>",
"     <li>",
"      A randomized trial of paracervical block in a different but similar setting (hysteroscopic sterilization) found that the procedure significantly reduced pain related to cervical manipulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/27\">",
"       27",
"      </a>",
"      ]. It did not reduce uterine or tubal pain and the block itself caused some discomfort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22413052\">",
"    <span class=\"h3\">",
"     Topical anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a pilot study suggested topical cervical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    reduced pain during IUD insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/28\">",
"     28",
"    </a>",
"    ], two randomized trials reported no treatment effect compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment for IUD insertion consists of a speculum, single tooth tenaculum, uterine sound, and a scissor for trimming the IUD string. An antiseptic solution (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ) and, ideally, sterile gloves should also be available, although a \"no touch\" technique is also acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Preinsertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pelvic exam is essential to assess the size and position of the uterus, and evaluate signs of active genital infection, such as cervical motion tenderness or pelvic pain. A speculum is inserted, the cervix is inspected for signs of cervicitis, and the cervix is cleaned with an antiseptic solution. Some clinicians also use a q-tip dipped in antiseptic to cleanse the endocervical canal, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14673755\">",
"    <span class=\"h2\">",
"     Insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior lip of the cervix is grasped with a single tooth tenaculum. Gentle traction on the tenaculum stabilizes the uterus, straightens the uterine axis, and helps ensure proper IUD placement at the uterine fundus. If a local block has not been placed, either inject the cervix with local anesthetic prior to placing the tenaculum, or ask the patient to cough just as the tenaculum pierces the cervical lip. Closing the tenaculum slowly rather than quickly is usually more comfortable for the patient.",
"   </p>",
"   <p>",
"    A uterine sound is passed through the cervix and into the uterine fundus. For proper placement, the sound measurement should be 6 to 10 cm. The provider should never use force when passing the sound or inserting the IUD, as this increases the risk of perforation. Pain is the primary clinical manifestation of perforation. In addition, the provider may note a loss of resistance while inserting the IUD or that the uterus sounds to an unexpected depth (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Uterine perforation'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14673762\">",
"    <span class=\"h3\">",
"     Difficult insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the sound or IUD cannot be passed through the cervix easily, the cervix should be gently dilated with a lacrimal duct probe or cervical dilator.",
"    <span class=\"nowrap\">",
"     Analgesia/local",
"    </span>",
"    anesthesia may be needed (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Analgesia'",
"    </a>",
"    above). If resistance is still encountered, the provider should reassess the uterine position and consider the possibility of obstructive lesions, such as fibroids, or excessive uterine flexure. In such cases, insertion may be attempted under ultrasound guidance to decrease the risk of uterine perforation. For women with fibroids, particularly submucosal tumors, insertion under ultrasound guidance may be useful to ensure proper fundal placement of the device. If ultrasound was not used during the procedure, prompt postprocedure ultrasonography is useful to confirm correct IUD placement in any patient in whom insertion was difficult.",
"   </p>",
"   <p>",
"    Drugs have also been used to soften the cervix and thus reduce insertion-related pain. In one small randomized trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    gel applied intracervically did not result in a statistical improvement in pain scores or improve ease of insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/31\">",
"     31",
"    </a>",
"    ]. More data are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , which may be useful in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8653332\">",
"    <span class=\"h4\">",
"     Misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    may be of benefit for patients in whom insertion is difficult or has failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/25,32,33\">",
"     25,32,33",
"    </a>",
"    ], but larger studies are needed to determine whether its use is associated with an increased risk of expulsion due to its uterotonic effects. In randomized trials and a small case series, the use of pre-insertion misoprostol softened the cervix and facilitated IUD insertion when the canal was narrow (nulliparous women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/25\">",
"     25",
"    </a>",
"    ] or after a failed insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/32\">",
"     32",
"    </a>",
"    ], but was not beneficial when removing and immediately replacing an IUD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/34\">",
"     34",
"    </a>",
"    ] or when used routinely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Although misoprostol softened the cervix, evidence from randomized trials showed that its use did not reduce the number of failed procedures, possibly because the rate of failed insertion was quite low, even among nulliparous women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/25,35,36\">",
"     25,35,36",
"    </a>",
"    ]. In women in whom insertion is difficult or expected to be difficult, misoprostol can be used. Misoprostol regimens vary; 400 micrograms can be administered vaginally, buccally, or sublingually, ideally two to three hours before insertion. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     TCu380A (ParaGard&reg;) IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ParaGard&reg; package contains the IUD with attached string, an insertion tube with an elliptical flange, and a solid plastic rod with a ring at one end (",
"    <a class=\"graphic graphic_figure graphicRef71726 \" href=\"mobipreview.htm?3/3/3135\">",
"     figure 2",
"    </a>",
"    ). The provider (wearing sterile gloves) assembles the IUD by bending the horizontal arms of the device downwards towards the vertical arm and placing the thread and the vertical arm into the insertion tube. The tips of the horizontal arms are then tucked into the tube and inserted just to the point where the device is stable in the tube (",
"    <a class=\"graphic graphic_figure graphicRef76035 \" href=\"mobipreview.htm?33/44/34510\">",
"     figure 3",
"    </a>",
"    ). The horizontal arms should not be kept in the bent position for more than five minutes before insertion. Neither the IUD nor the portion of the insertion tube that enters the uterus should ever be touched with a nonsterile hand. If sterile gloves are not available, the device can be assembled within the IUD package. The provider partially opens the package, handling the distal end of the insertion tube with a nonsterile hand and handling the device itself through the clear, sterile window of the package.",
"   </p>",
"   <p>",
"    After positioning the IUD at one end of the insertion tube, the plastic rod is passed through the other end, with the ringed end of the rod protruding from the base of the tube. Care should be taken to pass the rod only to the point where it just touches the IUD (it must touch the stem); pushing the rod further will expel the device from the insertion tube. The elliptical flange can then be slid along the insertion tube to position it to correspond to the sounded depth of the uterine cavity. The wide diameter of the flange is oriented in the same alignment as the horizontal arms of the IUD.",
"   </p>",
"   <p>",
"    While applying traction on the tenaculum, the insertion tube is passed through the cervical os to the level of the uterine fundus. Once the IUD is at the fundus, the plastic rod is used to hold the device in place. The IUD should",
"    <strong>",
"     not",
"    </strong>",
"    be pushed out of the insertion tube with the rod, as this could cause perforation through the fundus. Instead, with the device stabilized by the rod, the insertion tube is moved back over the rod and slightly out of the uterus to the point where it meets the ring of the plastic rod (",
"    <a class=\"graphic graphic_figure graphicRef57148 \" href=\"mobipreview.htm?10/46/10976\">",
"     figure 4",
"    </a>",
"    ). At this point, a small pop may be felt as the IUD arms are released from the insertion tube. Gently move the insertion tube up until the resistance of the fundus is confirmed. The solid white rod is removed first while holding the insertion tube steady, followed by removal of the outer plastic insertion tube. Removing these structures separately decreases the risk that the rod may pull on the string.",
"   </p>",
"   <p>",
"    The IUD should remain in the uterine cavity, with no portion of the device visible within the endocervical canal. If the IUD is visible within or protruding through the endocervical canal, it should be retrieved by pulling the string. A new IUD may be inserted.",
"   </p>",
"   <p>",
"    After proper placement is confirmed, the strings are trimmed to approximately 2 to 3 cm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Levonorgestrel releasing IUD (LNg20-Mirena)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LNg20 package contains a partially preassembled IUD and applicator. The applicator consists of a plastic insertion tube containing the string and base of the IUD; a flange for indicating the uterine depth; and a handle. The upper portion of the applicator's handle has a green slider that is used to release the IUD and retract the insertion tube. At the lower end of the handle is a cleft, which holds the IUD strings during insertion (",
"    <a class=\"graphic graphic_figure graphicRef59196 \" href=\"mobipreview.htm?20/53/21343\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Using a sterile or no-touch technique, the provider frees the loose ends of the IUD strings from behind the slider and confirms that the slider is in its upward-most position (away from the provider). The IUD is then retracted into the insertion tube by laying the device's free arms flat (horizontal) on the sterile inside plastic surface of the package and pulling the strings firmly until the IUD slides into the tube (",
"    <a class=\"graphic graphic_figure graphicRef77808 \" href=\"mobipreview.htm?18/56/19343\">",
"     figure 6",
"    </a>",
"    ). In contrast to the TCu380A IUD, the proper alignment of the arms of the LNg20 IUD is bending upwards rather than downwards. After the device is in place, the knobs at the end of the arms cover the open end of the inserter and the threads can be fixed in the cleft of the handle (",
"    <a class=\"graphic graphic_figure graphicRef54422 \" href=\"mobipreview.htm?32/28/33230\">",
"     figure 7",
"    </a>",
"    ). The flange is then slid along the insertion tube to position it to correspond to the sounded depth of the uterine cavity using a sterile or no-touch technique. The IUD is then ready to insert.",
"   </p>",
"   <p>",
"    While placing traction on the tenaculum to align the endocervical canal with the uterine cavity, the inserter is passed to a distance 1 to 2 cm less than the distance marked by the flange. While holding the inserter steady, the slider is moved partway back along the handle until it reaches an indicator mark, thereby releasing the arms of the IUD from the insertion tube (",
"    <a class=\"graphic graphic_figure graphicRef70297 \" href=\"mobipreview.htm?40/8/41103\">",
"     figure 8",
"    </a>",
"    ). A five second pause at this point will allow the arms to move to their natural position.",
"   </p>",
"   <p>",
"    The inserter is then advanced to the level of the fundus, as indicated by the position of the flange. The slider is pulled back toward the provider; an audible \"click\" signals release of the strings from the inserter. The insertion tube is then removed (",
"    <a class=\"graphic graphic_figure graphicRef79483 \" href=\"mobipreview.htm?34/60/35790\">",
"     figure 9",
"    </a>",
"    ) and the string trimmed to 2 to 3 cm in length.",
"   </p>",
"   <p>",
"    The IUD should remain in the uterine cavity, with no portion of the device visible within the endocervical canal. If the IUD is visible within or protruding through the canal, it should be retrieved by pulling the string. This IUD should not be reinserted; an IUD from a new package must be used for reinsertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17725184\">",
"    <span class=\"h2\">",
"     Levonorgestrel releasing IUD (LNg14-Skyla)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is similar to that for the LNg20 (Mirena) IUD, but not identical. The key difference pertains to the IUD strings, which are completely contained within the insertion device, thus requiring no handling.",
"   </p>",
"   <p>",
"    Using sterile technique, the pink slider is moved forward as far as possible in the direction of the arrow, thus moving the insertion tube over the IUD body to load it into the insertion tube. This results in the tips of the arms meeting and forming a rounded end that extends slightly beyond the insertion tube. The strings are completely contained in the handle and do not need to be secured. The slider is held in place with the operator&rsquo;s thumb and, either using the groove within the sterile inside plastic surface of the package or the other hand, the flange is adjusted to reflect the depth of the uterus, as measured with a uterine sound. The inserter is then advanced through the cervix until the flange is 1.5 to 2 cm from the cervix, and held steady while the slider is moved partway back down, stopping at the mark that allows just the arms of the IUD to be released, which takes about 10 seconds. The inserter is then advanced until the flange touches the cervix, which places the open IUD arms at the correct fundal position. Holding the inserter in place, the IUD is released by moving the slider all the way back down toward the handle. The inserter can then be removed and the threads cut.",
"   </p>",
"   <p>",
"    The IUD is removed with a forceps by placing gentle traction on the strings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTABORTION OR POSTPARTUM PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;IUDs can be inserted immediately after a pregnancy termination, spontaneous miscarriage, or delivery. Postabortal and postpartum procedures are convenient and ensure that the woman is not pregnant. Furthermore, they may benefit patients who are unable or unwilling to return for later insertion, and who do not have other options for effective contraception. Ovulation can return as soon as three weeks after delivery in those who are not fully breastfeeding, and by three months for those who are. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative placement methods may be needed for immediate postpartum and postabortion IUD insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Immediate postabortal insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;An IUD may be inserted immediately following surgical treatment of an induced or spontaneous abortion. Both progestin and copper IUDs have been used immediately after first trimester surgical abortions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to insertion, the provider should verify that the surgical procedure was uncomplicated and absence of infection or significant bleeding. The method of insertion is identical to that with an interval procedure; however, the immediate postpartum method of insertion may be necessary with late second trimester procedures (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Immediate postpartum insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;An IUD may be placed after vaginal or abdominal delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .) Post-placental insertion of the copper IUD has been extensively studied, and is supported by the package label. Insertion of the LNg20 IUD has not been studied as extensively and is not supported by the package label [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The Centers for Disease Control (CDC) support the use of either IUD whether or not the woman is breastfeeding, in the absence of sepsis (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postpartum insertion should take place within 10 minutes of placental delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/42\">",
"     42",
"    </a>",
"    ]. Prior to insertion, the provider should verify that the delivery was uncomplicated, the uterus is firm (uterotonic agents may be given), bleeding has diminished, and there is no evidence of infection. Insertion should be avoided if there had been a postpartum hemorrhage or if there is any suspicion of retained placenta or disruption of a uterine scar. Fundal placement is important for minimizing the risk of expulsion. Breastfeeding does not appear to affect the risk of expulsion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Post vaginal delivery",
"      </strong>",
"      &mdash; The IUD is removed from the insertion sleeve and grasped with a ring forceps. A second ring forceps is used to grasp the anterior lip of the cervix. The IUD is then inserted through the dilated cervix to the level of the uterine fundus, as confirmed by palpation with a hand placed on the abdomen overlying the fundus. The ring forceps are oriented so the arms of the IUD will lie parallel to the anterior and posterior walls of the uterus and then the forceps are opened to release the IUD. The strings may be trimmed at the level of the cervix, as needed.",
"      <br/>",
"      <br/>",
"      Postplacental IUD insertions can also be performed manually: the IUD is grasped between two fingers and placed at the fundus. With either technique, adequate anesthesia should be provided (epidural is optimal).",
"     </li>",
"     <li>",
"      <strong>",
"       Post cesarean delivery",
"      </strong>",
"      &mdash; The IUD is removed from the insertion sleeve and grasped with a ring forceps. A second ring forceps is used to grasp the anterior edge of the hysterotomy incision. The IUD is then inserted through the incision to the level of the uterine fundus, as confirmed by palpation with a hand placed on the fundus as well as visually, if possible. The ring forceps are oriented so the arms of the IUD will lie parallel to the anterior and posterior walls of the uterus and then the forceps are opened to release the IUD. The strings are pushed through the internal os into the vagina and may be trimmed, as necessary, if they are visible.",
"      <br/>",
"      <br/>",
"      Interval insertion after cesarean delivery also appears to be safe and effective, although there are some reports suggesting a slightly higher risk of perforation and expulsion in these cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/43-45\">",
"       43-45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should return in four weeks for an examination. The strings may be trimmed if they are too long. If the strings are not visible, the correct position of the IUD should be confirmed by palpation with a uterine sound or by ultrasound examination. The strings can be teased through the cervical canal with a sound if they are identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PERIPROCEDURAL COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Uterine perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cramping is normal upon insertion of the IUD. This pain diminishes once the procedure has been completed, and should resolve or nearly resolve if over-the-counter analgesics are taken.",
"   </p>",
"   <p>",
"    Uterine perforation or trauma occurs during about 1 in 1000 interval IUD insertions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/46\">",
"     46",
"    </a>",
"    ]. Risk factors include an inexperienced clinician, a stenotic cervix, and an immobile and retroverted uterus. The following signs and symptoms during or after insertion are suggestive of perforation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe or unrelenting pelvic discomfort",
"     </li>",
"     <li>",
"      Active vaginal bleeding",
"     </li>",
"     <li>",
"      IUD string not visible or unusually short",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If perforation by the sound or IUD is suspected, the woman should be monitored for",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    of tachycardia, hypotension, syncope, or an acute abdomen. Such",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    warrant transfer to an emergency facility for further management.",
"   </p>",
"   <p>",
"    When perforation by the IUD is suspected in a stable patient, IUD removal can be attempted by placing gentle traction on the string. Given the risk of introducing vaginal bacteria into the sterile peritoneal or retroperitoneal space, we recommend giving antibiotics if perforation is suspected. Possible regimens include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily for one week) alone or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg twice daily for one week).",
"   </p>",
"   <p>",
"    If the string is not visible, the location of the IUD can usually be determined by ultrasound examination. Depending on the location, the IUD can then be retrieved using a hysteroscope or laparoscope. Removing the IUD under direct vision helps to prevent injury to pelvic organs that could be snagged by the device. Laparotomy is required if laparoscopic or hysteroscopic removal is difficult, if perforation of intraabdominal organs is suspected or with ongoing intraperitoneal hemorrhage. Immediate intervention is not essential if the patient is stable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24631?source=see_link&amp;anchor=H6#H6\">",
"     \"Complications of gynecologic surgery\", section on 'Bowel injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IUD perforation is not a contraindication to future labor and vaginal delivery, as the uterine defect is small. A literature review did not identify any case reports of rupture of a pregnant uterus associated with prior IUD perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Vasovagal response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, IUD insertion (or removal) provokes a vasovagal response characterized by transient syncope or presyncope, hypotension, bradycardia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nausea. Symptoms typically resolve by stopping the procedure, placing the woman in a recumbent position, and giving supportive care.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    (0.4 to 0.6 mg intramuscularly or intravenously) can be administered, as needed. If the symptoms do not resolve, a paracervical block may be placed or the IUD can be removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/29/34265/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     POSTPROCEDURE COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is taught to feel the IUD string protruding from the cervix and check monthly to confirm retention of the IUD after menses. If she cannot feel the string, she should use a back-up method of contraception until she can be examined by her clinician to confirm whether the IUD is in place. In addition, she is counseled to call or return for fever, worsening pelvic pain, abdominal pain, syncope, unusually heavy vaginal bleeding, suspected expulsion, foul vaginal discharge, or pregnancy. In the absence of problems, a follow-up examination is scheduled in one to three months.",
"   </p>",
"   <p>",
"    Management of side effects and problems related to IUD use is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link\">",
"     \"Management of problems related to intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     REMOVAL OF IUD WITH OR WITHOUT IUD REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the patient desires to attempt pregnancy, the IUD is removed by a health care provider. Otherwise, the TCu380A IUD needs to be replaced after 10 years, and the LNg 20 IUD should be replaced after five years. Removal is appropriate at menopause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of intrauterine contraception\", section on 'Menopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a new IUD is placed immediately after removal of the old device, then no back-up contraceptive is needed. If the patient is switching to another contraceptive method, she should use back-up contraception according to instructions for the particular method she has selected. If she had unprotected intercourse within three to five days of removal, and her new method requires back-up contraception for the first week of use, then she may be offered oral emergency contraception as additional protection, although it is not clear that this is necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=see_link\">",
"     \"Emergency contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An IUD can be removed any time during the menstrual cycle. Removal is accomplished by grasping the strings with forceps, or a similar instrument, and gently pulling. Some cramping",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding is normal during removal.",
"   </p>",
"   <p>",
"    For the occasional difficult case, a tenaculum can be used to steady the cervix and align the endocervical canal with the vaginal and uterine cavities or the cervix can be dilated slightly with a small cervical dilator or softened with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    400 mcg vaginally, buccally, or sublingually at least one hour or at bedtime pre-procedure. Antibiotic prophylaxis, culture, or pathologic examination is unnecessary for routine removals.",
"   </p>",
"   <p>",
"    The patient should be informed that fertility may return quickly after IUD removal, thus she should switch immediately to an alternate form of contraception if she wishes to prevent pregnancy.",
"   </p>",
"   <p>",
"    Techniques for removing the device when the strings are not visible or the device has embedded in the myometrium are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link\">",
"     \"Management of problems related to intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/17/37138?source=see_link\">",
"       \"Patient information: Intrauterine devices (IUD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=see_link\">",
"       \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute contraindications to intrauterine device (IUD) insertion are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef63636 \" href=\"mobipreview.htm?21/8/21643\">",
"       table 1",
"      </a>",
"      ). The provider should ensure that the patient has no absolute contraindications to IUD use. Relative contraindications are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef56428 \" href=\"mobipreview.htm?12/30/12779\">",
"       table 2",
"      </a>",
"      ); the patient and provider must weigh the risks and benefits of IUD use in this setting. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision for universal or selective screening for gonorrhea and chlamydia pre-IUD insertion in asymptomatic women is based upon infection prevalence estimates for the patient population in the provider's clinical setting. Generally, women &le;age 25, women with a new sexual partner, and women with more than one sexual partner are screened. Screening can be obtained on the day of insertion. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Screening for STDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend routine antibiotic prophylaxis prior to IUD insertion in areas of low STD prevalence (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The IUD may be inserted at any time during the cycle if pregnancy can be excluded (the patient is consistently using a reliable contraceptive method, or she has been abstinent since her last menses, or she is within five days of a single act of unprotected intercourse and would like emergency contraception with a copper IUD). A pregnancy test should be obtained if pregnancy cannot be excluded clinically, and a negative result documented before insertion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Timing of insertion and pregnancy testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not use paracervical block routinely as the procedure itself is painful. It is an option for patients at risk of",
"      <strong>",
"       greater than average",
"      </strong>",
"      insertional pain, such as those requiring cervical dilation or with a history of prior painful IUD insertion, and it can also be useful for patients at risk for a vasovagal reaction. A paracervical block should be offered to any patient who is unable to tolerate an initial attempt at insertion without the block. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Each type of IUD has a unique insertion procedure. The provider should never use force when passing the sound or inserting any type of IUD, as this increases the risk of perforation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      is an option for patients in whom insertion is difficult or has failed. A reasonable dose is 400 micrograms vaginally, buccally, or sublingually, ideally two to three hours before insertion. (See",
"      <a class=\"local\" href=\"#H14673762\">",
"       'Difficult insertion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The IUD may be placed postabortion or at four to six weeks postpartum. Additionally, the TCu380A may be placed immediately after a vaginal or cesarean delivery, although the risk of expulsion may be higher than with later insertion. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Postabortion or postpartum placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An IUD that has perforated the uterus should be removed. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Uterine perforation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Back-up contraception is not needed after insertion of a CuT380A, but should be provided for seven days if an LNg20 IUD is inserted more than seven days from the start of menstrual bleeding. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Postprocedure counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/1\">",
"      Allen RH, Goldberg AB, Grimes DA. Expanding access to intrauterine contraception. Am J Obstet Gynecol 2009; 201:456.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/2\">",
"      Darney PD, Klaisle CM. Contraception-associated menstrual problems: etiology and management. Dialogues Contracept 1998; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/3\">",
"      El-Tagy A, Sakr E, Sokal DC, Issa AH. Safety and acceptability of post-abortal IUD insertion and the importance of counseling. Contraception 2003; 67:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/4\">",
"      White MK, Ory HW, Rooks JB, Rochat RW. Intrauterine device termination rates and the menstrual cycle day of insertion. Obstet Gynecol 1980; 55:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/5\">",
"      Bergin A, Tristan S, Terplan M, et al. A missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception 2012; 86:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/6\">",
"      Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/7\">",
"      Sufrin CB, Postlethwaite D, Armstrong MA, et al. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol 2012; 120:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/8\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/9\">",
"      Pham AT, Kives S, Merovitz L, et al. Screening for bacterial vaginosis at the time of intrauterine contraceptive device insertion: is there a role? J Obstet Gynaecol Can 2012; 34:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/10\">",
"      Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006; 73:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/11\">",
"      Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356:1013.",
"     </a>",
"    </li>",
"    <li>",
"     FEI Products LLC. Paragard T380A intrauterine copper contraceptive: Prescribing information and instructions for use. 2003.",
"    </li>",
"    <li>",
"     Berlex. Mirena levonorgestrel-releasing intrauterine system: Physician package insert. 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/14\">",
"      U.S. Preventive Services Task Force. Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 147:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/15\">",
"      Handsfield HH. Screening asymptomatic women for Chlamydia trachomatis: abstract and commentary. JAMA 1998; 280:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/16\">",
"      Howell MR, Quinn TC, Gaydos CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies. Ann Intern Med 1998; 128:277.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Trends in reportable Sexually Transmitted Diseases in the United States, 2004. 2005. Available at: www.cdc.gov/std/stats/04pdf/trends2004.pdf. (Accessed March 1, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/18\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2011; 118:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/19\">",
"      Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2012; 120:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/20\">",
"      Grimes DA, Lopez LM, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev 2012; :CD001327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/21\">",
"      Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/22\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/23\">",
"      Durack DT. Prevention of infective endocarditis. N Engl J Med 1995; 332:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/24\">",
"      Allen RH, Bartz D, Grimes DA, et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev 2009; :CD007373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/25\">",
"      S&auml;&auml;v I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod 2007; 22:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/26\">",
"      Mody SK, Kiley J, Rademaker A, et al. Pain control for intrauterine device insertion: a randomized trial of 1% lidocaine paracervical block. Contraception 2012; 86:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/27\">",
"      Chudnoff S, Einstein M, Levie M. Paracervical block efficacy in office hysteroscopic sterilization: a randomized controlled trial. Obstet Gynecol 2010; 115:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/28\">",
"      Oloto EJ, Bromham D, Murty JA. Pain and discomfort perception at IUD insertion: effect of short-duration, low volume, intracervical application of two percent lignocaine (Instillagel), a preliminary study. Br J Fam Plann 1996; 22:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/29\">",
"      Maguire K, Davis A, Rosario Tejeda L, Westhoff C. Intracervical lidocaine gel for intrauterine device insertion: a randomized controlled trial. Contraception 2012; 86:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/30\">",
"      McNicholas CP, Madden T, Zhao Q, et al. Cervical lidocaine for IUD insertional pain: a randomized controlled trial. Am J Obstet Gynecol 2012; 207:384.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/31\">",
"      Bednarek PH, Micks EA, Edelman AB, et al. The effect of nitroprusside on IUD insertion experience in nulliparous women: a pilot study. Contraception 2013; 87:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/32\">",
"      Li YT, Kuo TC, Kuan LC, Chu YC. Cervical softening with vaginal misoprostol before intrauterine device insertion. Int J Gynaecol Obstet 2005; 89:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/33\">",
"      Vickery Z, Madden T. Difficult intrauterine contraception insertion in a nulligravid patient. Obstet Gynecol 2011; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/34\">",
"      Heikinheimo O, Inki P, Kunz M, et al. Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception 2010; 81:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/35\">",
"      Dijkhuizen K, Dekkers OM, Holleboom CA, et al. Vaginal misoprostol prior to insertion of an intrauterine device: an RCT. Hum Reprod 2011; 26:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/36\">",
"      Edelman AB, Schaefer E, Olson A, et al. Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women. Contraception 2011; 84:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/37\">",
"      Swenson C, Turok DK, Ward K, et al. Self-administered misoprostol or placebo before intrauterine device insertion in nulliparous women: a randomized controlled trial. Obstet Gynecol 2012; 120:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/38\">",
"      Hayes JL, Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception 2007; 76:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/39\">",
"      Chen BA, Reeves MF, Hayes JL, et al. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2010; 116:1079.",
"     </a>",
"    </li>",
"    <li>",
"     www.who.int/reproductive-health/publications/spr/spr_2008_update.pdf (accessed February 3, 2009).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. Early release - May 28, 2010. file://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0528a1.htm (Accessed on May 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/42\">",
"      Grimes DA, Lopez LM, Schulz KF, et al. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev 2010; :CD003036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/43\">",
"      Chi IC, Balogh S. Interval insertion of intrauterine device in women with previous cesarean section. Contraception 1984; 30:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/44\">",
"      IUD insertions following cesarean deliveries examined. Netw Res Triangle Park N C 1984; 5:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/45\">",
"      Chi I, Feldblum PJ, Rogers SM. IUD--related uterine perforation: an epidemiologic analysis of a rare event using an international dataset. Contracept Deliv Syst 1984; 5:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/29/34265/abstract/46\">",
"      Andersson K, Ryde-Blomqvist E, Lindell K, et al. Perforations with intrauterine devices. Report from a Swedish survey. Contraception 1998; 57:251.",
"     </a>",
"    </li>",
"    <li>",
"     Hatcher, R, Trussell, J, Stewart, F, et al. Contraceptive technology, 17th ed, Ardent Media, Inc, New York 1998.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3267 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34265=[""].join("\n");
var outline_f33_29_34265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREPROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Candidates for and selection of an IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Counseling and consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Timing of insertion and pregnancy testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18272372\">",
"      - Women who are switching from another method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prevention of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Screening for STDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - SBE prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22413030\">",
"      - NSAID with or without misoprostal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22413037\">",
"      - Paracervical block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22413052\">",
"      - Topical anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Preinsertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14673755\">",
"      Insertion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14673762\">",
"      - Difficult insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8653332\">",
"      Misoprostol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TCu380A (ParaGard&reg;) IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Levonorgestrel releasing IUD (LNg20-Mirena)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17725184\">",
"      Levonorgestrel releasing IUD (LNg14-Skyla)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTABORTION OR POSTPARTUM PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Immediate postabortal insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Immediate postpartum insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PERIPROCEDURAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Uterine perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Vasovagal response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      POSTPROCEDURE COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      REMOVAL OF IUD WITH OR WITHOUT IUD REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3267\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3267|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/0/16385\" title=\"figure 1\">",
"      Paracervical block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/3/3135\" title=\"figure 2\">",
"      Components of Paragard IUD A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/44/34510\" title=\"figure 3\">",
"      Paragard IUD folding arms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/46/10976\" title=\"figure 4\">",
"      Paragard IUD sliding tube back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/53/21343\" title=\"figure 5\">",
"      Mirena IUD insertion kit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/56/19343\" title=\"figure 6\">",
"      Insertion Mirena IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/28/33230\" title=\"figure 7\">",
"      Insertion Mirena IUD2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/8/41103\" title=\"figure 8\">",
"      Insertion Mirena IUD3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/60/35790\" title=\"figure 9\">",
"      Release Mirena IUD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3267|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/8/21643\" title=\"table 1\">",
"      Contraindications IUD insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/30/12779\" title=\"table 2\">",
"      Relative contraindications to IUD insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 3\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/46/4846\" title=\"table 4\">",
"      Switching between different methods of contraception",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24631?source=related_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=related_link\">",
"      Management of problems related to intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/17/37138?source=related_link\">",
"      Patient information: Intrauterine devices (IUD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=related_link\">",
"      Postpartum and postabortion contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=related_link\">",
"      Pudendal and paracervical block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_29_34266="Skin biopsy MCTD I";
var content_f33_29_34266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73386%7ERHEUM%2F62041%7ERHEUM%2F80459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73386%7ERHEUM%2F62041%7ERHEUM%2F80459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin lesion in mixed connective tissue disease (MCTD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 234px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADqAWcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3eLxfpt4dl7ZSpHx8zKswGfUKSR+VWI73wu7pCqWBABxm3+VR7nbgfjXmEFwsh/1dmXQYL2zqj/kDkfnVo6qsZ8pXuZN3XCliv4jA/Gvalg0vhbOuWE19253d0vg+Td5hsgTxiFmU/gEqlLq/gu2hMMFnHM7DGEtW3H/gbAH9a46fUlaEf8hJ8HiNU6+9VzPIyO07Xloh5CzsqAke4zRHCvrJ/eJYd9WdsmvrD5B03Q5IYkXjDsoC/wDATg/jUw8YX8pKrb2sR9FfeR/n6VwJkhl3b7qDaoHP2klvXtziqVzrem2q+aoEqqQu63TgfUk5z+BrVYOE3tf72arDRfQ9Il1q/kbe7Sgd18zGPwA5qO2nvFnMqXDQyDtMzHP4MBXm0ni7TTBI8VxcrsBZszhMKOpGRkj6c+1Fh4j0STfPbRl5lOGeJXaQ8dSRjP4j8a0+pSS+F/cP2FlsesS32uEqy39pGN2QJWiAb26k/wAqsJb61dL+61eyjznIiYMf/Qf5Yry1PEejS24M19HZTk8JqVlcID77wrAD3zTZDbazbSBNT8K34iO2a0guBHLj/pmZSFb2JKj3FZPBPtb5GTpx6u3yPTP+ER1K5k36hq6TLnOySJph/wCPNgflVe40CxgZrjVPFR+xpklJDBGi/jtwP5+9eSyaX4elWS3ttTt8octZXaSRhfx4Un6OPYnNXNEu7CyAay8F2kjA48yKVZlwO/8AqmIHf7zH3q/qlS2kv/JUvxf6XNfZ30UvwS/U77+0PD8sn2ZNeub9gQPsWhOQAM9HliwxPuXXPp2p7af4Nifz7/w9qFlj788tvcBAfUuP/QjWdp/xMigAgttFtY3PynypGyox1KCPJ/MZ9qtt8VILC2Ml8EuZd3MCQPbSqvqFYsrj33KfaspYeutFF/J2/JW+8wcKkdk/v/yOrn1my0y1t7TQ44p02fItuGlCr64QEn19TWBPBNcN9ri1TUbqzL/6R/Zt7Kr2pPPzRNuYr7DDD+6RkiTTfiZol1ZPJpOmazdMsmHgs7EyMM8ljtJUD8c+xqrfeMfDl3eJcaro2v2N3s8tHubd7Zyuc7R8wJGecVjTpVINpwd+vf8AT8/vIUZp6IivdFtLCBJ9Q1vUWeVyLaN9UmnZyemEJQfhtbrVnTr2KzuLj7NZ3minA83y9EYRMT/dl2Ln/gWMZ5qrH4o8LxxyTW2h6nEoGTPa2xMkg95FOcfVqoweKxLI48NW3jHUUZsCFvL8lCexd1Z1Hoc/TpW6hOaaafztb9f67FOMn0Or0vW9PF7vm1y6uGA+WCS4t+T/ALkfzfga17G60fT43uJJYLOSZsNJdTr5knplix454GeOwFeYXuqeNHcudEvbSyz+8DyTTNtI9/MDD1/dis0XVxDKGvdOsp7iVtsMssNwNwHUbRHGP/Hj9KTwSqbOy8mv00G6De/6HZ+JJrBNZlvdFntbiWcAXESsWDP0BwoPJHpzkVUv9T1PUrS1g1iB9I0yCRJfLkO55th3K0pc70QMAdgUsxA+ZaxIp9encLamytD/ABW1naSK+OwwFAYcd2zxVWSHQUvJJtcn1+bUwxcwRBLZQ+Md2Lg+5bP8q6IUEkk9Wvm/0XzNGk0l2NW/16G81u6LJq0moXDhobCwt9+oJFjbvbOEtgQVG5iHC5IKl+NTSbCeLVoTrPhPxHHYxHzIZrjXHvxEyAsCYRI2CcY43c8d6peH/FS6fbfZtB8PWemRrnzbi5uCwfGTl3C5Y8/7Tc4A5yObm8carqU0M1863kAY+VbIfs7Tn+EhOWYcfdXDY5yKpUKsm4xjZW76/Kzt8m2YOLu7G/qPjO7fU5Z9P1plnffHHYXunxqI88KY3Xc6uoHIfIYk8AYAZcabI6rd3V/qGqq6fM1xpE4eMg5JSSBkdFJ9mI7g1ydx418d3l9c22pPaWeSA9pdwxJEiHsWfI54xuz+Nctd6rcy3jQK8NnMjBv+JYqxqxHTPldT6EH6cV10sDKytaPpZ/8AtqLUGtFoeuR67eWf7qdb6Bl/5aavpxmmjwOMSx/M6ehKbh3PYaOk+MriRlaHVoL+NRli8LxRgejOyKVPXH3uhzjGa8ii8QeIXeSzv9Y1JwG2vHcPKCnpznGPcnPPpW9H4jSwmNmbW3klxgy2OqPEAP7+4LJgf7YIHOB0rOpgE1rG7+X6/wCZfslbuz12PxpCqobu2lEcgGCksUqtn+6yNg/iB/SifV9LuUVJ7CfWET7hWweSVB2DBl4PvkHpXmS6pqDR2hTRb+aC8DCJTqiX32gAclT5TFSOuTj3wa09Oi0C5ZLbXbo28yDix1jU3tHjz/dXy13fUMa4XgYQ1s/k0/1/Uj2cY6v8DvY5NMWSI3WlatGudyrMXmC/9s1diB7baupLHdhpNK0qxu7WNtrFm8p946gKUxkZ7kV5bqWkeG7SY/YdX8N2yJ8xim19iPqQFB/U1Vmm0S2immh8TaKsLgEwwa3JNg+yMCxHtnI7Uvqal1d/NP8Az3+YlCEtIv8Ar7z2iDUsYW4sZrLPG92iKqf+Asf5VjahLDNctNax3N7fRnYjW0MMqq3oZMDb15BYda8jk8UeRdCGw1jQ5uFA2LJID/s/NEVyPTr61m3Hiaye9f8AtGwtGcDBmSKGJl+mMHHvkYq6WVtO/wCj/X/MpYaT1uev2tx4zs2JbT2vcnDxyPCFHujhwSP94cVBqPiLxagUW/h+5iuAR+7YLJGRkZyykknGTgHkjtzjz2fxfYQMyJa3pO1dqPM3yHsVk+0EkfQfSnr448uK6gvY5bRJcbTbq0dxvBUq3mzBug3HvnPXrVvASbvyL7rf+3P+upSpSlrynplr45uS2y/8PalbMOCxjcIT7FlFaTeM9KhtoZrx5LXzP4ZkKnHqP734ZrxG68d+MLYs2h6nM1gAPm1NUnIPf95HHjFYdp8TvF1rqNw2pa5Dbo4DZ0+wicO3cNuj3dO/T3qP7Gctkvvf/wAixvCSey/P/I+jrDxbp19IFgjv9rIXWRrOVUYAZ4bbirmn+INMv1Uw3SqW6CQbM/TPB/DNeI6N8U/Ec8NxP9rha0jwpubrTyURj0BMR2gnoAT19Kl/4Tt5mSS++zxzNxI0UbwgE8ncN+1j7nn6VjLKJq6t+N/0RH1aTdkj3xWDAFSCD3HNLzXkGl+NIwwDXD7gCVkFxHJF7jzH3fiBJ26Cuqi8SQyWSgXiWModY910Q0XPGAyORnPHzGuKpgKlN6mEqU49Ds2YKpZjgDqTVSPUrWWYxRyb5AcFQOfrjrj36Vz+qDV2tI4Le1jZnHyPDcszEDqcFdqj6sfaqFnoZ1ILm1vtNubW4LG4lumnLyrjBJLbmQ56Bhz16YqY0IcvNOX5f53+4hQ0u2XdQOt69Y29vp962lGSWUXVzDGrNCI227F3ZUlmxz/dBoq5p1paafcJZ32pW01+250j+WJ5FJJ3FAeT6kYBOTiilUrum7Qtb/Cu/mrgpcuiPlu98R3gn22t0beNQFWILvO71GAuPyql/wAJDqV0WiXV72cbdxUMQQO5OOgFelaDot3pd4ktppXhy5kAAlnv7+SaUg9emFQ4/hrobPTL4QXcdr4O8H263KMlzDHNmS4U9g642A++a+oli6MdIxVvkei66hsvxPDpfEItyq2U94BtGQtx95h1OeMD0FObXTIAsE8jsSoLyXTooY9iBgnHTIyPSvXF0jULWAxQfC7wyEYY/dTebkjHBcL19s1Dd6NdfYgLDwBZxXIwPNTdG8HPc4DE9sg49auONpv7P4x/zNFX5l/wUeUarM9rJi/u9NmmjbmGGSQuvsQynP40W939svIRby2qyMQFXcBsJ7EkqBj34+lep23hH7PaXE2s24ttVIDfZvs9ztC5GCXQvu4yDg5+mK1IfBPhvWIGOpaHZWUuNrNbXbKzL0zhjkn/AHjV/wBoUorZ/h/T+RDrR9Tx3UboCWNYdXE11zkNZMqwnuqtz+LKQD71RZYpYUjWytbm5fJlkKsw68bSMnPtxXrV78LvCkI3Q6tqCwjAVRCrHP1OAfr0pp8EaNp6xy6dFLEwXaJbmUK5Y/xALt/IZq44+g1o393/AAEKM0/hPMY9JLxu+lanb38ax77qF7aWLyR7+aQuAR1zUdpoes31r9rsbDxDdWLHKyW1pviIHXDfdP0FewzabZpHA9wscUicJLaWkYKtjk7nUjJx1Az6mraambci4gOpPHEjIxF5IABxyAuAo+grKeOlb3Ff1/pFxjUex4zBZ+VHII7nWxdAqBHdWojcE/woobJrrvD/AISuz5VxJL4wttRKZd7SyCJC3XDStMCQP9oj8K62TVDqEpjeXfHj712JLoL6lSxJAx/+qs28u7eCFG8y2AQqQgjjhCntucrjH1NRLE1JqyVn95p7CpLRu39ehBHoer7pxcnWrzeP+Qtb6tZxvJ/svHLK+QPUSflUNhqHibQhIun+H7wWqEs0ul6qHllI6O6KZ0B9fl2/SrVuhub0xw2vnO7ZcRIhbj04OfwFT7bhma4NqpVCVWRmT5GHHDEDDcEdf61jzSfuzs18/wDMUsH0lJMw5fGFy129xL4ZuC2APMm1KWwmdu+7yfLjZvcIDjHWp7T4g6nZTk2mlXzKw3SRam32sxenlSqqvjH98knsRzWnfy3RTzXtbqdNufMwH2exx+h/lWXHYWF6rifT5kizhiqSIr4/jCg4x7mtEqTVpw09b/hcI4SL1X6/19xq2fj5NUT7Pey3ekBAGfU5UnJgbIA2xQtsXPoQFOPm3HrrT6tb3EWLLxVD4tvJnURWMltNhx3ChX8sNjJBZD+VclH4Z0yZZFsZ3SNsb0ExcMvckcHr7mpX8AXRxL4enhlumYHyRceTJ2IdXdlII9ADg96l08O3fmcfLS35XXya+RhUoQp+X9d+h062c8c0Uep+E9Q0oyMFjuZJVuEJJG0HbJHDHzgAEcnpkmty08LXmiedeapYavqcEmQ0Wn3KrJGg/vKGVnH+yjH/AHWNcJqWtfEHQLWWz8UnWJtLdTA4kt4XjZCMENOiluQcZ3Zpsmqa1HbW1vYRSXNm6hI4hPNctCvQByJAo9gV/Go9jWnH4lZ9m2vvvdfezBwb0VrHV+I9NsII7WfSLDxLYz3RxbxJdszSZ5JaEyGUAAHOOncVlX1vq9hpgn1l9WtbFzsAkiWOKUngGRi7OpJ4wyj69qw7R7C0v3/sjUYNCmkAFxPfXK2lyf72woQGH+zng9c1HqOoR6bi91DXI/EE0THybO9mubhADwSzNhV+gJJ46it4Upxaje/qm3993b1bBQa0Q7R5Xaa4hn8TeGPsK8utzqHlRSkHdtKDImx3wMDsc9Havq01xFLqTsbm1tzhbqMOoYtknyYGX7gxyV6cc1xd5rLanehb15BbySbni023kMcRPTYrMoOBjALdc5Pate18L+Ovs1xJp/hp7ZoSvl3VyZVbaM4PlglWGMEg5ArqcIwfNUdn52X+QTglqy7b6hbXM0N3YanqVjeYac6rceY6yYHKRDbye33gOO3FZtzf2LWMN1FHrX/CQA77iWeQPB5e7GeDvy3YcdTycV0d94b8Z+IsN4g8TwQTIkQh05rNkNwyDoq7F2jPTCnryeKdP8PfFcUKvq01tZ2aqSZ7gxrHCP8AbYYwv1B+lKNakrc8kn6/lor/AJExt10OWt9S0r+3o9l4JHmk2rBa3BHkkgAEyyg4Xd/eJ64yOtb2jeM9c+HjXlkYY1umuP8ASY76PzSWwPmUoQcYOR8zKAePWr6eCoNSFvHf/EPw2hiQrGllbwEsh/vYwc/72ce1auk/CnwPZ3TG88SafdSyIREoCxqoPfAfBP8AnFZVsThmuWpqu1pP8bJf1uW0uv6mh4V8SeH/ABTHNca74xg0q4kcS3WnQY0wO2MfM7fPIMAcq2R69h0sN14LjcQeGxHqc5GWe1upZwAP9pCzOfULkjvjIzzVx4C8DXqxyx+LkjEEgY7p4CokUg52uCO3IIINd3p9hC9jtg8c3bxxjbutjZIifQLDgfjmvHxLpXvCUrdtUl90dfz9TGSs/dMy20C61OcvNHqy22/dte2tLdCfVFCiVe2CWz6irJ+GHhXUij6po11JNGeZLm6JaQe+x8Y9uPer8/iDR9OVEm8UzzyJhSqmF2kJ4GdqY/LAp0ev2d+f+Jd4gJbbzCBD5invndjH8q43UxH2HyryugTqLUW4+G3gyeJIz4Z0lNn3WjtUUj8QOfocg96qSeAdJ0smbRdE0u4h5aTT7i3Qq5PUxMR+7b/Z+4cdFyWrXhtL+6jZotXvwjLwd9twfbbEf51nXfhPXLpm3+N9bjj6qkcVsuPqyxKTWcKlSLtKrp83+n+RPNLqzlvE/gnwJq6BYJoPCutSfNGFYWr7unzQEhXGeMgc44bvXn/i/wAHa94bhgvNV1aG/wBPQiC3uYwduCflVoyGAOemOO2a9N1r4aX99p7wLqejTSHc3m3uhpPIzkY3bzJnd/tHJ6elc/ZeFtf07SrZbW8v/E8ABiuI42t7aRDjlTvUSbe25ZlYZ6GvWwmKUFdVeZLo/wBG1p5JuxrCtKK3ueO3usLFJ5bafb3t0QScq0PTsFRlZuOeuQRjFMvbu4gghhvmu7bzk3RRlXKBT1IBc4+nX1zXS+LLvwhNcBNU0PxVoWqLgT6fLeYSYg8OzOHYdjvA5/WuT8Sy+Hv7PL6JPc2d4HDfYJLpbyN0I+8soC7cEHKsCTkEGvcp1eezUWr/ANdG/wANPM7adS9rp6mYr2a3irI4nmzvy1ukkfAOMh8cYz3B9Kt6dq8U8c/2zT1kt3Pl2qWMUkbowHBB3EMBnlWzkdwcVHqOtCPRBpkuhW8eQZHkv7NYn4wR5Um8HnP3fToe1Ytve2s8RxILZG+aSEyMWPOMJ94/mc+xrZWnuDnzu7ujsdN1VINGSC9vNY03UNxaGVPLltgRxiSP/WRAnuSwPUCtPRfE87JDY68bO4tMBYbyJCJoCOAPMQhivPIcMPwridO1OK1hu2lMclszIDKbdfPjw3WF2Knceh+VuOoq1qurQTrFOmnXItowAsjtht3qXCdT6ZxWcqSk2mv68ioJSbTXzPZdE8Ua9YXUDDWbG1sSMLIgW8t3IIBV1iZ2RsEH7w47+nZ6V8R7tPOj1KCwuHDFYprMukDsDgqXYHa3I4OK+dk16PQ5HbT9Sb7RLGn7yC9kt5InA5DKyjzOuPT0NdlY/FKztGuLm0fxBb30mwvFLfrdwSkAAku6iVTtA+4ew4NeViMCqj0p3+5flr/XQwq4dy+Ffoew6n470C+s7iDUdLkO1wrreRqYt64yC6b8EZGOMnPHGSCvnfWvG15dXUtzFHpyWzSNKYXR/LVmOWIVmUHLHcQUIBJPXmilTytRXupr/t6xzPDyW52rafdW8X+jXbKV4BlTzFxnpg9PyqK0k1uB9sk1k0obcJEfyEOe3yhjn1+X8q6LyWDKpmSRE5CEY/Dg80yWBjhlWMQlcksnB54wDyfrWjcX8STOxVehlReJL6zv5Ejk1yzuC21jaXP2i3fHOQWAzx2xmuu07xlqep29xFFqUkpEYV4wojkj7HnbuB+mfwrmr3TbW9t44ZEeWFHLiNz8qtjrx9e9OvLKJDaSosbQq2dqt5e18cDr9aynh6U7XWv3jbpz6HU2uuS/u3ubmRto3RbWkLIe2VJOPwovby0hElxceYvmNtbbCH37jgE4BO388etczc6rq1pJBc6XdLOQdh8+Rg5XOdmcEMRzw3v0qWHxPpmqExTtbw6juPyRoU2nPIIJwee2ayeGaadtBRoX1S+43J0hha3UMYmTsqjb9QePwrHvJ2jGZMsCSCCQSffaD0/OnXdwkcMriKPytvSWP5H684ORnj0/Cs4Skx70aSJnOGG3BAx0+n404xOunS7hFc7l3pKQVOVdAvyAds54P0zVqd3nmkmkAlVcEZXdkY4BzxyfQfnWZFYzyP5UEsiyE7BIVBAc/dG4gndz04NWm0W/+SJrQ3k6N8yxFIwWOMkNuyD3PH51bgr3ubN0ovWRZOIUIzOWYgqfMG4e3f8AoOtVtVs4dVsZoHWa4BG58DDqc/l+X6VatvDeutK0O22giZDhnnHT36/n/KoJbHWbYRJcabcT+WrFrm3MciZ9QFYtjgdM49qSaTumr+oKdO9lJXLHhazcSqlou2PhWxuKqORkEcgkZ65BxyMZzralaQ2zXFloSzfYZEZRY2tqJcr/ABKAwIBOT0A61yk17cyWjjbrFvmPg2hWNiuQTk7hsz0+atU6laWkrxaXb30WoSW5jEjxuYlJIwWKncwxnJHQ+uTVSi73v/XmY1qbcuZK/wArlq/8O3t9OYEkhiuSQ2yW4YyOey4yR+ApkVqdGtY51dYZWma4chNzpIvDgqR5m5gpIUZGQDjnlj27m02QRRt5IQnadpiViSOCe/XP5Vq3c0L2BMMV4JzGZEnuf3Tq5HLeUxBOOMjdzjtUtvZ6r+v6/wAzCc5WUX+RT1rTZb28jksYiLoFp7ozoFYRtyrb0xzjJPHU1DJY6hDZlkQSj73lTurJIO2Tgkf98g8VowTaSs8ektI73d1tbItAUcopOeSxRQeCSau2V7dXZmLfYlvioPmR/PCGIGcA8HDDGeOOvWpcmla2nn/X/DERxE0rdjDguZtPgaSxjvYIiNz/ANn3Lsn0CISCfquao3MFleNBd38V5sKkRPLO6Mwx/Flhz9cV2l/FC94v2gWfmybVkeCBSYwTnJIGN3fIJ4qpFYW08sBa2JlAO6G4VXGcnBO3JOQAeD357ilGovi2YKtB62OUh07ThFKlpcGKOUASI0cMivgdXVtwc9eTzVuzs7cXNvc28qM9qWMCNbwrFExxudYwNoY4HznnjgVtX+nWZuHZ7Gzu7IKQv2bcs6txgu/8A68Ffx45q3Fvoz+XHLZywSAjie62k9xsccHntn/CqU3Lv+BopQlrb8jQfxFrjBozqcqjZzsjjBY+x2gk+uD+NYs8lwzHdqerEAZZDqU0in/yJ+gqrqQFtDcXFvJCjQpv8m6jaZGXJ4+Tnd/ujNRqjWVqHkuACZFCoFykYboPmyw9s8+9EaKjrBJfKxrGFNbInFjamJ2nguLuGRuWdnJAx/Flicd++fSnx2NlDhEtoUXO1UVQoJPbaTgjjoMH8aSO1u7lTcBLllmk8tdyqTuxkgKBn35BNUdVA0eyC3st9Zl3wLgWIaOI5+85kKqoPYgHjrir96T5eYr3UbM8hhCK2FgD4Y2+doOOmHGQ3tUTtGEXbJ5cJO3Bc7CfcjOTx14qhCJp9QmtrO/myioxUx+WRk8Hdkqfz/AdabqFldWMDPcXsZjiJkmmLFyig852L3J7dfzqVDW1y/cW7L8k/mxht8ckZ/jaMEA5xjfhiB75H4VUv5LG3geacXa3HRWh8po1OeBgjJHfJJHHaoYtHE10IoNWjLNGy7YJQgBA35KN1YjIBzjJ5q3bpdzWD3ErDTkeHy7i5BWAgZGEO8H7xxk85O0Ac8NwWhE5Qj/VitpeoeJ0gnutO12KGz2bl8qJF8vC5YFWUICcMc9unvWnp2r3Os2at4gvpbiXyd0aCztZircZPMZ98Ac+tYr2tpfTW0MMNtqPnh5ZFWZkRdh+ZVZlG+TdhtuPu4PQg1f1Lwxt1ezuLOS4vPtMTx/ZgDD5nGSGII3A89DnpUzp0+qSfoun9eQnGi/K/kPt47lvLS1/snT7cqZbW4luEt5WyScvtbluRgLxxk9TS+H9e8Slmtv7avdTMT4aWxHnj8TtbPcHnjFK0ktnPi08PR2mmxkrcMNiphRgKD/Fhsjqc479KFlWw0QW1leRwJFvb7PbYmZmb+KaQfLGOBwMk89KiVNS0aX9feSopJ3Sd9v61N628V67I7ol5dGSM/Mn2ZW59DhOPxI+tXtO8WXsBa4JtSs0h3lrVk3MB03BsZ9sGuQf4i6zYwndrVmsSqNiC2Tpjom0H24wfrWtp3iuxivZNV8d2k8sgiW3juSVe0iXJziM4COxPJO5iOMgDFc88O4r4E/T/gpGVWhKKu6a+W51dz4l0jWIlg1jRI7xAflEiRzR5/4HjH5VnalD4L1UQ/bPDaxtA2UeO3iGD0/hOCPr/OtWxtvA+oMq2P2GOaQ5HlP5Tlj1B6c+3WtmPwloigFLTqME+a5LfU55rj9tSpOyUo/16nE5U46ao8r1Xwz4OldQ0PiG8jLcRSXAMIz6o2cD321XXQPDcqJFBoltM0WNsbzXFxj04V1UY9hXstv4d0e3ULFptrtHZkDfzzWiYlDJtOzb2XgEelX/AGk1s2/mP6wltf7zxXTvB0T3Uj6do08fnsWYwwiFVPsWAIHfGfzroE8F62YwAmnFS+4i6neUn1Jyp5+lelTzRQIXnljjQdWdgB+tVYNU065OIL+0lPXCTKf5Gsp46tU1S0+bIliZy2RyEPgGN5V/tC30S5i4yrWCkqB/tEEt+YrYXwP4cFwk/wDZNqkygqDCGjAB64UHH+Fa66nZyRStbXdtM0f3gkynB9+eKwrjxS0UoEH2C85+ZEuREyLg5PzZDY9AQayU8RUvZtfgZc05bGsfD+jEDOkaecdzbIT/ACorltT8ctBbfaLSK3KlvmDyFx0x94cCihYfES1/U0jQrSV0jiEYK4kEbFgBjOP5U4srsqyHMaoQq9Mc+3UUl0QRGgAC7t2MdT6NjniiC12CE73C5HLnOcdMnrX0Ttuath5SbImQyMy5LKgyO/P5U2+t4pbVI5o1mWLBBAyVHr7jH5VIULeer7kBwj7JMeYmQSMjpyAfyqU26SJmWNccgbzu2n3Pv61KlrcOaxRS0sDLO8EXlMUXMpXAkGTwffngnkfSmtpVvMmzyF2k7w6qN2T3x2PHSrk0bPFtgSIgH54ZiyDB+8FdeUOM464PtRYJEm2OxeaNodyjzGySqnlSTweOoPB6iq53YtVHF3TM9dKklm8xrl1ZtpS2uRsRgDyQeofNas1hbPC8UrlbkICu/kknnCjOWA9e1WpFF7pUsLxwzKQdySIApHXDbiRx65xxVLSpLTVbQYkRZoV/dzx5CsvVcYxwPpg44yDWbm2n5FOrOWrexmW0+pvfC2nMphtQZIypWNV5ZcSnqcjBzkk4A5raF9bW0chthI095wJ5InMCkKeWI6HgjPTdxzWVeWF7cS3IeeCQWrGQm6k8tiQo5z6EHjn1qv5l7PpbahJKktv5ohE0MyleVJG0DIZcdD+FFk1ubOnCpZ3RrafNZ3AW3voXt5JECDbhsruDYj4BPIGR1+tWXiks5IpdWstSgjlY4t4TvL/PnaZFICKcA44J6E9aoWyQ6Xpket3lzHa2csmLURxCWVpMkbAfX5ec4xg1rReKm1GN3tDM6LwvnBIgJDxng/MRnPJHY1MlJv3P+G/rr+hhWvduK93YwtSee7vbqZprqK4uCxFqZPJM/OQnBHYcA56d8VpRaTC4VZ4zZj5Z2eHaC75y0TZBGCPlJUfTHFYeneFYVtnlvPtNxdLL50bXJ3yRsrcOzhiGOOhGOPeuomimhiaQ7GhY+WXLg+c3cgY6fTj8K0m4xSjFjnUcny03pb0GzWNj5hltrKZVVDlFu2bzNoO0OGblcnuCvJxg1mW88166pe28vlSyIzhhtJKZw2YwNxIwMNwcAc1o6jLbzjTWeOWGY4s4rhJViEUhJOyTJH+sJ2qF5OTnoKpaJb3jeRcWaXtjGWeCd7gNC+1UBX5G+eUFiFBAGOT25zjdJt/n/X+ZMakLPn3+ZYt0uJLGeCIzaZbSS8japOc5UruG4ZPOD9O1TxwavpsM0lw6yzLGUtopGZFlJHBbaMlc9cCszTr/AF/w/pzrf61d3kaZ8pBArOq5ztOc7mHrUNlp1xdXs+sT6jq2+8G9LW9clYMjhQvJVfQHpVez1d7W/P8AL9RSqSaaaVmdUHtRBBcyyJp5mnW2xOh2tIQMeWwySCc8tg1DOJPOeK5228eWVkdgoYjqCc8//XrDlZdItEvtSkYFpBErRE5ZieAuRnB9cDHrWeNVtbiaRr6+vYbwv5VrYPDI6yLuT5t+DlQXAJ7YbrggCovdar+v6v8AkQm1u9Dpbq6eKWK30m+txD5RE8FnKkuDk58wdCeQBjoB09ceWHyo7Oe+lTUDI3kzRzxZjkkcABmjAwo4zkjaDnkVDpemX72sxtbWNdVWd7YxXY8uGCdV/wBV5wIMm4kFSqiuj0bUbWbUbvT4ojdQWMAiN5J5hLzKxWXc7IFJQg5UMc8nHQ0m1Be7r3t/n/XfzJ9qov3df69RbRLO1uYQtoTc25KzpFJhlHI2gMcKMjt121kzTi9v3toLWX7JHEWkmdcBn3H5FXHIGGJJ/DPbXtrdSbibcNgfG88FyQRk59B9aoyaTPpV5dXWjpDbyzL9nE8hZU+bDESoOoxnBGSeM1ClG7vudEZWd76mhZ6i8EFw+nWFvcXSKjgDEUchJwcuBwwHPTtSala3MmkyXN9ei+aFiWeJRbk7z8sRBIBPbcSf5CqUttd2d+iyROWk+8yyBSp6KFzxzzx9OtWis7mBreTyxuzPbujTCUA5wF3lVA5z97H8O3rUtJNSRMo8suaLIptJtbi7tsaYfJgZZZljvcRynGcZXG5eSO4IPIzwKccURQtB5E19FJK8KNCEETsNu1G5Ea7Rt3cnGeR0p81zJPf3dnIbpoUj8zegVYhk4KDByrY547HrnpNbaPbPaW8FpA1vaQkSp5blDgdAuD8ynPIOc56HrVp8q95/18zS6teT1F1aySe1inu0mCHiIqynMuOQAACwz0OB2PJqtB4cur3QGS71rT1mh8uS8gDbQmDnD7RlXUn7nr71bvtEgsdNa5tZYUnR2ny9wfNkV8klW7MCTtHXrnmq3huytY4fKvYIv7MkUl73eqpE+4JHETnlm3cEA49yanm933X+H9f8P5i9tanzJ7PsT6bZXX9n3MNpaG4RXWaAlA0kDbivynoWAJwSTxmrl7bXel6A0E1r58+ozAMm0PHbybuHck53sCowvQnNZt0PsfhDxLbSPJNb/Z4YJ4kaV4MlsMVZV8xQysATyMLnjk1DZwW/heLVLfR76SFJ3MrST5mN0jIAXideOOFCsPlxuz1BTTd/Xtvon+t9v1MuaU5XWut/MzYIEt9QYSTW+k6fBPsxcwzfupBztQkkA9MZGCCevFSXtjZmJY7rVri4FvKHtZfMmnBDn721lEcRwx2sCeDj2q/NYz3cEOi2t3NqNtDbxkQJGFt0fJYGORcliN2CemB65rUj0ib7GLKaC2iPBYLuZs+7HnGecetW6nVv+vuv9/3nQ6ii05Pb+uoukafax2VokVkLETkqGu1+djyAGK56nnr3H0rK8TQQeHbCaKe2thcyXiQ2k927tF57EGMN5eCWAHBxkcZxWtLo6o8LSrNKY8Kvl4C/r0rUZktcER/PyF2EED24rHntJNO5zOrLu9TmtcsrcyXV9Ml/eW1soM6xKsl25bjYmAN5GQxzkAdc9RiXMU63H2dZJbKGJfNk86UzEc8MVTKg+w9etdTbQLbq0tvbmZ2YsY5pDhvqAR+X8+lc5q8N/dXGqX7N9gCqm2OGDamVKjcmXJ5Bxyndjx1ran/K3/X9XN6VWSeuxkw/2p9ttI4rm9eyl3BZJJFjV+RkAnqOo6Aj1JqxDcNvAZfNtVBjmRJ4mkZs4wFyHLHr8g4AqxBqc1wn2a1Jjlbf5gMh2epCKTkdfXA9q0L62i1HR9MS7WVZFDm4uY4i5lO4hVYLy2ABgn8vWnZWvH+tTsnaNuZKz8jnWtmm1WOWHToInjVgly0JKRf3Y1YEYcjnBOT+tFzqQi1CxQ2d4ZZ/3kcpjYqQRwckjjAJ28jnOanl0PS82Vuk+tRiLeYoVsZ1RC2Mnfjb/CvBOOPwNufSrKTXC92stzfSIVknupWMjrt4VTjAwOy4wK1tHt0/r+v+HM1WUX5f13HWGphZGEdvaSSlsAMMuDjP8JGD7DP49abd6nouo2Mja1oLGCOUgmSZo9zA/eVXDcenQ1et7KJf3NukKWqknyjK5KnvjJ7nnnmqw0m0Qym0aKFg5kkVHAJJ67/XNZqnT3e/lp+RLqwk7tWIbrxVZQJDHonhlz8uIp5v3qqnU5Vzs9gffoKKbcWsHlpIJgsGMkYBDZ7980UpQhHTlv8AJv8AzGpUeq+9mrH5UaoigMxO45AB/CnW++J2eUeYzA4G3aMHpgdxRL5DXG0yhcDjeeM88/zFOMWGdEYoxUFsMAcHp16fj/Km2ec3fUdAS8zOzEMD8owOnfIx7VNGEfEsfyIyE4TDAjsQPf0plpE7yHYgYDnHsB29/wCdOSUCKQxrufDMqFwoYhSQuTwNxwB2Gah+QmEQWQ4kbaDwM8D6jPP1Halmg2JI0qB5B95VGSwHQ5HX2z0qMzPLbKg/czFQ2CAxjPdTjgjqCRU6xDy0MR2xt03HJB+vcf54o2He5WkKTqYpVIEkJ3hl4ZDwQTnBP496TT1iS3/0N2T7QoMcoBJHGFPzZJOOnapFuClw1vKs8bEbsbdyt7g9x+FMs3/0iSEsWUHI2RBFx/d6D+f51XQq7tboR6k6Rapocl5LJcW1vu+2RCJZJZ0xhQew+Y9O+T3xSahb6VodpdRapbS2j3hH2fS7NYybe2XaFbaTgHIx9ckc1pWLSxXDTSrbfao8iDYpBTPU/MME8Dk5APPYViazoUt1dm6a8+0XLqSvn253tjuSg+Ygd9uTjpUJ3dm9P6f9P5bFUeXnXO7Ig1K3n8QXMt3ceTY2dnGIYY45x5SW6tkB/wCHzTj+EnB4OAM0+wttN12wNsltbQmG0MssjzLGhkBITcxGCDlVyB+YOaqWiahcPEsgMEbHJWQDyw+PvMAB0PqB9K19AsdOgvZJfEqi/iEe2C1NoWjaUjljtG0jAAG4Z5yeeaufuxt27HVJqnCye21ivEbvTNdisGjb+zBshG8r+5YDDsjBQChJB+bJ64POBt3WnyTLK1tDHNOnyqJJ9sLHI/i5OMegNR6p9o2Jf23h24uFcExWVvcJFDGy4G+aVyMZyAFQE4B61qyXaP5sNpEQq8A4KlvoT29/zrJ1G7NfP/g2f/D9zhlU193R9f6/yMqCO4gtvMuIbZ9QRfu2u7YDngKW549T+lSLfT28P2rWmijRUJY7+nt2H6VXv9QfTbeWZ4Q0EQGPLmUySuTgKqd/97OO3NV5bvU57ZbrT3jjeU+W1vLHuBTGCCcEHPcd/atVBy1diea+hsyyG7ZJhM8aMAVEaKOPrVHVtQt7JbyW6tryfy7ZminhRPmlPyqmd+Q2SGyRj3FRrbaldXcccErRQuhUBduFYDgKMHJ9+1VIdGS11mTY8F3dxv8AaJY71C8MWRjKsFIBPBwMngEdeUoxWl/69egrLqynZX7y/ZdOuryzS8kh2PZx3AuLpuvz7g3TGDnb3/Cm2GlPqE+pvpsk1zFYN9mmgE0pcyY3Dy0PyH5fYE+vatVfD1oZ7q6nWQF42iSeIeS0EZA3Kkgw/JBJY4ODgY70Boq/a7a6sdTWMXME7S3AuGZZN4QoI9xKLGfLXhjg5Jyc1t7WNnyu3y+fr5FOTWqNjW9P+0G1s7Nl0idYvOknkiXy2dsAsyggtIAMkkYwQD7WZPtd5dQJPNqDpABJFcGPzYQisAfMjDKfnXdjsMZI7HO07Trmz0yVNQhtrmMxI0E91LHJcrKeGCoigBByAeWOc54qefSTpssbWM1wlxcXH2q6tZVbiNlw+CThD8qgZwAMnbXK2vhv6df6+egLY1hqV5K0VpFDezvJOyQXDWsRRYVTcJCo+fBwUB9evrWXdSSXeqG10jS7grBF8rTKokuJGbHykNtVFAJOV5DA54qxciZLe7u9Mmls5JWfaDdPMsbkDIMeQNvHyjsMgYzVYy332yVNNWK4hRobqYSQ/Z1CgEFMg4ZiRnaSAd3PSpiktVZf15af1pYdOMo+8c1qVyuttpunwmd7w3wC2sduN1wiDDAMzjhMsSccgDpXVX//ABMLy6tb6MKkoaCeGHOZPlKlVCnB3cKQD+ffm9H1DXbrw9JqOnW8RsLybz4FeYPH8p2+UxRQUHLE4DZA+9iuh8IavZ6PcxWss9xf3d2Lm5jM6AtCEI3eTIQE8oDPGc5z1zW1ZyS91aq+33vXpa3/AAei1nPRyWxh+Hba41LWry9v/skdmql8xAN5e442xgjI2Dg9CBkZ7V1EcLyXWm3M9rDuiO4NNIU3xsjLmLnfuOCPTHPSsA6xY3em6jcaHtuXj8qeVJLlIInSZGcbRx85wX2gjg59BWtdy3SpGJ7iSeNLdTBfMNtrucBgqyn5XVuRnIA45HSpqc1+3T8P+D/kTOoqmiZbvbuC3RrfRDdiS4nM7NdhZljzyVjyDgdvTsOopIJWeVJbprdJLyL7P9gUboSFyT50eflLZOML9cZrOhu7ueyi1HTWSGdLmM3BvAdkUGxy3kqCP3h+7k5xz7VPoscMl7vvbuaK9xvuo7OAtCPMLfOC53jI+9n+VZSilF/8O/62ISSumU9Fj099Cn/s62+yfbrsQXU1ighgEcamLy5EcglQiFQI1IPBGRuNMsZXvdT1S0ni09rLTVjMnzEyMXX5NiYJK/KQd2Dxx7XIY3svDUepvfW+tXmqqVF684a2VxwGTaufmxkD+HkUlzqVzbQQxXaSXd6kQkkSytySUxkKgYjLEZwCea0X2rd/y3/y6dNCYSf2TRkaC/06MWonWKVQQih7Riv91ujDjsabcH+z7eJLa3DRlgqxRvjy19ST0AFUTrVkbiOBt9veGD7VJBIsiEIWwNwZQNwwcgFuhPTmkm1pzqIgsvKlaKMSsuTtcMSB82MNyMEA5Heo5ZdtPMqCcnaxseVEZt8nzlQCp3lQOPyoEX7pQcZzkGI4A54qlc3KPZx+TLZJdXCM8CXkjRxybGVX+YA5ALDnHUgd60bgeXKY4h5u0ZwgHmEeu3qM+hrPb+uwru9mZeqSi3vbOOOYNf3LhI4JJeXjBHmFVAOWA5+vcVe8q3CssKyDL5ypClvc46n8ajmuRA9vM1vdxvJlNwiYGFSMnzO6A4Gfw4qOWeZo4ns445FLASMzldq+owCSfQHj3q9WkNFO/s449UtWkAVzGxIkj3b1TBwWPIPzHb6/MK0PKEKRgESAcBmycH8ulOt44raMpbrHBBnds+6Cx6kn3NTjmbYjRsSdu2NgwB9D6H2ochub2bKjRSOW3eYiMeAshC+/HQ1n3tjbR3Ud/Ijl7eNwr7QZEzjhcc4ODWz8rCR0IkCEgqmC4YdRzxn/ACcVFHNF5dtcPDM6SorGGcKrxkjO1tpIyOnBI96am0xc1tiu5YQgSRmRioIDjDISMjIY59OOtVGgKEuEnXzMeaWYfO2OCf165q/H5yXSLCkZtirbjuIdW42kdQR1yDz0wadLEjXSy/Lv8to0xu2AN1IXOC2R1IPtTUrFKRiXdssyLFLC7qx5YcFcc9cHNFbDggFNzKR/FjbkfjRQ6s18P5stTZhWtuIwxjRAzg73PP8AOldIowwVFMhA5z9457H8elDXLNJLb24jKxNliV5U9Pz5qRW82Ms5WQoQ4fylKhh90gYxkHpWzve7MnfckTMMKx2wUg/MxJzzTEYwqRcYMnUBB1PoKqW3mTL5f2ma6YOd7zEFmJP5Y7ACln1JLHTp5rexOpIsoglKybUiwxDgHaQDkY45yKTTXmK3TqXbO486a5CQyoIMfO8YUN/u8kkfXH0FQXiXN1/qn8uF+WIGGHHp0680wIk6WN08rCWHev2K2mZkTLkh3JA3PtC9gBkjFPAJnxI5ZcdGGCD65oWjuKKurloxgwoskx3AY+bo3v8AWmXUMkkJ+zzMJFxjzAGDH0OT09+fp3pXIYeVIqyo3BySCKUZs8KIkli27R82R06H0qdd0PyJFSMQKZgyk5A2gYP5cUWatHbRx+Y88xADOyqhkI/iKAYB9gapNDc3X2aJYhLASwuA3YYG0r75znI9MHrVmaOZUVrWESKWRZCz7QikjLk4OcDnHfHWhpdxPQNKvotSFws9r9lkgbymF2u8Of8AZBA/Ice9RtfWmnv+/SKAEARyJGkYkJPT+9np2xz60691JIlERfnIVdvU+gAHPpSvNawu7SyGS7gjMhhhy0oQ8AhBySeg9aFHy0Y7ol0rUmujczvbIhiK+VOzMyy5z0yo5GOR2z2oaZlR2T96WPCwLvbPUk84AqnftH9qhBlMN48ZWASSNsiOPvMg4zxjnPtzzVK0mktVntrdbMyoA15eeQLOEIVy8pYABvl5J7D0qlT6r+vmRJ3emxp6ZfveQxGML9lmPzzTRgnA5Bj79c8+wx609YI9Qldr0PeCKTMSMilYQBwsfA9e57VHDZx67C4ubWFbWCT9xmQ7XX+F9qnDFuoVs7QM8HirKXEFlcvIyXIg+yFpJDM/2aFUYHO0/IhwTluuFOeKmTV/dWv9dQbSVySxszHpkbQwR2jykTbJpirJubLtvKfeUZPQZxjiprqNYtWlhtI7UPMC813tG98jCsWPXqOvTsKyksrO90+5WytJzZ6rDMb65Ev7toz99RuOUkcDClcgY7Ve0e60qy0qKG6ld7G3tvLBCZcKyFFznPITAzznBqZp6tXb7f15kJ3Zm+F7221G9vrqGU3Mb3AihncsBJDEQCTnj5m3EYH3So9q1W08fZpbe7MLnLGMeWEKrn5eOgwMDHpWZ4Y8PxWFtPY2sm12K+Rf2rsJmgAz8642q2Txt5q1ooniWW1itljhtpG81nLMGZiWzuI+ZiCCewzjnGaqTu24vax0VGlU9x6dCXTbGeSRxFDKog5hI24duvXsuRx9KTS2trKEJ/a/lPcXDlklbc01wx3+WhLEnj5sDAxgKOuIVijk1bGoXczJqObdNPS7Ecm5M/PHFnawwWyMZPJPQCsSDVIUaW4ttPg1CK+X7RpcFjKjShIlZXXyn2sWXJyxYtubAXAxS5XO/wDX5/P7mROXTqbtpfwajZ3V1aXC3ZnEqoIpVfygByWGQRtAHGM45FXFMX+hMlq91uRJliwD5SGRlM7IcEoANw5yRkc98e80GdbDMNzBYXV2sM9zaMjGSE4ycttAlcng52ADJ57xJ4evtS0/U7VYZxes7JNe3aGRQ3ynchDKw2jABBG0rxnAymoPXmsv6+/5fkynL3bpk9je6lqumWs9q9ubC5FzHbzGBrcsC7FJUt8eY+3ncGZEweM8ZuLFHZaYk2rgS28AEjOkSokk7AIdirkhjgfKBj06k0lz/pDzySRtIEeGKLbdEvHCpDR7jncBwCQfvc5DZqC/eNdahk1C58kWNnJcQ2rhmfg/PN5aqSW5G3GTjPHGQ0rvb7t/w+7a3W3Qz1SvfU29QsbCe5Dz2cR+zurwmWNHdHxw3IOG56dh6Vm64YhDZaNBctBLJamK3jtFkVIZdoaJDGPlOSGxu+TCgY6U22ea+gnk0ot9pOIPJnR1RCDggqeRkZOR1z1PaTX/APRI7jUtLH2bV1jVI5svmYofkjkwR5gPT5yQN2elRGPLJK+v6+fluOze5Dqdj/YaW+t+LYFtNItovLurWxtxcBw3RyQN8apgE7BySewrTgvtb1n7I66TfaFo8ckdzH5NyouJQD9ydBnYu3lsFj90Z64qaN4sfxHODd6bY2moW6Il2yjzzC/XygwHPJPAP5d3LHd2WieXa6rdTTSAbZLyQyPGuMFGkKgsSedxHoO1S4T0jUS5vnZeluvm76W20FJOTu0WNV1C61LxK5jVV0yGHC78FtxPO0dge56nAFV4XFxeSPBdA21urRS24Q/67jBJ69BjpQlzJazqJLOeXEW9powu1iDgIAT9489eKgHnG8gfUtHjhm2F/tAPzRHPCOQQC2CDznHODxmrjFRXKtktNjS2lkGo6jbSaZFdT6be3UJh+1QCK0LEOcLhd2GWU7jgdcA5IFZ9/YXWkWV5peqQ6fqGlXVuZli2C2uA6Ku1SBlZTwd5ABz0BHFa9vqwOpX6Xkot5rUKSzHbhGJ2sT7kN09Ku6kRNMHlaC1OCYLqKFX+zOR99Q2V6dc8GjmcGlbT/hmv6RF29LnM6xeNckvdtMkMKmWS0jHmKojAB+6PlA5CrgZI6g8GTRIUF3NdRMzRSQrKrJCvQ9E3D5guRuOev6VDKZ9Is5SLi5nguWV1t2AKu5bIWPcM+XtHmMS3GPoKv2MN9c295qm6D+zr25/clJlIt40whAKsyyM5BOF4BHck0NqMbdP6/wCD/wAOb89lymtvdtkqlCud2GHr35pd7M7bgSq8+3NUbqOO8mMapcR+QAzP5mxWDZwq8Hdjbg859uRVbVJxb31nJLrFpb6fArteWryE+ZGcZaPaCzSoxHHK8kH1pKN9jFtpXNUtJ5iRRIcMpbzsqFTBGF5OST7DGATntWfHHFp9xeXVxKizTneQEVdiKvJJUZb1yx4HSlmW4Equ8d1+5MkT20EaMznbnJ5424zgkD35zTrnUdNhtJTEsrySoDOPLVVWMj5RI7HIU7uGGe/ynFNaaLX+v68vxByKt3qGmxSWn9r3EX9l61EkUC3EAMErP8yv5mOjDA5OORnOeNa2km+0TxzlIQpPyFBtXn5eg4H0rlrSwFzf3cKf2ZFdTKLgCB3mCBEVQVDkbZg+0qQgBTjCsMjUuorx30WDUdVvUvbEuTIZR5kyMTvjcHhlC4UFstjJyCcipKLsl/Wn/DJ/eD0V1uWbtrm01K+vnuprtJVUx2abVW3AHIUe5y2TjrirCS2n2Sa4fbBGVMskrgIoAHJck4GAOTnt1qBoLW2uU1SS2l8vzfINwCd0KN0kkG7YFXu2MjjOeDUF9rkUFlb3FzZvb31yQj2aRCVgSdpyFBVlxz6bTn1qUuayiv6/rr94tdi6oC2sSQKhjVFEYZyqqmMrgnPy46cYopi3Ju7m1sLO3kMkkZeMW0BECoAMKXACoPQcZ7UVjOrCm7TdmVzGVHZwNFOAPJeRm37OCxJ5JNRzAGznS32b4wfLD5IZgONwB4FJqcwjhZ45RCVJUFu+eMckc9vr69KQ2sdpcXV1FKolhgW8u5XhaaJCo+cbQwzgDO1T6nrXY+7YpNoI7LV20lp9PVdPvYUE8bnaRKwOcFGU4XG3PB4JIxUx+3ax4qktZNJhh+zwvPI8Fx+4mWTl3RGUZYuOWwenJBNVLm3GqMLfTtV1KxS6t0lWe0UPO4jR/N3NJny2kBjOCxwEXkc00azb2GqQXUCTSwadpkYhkyrzQynbmNlBLF9hUuMsoBB/iqbSk3Za6207/Pvpb1MHK7u9y2tts0+7Gn+RAkLKQYCXb5sAFz/CSSfp+dOF3C7W0bgAy5CvuHzFfvADqcHr6ZFVvKWzuJ5jbKEeR5wVtyu87sFWKsfuruZcrySCCCDTUS2gtIZ55FuIreEKj/ZQwYyMCpLHkfdBYD+PHPAq1Z+f/Df5lqTRoly020W+9xjGX8sNyP4sHHGexpITfuJUurCaxuHLmNHjI+XJ2k8nnGO/+FQahbXlrc2FrFGJftlywjadmlJ3FnOSowgHIGeAAB14p5uLQR3FjdLfLJNIk0CxFvnIO4ZmAwqcAHJGc7eeajdJrX+vUrmLul/a4I3eaVvKJ+WREIAXAyGPQnOecDqPrVTXdQSzjSG2hu5ZG5It4mZUBzjOB7H1/WoGXIa5gEy3BDIywO4SUE85QHDEEd+nPvUN1rcVheRx3F032yCAtPpsC+YwLfdZjjC9D1PPWmoXlf8Ar+vP7ylHlka9rJLDpYuHTNwPl2YGfr6c1BeXCWOl3N9emKCIIHmeXCjkhQXYf72Bz37VZsZDdadZXM9u9tc3IZvsrtuZBvKqxPH3hz6fXrWZ5cN7eWd7ILqNmjPlxTZTEe/7xj7M2MgnnGOmaiNm9e/9f8OLd26jpxB9ttjfW8M8+S5kdVRoUUcuDgkYPyqMjrRBc3WojTLSztgkl5ETJDsPkjAJKO45HzEckHJ6Y606W8aW78sgxTzPIYd6ts2x4xuY8Ddxgnr2HFaLaqbbzbedYraaaAMztmSNFA+dFHAYc9ePoelOV7aK7/rp/l2G3bYyNFfWEuJ5Y2tYbORMQSQOdn3vnbZnO/AOdx7rzitC7vYo7mCOC8traxgYieWVgXlkIGEUn5RgnkgHPAA9YUmtJJ7fStP+yNDErS/Z4lA2JGefl4A+YKNxIG7qc5xE3kX0DXWoS+VZSBdtjKsbwEkZ27gCJDvGSfVeMdaUk73t/THUmpyulb+vzNa2WbzWuJYi5iQRgyMCrjuxTgDJHXg8Y4qGPUIIrLULiZ5ruW3k/e7j5kg3OCqDaoOFJCgc4GM+tTSW9zCLS41JZYQyjpmOOZ+DkDnaeOFz/U1IHW3vYVtoXS4uyxZ0ACoFHVm6jsBis7p6/l5ENdRkUsOnObeW433TRyXJ8xhHK+WJKgDhVGQozzjHvSQG8u0sJ7lzayEMXtM7l64U5z7+meBUWkQafDNNq1lbSM04cQpJAYmiJJ3naSfvMS2fQinaVJCstxDI8rTRz7pcXTvMBIucK3VdowVC8YzjFOTSvZa/193+fkJX0ZX/AOEfi1PxhehkvxvtIUur5ZgI0RGbMSBWDRMMsSynPPu1T6LJFe2tzf2Vu9pb6i+fs80OwxrjbghhlScEk9yc89aqW+iRweGr3TZA8tpeXEjTLcTFTcFzkRkBuAFAXauM4OcZNaIjtYbuyJ2nUVgMCQ24Yxqp2k/LnGRtAB7DIz1ob3V7/wDA679dPSw7a3Fv5bm3t7q4jSG4hSNWCu7eZx/rAWPHA5A74qKwluY765C3k81hqOWj8lVjtoQQm4OcbmaQAsrY/ifPQVLql95UtvFH5IaclAht5JWGOpXYCB/wLOfpVO3d2kMOoR3dxBjy0njj3lyc5V1XGwDA5JIOe1Ci3HX+v6t0+Yr33LcT3VxaI1zaCxvEYf6sDdMAc7sEn5OSADzjrUus+WLy21CWJLkygCa5tgfNhC4OCR82045xxkdqbZXUrWTG8sI9N2EkhZPM3ryASQB2J4/WoLaO7hllv7a6eW7KnbOY8bE4BCx5APtnjuOtK1nd6f131/P5dA1L4efzmM6K1oqLtMcjGR2ycjpjA4IIPrkd6oXVwPtMIRUmUq5vJGyqpAQdpB4BJIPr07Zq9tdBGN7tcYwTsAJOPpzzxjiq+sxpcWF3avD9sj2LHJCjCMyBmCyYLZ4AJ7dAcDpSg0n/AF6f1saC6fbTNBcSXDJ5BdRbRgfvMclw56Afd6fmap32qXMd+oa0Z4XYsJSdyhQOcjrnnj1rUVVWyty/3Tu+b07dKg0k3M7WRvLaFLlGZZIEfcvU4DN0Jxjt3pqS1k1f+v8AgFJbjtKtLzWZlmiK26ROrr5i5aaPB5A7DODnv2qGGDVr3UbsPEZLVVBAQDbvDHO3+9gYqaA6i+iWM8lvcaTcvqbxyxfaZLkyHeSWLsCQvB4OAMYHBFdzcXkOm6bJduk0wGSREm+SQdflA5Y45x1rnq15QdopO+i8rPv/AMEw9o07nD6wDDAou96RSusQVUBb1IYH1GRj39ayYbI/YbwWN8q2T5GW3loHwB8pY4VAMfLjjnqTW/f61Zz3Vktndi8jvopJ4GwAQqFA6kE5yN4yCvHIJB659lbWwtjbyPd3kUMzMWupOYypz97A+VT6k/jXRTlKMVfT+vP0KUr3Zn+H72O7ZdMkgkkMfym7CYQvu4BU5O4cev5Vb+zXM+t2NvprWTaTFHJmJiVaFh90xBSI1XIOQeQMY5rOFjIXjuY3MHlyi4S4iwPMhDDG0g4If2rW8P6XFpml281tfTSabPCLZYxl1LeYS8vmZ5LZwR/s9eaus4xvKL1/q433FuTHBDAHkXzLgiMOi7cNgngc44U/41LZvFbSSS4SG6gXgnG5FIxkNyAMHk9hn0qtYams76nboIpkt7z7KrW+WKbFVn8zJGOSOmcYA5yal1R/s8CuLmOKWZ9sbFflAYbV4zzlmAx+fWocfssfM2rGbDJDdXtlfWku+31KzM5YRIWudvPm72+baASqrzndnjrWjNZylre4t0SZWZIpU+Xf5Z9icAc9euMAelZT/a4tUmjmto203TLAKJ1iVBMWJwqY55LHjAAwOTnFM0SOxk0yWzls9TeC+vlsp3vppbhrvcVyF+cnkKDuJAVVbgc5Je8r3/r8Olv+ALWFmXtPtJIo2kuDHPMxk+bCnI3ccgA52+/JxmopoJbPwp+6u5Lq+Lu6ysiRvFEpHy7ucAf3u5zwMUWMQldo3t/mgiZYrlFClFbjCAdMcgnAA46nNTzm1eO60uUXTGPYpEDeWZSTz8x6L1ycYPIU+ul+WXzu/wCvn5eYm9DPnsbttNA0qaaa+1CHf9ledprIM0Y2tJuyduDnC93zj0mn1QXVwbRtICXypuEAvFeaSMHBk6KAucqC2WbjgY4uWktgXu70RQQvC7RyySsUXBAb5XOWIB54IAx68ViQ29lZ2EDWdnKluqhIIbCJWlPzZL8HdLFudWYKccgkjNVH3t1qv67/ANd7grJ3Zqagsr2y28fnASqCSVDBCMcEev8AhRU0lxdy+VPEw8zdtuC6GCRCFI4UcE5IGckYzycUVy1Kk4NJT5fu/WLKV+xX0+4t/Ivbu5s/tQsQyMqEMDIDjfnnIDdMd/pWDd3sl9pWoJY30iy28iFrgT+SrORkxFgGbGCOi4bOBnk1pyWtrNqMhjheIiYzOHUiJmXPzNxjIBJ9elR3AthYrcQyRLaiRJBMIwHcqcoRtGW68A5wK7Ypc17dv6/P+kSkupnTC7lEd1bWceove2+XivJ5Ft33sckov8WOAepAx0PEiT2sdlb3tpqDRW8G1LjTrLy/LSSNNsiOAA24bkBJ5AjUcDitazMFv4gtd99tludsNuGIMQJDPvYDvtBwTjoOtO00y3GVvkuJILN2azmuZlM0zSb0cS8Dg5OMDoMY4FKU7dNP6/r7zKVrjNSMenQHWIpZ5ppEQJaonnNMSMqWU5A4H3jjGc9TzPa6ZP8A2nZxQm4CkSTXAkbzWkSRS6xAkgqokP3lyygbc4yaq6dp0VzH/aEMBafVIUilkDbCsRBUcngkdOBnpSRWa6Za3dnDaRB2ZX3urzea21FLSDK8YXsRgAHk5FJ21inr/S/DoNrQmS4a80vyIIZdMDSARzbQstxtb518thypAPz8cc5PUwaxcrDJLbWsUk7xRxPI8iCNJFboFckAle/f061avNJSC9a4sNGhu/7RkDT3KTCNw6sAWG4/MFVSWII6dCSKfOZbszfZJYxc7AGYoCQmOMAjAJXaeRn+kxkr3W3/AA2+7/rRdnFmJpd1bzalc26akb69QB7pclYoEBYRpEjKDjbgtICQWHbOK1bp5ksnEM1vEqEMrSwLJtbjJHfPbrx1xWXfXDS27WdgNskpV1jUZYRKcLwOpYjJ5xithXlllXcoMRTczK3RvetZx2f9f10NL2RKh2hWKSPJMxJYnJ4HLOT1z/Q1FF5kt7MYoGjyxKhxuG369T0PWqeqzQz2qQS+UYblxC0cjbd6Z+fAPXjPHerOiS6vd3OoTX8UMFqs22xhjYARQbQAGI4HIJ49fesnFqPMKN+Yk1BYpfLtseWVlyxaMMwCj73cKeDg4JGOMcETXjxwwRtJZy3aRFRH5a+YyjsT6cfiaIp7Z7gwNIjTW6q08Kvhk35AOcdPlPb60ahaAsY4zfWF5coFS7towZI0BLA4YEEE56jnt6iNmk/6/pFczGtJJaRJZ29skVlLhREq8lmYk7ic8D37nOfV3iS7k8H2Gl3l/ZytpSXGJIrSNZMEDKqqADkndnOFGOuSBTdTtI7q1jtr66h3XA8uOORSJndVLFsDpwCfrmpYtVnje2vI9Qaez092tZo43HlldvzhlGVYjjqMgjHrlSV0mvPvr219QjJKS0uYelLHcXt6l/eS3mnay0l5BJdrIlx58bF0iwThQkYPIUBuQCeK6EpKyW7CVIBE4eQSY2mI53J78HI9/aufm8MW2jW95r2m3MTarqly9xb+W4Dm3uCB84Ykt9foPWugmh+0FYHnQQQqWubYKjG4RjsXdn5gARnIwDkg56UbpNPT+v8AgI1rSpt/u3dEbXkskFvcWds91FKMo0ZDLtGDlecEHA56dTT7y8lOpWJnykADl/3yqhkOMIE2/MMZwQQB6Gk+zzWbssUanG7IjJxjBCIq9AcAA9BzVLVUigaJY9IuLq6nPnXUqti3tAvQljlmfHRFHJPOOpaUW1/X6mDNCCVpZbiC7QXd1ZsrbRB5JUMeCrHj7rdR9KW2it3vmluLkpHA0ioto/7ydghBiA/jIBycdPr0nkhfVrE2skRjS6twJkuFyVUj+IA9icYB5PAPeq11ZxaAlvcT21uYI0WKwupyXm3sDuO0DChiSTjr34FRzX91bv8Ar+rdBWurGle6m9npq2ekzGKQhlU3rBQCeMnPzO2TjHqQPasfRlmTRmjv9TnmlhLK0oj5Dk5GEPYbhke3bpSW2nrHqFy9/bQC7SYbJid5kiADLnJ4cEFiRgZxgZ5p8Mss11dwyQbYIlTZMzf6xnz8uO2AOvufSiKSTUfW+n9dSlDqPjmunsXFpummhcW2JysRaQkF5A2OSAeFHHHXHFR2rSz2yTafevcNGy27vcqyh1X/AFjIAAfMIPD/AHQR0pSrzeJmuhBMUhto4IZJGDoycs4Vf4SW6nvgdgKbp2lsupx6le3rzagbf7MzKSkPl794Cx8842jJJ+6fXNVolr6/8D+vufQUWiawhSFLUW8d5aWkW5RHL/rW6/eySTknO4nPWrDzhCoCyP5h4K89sbs9gPWm2iCztlWO8mmRMuXnkBYFmJPPpk4HsAKlAbz8hW2nruIHA9azk7u7NYxS0Ir1d1vsIdRsZNyP8xBA6HsevI5FZxsQ1tPZ2k6W1tJDsZsnfuKhQS554A69c96tM1ul/HG6LJdSlhFPsZtigZYcDAGO7HvintatcmdJY4zZBFUMB8wcltwbHT5dmPxqk+UFZLU6S21lLawsEaOSSKQLG9xFGWBbOBweevVj9ah8XXslu0ljb27tcPCZredn+UPnG045HHesDRrC8g0wRyXpeGFbhJrQnH2hZD8uCT90A9ufpVSztjCv2aJSNJtvLeziZmLW+3ACj/ZGOP8AJrKNCCm5J3t/n/XlY5407yJIoZHd7u7uzeSSFXEZUHyGCgERkYIUkbipzk81BrVmtzb/AGmWKb93GQjL8znnkrwQD74JFaEl7HDaSPAn2woVEywkOyg4JBHchWVsDkg8U5rmP7RbwHzDlWcAcfICAQR2yT/Ot4ylF3SNtGrIxJkSfQLOOdGtVh8tDGZRtQqSQS2RkjOAOhJFa1rpl/pctul1b25tLywS3u7JJxHbWPl52LBHtJZiWOTnFT6SgS7j/tFRLC8rLJkAoo7cY9x16UC/vbkKL5IYLgtIkotm81c7jghmGeQAcds9aic5N2W39fPS35fPOavKxQNta2sySxzx2LvdxvNOAoWWTAAEu7swAHHJwPep9Qt3mljt7rPkBjCU2gDcDkkg++DjtxiplsYbgSNcwrLGGVgsi7wcHI68cEAj6VHJdR3MbvBKlwVncO6OGG9Thlznsc1XNroVHWRS1t/PhtIJZWQu8LgS5AJDnKrjgbtqgZPUjPu2NnvBcXJm1PTJJbaC3BkO2OH52JRBn/WkqAW44K9atFhJci3CzLOwWeF0ViAAw3At0yByB3GDVNUt5NSkSTS7RGuJppJt8bN5k6kPHKr7dv8AHu5IIKnbnBxaell/XX9PMJJaFa41Ey3ui21qr2yyXd0sscikb1jjDb8+gYgAk4xnjuNLVLttW1IRafJHcWFkuAkEykGQgEliDwMHd1yQwxx1ztl1/bcqXSQyacYMRuygbWIKyKSeu/Kjb6LWtbx2lvmCzjggiXaNkWI0UgABePQADFOpGKtZdPzd/vtoVdJ3ZmzNcfa5bG+vLcWlrEs8lyilU8wlt6DcpQoFK4ABYnOTkgUh8++i+2WktkliLYm3nM4eQwMFZXVNgkjzjBHGMDOe0uJA19PcGW6kDORbmARrsRd8Ydm3AFHXIkXH3uRkCobePzbqbVYmihF0IJDJFsYSqVJZncjc2eOh6IDkZIpt9f6/rsZxupaGnJFPcxRzwFzYOu5TMoEQJxhi5XdnqOP73I44KY+orqNoBZXn2mMMJoYtuMB1DZw3B4bd7BqK8PH1XTqKLT26OS6vs195tB+djHkgeW+nVhNHdMWgtnfMnmQgA7sHgnOQP61a1GyhiisotUkntbYzrGiiRlWZtpIjbAx0VjzgcfQVJpKW1h/pV9eGd3O1p0k/dwoEYAnGfLwQSSQADiqemwnU1g1K506+s7Msn2ae+dllucDO50LHCdx0yAcjHX6By130X5+X9eehzc3RDrm6nmub6a8NxY2JVlZZo1k83gBSoAPy4GQACT9Kjn0qKVraxjuII7i3RLlWUbtjNwJ1ZgQWxkAj7uT3xiTT5pI9NiaxuY5bGM7pbm9LM9wrHGflxjIOQxyAB0Ipt7efZrqCa1VnvJbRoobQwkLMsTADkEKq73U7jgkE8+gk0+WP9W7/AC8xtaMmsZnh1I38MFzd2riO0a/E/wC4Uoz5BUngrtAJwCzMAO5omNpPYTz6xDc6naCcQS+eBmVt2Q390Rhj6EDHtmrlpFeyWlva6t5bXahpz5KnyYiDknnp94jqT15PNQG/Xy2XTovtZjnW3MGPKEOeXkfcOgByDg5BGOuajVvT+l69Pw9CUgvILtZrl4rmT7VcIHSdoxLa26qwyoUkZbazcEYycnOOZtVllVobK1gKG+J3yTQ5hJ4Z2k24IYqMDkDPU1T0u6t71p1t7lcXSl4YpAY2l2Ag4Y5ypIJzgDvUum6et1p9teveRWGlwATXUpYOj4XLAysflXOctnkfhQ48usunl/Xb0/EbsYnieWFIlFtM8sGoT+aPsbM3nJxtG9ONg5z0ViQD0xW5b+YLtIZTJC1uu2WKSNky5UHOCPmXDL0zz37VT8Sa1ZaMizabfIjXTJJ55R3MKsBu8pc5Y4A2IuBk5zjrkfaFtdJhu7VL2xsyRKG1UtLPIWbJMrKzkFicnkkcDjttGLnFK1v6/pf5Kw02zcNjb3V1Yzm2le5iWeVNygpH8oGWborYyF+prb3NCkId1wUx8oOGyR8p9+h/P0rlY5hfXkNheRzvcx7bkPGWjjwwyOQcFeM457ZxXUyW0rSRJlBFBnMUik/Pjjkn5cdcfyrGtG1k2VG7KguSu1GgK3E4YJFENzFFONzEkbQPU9O3WpbK6/tPUk06QXBvpwEkd1+8NhPyseoAHJGcEjuaWWIS28sf2qSO4m2hbiMKWhYZOUzkE55+YHGOlaWhpaWuoy3dxJ/pccTRQLIjNwxBLAdjwBxjgVhJpRbS16f12CTe6M6WeLTtLi05ZJI7xpxDFgGRgPusSB95QDk8jH3ugpLyFZrpFJujZoW27ZVSFn2HJYcGUsCT3xtB7VVv7W9ldhB9lummZDNa3bSeWihsltqYLAnPGccYIOcizfR3Nla28+pfYvtNtYTSNqVxF5McGQM4iDbtnA3cjhcA5NUkk99Xf+v6+V7mbdmNsI7TRPDUME8itLDJ5dsCg80W4wWXOMkbj+eKhlChrSa3ZLS6vJAjlo/3kyoCVX1BAyewGfU0otLZb2PVrqSBGKoZJJfkUrxhRnkBmYADrzjmpYbhYpb2O5+zebLKWKQkszIAoO4fwkEDIGRwvTmqe7a1e7/r8f8ALc1Q2e+m8sWkpFpfXK+U0w/fCylKbgWUgbwcY5xkkD3pt/Y/6cHgnvJJZT5kgjk8lIokwZCCOQvQEE5PIGMnLTfQWtvOwt5FCgLKhgJLc/LwMk+vT6etXNNFtda5bwX1wk2oTRuwUqR5cJKkhlzzlgvX2FLWHvJd/wCv6f4ilHl3N+yRorYCQESOFdgeqjaNqk9SQOT9ayb5pLu4idVQwwt+6DPnB6lgOx7D0qfWruONLhILgSxxsC8xITdkgbdx6nJ7fSs11lmj8uC68qVZtjOUyUCn7gBGOehPv9Kwpx+0xpaXLM8brPNKXjjQtyH+faxPUH/Oc57YpskqxRMzNmNU3bcbsAHn8f15qvI0wRXtok3o64eZfu88kAdTjp/hVkJ9nu1kndyzJ8tuzfInP3gBySfU+nFXbubWsrFe4vZYLdZTNFbxOREWklxgtgKuO5LEDA71YtprdleJMlkABVuCpx1Pp0NV71oFjaO7WEwh0cBlzhgQVx7g9PQ0szpFLFHJy9wGKnGCdvJGfp61VrrYpR7l2Ry6sJFTCrwoQDB7f0qnO8s9hI8W/T7qSIoHliDtEw4DMvf1xRI5SWKR7kQ2yZZwygiQHpzjgjrxjPerUbRGFnDJtHK9gB657CpXu2f9f5CaV9SOFi9gwKCVwmQRkbiOCB2AJ9en4U62RHWF7zy424MiR5wTnnHr7GqaWrvqZubqSadEdZYFcII4DtI/d7QC2c9WJ9qnLDeZlcxsoJwpPUc8D1pNdExW5r9Cxh3S7fWNPtIYo7kNp01smZGXByrDrnpz3LVXi1Bbu3EtiyOssYeGTy8FMjhipPr2pl55Of7UkEguUiCGRixKoTnlR79gMiq9rJDeQxzx3EE+3cqsu5doPVMMBn15FVGGl2v8v6+ffQzgraDrKWCF5IE8lLsFZrpY02HcQVV8987SAP4QMccVdRkniLZSIY/1wAYBSeW469emRz6VTjtSWkcXU5hZQw85sxqynO8HqDjA6449aLS7kKXbxmWSLLFpCDsmA6OAeCD2bvmm1fYu3S+owXMEt3bSSvHC672EbOAwBKjaecHouT0BPvV7UpJoraSW1t2uDHIPMiVsPtzyVzwSBzg9cVimRLtbgPfOYZIHjmU7VaEHOW3YJDY46kDHrUlq+n22m6ekWqQ2dlLKI7ZBK5NwmS2zLZbIx1Jx0HoKpw28vX/h/wCr3InpqX7qW6GqRqss32cwZVVtx5WUbkvLnOW3DCAfwk57VW10TQyWj28TqG3CdIoECZYqRM3Qn5FK7ueXHHGRbmvrePTRqk1wItOYK4m8vcjKeVYN3BGAMZz+tUU1CzNmby1jnubWV8PIkbybTjl2HZVwPpxjrUwUtHbbTb+tQjbuRG8uzrFvYC3lDQqkj3mMKCVJXyz3OdoPP5c1b1vURbzwkopWeMpKOVG7cwOG6KGIJyfWod9rf3toVl3TNCCEL4bYrbmxGT7LkkE4bHfFUNdkliu75ILe3jV9PWSGVvMlRmjJLK6fdVcP7M3vt40hFSmlbp/X9eQ9nY0tUV7kaTAqRYaZZpWkiDhRHlxjPQ4Xr2PvVW+1KLyLuLSIIYIbW7kkvJo0kDzwFSzyRMFIeXkYwSG6bhU+pRNPfXdmk0lrZw6fbs06hWhdfmaUfMDkbcK2RkAjpT4Z5LOwUWMljaqHjW1V22IpA2YHPzAgrwMcEjPNLSy/rfX8n8rGctVzGdp2q6a+kS3t1eT3Umn/ACrshYSFXC7cpnPKsCf5ZBro5VWFHiOcRlXkBAwDjAPr0Y8Y4x6ZrLgmlj1G4lutQ2i2j8qYhVSBx97ejg5BB3Zzzx05yW2EJNiGuVVoiZLmzIuXuyImwysJGXIyGfABPB4PWlNczv8A1+n5dfLVbOyINQs7iO4e6itbV1WGOJWkdhIcFjsAJ2jG5jnAOOOeMFLp0VzfJZak08kMohKuscakSBjkbyy7gRgHAxg5BzRXjZng516qktbK2jts35nRC8VqZmr2jqLm1+0ynSmmNr9hiVCmG5O4MC3PO5s85wK05rq4e+udUbTYIpEQWlvun3CWBcFNw42AMX4HJHU9KuajLb6ddCTzxcLKRGqxN5jrMTnaUxlQF53d/aqeoQQT2rEyiEMwYyxfeJ+p7c176lzpNr+upzKzCwivCdSnlhV5biLySiMSrpjqisdqk5PGenWrSRQ3d2zxG+83iCYMGjG3rujPRsZC+YpI446VALpksgloqyqFXBc4BI9c9h6Uy9v57+8iujqERjRGds8O69/vYCqD3PQZpOEm77B6E66pbLElib2Oaa0TddtNchpQTypkA4GV5HWrmmWv9pWU8jQ2/wBiLYEouBJ5qcfMTxznK456DHWsKxvYrywkuDaMHRmys6+UHIPrgsF44bBJHQdKtafqcU9i0fljMDYdYAY4wRn5cZ4wD049eM4pzpSSdlqU9rIs2FzFdOwtrZk06GOSHzRFmTcrFDGVODjgnPRh0qC73w2VtaTxJfFztUTxI6glgcFcbcDoODjrniq6Tz3U6rPFbx6fEuUT7OPkcH74c9tpAyPU1bgE93a293YcSMys/nrs3RbsMCD0yCCOlDjyO7/r1f5k2uSJpkM9yLq5iiFyvKPLgsfdc89T1+laDWY2RldrZB3qxzu9cj9MVVO4a9NK9oElaIJ9pcqCAPuIueg6ttHGSTT5rx5oV/s+VSVm272Xevyk7kPp3+btWMnJ21GOuy8NnK1owgEalk3xl0B7lgCCfoKgFxFNDHctM5dMNKgi+YAjptODk5+n5GpdSvltNzSK2EG5mXA2jnqTwDgHk+gqW+Ef2IPO0luIw8kjZCqi4+8fcDnp27mpTaSuivQZqglinsrhZxDaoGOyT7s7H5QWI6bScfn7VGH1S3t1mS4s7a9WFkuJUiLQ7sjJVGOdvBHJ6H8KLlUlhkWZAbOWMrHHjIaM9CW9Ppg9Oal0xI7mCS2tRHNp8R+zxKrtIxVBtK5PLehJJ5FF7Ru+n9f1/wAATXUrres8Eclit7PAJV2XNsd0UzNujdWxydv3ugUcfNkUL9m1FkupSINShjkitria0CyRsyH+BgN4UclTx6kcVEtnqV5ps4uxDpk08iRoNOlAeK3Vt2VyOcDdjPHzHjvURWU2baneQWl5d2cLhpWh2BYC+SicfdHHHJJHPWraXR67ff8Ag/MhK+rKP9oQXP2u+toLy90mZ0E1xJEpMsikDzY0PAiyC+4HHBI5qzHbvPdWl80FrDemJyhhkMsLNn5GY/KW6gnpkelaNnbQymS9tt0FxcutxKzytucYAIBbITgDgYAIzUNrIst/DJb2xS4XMMRI3vFGTnbgcenQE544pufRK3/Df1r+HQ2jDQl1ENcM9lHfNG8USGdYkAZ1bOWB7AkOOM44FVbQSabYXUGnqt1qcduQ0dtGGnkOCyKFyPlAIwNwOMnqc1fuimh30c2qvJc3k7FbLTo0Xcw/h808DC5JGeB1Jasy0sF1TTJNYmsmj826kkuZVkYKZFBXIdSN6YyM8rn3AwlJcn93Ttq/wut/02IXvaIsxo5urYagzfa1gCSW0RxEuCNz+WSQPn4BOccDNaH2O7hjSadPLDDKxxsNpHoCOWJFc3BeXK2ctw0FtHBKEt4redBvVWIXEjkkbWc5yBkAgepN3TNNh0y3tLZoIrV4tkJjh3BXGOMMWJIz9T/RSjbd/wBf16+puk1oi3/alnp9gJ7qfykycsFLhT/ebA4Hvj1qxfmRJysh4O1QyDcCCCRyOue1HzrIiBZIfLYyEJGMOB2OeucgUXbXF28cdxKFiBBG1cHA7n0x6Co0voNJ81ypA0dw80xwURQCEHT6nt07+9WLe5S4u5rAM0k9uELhEYhN3IBYDaTjrycfWoJUMcjlUMkzyeV5kzHupU7mzkgAnr0z+FWNiFQkUxWaFQD5b5498dj/ACpvU0m0Pi8u9YxNGsiKwJiKZXI6deOMVFL5cq3CSxoY3XbIhx8ysMEe+RgZ546VYuZW2+YUcj7u7lgD2BOc8/Sq0gUDhVPGXWQNx7cfz/8A1UkJWfQYLLTf7OS10x1itQhimjMxVxvHbnOOT06YzSwNMGVQUm28CUSbiQPXinM6M3+jbWGOI1Xefwxz/j9esV1HdonmCMRyHADY3Ko9D3z+NVe+kn95cY2LDfPETJKoOMkDByOnvTIgIIcIgKhsYTj6EgdKgt5bnzxJ/oqwFcFs/OWOACOCBnkc8noOtMu7iSHzruC2mkkCFDBuABYdcZHU8cn9KfLrYSbV9C3LHGLb7Myq1uVKeTKNylT2IJwR2PHIqhLYzpJOf7Quo7B8xqFfDI4O4tvP8IBChANgAHFaa+Y1okLxMjBQQxicHqSDg8jgHrx9aq3l1Bc3Utg0p85kzt8tiMkZU5wBnqfxpQlK+hk4xvqg1f7PpemTXLQ3KyRsPNmiXflTwzsi4yB1OOf5UyHWFjifULJLt4mxA8T25Uv8+0sAR908ENnHFVwx865gZLlGm2yvcx5ADLgBQSfQDK4wefeoZ9PkuFgWKSW3kspUmgJTbwGyPkJxjBYD2bvirUYNWl/X9P8A4YUYy1ibl5rF2rTQW9syC3VJvPu22Q84DIpUElgM8AdcDvWZFBb2ls2piS7lv0jNwWYsHuyU2qZUyPMwhUAHkY4wa0tQe0n0eSGaCSRpW2N5bMu+NuCDtwwwf4hyKqRQy2mlxxuwmkVtpLRAEZJCDqSTgbSSecZ46VEbKOit+qMow1sV7W2uoJLK7luFVViYuLckRvLhd3BJOOuMknmk0eygitFisHSKzhL4tFiVVJLblORkggErwcHdkipWEkUjFREsciDYu9mLSDk8dBweo7Zz2plpb3kd3eSxXQuIWx5cAVU8nIHHA5Jw3Oc8gYxzV3bVr/1/TOl236iXCTwWTW1mLmee98/a0iq6WxK42N32ttGOG5b04qtpSXEE8Npq0RkNopa3uJVR2hJUIyYwDubGcgADj6VahvopLjUILgy2ptGYrJIdglUKG3rjPy5OPXAPFVYXmWzs3uSoKqykKdxl+UZXJORjI/Oq1tZ/1/S0/PqZxjrYnNnIL37NHe2gnkjlmTTWsw8ToxHlSOq8nDDGQRuyQMYyKUupRQ2bIpkSHS7sWM4jvxKk4dQHD7lLoUZhtAbOWIzgDFgRWto9rBEzQpNCtpFGtw0REagvtRc/w8txg4B5wBVS6gubi6uLaZtZ05YmjWa5A+yi4kJLeZGqcYYMQzHnheOtONpP3v8AL8t+3W35YODTsy3b288V/wCRaXM18l2XuHnBeVdgwoRSGxGyngjocE9aKu6q9wI7bR3aJpHJmu5rhfmICr5e0r8ufvAg89+p4K+YzijOtWjPma06NK+r11a/4a3odFG/KO1jRrW4WSCMCBBdJc+ZFy5dXBzk5znGDntxxTLvzJre9itRDGyZYFlBWPJxnHTpnA/nV64ia2+3LDaOCLiSdkjUJ5sjHOVLHkMT2OOvoRUclsL+3WCQGJDiRo9ucHrzj0Pvjivo4S0V3p/w3Q527mTcRubaIxvFKSMBTkKWHUtgZxx0HWrCbgsTwxL5pXAO3ooP5Crb23kOQ5k2bNqxKRnP95j/AI/lVLyfssOZpGNkEMlxjLShx0JboRjsBx7VspKSJ32IL1pzLBDp1mk7bh50xkChQertkHHHAAH5datTWUUcsMt1cFYoiCP4UZs4BPfGeg7nsaSO5tDIIrJjBczbZpl2HcqHhdx5+Y4wB2HPpV7y0lwbpVebfvUuOjAYDAZ7ZOPSlKbjZbfmaKN9StcX6wC4FrDeXs0YUssKKpk3NgKpcgevU4wCea0nd4ZDmNvnOSTjCj+p9PzqpPbQSO004/fbdkb7v+PcdMr/ALR6Z61FpbwQWMdrprSFY+WNwWJDkkkszDJAJ4HWsmk1dL+v68v0Hazsyru019TjlD3Kk3DQohLSebIBlmI5C4G5QTj8M5qO8js9TluoNJmtPtfnJNeGJioZwV3M20EE7FwOMZAzgc1oJY3M+liE6hN57k7riBFQzAHlQMEbe2Rz6VHdWjNbXVtsktI7jBd7Y7ZZT3xweTjGfxHrV8yTunqv67fgSoKwuoILvTJ55nuRFC/nbbcBXk/uxFTwytnBU8cZ4xTdMsDHpkSzPeC7mjDXEsrKsnmHAx8nyqQAOFAA/MmTTyUtYUuII45EJ/ceZv2qOBuI6t6jJqK21C2uLm9hS2MTwShZZpgFVmK5OzGcY6Z+uAetTaVnFFNa3aJL29gju4YJriJJHbbFDuJeVgOFAA7A5JPHIzVfTTcz61eI2nS2rF0jFwzgidVHy8AnH8WV4znJ6mrUctm1t9ohVZFjVhvyApwfmVMYIGeDjOc81Wt9NZrVRCZbOZi0hWGQtsYgr+8BGGwCflzjPXNJcqTvo/69P1/IqSvokWLrWYNOjsk1S9t7WK8JUlnwHAyFA6Dl8cnA44zSq90qKNUvWZWUJ5EchMO7oMAcsT6c0RSWGYLC8l2yJHtEYtfNkcDn5jwq5OMdASOB8vCadqFtdQLdLFtQZS3kxvaZCMkoxwWzjBwoz2JXBLtZaL+ultP8zG+pZkmUujxzxtA6sDncVUDgtnhQB0556YqhYN5GtXKW5lguYVUAPlURG6beCNxHOeW7ZFU9at2llvdMa3T7K2y8nhitSzqSQyybyNitlW+UAkfIcr0oRr26a6tZftEPOUK3WX8v+IkkKc54yM+9EUmt/wCv1NqdJzWuxshpUfzo5DG0p+afG529eTz+VV7XxJdfZFVJNTSMvjypiFmAPALKc7Qx6ZP1AqTwQkmp67LY3U3lxWIW5EQckyRksiDJ525Qk92PoK9Gn0yxnieOWytyrnLDywMkDAP1AJx6VzV61OjLknG5nUqJOzRwJYXasbmIhmYDeHVvNGMglQuFAPHU9M1mX8Eqala3UKqltAZTLE55ZzgIwBB988jHbNXzFp9pPPb6RcA2Vo728dvA2VLKASp4zweDzjJP4VHw8TK9yzPJ+9dcZZQOqg/dXnGTnt25FbR0+Hb+v68jWnZ6tjxNbx6tLBIV86NTOVZ1JycYO0HPPbGRmn2dpIjQyXVxG0SP5pXG0u2OnHH8Qz34qoBtllvLeGCABccEtJISfuqcYAzjIA7Z4qKx1a5uWH2vTbq0l3CBvNb5e+CjY56HPT8M1Vna6/T+vuNXFt2LdzFcTi2eGWPyhKXaMJ87Y7bs/TjntTrWKG3mnnZlSRwF3iA73CqSoLdMjpjn2PPFSSxknnadrmWOZCd23+PnuOgHcn2qzcSSuxaXc3ybWEpwuScg8eg9PWh66JluDehVttauNQ+yy2sk9qzQsfN2o4LFD8kkZIbIyD7Y5POKNQvJGNkIbyRLyFS3lhQsF2D05Kkflgjn3qWVluIpY3tVlhMbKPNcfNJn7pyR1HUnjp15xmXmnXCxs3mvDbmUbgw8wE8DhT93PHTvj1q48t9dBRoRbNCxOpSQl7g2vkucsfMDrGf8/StO1lKhIJ43IIO1tg2kjquPXHPv+FVJY1BjYfaYbVoyrpgeVIPU8dasOqStGFMkXl4KSR4Kg8gd8/p39qzlZjnd6MlNoL4JJc20a+TmWFZMA7gMbyCTjH6HpVJYb2d5livBFjgrGWQuD3Vgc5w2MjpU1tp9nD9plgjVp52BkYglm7jJ6e/FTwRs8RaQBTjHyc/N7e1K9tn/AF+JnT0TuVLXSpYrONIJx5IBRH3ee6/7xY5PTv3qGC0hgml8sIHkk82RV+Vnc4yT+AHPbpWjJEgQmVZXYMOgJznqeOfxPSqhjzqjIXvHieLIPkoqpj0bOSTnkEcY7U1Ju92Up2ev4FKK8hudRnhJaK4tiQ6ucDaemPXj+VWjK8hQTSFgDsR93yjPQEHnsfaohO1xq09mllNGkAXZcsAUbjJIb07HPQg1FqjiLT7i8aNpihRD5PzdwCwHTjvitLXaS8vxNE4NJsgn1S8tp4LNGFz9qkeXbcghYYhtG2NVXBxySCd3IPIBrUuAbibzEvbpA0Oz7KCoRHBDByuM7/TPYdKgsZ5TKxhuzKrjqI9u3Gcgt0IIxxjsc9aspPNdKspeSZx1PDMo/I9vpUyfZGUqVpXsVtq+VFO0DqiNgSYG3cy4Kbj0JxnA7DnFTlIpEEM6N9mdJA6Rvs3KQQ2ec49Md+mKZJFKtxEIbjEe7ZMjAgSA52nKnA6jqCOOneo454BLHgyRRwoAJbhSjPk5zggED+Xelr0G2pKxlWa2jaPBFCki2cqxpFHIPJ2RDIdWHUfKCOvGPen2d9cXl3JcbLOTS2eOa1EBJYxtGAXOeoODwQCAo45q5HLbRxwpcywxvfv9mQZ2bmbdkL2J+8cd/aoZ7E3GmPAJJ7GHzmjitxhZECjbuUnIAOFIY8cEda1bTvfr/X6b/wCZMmoySLNsosvssIuPNncPJunUuzMzkkBj14Ixznb9MHNddOsLa9tNSmW0trN0GnXdvhZYVmUvJGhUE4LA/f5JLAdqfp7TPDFDdhZpIt8SuoyGAOcMAfv4PJBxk8datwCG+E73jSJEkb28sO/nDkZYkHO4YGDyRu4PelF8rd/w333X4r5sipT0TLcX2u0Ms1ybaF2ZkhiXPlwxZBUt/ekO05Y4xuYDjFFMkkjggOmwoI0jVQhkztI5Pytnk8c+mRRXgZjQrVKqlTdlbvJd/wCVNfjc0pU4uOpd1qS7ujOiW6v5dynlo0wV7iPgPvPYg5IXJzgZ6mny3NvBqMdjI7CWRDLjYcYBxknpk4OM8cHFO1Kylu7l5LGeGMyOI2kWENuQNnaDn3P0zVT+0HguVR31OQiTylVYgDI+4nbEMcYBG6QnGBxzmvbirpJf1p/X/DbcbTWxaVZWmaSWTy7QNny1jJfAHTk45OOeD2x3qVwWXYAyqedikZ+pP9egqmras+qxiS3s20pELOTISxlJOFVcfMBxlieecAdabJtR5fOuFMefnCKAPoT/AE/Cla/U0jfoLMsDiaH7NFO9wAjjgK6gdCfQAfU89O9lcEo8mIrcKWyBglfXntnv+FU7p7iytJGuLa3nvXm2w2i5VwG+40y5JAC8kcZ74HBSG1trW6mt/tYkZf384mcyM7sDtBPYcfKg4x0UAg1SStdD5lexTXUHtLm4urv7XE0lwba2ijxI0/TDR8AKMZyzEkfU4qxNf3b2IR7OJb0BpEtp7nCxpv2hmIz1xnjJ4PWr8eiNLcPd7p4tNh2yTQxnaZW/vMerdAQCQFwcA5qBLaLT7x3srcQ2rqqwIu6WbI6MQx6AEkknJLHPJquenLZa/wBaf1f1M0/fL4nKTYR41CKFlQZJV8AhcfwjnoRnkdKxpHuoNQvZZ5JBBIV8vfGqrxwFBzuZ+Cc8DHHGKoQC8kgtLLSbq2tYxKZZhbxeY7ruzjABAZuNzE1t3UwRhCYFcxncyoxLdO+37g6jrnmly8j01NlBrdDkmkLvDKyQgAYJIPfLYGe3TnrXNWk8X+kvb2Qgikby5zHvKyHJHyl8A4BBO1QM9zitKXZdPJBImzcPmEMW0E9l28EqBweST69qtuqXMbQPICyRiMMJWQ8jnryCB0JH0oVomijylWKJ9sUl3cRxzRR71ZEPlrn7pAPUBc/MehyQBxiwst1bQbLISllBceWVzIw5ABJxg8cnjr9KV1vFijtXS4W1tQYyhKk4cc4YDp659KrRJGsxZcKrAozYLFu33wMdu1T8Q+XmTTNnWGkuoGu54j/aEDl0AIjJ3DG1d3CkjKk88Z55qDEcwtbi8hj+2QjesQfiM455HbFZUtzpNlbia6kiskU7FdlYrkjHc4J/nVoiCK8ljuLmJoxgASOIdx9sEZ+nWhQaVkv67Iz9nGO7IBvtkSMNNPgDNuk53uTzmRx/F0wADjA6dKW8uILGN706ijxtHvea4j3Opb5mXj+LIwcetOu0SRpHtG3tKxMgJwyjGMFfQ5P4VnaRoEGpgaJpDrYxuB5j2x3PCmcFgegY4+n1qtLc0vmbJRjG+x6b4IsYotIj1BIZopdQjjnZJ49ksSFAVjYdsZPHYk0/W/EFvDPLpthsvdSGFlgSQDyAwyC57cchep47c03W/Eq2129ppscd1cxnbMxb5IDgEBsclsEHHHBBJGRXnUMLzXupTra3jxyzFvtEMm8TsAC7gL9xScjJyTtPYCvOpUHVk6tX5f16fP5HBTpuo7sv61bXkMJgsYo7IwtukkIEgOXBYcYBLAEHryc445qEyoAkkX+iHaUCIP3jH7pXs3b6dhnAJJBab4JoXVhCxZEZy6gkYJIP3jj+8DzzSXbNFYpNZ28crQz8hZHiyhI3beNytnkDGDmu9JpJf1/Xz/zO+MXFWaG2epJqLW9zbRrJb+WrQ7WDBwDt3NnBDZzzt/hPBIyLMMqQTzM4KIZNsatu2hwPl/AkfpVaPyrmNTDHDbthVHUyLJ0x0y+eetaNvI4FxJFI0jFihZUC7Wx1GB1Hf0pNdkVJqPuvchs59ob/AE1YwGLOrRBt3PI/X2NT3F1GEMUcbyTybljKHcWfI4Veu3r19PwqBJVmX7M0TrmUKGjyTtAyR9eec9sVMLiO4hYC3kyMoJY4to2k8qC3Qep6Umuo3ZspXEsx1WGzube7dyu2MwwkKwzksWPIHOMY/KrH2SGyaPMhgb5lcyZZpUOMLtOQQOe3THIxTF/s26tBbLZz3Mb8Pm4Kq4/uqq/MRz1wOtNu459ONvLZxQhAuH2De8UY+6EUnBAwBnrVLXTb+vn+Qm3exJmIyCO3iMLKxCyO7FX9ue1NiV0utzsIJEAGI0+Vx6/73q3U/WrnkxmBbi5MrSEBipiCsQe/Xn86S8eylhkuLcBGi4K7sDPvnGOfWle+iLU4vR6lYXyR3rRx25lj+YmeadUye2A2OB7nP1qxdXot42ZpkhcFV/eR5DFvQgkde/Fc7c6lpiRrE/2+a7dz80aDy2PoMHJ/Kry3EN5pz21zDfJEymJhgtHsbgghsEA55wKpxtbT+vnf8ipYfS6v80bdpeQT+as0pilVgOW2qp9lx1+v5VTkk+xi5+xWSMvmeZI7ttS5JBJbIJMYB4ZmAA469qd7plwqs14QRDHtidZWPlgcLn1UZwQe2CMYqG8M0sVvb6gkaSSH9+ty22MoQcqyn7+enPBHXNKMVfTb+v6/4Nmc1Si7Xiy+lzFbwxJHapDLJESI0mOwSkE4yVGV3EDcAeDmr1vI1tYySaq7MRbeZNbWoLuMDkRjGW56dzWFDDJLcSRW8MNrcSruivImWVERSAuFIwrkcYIIA5BPGNOS5ZdRleWRFVSpSIPuZWBw2CSGGOucHpxTnBbIyaewzU5CxkWO4zu/dLNAF3AY4JH94e+efWszSkuY5YbG/W2vbpwSkyr5Xmbc4KgEAH1PAbBwM1bvn869R7bTWASXy5pJJHTevZ0ABDfQgVWuNkdms32iGziU/LK7LnnHIbOQvB64x2px0Siv6+46o25btDo5bpNQEck+20j+bYFJkduQ5C8gAY9c849Mys8r+d5ULZI81RMvLhjklcD3PU1Bpl9bywo+mzRXkU0mxbiNchCM5bHfnvz19K0jbSPpsWnFHe3EbRSOpeNiNzEsoHzd8fKe3BxzSlo7S/r+u25Dkl7yRFcWdvdWsYSAXEIYM29+VYZxtAH3+vr/ADrChvL271ZLhBJJBZswWUOQLiM8bWGPmYdCjjcpHBwRV29sLm4nvpLWcwlQPLt7i3R4JVYBBGknLqynMnzrkkgZKgmtG0d7bSLiK8Rbm6WUtuibYXJA3c9iTzyeM078q0d76en6eXYUaikndX9TOa8k+3C7QT2ksh/exxuskUqnIyG28NjjG7p+NSQtIL8PpdvZFpELPuH79JOxZACGXseQeKSCG9mvAY/tluzcyw3UnOPcqcOn+0CR6jtVua5e3C27LFcLO/kPCkgDQkKTkbuZFGASgJIDZxgUPTRDqOCSUSqltcW2kSW0rqFnfOCkjKQDnHL8HI7Hp60VJJDMbR5pTG90IVjRJWbyc7wSWUDKnGcEd+OlFc1eU+e6b+Tmv/SU19+okqcdHH8v1NXUpfN1HUbY6tJDJHZksxQItupZwsqk/JuADcf7IJ92XkccmiTSyz3MkXkj95GC0sowB8qrjJPHTufrTLm2+13pkmtNiNNLBcRXn8UeDgoqkrksFxu6Cp4w80K+bFFZxR4jjjLgKiDpz6/n1610KySs/wAvwORRs/ImjnS3h/dgqqDC5OSPr71Wg02O08N3l/DeCC4JIslRRIVkY8nkgGQjgHPy9TkjgdZkmtmSO0/ssK4mjlRmlkyMDYAQAM5JYntjnrWcqagb5YLfKW+0osgbBt0A4SPHTPfAXP5mhRvs7dfu6Glr6LRdR99ff2MLaWOC2iic+Xcb5mlkBxgHc/8ArG4BZ3I4GSDmr83l6fM1y8uE2s8mz5jJISBuY+vYD+grPu7JdPjD2sYlv5cW8ZlhM21C3zFUHC84yxNaF/cPFBBZhBvRsxxsAvP97bjj6mqdtLf8P+YuTmdokviTxQltBbaXp9jNKZim2GLDvK2Mnecj5Acbj14wOtc5NLcLehnjYX0svkmKXn7ICASiFhgJlTtRAx9Tnk2o4DaM731zMZWYKttDGXLZbA3SthfX5QCcdOtX1tjBKlskEVvIyl9xLqxHXcFIziiChTXur/g/1/TK9nTptWd/66GZDZ3sDEXd35Ykc7m2lflzkKFHIwvG48n0FacYiSdYz5xtVyywBmRGz/ETj5uncnrWU08sPnLNp80kSTCJXcKzXGQf3iqp7epxUcdxBaXU8EM0wuZxuFrdTbpABxuAA+Vfqce9W4N/8D/gf16GjfMjf1OUvExV/LbcVcKcKB3y3fr+dZ17JBPbrG8iG3chEV5Y4iCTyCVALcYznkkD3p0Vo0srvdWMDlVwWhZ23HHAJXP6dKj1SMzWaJDDYbs/JA4LeSAOp2KcHk49+uKxikrIaSVktxpso202VftUkcTn9yyZBx6IMgDtyxz15xVrUYh/Y0md9iDGFF1HJ54TAGMvznODuJBye3SspZ7oXCWsk009xID5aywERgdyFGdv/AyPoaffW2n3Bks9XXzLeHeJXvTHBGGjwXO1nUlQHUZXI7lj0rTlfMrvz/r+vkTVlCO7Ldhql5eWKy6jYwwoCQG/1gA/h2scHGcEZAPIHFMnCa8Ar6f5bWkylLi4jQb8dQg/h5xk/wCNLejzNXS1vhbxWUANxHa20pMl5GoXDBFOCEfgjJzlcdCKv28rztc3K+S+5AQoXBCjICj05zk+o9jlO0feitf6/r+tJUlLZWsZU8Nxf6omh6KvmajJC0827CQxrnBd25J5YfL1P6125ax8FWFrplgFm1a9BbeVwX2Ab5X9FXIAHqQPU1r+E9Cg0bT02rG99OqtcXAHMj7QDz6cDiuR1i6trzW7/UWZHhUrawygc7EB3AEnn5y35CuJ1ViJ8i+CP4v+unZGHO60uXoVVWASyqtvGscpZ2JXHmEnczEjuTkkn6VUkdrS8eaF38wPiSSCQZBBBCbQegHOOvpUbSTfaVubdpFjlkMM+8OCoVCAAvQdQCBgHOTV+7SNrMxRCKB9wZguA7Hb1Pfj3rqtY7V7unQq3E8k9w9xcXMyTsejRkhSenUjacen40k4H2ZwlyJGwpDRIMnB4znGME5wP060zT7S5R0zcSSWSxLCPNcbiwGAcnknPJ9c1HFMI5pdyvNgqqgnhvZgATj2B5p2S26GkUnoi39qjs/KM9xGtxIA0hnkYDyz0JPqeuB1HPNTWlzC8DmHUdyKOJRGWDg9OAB1qhIksQheRZLf7UfMZ5UKt1wCVxkZ56gcDip9RgS2nmaO5glAjO14Ml5P9kgcg89/160rJ/1/wAdOK3epDFJPMjrIQAZNhl3bBnuc9zz+H61JHaWy3BSeZ9jfeeWEszAdC0YxkZ6Dnj1qKeJVDT5vYYxgwwsgjkjwMFTyV2k5OeuetNglmyH8y5ifHBN7zjtwFH5ZqtXsXH3leOi/EvNJtCx7bZo0j8thGWQNz3XA4wc4IyenHWn28ccIMttMGKj5wsapgdPUkDnGP5VmJJcLLc77mSCCFTPdu5MhVAMscZOTjsM8kVa0S1kun1KKa3aKNJjHb3DpsaVDk7gnKhACqgjkkMxxkCpceWO/9f12MpuNN8r1f9bixm2S3u5NcvXS3kmVvNkcRRqc7VTOT64H/wCunpbq+oziYeZNA+x0WSN5FwBjcxUt75rRnh8nTmhaGFE++J5FWUR4HDBGBXIwDuOenas67u7FmGo3v2NbhRDFcXsNkVe5LnajeYOM7hnA4HfAoj72tv66bf59jJ1HF+Qmo/u2FwGQgFjPyWIXHy7R25OOmDzVaK++2TlNO86VQoBJGAvrjjv6nP4VW1E3lvP5sF1ckADy5IMldv8AdCL82efQ+vIqWGa8tTJJfteoAm5VKYLAck9ySRxj3/CrUdDqhyqF73/r0Jl4QW4iFuiFmXyYSyYPXd16nNNubdJ7dFWWLdGjRhslQwPODno2eR2+lLa26vDDNbz2yWtxiRiWEgYnkMQTuz26cVJe3f2eZ7ee1htzgHEaebhecZCn5s5J9MEdwRSer0JjO1lFGfCwjgVJ38gox+ZU+dcqeQOhxxwT159hJZ3GyKNXa4eVQFEsiLvPfdjBOfpjPp6Ns4x56TJYvBHj5irLIxb1Oc7R6dP51s3MkGn6dNdyWDytjczPETIFx1TaSd2egGS3vSfbv6CqOMXe39f15mTe3L3sUggDlIzh2lJhTcf72M89eBVaLzROI7tLMzMQUWMFh+eMfiat2ksENgXeWV7snEYLfNKo6HOF2dewJOOtIlzd3a+TNOI0U4WBIdxY9Mb8DHTpVNaW6GkJSV0lZFS6jhjmmcW+2aJgkrzYfn/aAHA/OrNlbS3l2II4x9okH7rbyXAP8Dk9B3AwfWmi0SzS2efSWt7beVXfLtkLDk5BOOPTIPPXtT5tMSO+iu7SRriTO7a6kEKP4SCSc4PUDtzRdJaP9f1/rYr2iel/vLFu50aaYXEZfLiTzN5cxu2dz4z83P1HeprHTxbg28095cR/cnPmbWZhllkHTkA4Ht1rAeGdb15xcMZiBiKRmOzHcRscA/Qe/WtWFbWe2C6tLKiORIriRj5hznJKnJHTofwpSXW5hWpWXNbXy/yJZdPuIohLdRRarKqqFlaERGUjqCASqnoM9BzyaU22nQ3cAgnVrxnaS3hNwscjED59p6AgdenTFZevanFqF5DbW32xZIh5kd1al0ELHIyWb5G4yMNn25xWnJqEtvZRbrQyEgB3Y5DHAG7OOcnnihppK+7+X9fh18mZxp1mrL+vvHRpOILK7sAuoabd5Uzwz+csrAEgrhsFRtYEdj16UUW32OaFryGNYnU/vI4RtXn+IDv7nFFZy5nsv6+8l05p6mtfXETXMzswj2yP8oXLnDHse36VQvlmSzkmtmjW4VQYY5XJLuTkDJ+Vdw4ztJGc9sUy706wknv7e3MiSTu5M6OfMUMck5PqcYHtTZrUSR2rFZZGtG3W4B+eWTGMuem0Dkn+VaJJWdyJRvoiKa4fULS133C2xlw7CFvNAUH5kQkDOem4/Wmwa7D5n2SwsLm4k80JO3MQhj9V3A7j256+wxTFtZLJ5JZ7xpnuVCpESqLwSWYEckdvTAxxUpSQyo0dxbCYqDEbj5IzI3QHHYDn17Vo+X5f18ylTSVpbF+b+0pEAMklvFHkDdL5pXrxkYUtj0AAqPR9KltnknuZ41uGbKfZ0ZiP+BNy7dycAc4wKbAXhjiWGaW53sQ8yISZD1Oxf4U/2jzVyIWd3emLY3lqFdpJfmhVx91VOdpcdSOccZ5rJyaTS2/ruZzbirLRGJerdafFdDQEtrWaKYLLFcITG3m4dpyxBLuq5wEOMsQckVViS60yApZWun6XCXZIEgjKSGPdlQdxLFsck4AJPTHJ6LUiLXTZLxThI2G5pUY5XPJCLUP2Fp1aS6+zyIsZMDxW+6RcjkKCRjPHQj3q41NLvb8/689Qhywd2rv+ugywsriO1DyOgaXlEdck+67c596q/Y4rjWC0kEVxdE7s2aNI6Y6lgAcD35/WrUNtBLpO24tp3uGJANzGbdMdt6JIS474LAHHam3ct7qFtb2VvrckRgKBmhDWkZxz8gjxluB8pJGKm/vf1+H/AAbD9rN3cF+hqadDdakjS/2ddrGgx5t7GbZQM9AHAb/x0VHLbXlk91c2l7pc8nylbZr5I1ix0OdvA+ufpWdJYw6xqMlzqGpDVdOizAlrLKZY/MBxIZAflLAgADAxzmm6rbaL58FjbafYyXjRtOlp9nREmVTgcsuOp/njoalK7svy/wA3/kYvme8v1/VDJBZ2F5cS2jeGF1CRSotrC+BmnlY7mDfKApySc9/rUWpWt2be/CadPcm/urSKBmBeK3Z3UyEFNrRxBYslskFiM56Vor4ea5sb23sZpdNkufmM9qAXiK4JChht2/LyMdKS0vLW+1g3zWt3dWMcTCEtiO3uMgHzMnqMdAOnPHTDUl9np/wGuq6ohr7L/D+mY+l2y6V4blsNTnu9MmjYFCl2biZDJKQjxlFJLbiAZGTHJA6VvT6de2UjEZnaaZ5J/MUDy4myRHGUGDtYnHOTzzXP2WnyLrF1Fd2k40lrcwPqUjCKdlZixhikVt+3kADjaM4zmtrRoLi21W31KbX5Jra4SVVhzElrIu5gmSmfmQYXjHK5PcVVV6uSd769/wDhnprfyGuaDNKDVL1/B+pWEE0ltcLJ9jsLhwGacYXeUB5IXLKW7EH0FZxjxbSWtsPKiV9iIG+ZyARsBPTjnIIyfwqS6ihtJCYGy1umNpiJKrwfvY5J64Ht9RXuNSkhWC3JmSZitxGGkEXlIVxnjJ6knIH8RHGOcIpa8vV3/r+u9tzalG22txjWMFglsoiuDEeDvnd/L6ZA3sGbJI+6x6VFDZkSfPEI2A3ghWQ4zxhW5J/P61MJ7WKzEAb7RsJbfDHhcnr1wR+HB9O9VluIw0bvHc+eXCoM4Yg9CBkn/vnP0rROT6nXBSirv/gF24Yxwb7VA7wjLmNdpLMOFwf4jxx9aqiDVhCN0/2BpolZ1tGCmA9SNwHHGckcnpmr1xqbHTpUjb7FpcbbC0MeJXcjkL0zK3JOfujk46Vn3DQxWL4jW3851Uh3LM7N91f70jdzj8hRG70sKnzbySt5kTEK9v5bzSQSfO087AbxnAYnrgY6En0q2XsrnS4ZZj8ssmYjzmVFJy/TcFzjnueBjBNV4bcXt9PayrGmnWCxrNc3Kuqq4UbPLf7u4HDcbjnGOel1rSTULWy8oW+o21lAYXawnaO7CAgx/u3BBAG4EHnnIPaickrf1+O19v62UqnNJX2RTkDSM4iW3mBGNqxzOAfXbkgfU1cso7aSd5DbxSPbOsbTMq/MCG5jwNyjK4wWPUHjpSp/ZDzuhS+ZYig8nzo1UMRnBwufx61Wma4gmuINgsoCRHFIJUD3EzDiOIOfmbHAHGT68mhXlo9PWwqtWHKXbQrp0Yk1OWyjutrSyLbx7Xn2DJYISSRyuTyMkDvWVbTu99c2ei3MkE12YZ1tVBmlicszzvMGB8vIKgZcjAGADxWhtttOGmyy3VxDK8ccRsZoxNKq7WYxFkyUZmAJZjtLIAMcVknVbu1aNbiTU7KWS6xFbJdmMxN5QkEHlggyyEYGE3Lk8nrWkPeba/4H3dV6ff0ODmTO40q2N6At3q2nxXc5ZoI4gSzKBuB2uQT8pVjx3znBFc9qrmzvbS3u38y3nnCWIt0YF22kscA424ycEEfzqm2jSnV4Nf0kwzag16LqY3KGKVnEbJtZxgqgHBUKc5H1rq5vFJlgKa5oV5bxDYJJLN1uF2n72QMPtHfCk+1c654SvH3l1Wiafl1fy/4bV2jZrVHLaO6zyXMOjQaVbWsLMAsWXZ5C3Vxj5Rjd2OSR6YrXc28zSbBJJ5bbGBUkj6fdH+etZ9za6rp9uL3S0sda0iSNpGubWZUdeSRkfdPHGcjkHNaGma1b/wBmNdX8SPGE8wbVaNguM4G3du/Stprm96Gv5/O+v32GpWV46lSO+hgvLp7i0cJGmwyPErLnJ+VQeScYJYDAyOc5rDmltZZ2uFS7A6tGrrGGOehZt2PwFaTTw6ldvBH5Iguo1uLBX3faNo4fzEI4XdxkcfMM89YrjToJf9KS4lS2Vf3ltMEIUgnnPHfHJz7VSiovVWOvD1Ip8zbuZVndTWd00sN9Ikkh+WKR4+Bn7v3F3j2Oauwwweb54jtI5vN815YyYmYkYyBk7ce3BBI473Yo7O5gJEmmTJ2f7XEDn0wxHSor1EtJ1cWVw0jfdHmDH1xzx78Cm5a2SsdTdOcvMfNPJ5NxJK0hu512+dvBfb/3z1+lVUSe4byr5TdNjKSRRxJLMp7vgKHbHpj6GrayMGw8Q2x/eWdSjDcD93IAH51Bdv5kSwXESuF+ULICHHt1/Tmp9CIwV3bcrJeajY6jK+ngTaUUZDAmYLiAj+8JGKj6jae+PVtrNqspZNTsXeIDzSj3RJBPAkEgRRuwT69uvWtF4YZY4J2do723G0PGGbzFHTez/eYZI6nI4xxVO1Kx3wnthDIMkeSu/YFPYwsSqkHoRTumr21/rz/EiK8r/wBf1/wB6GcqFt5pBIgLFr2Lzox6HKnOfcYz7YrKh+0m2XzLmKOaMszFC6xkZPUFicHj/Gt2TU7ITbrmSeSUMEAtHZZA/cZxtIxxjFY9prWnXBn8i11bTb2KQhoryNbuGTHQsxXap/3T27daEp9F+X/D/gylOz2f9eiLtrFLcIojtVmnZctNNMWSMEYzzgKB23Z/E0ybw7pWqXcMM9+9zqu3CM6E27MOkYcnIPHBAA7VM0qzQj/iWWk8gYMDbloQx9SMlM/QflVEXyt5dmLXaSdqvbIzSqR1+8zA/wA6n3ujt/X5fcVFOWq/R/56fca2mvJazxRf2gzRlDuGTGQc8gEgFsd+aKjivb9rmaWxBVwFR5J7VfMZgOTnjnv1zzRWUotvp+P6IynTnN3si3fxW893LaZbyBM0jnfjzGJ6nnJ/Gq9xdXP2rZDHH9iRNsXmAtGZP4Q3QEDrjBzWwVH2W4OBl5XVjj7wz0PrXP6xczjWbCITS+UI3OzecZAOOPatIy15TKbTewzU03SRzSXXn3ch8su7g7vZQPy2gcdqrK80FxNHPLNNOrsipHCUBjU/LkPn5iBg4AH5ZOZ4xmktY9R+zSPD/wBc2K/xH0rqPhhLJdRwR3LtNHnOyQ7hn1wa0k+SHMbSlyxu1ewk8c32a0e7ikkadAZP4V3A5x5eSc9COR+NJb273motLOyfZomxChBkkJ4yeoAxj3HvU9y7hJnDMHLPls8n5sfyqtZqPtIXA2iNAB2GTzSjezsZ8qfqbjXgJd2ksi0QwGRkZ/TLYJI9+ePWqo1SORVYx75yGQrEoQtg4yWbPX6EdO5qC7+W2s9vHmXDh8fxY6Z9cVVtnb7Yp3NkLIwOe4HB/CslFNXIVKKb8hHikuoFjN07XPzINyKSDg4bPQgHGcAHg9M1JGlxFbJHcXcNyiRjf5BAidmwrthSShzg45Gc8c1Z8xxca04dg4hRtwPOW27j9T39ak8RqqW8ZRQpCr0GO1HNzNLuCtNpFCfTYbi7t7ZL+ee6kQD7O6MsaAYyQSPmbrnP5Cn3cCaRqN0kk0ke+5P2EzS7NsYRQUC4yyZBOfVuKTVpHTULGRHZZDO6lgcEjA4zVa5ke8vNLubt2nuFE6LLKdzBf3XAJ5x7VpG7td6NP8P+GIg3KcYt6Fy6uxcCOJZ0aQq2SQy7SP4SBww6kNjP8qoXyfbGt5YriSG5hAjZPPaKKUA5BI4HPQjnPTvWpoEEMl7rqyRRusUCmMMoITPXHpWPIq/bZkwNgyAuOOlNaPQ6qVKLbjbYV7Ka2+2HUtKUJfAed5ErR+YoGBgktgY/uletMiutL0+KI22lmzsFUo5RmlMa88BFAHYnaoz3qt4knli8PagY5ZEMQ/d7WI2fvYenp1P5mt/V2P8AwklzHk+XCg8teyZ252jt1PSnK9k5a79+lvkQnCUnHls9f6sQ63crcKbE2qTWxA+0yNkbmA25AByQMHnIJP0punyi6tktrO1McSSGS5vJnVQzHuWf72PcsasxqN13wOIocf8AfKH+p/OpL6ytUu3ZLaBWC5BEYB6isk9OUcYRj8K1IrBEaJru7jhmhX5beC3jd3lI6OC2OvHBGB2zxRc6u2m6TNeatbJp3zbFtIHBuLjJwEeVupPUgYHscVc+zwz6hqCzwxyqkJKh1DBcEAYz0rF0sl73a5LL5Dtg8jIJwfwqkk1zSV1p/X/BtfzM5U3JczY3UW1LU5IZZktoraIeXFbqSIoQfvFm6s3TOBzxjNVibHUrm3bU7bUEEUhAMkhgwccN5SHeF4xljyD0q3cO08CrOxkULkBzkAnqearWZLSohJKjkA9AcjmrT5Vpp6aHRGPtaavsi3eCa4XUDbPOE3RlZJY8wSA5x5Tk4JBzlcgg9vW94ZtNVNsqzSWttB5gW4n+0LDMU7kFevHODU2oqscE6RqFXzkfCjAzg8/WrHjP/QvDttJZ/wCjyMyBmi+QkFTnJFZOTdo9zNtqHJ5le/XTbue4l1O6tWW6QpKglEgmx/DtIGRgA5yT9M1Sl8P2N1H9r1KxgWPcywiKVy3klAocqAPLyrFcdvU9auabbw3mnGS7hjnkiQSxtKoYo46MCehHrWlgf2akmB5khO9u7fKx5PejmcF7raMKi5WkP1aytGubezvzbTNLIJIgWbll+46sB8rDgg8EEcVxulxXtxeWkNpLJdpBtt7TVo1UpeWeI/NVyS75Llh5gwCRznqNWBQLS2lAHmxMojfugZPmAPbPf1qTUYYodS0l4okR4Y3jiZVAKIyDKqewOOQKqKcPd30/K/8AX9K2DpNO99i1a6Ro2mvNa+Honh8qNpbi3tx5ZuAiny03t1Y7cZyeCCTSaHKNXWS7zdQXFs4jmgkUxyQllDqHyOQQQcjj3pmpu+2BNzbY7dwgzwo8pOnp1NYms3Ez6dbs8sjMl9KiksTtURQkAegyzH6k+tKClO13q+ppy6LXc6S2jn0e8uZdNaztfNJaZwAFLEdSOmTx9a57VNS1a5tLaaa2t4jE4C3OnEGFxnksnVSf8mu+aCKbUrJJYkdDHuKsoIJyvOPWuE1F3i8ey20bMlusjKIlOEAJJIx05JJqqE03zNJuwQipa9TTsLm9huIrbUfs0eoS5eymjGUuI8gnAIyrcDcmTggHmqetx2sl1G6XMMss4MVnaOwCuxAZxycbsrkZHB6dcVu2EaT6XrMUyLJHDEssSOMhHyfmUHofcVn6LY2kuvWlxLawPPHcmRJGjBZWKPlgeoPvTg1700tr/PS/9fPvpEW73XQyIoUgvbSH+1NLjeWUokMsgMkwVgp2ZyOXIGTjnitf+zDHOy3HlRqyp+7AkikjZc5ySCmOT0Bq/rVpbJsZLeFWSXYpCAEKfmIHtnnHrTdXAEGABhmjU+4PUVnzX2/r8DWU6jalKWpmvsRYkt5bwEklVRo50U9MgHHY56fhUd5HdzNLb36291BMjRs0SCGTDDHVcEMB3BHXrVuzt4YL9kgijjRo2JVFABI6Zx6VD4mmlhulEMjxjH8DEen+NVe0rIu1vi1J7u1jijt7fTQkRCRxoVnB3DOCuOQSOPr3waz5rWW5i8y3RbkPwJ4JVK8cHK59ueO1a2tsX8OBnJZhPgE8kDy6zbon7UDnlh83vnrmohJtJl0ZSiroqW9iLaUGSW3t7jAX5ENxKxx1HIjQfjmum0+7WwsHlS1i1V3xuVim6If7WSdo+mc8VyNyqreXKKoCBVAUDgfu89PrzUcX7u00+6j+W5E7KJV4cAMMDPWnUp83xa/19/4nRUpyqxu5GtfW+maq4ng04WFzkbY7O4WRv95o9uQPpkVmz2Gy6Sa6mWSJl+Z5WEbKfTK7kcZ7cEe1W9UjTfZPsXe075bHJwy4rrfCcUckCiSNGG2ST5lB+fzJRu+uABn2rOdT2Ubrb+uupEpyoJNO6f8AW5yyxFo8WdvJdORhEt33KcHnIXk/hgCiud+JOp39rpOorbXt1CBJGoEcrLgbunB6UVhVxTpuyX5hGo5an//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy of a skin lesion in mixed connective tissue disease showing an interface dermatitis with prominent dyskeratosis and suprabasilar lymphocytosis similar to the changes seen in subacute cutaneous lupus erythematosus. There&nbsp;are also conspicuous vascular ectasia and areas of vascular dropout, a constellation of findings suggesting that the primary antigenic targets are both the epidermis and the microvasulature.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin lesion in mixed connective tissue disease (MCTD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 236px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADsAWcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3LVPHlhbCQ2724iUcT3MuxSf9mMAyN+AH1FeQ+Ofijql3CbbR9T5llUCRoTBCq5+bcq7m244xuOc9O1efHUZ9QeRLjYiRkNMA+4oP9of0yKy3l/tLUEtNFjknJIwc8f8AfPTk547+h4r7ChlVKm/eV/6/rax7VLB0qV5GlqsT6ncG5+0zTWygiBrtvKDEkcpGCdo7AZJ/vHnAo/2hBb2axadbia6yENxIQMnptCjhR77t3rjpXpukfCGWHR59Z8Z3ZsrOGLzZEKF5No7FQck9gD7Daeleg6B8LbB7dLm9V7WFiHjhkAeaNccbnPCt6gDA6DFbTx+GpR30Xbv/AF2+fQUsdSjom3+R4XpXheW9gkGq3l1NLI24wafGWc+5kb5QvPYN+Fbln4M0SB1SW3iNyD8wnuDcyj03cIo+n617wNO0S3Y2enRW8hj4muLgecFI46H7zds+2OxxpaePDulQ+fE1t5oGDJsAb6AY+UewwK4amaO14xf9f15s5XjJy2R5V4X+FkOqyxzz2xgsUJADLsBPcjABPbphcdyavan8NPBE92Et7uNLoEowOAp7ZyxA4x6n6Gtjx98UtI0yylhhud8zDGyIgMB6uSflHT65rwzUPEGsp595NfS29ozrtNrCxjBYhQNzKVJ6cD3471VCOLxHvybiui/palwVap785WOsvPgfrF3cCRG0/wCzSjKCxkXMa/w8sBuz1J59uKx9S+AXieE+dprW1xCeGiEwWX68/KfpkVX8O/E++t/Kt0AvkLFdrzrE+z2X+6M4/wDrV0g+L4heNrKYxbhuYRAuVAGTvGOCPf07VtKOMjomn8v+CaSliY6qVzibf4Z+Kf7VbT5PDN7Jcj7kvyLFj1ZyGH65rSn+C/iuF4zJoL3CHhkivIep/wBrcpAHrz9K7aw+OaTb1urllkYARosQ+YHPII65xwRxgE1zWseKvEVzM0+g6zHbysSTGuSG5I5Pr2/LinH63LRqK+9h7evJ62MW9+Euo28TGTQfEoeMZaISJLH/AMAZQxPr0rNj+HM401rtUcwnhfNvooDkHncsmGyPTb+NNuvGninT1SabxHei6RWbypQcxMMDn58MuRwe27NZn2bV/ifqUhuZLC51iCKI3Nwk6IdjPtyx6OVUAccDd36Db97B2m0L20ofF/X5h5/hGyUQwFdXuCcSC4t5Rj6GGQjj6cis+WfQTMYjcW9nvYsB9ifA6jgudxGQeo4NYX/COXK6xcWtqPtiQNiWaFVlQZ68t8pOPQ8nH4a+h6NocOvWX9uWd9c6W2Y2IkZ3Z8EJtAVRt3EZGc8EdeKr2dTWSF9ana7X5m5ptv8AD6NM3uo6tqUvIENoEgiX3LnJ/Ifh2rotO8T/AAsgKxT2GpPu4Z7aIKkfTgMwLt35JGewXOBxt94fjOtQi2ijuNPePfLcRobdBHniPaD8xwMbuvzc9K6hjpjEwQWFvtQbhDaxlQecDB3Hnrwcn5fTkjoylu38tP6/rUrmVRa6ff8A8A7O21r4VWNiJ9PjvZwM4glcIc+4UZz70+28QeDbqYXf/CORRojFHS5n3qwwDk5bHArF03SLP5dliqqBgMRkEjrkEf59Kpal4dmnlf8As29uCVUnyVIUu3rvPbrxt/xGaw8b6yf3spRpLds9M0vxV8MZXCfY9LBYbjGMkIcY4Ujg8fXn3rpZfA/gHxhbg2kcJHBH2aQKy18q/wBiw2813H4y1q6sZY4fNgXBAuZN7KQDg7QAM8qeD26Umha74gsb2A6Je3zWzKBukhZkJA52uevOeRjjHBNYTwMr3pTkn63OTlhJ+42mfTA+AHhdt4mvdXaM8BFnCgD0+6TVZv2efDgkLQ6nqqLgqAxjYgfUrXnn/CzfHGnxxS3d7FHBGPmR3Bds9DyuR+Nb2m/HS+uo/s8s9pBcEYM5iLqvqQoGWb0Hqa5p4bMI7VE/69C3RxNr834monwg8V+Go2fwn4jtJc5Lw3Nqqq4HQbSGXn8BWTF8RfHuj3j6be6VodxdxqC5t9g4PTLKSn8q2W+K3hieJn8RyX91GpDYuVMERA5GIQSCOD97ca67SvHng/xDp8emWyp5DghYYFCiNRzkYwV/AUm60f8AeKfP8kv+H+5Gdqt71Yc39ehwieN/HOvTLb/2Xpbx7ebERpI8p5BPzHDAY5CjIBzXP6n4c8T6rHx8OdFtEBO2QWbqxPc4DDHPPNeuN4a8HXjtd2t7JZyw5mMyP5Rj/wBrLDjFZN1qGp+F7Kb+zdbutXtlkAC3Q2uu45AVjnd16dgPTmtKdeN+WhCz7NNfiv1KVVXtTjZ/15ngGu6fNoBCSpqGn3kgCeXLGhibj5tsi4yDnoF/xrJI/tOIFXE11EPkeI7Wbn+6QC31BH1NfQut69oXiuzm0rxYBBexcxu8JJ3HgcDAbPscjvgZrivEPgrwpYLCt4/9mK7mO21WGQywyuBn59v3HI56Y68HrXoU8TeyqKz+/wC7v+Z30cS2rTjr/Wx56dMu72xkuHls75RGvmy43ONnP8OWHcZIGQD0qr/ZdvdXkcNzBHo4ZAWuPMMkRBHDAZOV+hP17V0mq+GpIr3yofLvNQjQTxXmnyAC5i6Fg4yCB3OO4ziotN02y1q2ezn1xLa+kbItJ49h8wcEnJIY/wC7jPpXSmrXvodHtI2uV/7F0/TrCSDXtAuJieIdW0+WXJP8LKHwp9do59qoaRPYx6bcaI8NpeNMjeRdKmyRXP8Az0z1H0OR6VsaSnirwvqraTYNbmO9yhiuJyltMuPusGO3nnHv3qhrAXT7qWa+sxZXHmKt3Y42lJMf6xOTlWIyCCeh55ojG8rfr/X+RiuVyaZnaZoVqbYNPdKuoQEs9pdKIhMgODsdjsY/iM10tgsEd3enwnqUl/okUSzT2t+fKcE/eVO4Kjjd9046ml0rXtDvRHDqsDywONjXkTfPt/6aoRgj/ax/jV/VPCdjoTLf2Hm3ujzbSjwbfPtnJ9h86EY4yKJfFyyE5a6v/Ix/7B0/X7l5NE1FbW4ZOYp0GS3oxBx9SPrgVNd6bq/h5I47i5uLQSKCuxWdQw+hwV/WtBvh3JMXvvDOtJdOR5kULYRyOwDZO3HTnP4VVGt+LNHun0fXdNLNKN5sNQjUxz843oxIz6ZUkVN1J2i0/LqDqS2g/kzsfAfxR16AfZby1tb1IWEZfzgm5R6knrzxXsfhLxhpXia4ube2jntrqBwjQXC4cnbk4x+PftXzZaXlt/aUl5p+mfYZEO2T7Ohd4jnkbGbOAfb613dlHZ65PHcaZIukeIIRkiJdizgc5UfQfd69wK83G5dSeqXL59vU5MThqdRc1rM+gTCuOlQvbgnpxWX4N1mTUdHt/wC0isd8CYnGeGYdh74roitfMzUqUnGR406Li7GW1r8w+7k547/WmGzBz8orW20hWl7RkezZlPZgL0/HFFam3iij2gcrR8j+D/hlrXijTtujxJaaYxw11ITGknuDgs/4DHbOc17n4Q8EeGfhjpH9oahPCbmPO67lXaFJ/hiTnkjjjLH17Vl+IfiuJYZbbwtbFpFO0XLbWVR7DO3PsT+FeXeKNclbdfeJ9Rk1S4iVjHHHIVjjwMtzwM8dFUHt3wfo5rE4v+I+SD6Ld/1/SPZ9nXxC/eaLt/X6+p3Wo+Oxq2ovrN3bSfY7NgdKsJjsUtz/AKRLjOW67V52jnBJOMHU/G/iDUZFn89YIic4EgZ+T0UdB+mK8+jj8Qa3cQX2qt/Y3h9iWN5IrYUFCw56YO0LkZ45HrWLp9t9rkE1veSarBEZd6xINzrygOBjHUEAgkgg8du2jhaSslHb8P63/HsOCw8XZK/mdpr3xDlRF0nSjcS3fJBPzNLgHgYPp/IjFZunaprOqXH2WG+CeaWDo5BZeoCsByBxxnrg9KbpdnY6NqVvdjNiDGY55S52tuJwhJOAfu/U469a7FNXhitlt9BgjCq7RbLZVARgfmU44DcjP1rdRUNIq5pz2+BIrWfhtLIy3DWyXN9tHlmVcqrey54PXOetZjeRJk6vfaikNxK9orW8ZWKOZWyA67CGUgkEYwCMkHrW9FDrdxMxM6wEgYiK7gv1bjn1GMehqzNpbuHW51LZDJIsslvDtKyOvAOWGVzxnaRnH40udp+8zKcpS66nlt14TttVmlkluJbe781081TlJ+8cqKeUPcp/tY9xHqfhzw3odzcT6jrck2pTAkRBPKy56AiLJVc8nA+gPSvXY9IsISQqwxSSHA2gE59vQ9a4HxV4eu4p5tvhqK6tpCPMvJ5zKw7ZUJhlPcn3PXpTi4Sen6A2nr1MvT4tFsp1Fxc6ja3KnzG8ybCMC5xnoNrFd2D0PB563rPWBfXclpprwSPGruqROr+ZjONoOBkgHA9eD2NVZrTXY/DqeHZzfDR5pTG1lcWSXAg6nesqhTkk/e74/wBkZ7rQdNit7NILbTDYW+MIqAv6Z79D6jqeTzVOTWskClLyMC60J9RiV9V1j7FdNECtsdOSYICB142s3UFRt9iaZB4bjg41Ww06Ytyk1ughdQeuRgHnPOMfjxXctYLap58zvuBBwsZOORxtHJJx9efas671mK1uGg+yvKVh89pmZUjROclmJwp4Y4ODUKq38P8AkJTV9xttHaWUCNCCUHCImWz9FFRSyw3TkA+SxGSJVLOR6BO/bv8AgahvVuIYnu/s19FJhVKRXbBCWIIPA5+9xj39Ks2j6XaXEYjP2++kRWa6guFlU9zk5LAKD1YgEnAGTRayuP2upHdx3FnNCLTRkuw7jdOSAFAIJOPvHIyBjJB7NV3SLa3CbmsRbTN8rfumDfgzDpVzUbZZobeaeY7VZd3lhhn8BzzwPcMc9qfqGjraH7ZpOreZBIi+VbJLudzg52q3GecjnBxg4PNZOaas3Z/MzdZJ6kT6fKExsjePrsXIBbA5bJPGBjGcficCtLL83lqtu5BO1Ux8oPQZAqe8uzEhj1FBJ5bKSyH92wzkAhgRzjoTjryODV1PD6qLm9vPHS6jZTZjtbS4sBvtiQShV0b5DuGAGBVsbSCekOpyW5v1f5frYmVRQd2jz/xLa30Nutxqa3VxYBi88+nmNZFUDhfnzxuwOSePxNXJYbTwpYS3kWqX+oMxBt4pLkXHb5SV2LmQndhRwAMknAz6BpoJtV+0r5V4qqJZEJUK+35sKCcc+59qoXOgafclxAyiRg2XiiVevU9OT06itFWTdpFKTb3Z4zrQtL6Sy1G+n83TpYifs1xIVkaTY/llgASVZtvPUjIBXtHFctcaqksNraafaKrefsCxtLhlBZo93b5hyBgk5rv5vCmu+HfGNp4l8Kyme4hwJYGmRGePBDIMrtAbjn+E568Y4vWdFuZtUa6t9Nj0qGZNxsFheWG3YEFMSM4LtgscgBd3AHeuiE+aXu/16/1r+bU2pXsZ+s6dp2p6mqqJ2jC+Y0creWudpO4qvztnH3uANpGOc1B4W0a4g1Ty7Fp7myyI0lUlZArbiGGOgJIPf0zXoej+FE1m236pZCJdoCy3WDJheAMdkO0fLk4BHNdJaeHjaKotbiCSQA7CwxgnoeO+KUp04u73NIS5Zc3U8lHinxR4V1RWub2XYGZVZzkOEJBOzqBwff2GRX0R4G8beFvE+laUmr3K3Wowhi7u7YikbG4AHB2jhRn245rw7xhpuoYd5YGuZbc+bma7VDC68+YO4z8oGGznnB3VxNmkrXcwtNyzmQR+Sj5ZQ4J+QqSCBg8jrxwDWNfCxr6Xt5rccuStpI+0NT8B6XqqebYXTxnlgQ24Anpj/wCvnNc9r3wrWW0ulicSpOB5scA8vzAD/EpJUkdjjIPSvnTQvij4r8NiB4rljBBIBIXGTt5+QjpggHBI6j2r6D+Gnxw0nxMwsdWAsdSUKcN8qybum0dc9CR2BHvXk1aeNwvwS5kvvMXGpT+B3seI+KPBmseGZfMsDceUku5TGpDRP0PHBBOBz0I64rFF7qfiFm026G66B3upTaCR1yQMJ9dv419q3UOma0pjYwzPgHOAWA7fhXifxO+F0iTNqMDMsQwRPbJzEccl1/u8fez35rrweaQrPkqLlkdFHHXdqiseTad4p1HTQdH8SabDqWnFD+6uX2uydzHJ2OPQ89qh1i0tbzUtONrq9zPo8g2JLcW5me0T0dOrBTjGMgZP0pdTvL+3iaz8R2Q1PTN+I7raI5Ys85VsDPGcA9xwRzWHHeXGmZm0S/l8mNsADhhx0x0YY5wRmvUirO60/r+v+CdySldnV6/rmrXk9jYa7Lp1/wCQ++G7tgFadcFSA4GQMYJVgMEA4FWfB8U94NS0eLWRbJMmUs7iIMXYdMMThG6cDOc5z1qpc+ItN1I2194j0WOJLhViubm0G1Juu2Tb/BIOQSMZxxVyfw3aJHHLpuqw6jBO4+yzq4Eg5AKMueuMEZxz9c01ZRUNv6+4y93l5dhvhZHtb1rjU5haC2mNrdlcpNanoC6DqM/xdMZr03U/C+q32mpZ+Ib+K/0tt8lvMhDeSpGN2M8+uc+3euSg8K6bbaxDb6hrTW93dbooZS23cSM7ZR168YPGPzqIal4i+Hmp2ljrkBn0aX5IJ4Zd8ZQc/Ljpjuv86xqtzadNq/p+X9epzTm525Hr+foc9qeiS6rqctnB50+rWajy57BBJ50Y4DbuOBwNpw1U9Ol1jw1rCWesWmp28kwZ445Mv5gHLOMAkMPbpx759avWtXudM17QrhbG7jOfMtI1kV0PAJBH7xc8EcN9DXXane6H4sg0+TUo7Q6xYEyxAHaJEb5WeI9x0yvVT1HQnOrjHG143i9+6f5W/Ix+uVINNrTqcFoXiOS9t0WS5uQAQBc4xLAR08wL94A/xgZx14rsNN8b67pkUcl5LZ6tbOx8sxXETNIv+wVOT+Iz9azfEvgOKyjOpaU8y6ewDlYlBaBiMZIHJHuBx6HocHwyTZXLxXl4unQyp5jXPl+ZBMD3kTOyQEDh9p6diMVyTp0a8OaKTXp/TXy+Rv7SlXg5RXyPWtO+JGi3fyOl1BcAf6uSMDcfRTnmt3S/EemaldG0hnMd6M5tp0Mcox1+Vua5S68NXl1DFf6XLYXZ2h4HjXyuOOFYcgdeAQPaoIfE+r2eoG38VaRC8CuPJlhgbduB4xuOCQeeDz2zXjTwtKa/c6v11+5q7OCUIS+D7mekSq5QiNgr9iVyPy4orHbxTo0bBZrwwNnBE0Tx44zzuAx+NFec6NT+V/iY2PlBtR167gSO6trfTFMgVYvPVI2yAQAhIZyQRkknPvWb4n0vwzY3AfVJbqS8gVsQecPKIABwCcKpA52ggnoAeldDoVpbwCdnhWfU5HP2q6njU3JkYkksnWJTjIXrgjjJroNM0gXMEU1/Y2hJXG4qSpOT0HGeMdsV9zeMFf8Ar+vxPRnXdSPKzz7w7YeH9Zkjg02znmKNl7eSdpYYlIyGHJT8Dg5HSvQrc2iRGNbYrbxMyDZHwzDg9O/r+FVNQ1DSbW9XTYZr4sQZGtrSKKJY0PDSsSPlUZ+pOAMmpA1le7o7ywu927L28ziZUcDaCGHQ7SehwQzdSTSc+fRbGSfLolqQQGz1C8jittNRNp/1wZ4njYY2gjGccde2CKtxJa6BZy/ZrdI4Y8uSpGIk/iOT1APOMnvjpitZYBcW6qI5IY9oYyM/Le1R3OnwxlriVRDldhdyXZkznaB2GcH61HPfToVdHMReJrsXdpEbMs168v2aBTud0j3As3Pyn5G+QjP3fXAnvdXj1a9+zwPCUkVjBOwbbKVyxTKglCArY3bQ21sE4Nb6W+k+Qkt9cx3M8TRpLcXHzXDPnMZeQ5ctyADkZULnIANVdWtDal49J0szzFi3lvLsjY5zlhyOuCByM9qcZRv5/wBen9fhHNJ7FLw7c3t5rIkhtlt9FiBAe5iKvOSONoYBgoB6nqRhehJ6S61G4S5WKDTGmDEjIkRMYPPBOcYycj0x3FZSR3dwY5J1LEfeRpM7T3AbIOOByRn6Vsw2aTBYrqBLgqQ4DfejyDghux5PI+hqKiSd3/X5Ccr6lcakrSShT5M0RCtC0nzZPK5Iz1HIq/FJPLaozKqyyKGO3nGecZ7/AFpYNDgtwscZjWGPhUVQu0evFaE1uDFhWC/TvWM5Q6C52zNisreFC0k8ryuSx3yHGT7dOM1HFb6jFNKbKcpZyquYHhDDcMgvu6kkbRg8DaPetW3gjgALL5rn+8O1RTTyMz73ZEz8qpU87YupUuINsTb4ZZGLFi2DlievT/61cpqelC8M6tPo1hPhWhin2xmcl1LbpmB2gbQdoViTtHHFd1arMVDmJjyQAD/nPFMuNFFyGa9itwjHoz8A+uD6Y/MVUK3Luym9LXOAiNwdWntdH1e41uJMJcfasSwbsZYpOBgjnBU/MCMAc5G55KW+xbezRVlLLFtdQ0jAZbYCwJxnPB49q2bfS0hOPOllwSFt4YlWEDsOOSce/eoYfDgFraQm5hMdo5lga7hWWSKQnJdcLhCc9B1IBq3WXT+vu/rzDnaXcx7G8nuI2trQ6eJpN5Wa7yEU5+XzUKlsAHB/3ck5NW3smtblPshtLhjkyS2qs0Ue4DAQt24bsR24ArXl0y0iWONjJcOrEiR8ZJznJI+vTGB26VCYpjIHt4P3e4mVNrbkzkKRyfbrxyTS509Ykpq9yrb/AGpkAlTHYBfT/Dms/VLS9iv1uI3mjt02KRGobg5y+B824HauDgBSW+YgCugy5TpJGw+8u7g+4/wqlOG+0I0csingkMQB9PrRGWpdzKsdSvJbqJBa3MFttZil1Fl+fu5fpwBnGM/ON2CMVqXc06OgRFeU5271U4A5PUjAwMnOBVmAtHhJP35YgB2HYn9McVkeINAvrxZIWMFzp8iFXjkUSFAcZ4/+uCOtUnG9tguYviG81tptUs4IgL22QyxlJVlSRdpbG5dwVhhvvAZyoHLDEelX8On3lrFE2pTPJC00yXMeRasWVfL3A4c7s45ztBzjmui0rSbi2tbcSWjRLHEka4bfJtUYUM3faoCg88D3pNQjaRNpnXY2Q3mrt3j+7k8emRWqkvh/r9RfEtWZ3iWCTV47a+0vbJcWxKOmcCaJgVdRnoSCcf4E15fcaJeW3i+2u7TTxo1uZUdViYXCxSM33S2FZU44DZAwOcmvX7GKNIJrdgJCRtYRsrKB06jvVBreRLeRJTE7IrElsgADbxk9sd8+tVCSWnYrRNM8P1qHxBYafBqpupruO4d5LjzEDJCd/wAsbtz8zbcgfd7DJDYq6NB9tljbTopYJy/+rALDdj5ir565GcH8yDge2XOg6Q6SyRRy2tyH3gxR5QuD97a6kcsvYDPHY1b1DTra10yNNOt4beeDayNsHAwd5PTnAwfwoTine7+ZpTm4yTvc5rwh481LQtSiS6aZlyR+83B1x329+nX3ya+lvAfi+w8T6cjW11HJcquWQEZxnGa+NbHUZI7qKaSf7ZeXMm14pCAWCgjePlyvIK8HGeenW/Dr0/gnU01DTpnQuxRldiucgMSmQMjPG7ofbiuXG5dDERfR9zWt7LEK+0j6K+IXwwM1veah4Zu5baUI7nT+sMhIJKquCASegx3NfOHiHwxqfhvV2s9Us/JkcBeM+XPnsCR8p64+n5/S3wv+Kdr4ktoYtQJiuJCdrEYwO270zzg9K9G1jS7HWtNmsdTt47m1mXayOAQRXnU8wr4KXssSrrv1/wCD89fM5oV6uGfJLVHxv4I8bT+HA1je2yavoj5W50245kQZ52BuCMYyvTjtW/q1v4QvdOSbQnghiuQ62N3/AKswyAZNrdoTx1+WUe2em42Pip8I7zR7uS50Bhc2a9IvM3SxdxgHn/P4V5PahY75orwmG8VuVuId8bEHo64yDnuAevTPX3KThV/e0pb9v1Xf8ztShWaqQdmek6T4htNfsLfTvFd/dw3MAH2S6jt186Ij+FpQrOOcYIGPU1qx6Lo3iIS6bYSytqcSh3W5uMFh0EgbhQwYgEED7ynHNcvLdaFqjbtRsINP1cAYIuMWl0TxlmO7y29GOVPqOtWPEVve6bZ2sV9K19oTEGFLlleazI/55S8hkI4+VivOODg1ok72hp/X4/f+IqtPX3dGW9L0jT4bG+03UblNJ16zZmhvkXJOOcSKuCwPQkBvXDVXOoxx6YINeu7z7ckx8xHjUqSeVkjOF+XBHyn5h+lJ4av7e1uLiddIm1+C5RYjPFMyG2A+6NxJVRkkk564rR1O/uhYQWfiuTXLWTzM2NxLBb3NvGxJwPM5yhyAynI/nWmql/X4bu3l9xjKb5rPU7nwJ4j1K2tI7N2nvtPC+XIk2A4Hp8xG72ZTmjWVjkm+w2FxBp+qxh7iC2uExHdr/EMNjG4DDKflJGeDhhwWpWGoeGrC3utbjsdb0GJtjtYq0LQD+EMyncU54OSBgZ7Vr6ro+nap4VttZ8HTarA1mjXBguVkuIkTGXaORj8pAHIDEdenNcbpU+fmWnN1S0v5/lt8znSinzrT+up3Xw+111aXSNJiOm67bKS2l3eRFcAdRGx6MOhHoQemcej6X4hsNXaXT7+BrS+UbZrK7UfoejL6Hv1r5QvvEV01zAdWmvrXWtOKyxGRdiopxjBGPlI7Hrng16xo/jTSvFmjwx+LdPuLe4tBuTU4WVhEc4zvJyue4YYPviuDHZbzPnS+a3T/AFX4ruFai/j3R7VFpGnQIUhsrdIz/AsYC/8AfPSivPtE1bxDZWAnsZ7LW9NjfyleEHLDHDHB4PPIHcEUV40sHXu+WV/n/mc7h5nlmi2VvpyahHoVrZy3zIbm4neQILiYA8DJJ67u3GTx1rR8M6u2r2Ud3OW2uCVj44GTwccdPTiud0Wx11RbqZNH+0F/lulg89om8sgMm75Qzg5csWJ5PIwB1OnWDxSMArOS33YxtUflyTX1E0tTZXvrsVbi0uL6dnVhGwYkbFG5F/3uoB6kA9eauaZpKW4YSu0oVmwCSAF42gnOCfUnrgdKvRK7SeXt2AY4CDI7Ek5IA/Wq+rXF2QYNJs7MXWyTY13coMuoB2/eOC33QTjB9cVi59EXKRftokjIEYU89cHbx2HYmsy9ur1bmUx6at3mRIoUa5EPmszAFSSONoDNnvjHcUX5ubXUrBbeSZ7SaIi5YqJRBKqBmQOu0MnbeRkHjnPEy6osvymPfGyDEiyDByeAR9Oc80op/FuZ/FHRlS/ge6uo7YabaWUUbOkqRzI67EyYpMLg7CQuEJBXaeg661gsMEagzM3mAlSxyrAdSCcA9f1qp5PnWU9tYW/kMSGBjUKDg9+CMfUc05dJluLyJ2htbSKIytshQASPIVLSY7Nlen3eenpTfRuy/r1CzjZC6tBNdwXIik8uQK3llpRDliu1f3gyVIJzuxnOBgioL6WW11Kw0/S47mURWA827kKOkspKjJCEA42szEHIz0OQK6KIKkUaxrIFQBRuOW/z7+9PgijTCwQqijOQgCjgHj2FZqpb5E2u7kG6QL8+AMfNu/pQhjjQtlmA7lsCpJ7qCNsz7T2Cr0z9arGS2mG9y2T0UcfkP61CuyxsmpsPMEaReWkbSu0jrGqov3jljzj/AD1GYJdatYPL+1tDDvdY0YsMF2GVXPQE9hQLC3S4lnRJYvPh+zuJ23I0YJ+XY3y45xkjPI54FS6bpFjDfC6mBurlV8tT91VTII+UHHGBgnOMcYqvdS1X9fkQ27mxbsz2o25LkAKqEAkdqqSSeQGDo5bOTv4NWDMC8hhRndl2rnn5uxqVLaRvnkeIhTwGOMjHQe1ZXtuJPqZlrK1xIFjgd1IAGM7jjt9P881clWUcN8pHIUAnB+g/nVxbdpXPlMqtyNg64H9KdFafaJEjSf58kEuMheM1MqiDmM1lKxiWIK+cgHdj0zk9j9f0qGzWee9hiMawqG5ZJCML3Puf8avS2rNPskaaKM/6xoj844I3A9OM5/CuR8HaF4s8L2WtjxDqNvqOnx3Ub6ZO0hdnL53bRnKjBGVPRunqbi01vr/mPm6HV3YsYp3Fu4YjALhuo9j9arlYVYEWxaPBO/cDt/D/AD1qyLSG7gM0KDld7YYcH6dRzWFeWl7DcPHAJ2fbujSNlVpeD8qlwVHQ9evTjrVU7PS+oX8y6bhI4vOUj7OcEtCu9tvH3RyM8+nFZup311/aBihsggESXKqN8sM8Zk2kibuw3KSNo4+uQmjz3FwrJeRSiZXKF/LwXweuCT169TWrHZL5C24fy4QSwiTdhT14XcQDkA5ArXSD1/r+v6sDTvdGcLDWbmwtrq21sWaSyxRiJ7NpXzuYENgttVsKQxB2jOTg5qxZyvcwxJfSvOI8ZnkQKG68MoG0Djr6HpU0avZyEQXEmZM71I6n15qO+ijSK3e7n03TUnVjbS3t6tvvQMA7KpBz972JyO1JvXXrtt/X9XMrcr1ZTvLZLaVFntpGk3KqvGPlCkNkkcYUZyAOhPTnNRSWhubSWMysobo/+z1GcdwOK0VhdlkR7k3EBO0dGxjjIOckEY596qPaXVldqGBELE4BUAN0/TOck1anfqbxstjEke5sX8mV4kiyWQsp4PXrnnqOf1pjLb6iqidkMhGEdQSr9unXnP8AkV1iohiMczIUYco3/wBeqEul2iSCdIkWUH74HP8A9arjVXXcptnD3nh1bK4htbSwijtXhaK5LykB0Qhoo1weTu3HPGOpPGK0YLfz9Iu9N1O3WbTpFVXikTKr2yjKMo+eeM89ua0L+4uFnjNqrPbnO5cA+cQM5HfP8+lXbuNLuxL5DRSLvUY4YEZwf1rTm0SZUZaWPHte0SG0tMaLfWyC1XZPN5vlyqAThjjG4AYzgEnsPTq/gr8b7/w1qUfh3xvIz6cW8uK4b5mgJIx8wJ3IQevPQHvVltGsby3kRp/PkCvMELLujBDAKhIyAu18Z5G5ua5vXtBtbjSLfS9aSJjEix22oQIBcRHGERkwA6nB5JB+hqcTh44iHJ+H9fn+Y5ydVWfQ+yZIrHV7NHIjuIWGUdT6+hHTtXAeMPh9Y3dky3Wnvq1qoI/dsEuoR6o2Pnx6Hn09K+bvhl448U+Ar6bSGklutPwzRwktwQMnYSOCe69B6V7l8Ov2gPD3iS+i07Vd+l3sm1Eaf/Vu5/h3jjP1xXgvCYnB+9T1Xbr/AF6GTpzglKPU8x8QfB+8SOC78G3U+rWc+WiVvLVh6puLAhuuVwfX6cnq/k6BpT6NrWi6npeqROhZ3OYZGU58zDDAOOhwc5Pbivp7xDoRS/8A7W8P3Am0+8lSW6tozvheRWBD/KcjJxkj05znFSxapZ6rGNE8dWVvJO0YYSTR7UkBOMrnkHPGByP1r0qWYzUVJLmX3P5rZ2+XR+mixM0lfVHztovxOuNJSZ7bTNMF1KoBntcRQ3AHaaIZQnHdcMK2X1qy8eWy6ZGmmaVczqf9EnikmEjDurY47nIYtXceLf2dtOu5pLnwrqT6a7fMLeVd0f0DDkD8CfrXlPiPwX428CMzX9gLzTGO4yQp50II53EgZjPPDHZ3x0rqw+Kw1d3pO0v66Pe3/DGqlh6mq0l5m4194x8Daa1v4g0o6vocymIX9qwMsWB/FIoIOBk7ZVJ/Cs34V3sWreKBZaTf2fh65vYir2lwnn2d7J0KIuQYtwLcZP8AdGeBWbpHxW8Q6bKJLe482F8q9vKuQwx0bOdwPvz9a0bnUvC3iDT5dSvfCV5bwzRHzJrDB8hgThgwbjns44GVOQFK78k7NW36r/J/16aEzoyje61fY9TE0+niPT/iFo0VvLpyfY4PEMUQuLeWLHyrcKR9wjGQ2OQSMHkcLrN9/wAIHqn2/wAM217p8HnNBeWbO0sGNqnfG38cJyVGem0YxnFZ+jePvHOj6egjkXWbCNfL8y5gkljQY5VpHVTjpkMT7YPNaEkOveNPClteaZ4f0y5axkaRba01ESTRx/xJ5eMle23LHBAAzg1lTpeyf723K9Hrp9z29NfK2t8fYyoyTlt+B1HhPW/Dt1e3Gpabc3WgXZQNcmxIEL5PDPH9xic/e4P1oriPCtlFqF8Y/C0kU11bh9lneXn9najb5OHjDDKzIPXIIGcgcCis6tCjKXvSXzcb/wDk2opwp30djY0Dw3eWviuV7qOGwEUDGe2tpFeNXLfL+8+8XKgZyOhXqRXbK1077LdBskBACctn1HbA/GsnTnFvCV+wC2LsX2E7iWPfg9cY/KtW3kcFPNZUkOMKhwQe3/66io29/wCvxY+Vk8duY4/LWMENyQB1PrVU6LYpBJHJZwyeZnd5iBmOTnJPfnuasaj9oa2cWkSp91flkCnaOpJPGf8A6/HSsfTrTUI5Qk11dMiks3mxqoyW4CjcSCByT0OeMHis4N2vzWJeuli9LbW9qxW3VYBkbyuFyewz0qWwtba4b7R5YkVeADnn8+34ZpNSt4pzEZZPkU8L2J6ZPr6YrKtNbkWWO0KRQ722x7UOM+hHBVsKeDxgd6pc01puX00NW/a8lnTZKtvE3yqzMFV23dM7TjjAzx19cGpNHhuZbZJL1GtboALLHuDFHxyMjg898CpxHLFEBNl5SwbEbYHTgn0+vBqOR7vZgqqR/wB1AST2qL3VkRqmXGiTHLbsdahunm4EX71myANwUcdPw/lTY4pmUYV2wvQjaf17U4JHHGskqFMkIqpglyeirn19anQL2ITpMktu0txKz5X5ox8iEYxgch8j16dOlTWulQWKottuZs7gTIWYfU/rVKz19bi5nhgt3i8uZofnOxnZfvbc/eAyOn61oyyXDRO8O2JygllYAKxPT8OMc05Ops9CW2V9W0+9uRC6vOixyeYyR7QJxj7j7geO/FMgQWsbyXJwFVh5Q+bbtXJO0ZyAPao72RoLq1hkMgluiUjjKs67VHJJ5CtjkBjyPXvoajYRSrGJFxLCySK2du1kbcMYI5z69Me5pt2ST2YlLS6CwuIrq1EtvcF1ZAyY4BU8qfpg5qrrM11GsnkXMduxYASyguEGPvZ74OBjOOD0qSxtZfPLEFAwyQPmUAZx+nU1PJdR2ynDEMM4A6tnnjP0pWSlpqVqtzA0qSSM20Lap/aF3CgW5lSMosjlchsdPUALx+NdC4lunLMrhgMlzuDYHrjtSySLFsaMqnyfeXr156/0xVe5kklgUW8sqiZcCSM5YHnII6MKcnzO6VhIs+JfD7XtlFDdXFzaQRv9piudNlHmIwHG5T977xPfoc1k6NDqtkDaXskF9Kn+puQoQsDk7WH8J7DHXpTrKbVthjt98oiO50CNsU9MjuDjtyParNhdWc8TfZ9St5S2C0LSfMpz3+nH0zSjzRi4vX5f1b8h2aWo+CSSGTcsflAnnnCu3+yegPqD71eYLPEFlUybh03dD7c8euapXtsxLRXSQusgXORyynoQeMg+/wCdYWs6Fqc2gXNj4a1OGz1dZBJbtcgBZYwDmIEghGyc5IPQDgHNKyavew9GdLIFjYxEyIDjI7/icVINEvp44bjSo7ZkYnzfNuGjKemAAcjpXE+Ar/xbYCSw8daXOJJJPIjWJFHmE8qY8Ha2D6EAiu1tLyNnkihv4nMblGa1nV13DgjBGR+X51M1KPw/8D8CJprYjllAlaG5wrocMcjt79xyKx/E2lQa3pVlY6vpNnqNpauXg892/dFlI+UqQSvTj2HQjNdQIoGV8p5p6HJGR/n1qrJHFb5xHGo7nnBHuelKM1fRaiVuqOXZ7XTdPubmcW1hp1qiBpJiypHk4CgLkg8Lye5HJOat6Tq1prWnqIJnUIcAOQcc/lg57cVq3lvZ6hYXVjdxLNZ3I2ywsce4ZT2IIBB7EA1iaZoEWkWsFtY+e8UIKq8xUsVOODt4PTrjueK3U1NPm3LQahayTKqMx2lgNwwQG9eo6dex4/AxWUk8MUcV3GWZ+HYHcOB7fl/nJ1mjIUjG1s54HX8aZN/q8rGjH16ZpqelhnNXEFyhdBOGsd5IjZQCDkk/N1wMj/63dbjVLfTbBG1FlVGZYlWEbiS7YHAJ+Xn+dbEex9/mQyK5+/G4Hp29fqKzp4ksrg3cBkEiAggZGxW4IPTIIyOcfXjnZS5tGU9NjLt7C2NrfppTQSrcsWkKbRsZsYywBYYxxwef1qa/4bs7mzs45/PENujII0fbvOABk8nqOQMZ9fR/h3RpNJuWmUNBFIzud7btwb5tvHAOWBwQDg44HFSajexJJdRXVwlrHPCRaXcis0KTnAQSYz8jFguccde1bcz5rp3Kulqzzh7dbT7Fa6rEkkUW5UikkyGJXBy5zhfu45OCOvFctceGnmmuRBcSMYSXeGVDlGzwoKknuBuxjg/SvZ7bRre+037NqsiNcIigTZDBm2gnGRggE8HA69BWGtmlprEemRlrm7mXImAVnZehCA8YUYPPHsa2bhUjZotSic34f8Vah4d8LXelRatqdrY3jIZUQm3u7VgQMxS4wyN0IOOg6d+ks/inc21tbaI0FzeWdtGGU6ri7nIIzh3UAbSvGMHGBzxVO98LNr12IUvId8A/eSlGcPnbgKmQAMclSTjtgGsaXw3qNlq+6ISXBiw6TBt4UgYGC6nDegycYHXbxH1ek5XtqNcvNeyPTPDnxiksFhSJZ441UZgVjPAR0zhyXTHHCsV46CvWfCPxW8Pa6EinvLe1uHcood8Kx9MtjB9j6Gvle50W+sLcLaxrcQBlM0dyjCSLIPzgjBYHnkE4IweprJsomP2lni8iONN8pDrMqKTgZx99SQOV3Y54rlxGWYev0s+6NJUcPU291/gfXXjX4PeEfFrSXTWZ0+/lGftdgRGWJ5yy/db6kZPrXiviT4E+K9LmvU8L3N5c2siMjDz0jE0Z4Kth1JyOxXHNcvoHjbxX4GRHsby5XTfvCGRWlh5HdTwv1BHTivRNG/aVk85U1fRbd043NbzlWHvhhXIsPjsNpTkprz/4f9TndCrS92LTXa+n3HkiQeKvAtxD9sh1bSSrbQ7blU56D098dx1BFWT4uvbS6TUNMktYbzzVfz7ZcRu3ffGB8uRkHAUei96+ktP+L/gjxFZm01gNbQXK4MWoW4khlGeRkbgR9cVxviz4UeCtSLXvg/WrTS7x/mWCeUvay57c/MoPsSB2FdVHGu/JiKbj0va6+9f8H1NfrNvdrRscF4n8ReE/GVrBdeJoJNO1ZgvmX1qMybgMYZCSJVwCAykEZGcdCVkeIPBd5YpcDS/LF/EVNxpssiyF1PAmgdeJos+g3IeGUfeor0IcsY2hJpfJ/o9O3QuFKnJXi9D0+fUZ/tdzaWpinnhVDttwobEiK0a/ezl93ykBlO3nAINX1T7OZCjGbadsknJCjPyjjpuxnmrEWnOkdtHdX0t7LApSKXYEKoVK7RjqNpxznA6Yqe3UQyrEp+Rl2lY+AwAxg+oA7dK8tyVtDjjzLcS0tAirNcN87HIXJ6VbWSJz5TQlYwMjHAP+NSCWNvkwM8DJ7+3/AOqnhY0TIjUJ04FYOTb1C5RuYzPNKPNRoCVKqvBBHB596mFpK93FcXXlEqvyzC2VHkIGF3Hq2PXj3q87wwxiWRCzE/u0HU8Yz7Dnr/jWUNUvPPG1WTLEDa4chsZxn1xzTi3LZE3b2L93ZgdLkmcfMN3yrgegHU+5qje3c8EojhCB2idkeQ7VZlTcE68ZPHXA6/TUC7lXztpnyNwHI9ev41FNbQ3LbTKxZG+b7p2nHT24NKLt8QX7nOaFq+o3Vmv9o2jWNy25ZrUybzC+4jGe+cBh7GtjVrm3iso9Qvr2DT0hcSK8zqACCOQT15z+BqZNLtFuVk3shPHK8Z/DtWZqsdnf38Et9FbyTaeG+yy3IDxoD94hG+UknHO3PTB4rW8ZSTihOzNGWIi5tVuXMshbMaNllQ4++M5Y54wAefeqmn399Jqd9b6to9xZeVM0UMrjZ9oQD/WBf7hA4z6fla+2Nc2DX2stZRQWsfzSkGNVXJ5YYPJAJ4Ax7VNoS22pyJDpTRISdoDqRx1bPfgdB7/jUPSLcuhOsTS0VNOe7YXc8kClOHPGCO35evpVcvbIJRkTynIQsOCM91z6Y496l162msblra3QDfGMhH+7nPPPTjjv0rnL+wD2/wBogjaO8U/KwBymcHGepAwR6HNZ00p+9fRjXfuUbnQNPuJY9Y0bRdHuPFQud0y397Pbrcx4wPJCsIxITtHIA4Oeta90dLkv44rO5ltb5UEk+m3IImgBzzj2wR2BzwazdL1B7zxv4g0Ge3gZrExyoXJQSxNGGyfUg9xxVjXI7nVvGkLXPhXSkSGPyYNTS5Iu4xg5L5274iWxgEkZJ6c1q3JNau1r79/Xp6bE3tLQ6n+0NMsNAv7pIzetaIsrJIPLL5GAvOe4x+IrnNNg8kX1ta6jdPIlw8wLTqSAerfJ1AbggDgE45rDfUdC8T+I9f8Ah3qdxd6TcahbRNDINqrFIjLIFjJPz52qT0zhgDnmtPTlvJ7+7uLtrcQWu1DE9q2+EKpRUiZcCbMiltzD7rkegEwio82vb9Lfjdf0rj0bRq29wbVorvyoF1NosS3CE72AJwN+MkdcdjxSa2I9StXuL3T2u3wQptmWOVyB0Dkhe4J3Z4468Vk64up6n4k0W30RprK3VWe/eWJSpwRjYuQxzyAO2M9q6eO2trxJdNlFxELglILrkRxSkZXcD3YjGD/WlJqFpPf8lf8ArTsNOzujmPD1sG0hIdWvJbPV3Un7J9pW4j4JwFkA+ckAdTkdO1TvFcW4uZ1AuUXAm2N9w56Mh6NkdR0qHUDflr2yv4XFx5CFYWRQkLK7N5yPnc+QcAEDHOffqNE0S4uNE/tpXBkeN1K+ZsOxSQWzg5bg4zjg9auc/Zx5pPf+v6+/UpTaV5HMf6HeWclzNNcR3UbI0ESx53Nn/aYE9+ByO2ag1bQL7Q7h9WS1QW0/P22EBwybvl39wvoemO+TiuP1W38XjQ73VtJS08QeFJ3KxRaZIWuEiUcyIfmxg4DBvm9AoHHqHwn0fUJYtH1FXkPh2W0Zo4mnZy7NyGdX6DJfhQOq9hinUrKlFz5tF0fpt66eZp7RRV0/kY+latNcu6SrCGhj81pEcZKZA3Kp6jJGfTNdn4dSHV7e4tzJGshUqhKh1VuxKHhh7Go/GnhXw/bTWt5bxrYXMkhTFrxu+Q5OwcfXjnPPauVso77TZ2ls5VmiRQc79jFfXnr9Dz7mseaOJp81PT1/qxEuWorx0K3iXw34z8N6lHdi707VtGafDbLcQXCo2OoQBSQSceoHqQK20crF++jwNxBPQDHatWHX9XW2lN2HhjRMDepVmJ446jHvWUt2p3qcjdwQTzj8etOEqko2qJXXVCjzWswYI9yVjDY2cO0mVJ68rj/PFQTLfhrhraMS+TE05Cgs+0dQqjlj6D9RUrhU5ixtPoePxHb8KktLmRGMsZKOhHzenfrVXtsOztocV4V8UQ+KLea6s4oyIdomZWAdQeAxQ/Nt3Agntx1BzXQ2dx9j1W2uLq0S4jibcUPPPZgO5Hp7mr11DDdXlxdra2Md3ONs9xFCEllGQcMwwTyAT6471WuoWSEfIcJ1/KteZS0ta4076NHJXHhmx03xDd6noupT31reczWF1FlrdgDjaeOmfr6g1PZMZ7UhUzIuVDbflOe2e479+2cHFbUOpHLRghio+42Dx7Z5pr3MCuJJAI2x1I4Gccfr0rdSns9WUtNDlY9UtZYXV722t74natpM4J3Y+6RnofUcfSobzTrTVr7eY1F4qBcq4Uj1x3BUg/j0Oc1qXY0G7vUWQWzSjlDIpByD2b61LZ6KlkkUlgluEiGFVAqkjHsACfwArfnS20Zeq1Kel6DPpzAx+WsSKY0IGXwT1YYx78dM1bXSmWSSVbkQMzElB90noGweM9+Pzqae6cQBpIwkoJGNx4P1wKguVGoxyrL5ixyDnbKVBHOemCB075z2pJyerE2MXSbYhYhe7pkDLng7gcZUjJPQL6dKwdT8K7XJspLMEDIiuLc4J5Oflx6f56UW2gsrrDYeREEcIkq8eaBkksFI6kjAJHIc/wAQrpRZy/Y/IvJ4ZGwF3BiVOP1z+f41fM4vSRUZWR5Tq9r4w0uSRrMad5aIFZtNcHaO29Wy+PoMe/Fc7P4f1m+tzcN4auBE2FW7tYTEjg9DtOVPXPGOvWvW9Y0e2lDmOWeB7ZkaS6jI/du3C7ucDjPUdKydSa50WRpQssu5TIZYBswDnlgH5PHcfiM4rZWa3FrLqeXXGl6iFULbzLGBjbNICwxnkrgEdDzz9c10Xgrx1rvhxxBBqLPbqcyWd7mSMDodu4Eg9Rx+tbVtrEGoSW8MN1DC8gKwxy2iLHIwxlfMQkBvYgdR+NbVtHtb4P8AbLFoJk5M9rktE2MMHXnOPl6ccdfQlShPRq5tGr1nqejQ/E/SrqC2uYPBNq+qxp83kGHEinIb93tz1wc4z+FFeMXtnNosSTyw3T2h+aLUbFh90+q54OTg5PeiuWWGoJ6x/GX+Y5UcM9z6ckeOONkt18yQnDfwiltrYzTbB1OB/wDrrB8N+IX13S49SfS7rTo5j+7W5YEsv8LADoD2/r1rd0udZpHk3FhwPkPT1zXnOLimcrWl0WZYIYZjkZZR1U9OeaiubyKKTZI20j5guMkHHf8AwNSXDvuU2+DM/wAqMOiDnkevfA9aoCzJKR+cx5wzntnOWb+dTFLeQl5li0udlyXjaO5IJWSO4XIKnscDjp+H51NEIlmeeC1S1UDcyxDcikkjd/48T9a53xJpdt4q1Kxurq5E3h+0hMdtY28jLbTyIT5jyY5b+HCjrg+pztWV+08FtHa2drbWJwRAsZXC9c4bkfQ1XK+W9tev9d/lp3IervYf5sSOiojZfo7df/1cHin2mmWVrPd3lpbLDc35WSdxnL4XC9T2GeBijzp/LuJrW2tGjhiZmM6s4XB+ZtijOB1+grB0LxS+s28sthqFrdW4G5ZrdmCNgjKkFRtYEjhuxo5ZO/L8xaSdkdNGEVii5Z3yzA9cKOSPanG2ikcuUEp+9kjGRxwPf3qlBG2oRlZ5ZIUkyssqoFKDsVx1x3p+uPFp8rEmWbTi2xbuJN6QH+EyEcoCf4iMepFT9q19f6/qwbOw7VYW8u0vNNkkW9h3LLBMgaMqTyBkYZWBOR/LGKz9Lh8rU0mgiNqyqGKoTtjxnBHJ7nilmv54YmRlyxPyEHnpyCD09iOK9M26Vc+GnMcYureCAvtjAaUEDPA7NxUVazw8VdXT0/r79BN2PK/Fc9xJ5vkX/wBiuXaORbiWMzbwufMjK9yRtA9O2OoV7+9msdPktbe1mDkfa0mlZHSPHMiov3yOPk//AF1D4k8UaBp66BePFeR2esjbHJNCCkBwMCUZyrEnGACMg10lpZXEXnyRCS3ZEE0M0i5D5yCFPT8fcVs5qMFdf1t/X3jumtDjr/WNKh0+O/8AFVpdCOQNZobC23XEkZOCArcmEDLdDjp2q34bu9L12/tNOtb+aaC3nFsz+fgwouMALtBAICgNk9c9RUd3qXjjUnhlvDoUNtFIRbQXEUkhkRvlIkmDDDEZGQp9RnrUs0mm+DdStr+wsr3ZK5M9y7p9ntiD9x2zvJIGOR3HNaJtprr0s9n/AF+omvvPVvE/h7wzc6e95r2m6e0VihuPtM0ILwBPmLh/vDGM8GvENM+K/hzUr2S2ey1sXN06fYYzEDJv/h3MWAZSMdegzknOa9f8Sa5oOraTZ6LfNIz+JEktLe0DNG8o8ss5JHKqF6tz1HBzivJ9Et2n8Q3GsvBJaPpMyaaNLktVhW2WPIXEn3pE27mUAKpO0sCMCvPy+LUZKre/TXz/AM93sTCzumdboej+H7INoKs9xeGPz5JYCx8ksx3Mkj5Awc8ZxtPHpWt46c6D8PdU+zXVzp7x2v7jVJpUVVkJATewJ53EAHHccjrTD5d3BKtrdsl1gvFIzBWOT69Ouc1m3Wmjxr4WTw/4j024ksTIk6yW0pRhtwcc5GMEjAPOTjHWrnzSkpyeiavf8+gnB7mN4dg1GHQ4rXVbnVNQul3yG81C3aGZc8hWDZKnPTBOcZ6HnZi17V/Deianfzanaano9zKFtAIButWZcFCwIVhnswHU5Pata60+S2iWCOSSKzSTzVEgDMuF28AZY8HgCq2izaL4mhksZGWzgnee0k068QJK/lbfMwCfmHzIc9twzyKudSEo80lePXT+rP0G7dTlvhVLZeFvCEUXhWRfsss8kkkt3IC8sjYAYhfl+6UwATx15zWjb+PdTlnv30K60u4lgkKzQFWMLMBgkEHKk45Hqenc4ni7wzZapfWfg/7LIhhv21AX9knzW8Ee3zWLMfmcs0SkbiRuDbcAZ2dcEJ1+fUkjsEu7txAryXIg845wqgFMk4Iz1PP41ryUZyvy3v6fL+uhS5W9Ubl9qEPiDT9OnvNGjtdZl2CVjjfGdpOwOMFl69eMjpXLa/8AaNJZZyCYnZ0eEg7tq9TgnIBAJBzg4PTvoA3f7y2uGt0v7QI86wyF4k35ZCHZVz06duhq81zLqojgujEm1hIvcsRk7Qf7me31pU0qVuX4e1wi3Frl2M3wl43sLVpvDXiWMSQW2GSWM72jR8keYo5288OMjGM+tWUhhW3XZKs0UjHyyxw2AcDP5Vi3/huBL0XEVpG8jRiMXCqRL5ajAjJH3gvQcdAPQYfCQls22aREg4f5N5jzwCcdj78euOta+zhdzh137f8AAdzRRS1RoYntWO1lmhz/ABHDD2p6zRxnY5dUb7uehU4NV7WLy7ho7qWBTKpRJ3XcivnHzDqOh/oap6WLuzlntL4+dCvRiQxQ5IKkjg+qnqR1AosmV1sasirDIPIYg5xt65Ht/wDWqG7vt9owWQxbOd4ySPcfl/8Arp8cab1MbOiEHDLyPeppYtO8jZLvmmI+Xy8Jt4PX1GcUtE9Vcl+ZlSf2teXN1HrmliCK2iWaHVYmjMM5zwgKHlj6Yz1OAOr4rZLlpba8SOVMDBwCrfUfWs/xRpGuldMvPB9la6jYsNt/FIx86FhySBvAIPTAXjHI71f0udVjbna6MVIAxg/T/P6VcZe77v4aW/OwRXuvUS58P2s9s9tdt9pt3XaFl5GfU+pHb9c1Ha6XBppK2MsrxkAIGkJK9eM9xzmtUziRCACR0OPWqSwlickls5DdlpqcmrNjV1uReTuuF8xd0ZGDwMDvnj8fy7Vlapo7qQbSPeOy5z36n2/xrX2uY2ibkkELIO4/xrn77SbRdjw/6LqpYtDdJI8hdifuyA8gLggjvu+X1ram2nuPm5ehW0u2nt5AzW8bSAYaJP8AWqfQgcH6ip9Z1NdOtlm2SC3AyxjXBX1zxx9elbcRkykVyFUsAGZTg7u5FZFvJdid1ZWfT3IjL5DFSQBuA5ZWDZOORjnitFO7uyubuc/Y3N1++TTNQgkhuo3WSO7WW3d/MVVdsfckIVTtHVecCuh1PR9PnsZYZGR4SmCecZH8Rx7E1Jc6N9qnEl8sK28QG0gZwQMArnOBg9BTtOsY7aOaBZ2kSbIJJzgnPHt16VUqi0aYJHnN/wCFtQli87TF06WyVkaNhOAwZeF4AHIG4Z7jHHFbU2nfZtNt7e5Lf2gsYVpVjOGHQdOnrjOP5nZfSVlhngd4o5pdgaVUCsArEgkcZz39cdayfEGpX1jr0Vvb3X2eyeAOpKlxLgbRn6sfz/GtlNyeg7qxmaNNc295MAIpvLLCZDuL5J7gjDHp83oKK0YZbe7MBudNSbIK+ZauFkQrwQVPuOlFOSTd2iotJHWaRoujwapc32mRTs05X7RdyXXmrIqjCxqPqCc4HTrXRF22oxRlXOFRMcU0+XFEsStFAjEMBIDkg8biBzj/AAq9MkcNpvd1MOzIbIO4Y614853ZktNBLUOxGxMAdWI+7n+RxVK7uB9ojjcYtpMorMCQWPQcdyAfy6Vmt4hg8+7sURXuYUjufs6MQwjYhd+eh5YcVNPfS2r3UbwyXKiAultGozO6qWQDnIJOR68DHJpqm1q0LzLGnWccNphhtjRzjA+6ehP+e1atpEkEOyFRh2JkY8sx7ZPcVT8OXkOveH7S/wDsUunO4K3FnKpXy5BjJG7kr1Gfanpq2lrfG1+1I0u0OUjwSFJxn6cipk5SbRF7q5MqXNhdrc2M6xOOSrIHBOOo7j8Ov41mT2/2S1vY4rczXttD9qS2gUL5x2t+6ij4UEY7Bjz0xW0LiP7Ot/bSFrWJjFM7JtWJ9wCkMeCD0x2Jrn9Zv55AhW1lu0afyJreABzbIekhiYZcbvvnqBg+1KHNJ/1/X9ehBpadffarFJJ4ZLWcxgmKTGYsqG2ntkZwf6U+JHilD28/ljnEijs3qD1U9KW0UNpsn2fy45nbyfKUHbvOcHJ/hIH17dqZ4k1t9X0swaZoFzZ3Vjbm7e5kVY4mMZOYApO5hIiSgMQADt5NJu0rJadfL/gA5WN+PQpr/S2vWSNgFJBLbc7ePQ9hXJ6tCt1P51lqCxNEkkPyoJYvNK4QuQcqUcDOD6g+tVfhZfajoGs6jJNeX2radqU0d5ET8qQ28i5VymOGBG044OO2OWf2FFbWtxeaN5tmsGr3FxMVkMvniRwA5VgDGTtIZMYHbOaVNThVcZPTo+1+lv6727NXTs9maVxAupQ2VrqUdgbiSRQZ5IRK0DYEm5cnruG4elZmj+IdV2a54SvYpYPs0hjtLy+QPxy3mbcYMZK43jldwyM10UssP2NYjaQ3dvdttEBfa4GN25GxwfTp3zXFfEme40rw1Dreks91FDcKZZHUuxtyCu3scBiSVPfnFawSm+WS06evf+t/PUEuZ2OgtbxNRVoPNMF1bNEbywlXM9qWXcI/Qo3UMM8HqKn1jTLW50O7luot1lIfKkOcAsR0X36Gr1pqwt7i1l1LRzDo+p2qs2prMpe2df8AViQFQdjA/K2TgnbgYrNuP7Sn1ZrbSrZZYRLmTzpVSAQbypO0HduyCOgxkfQzGTb7Jf01fv8A8Pr1SlZlPRfDX23wVrngvSL10jltRFC97++eEGRdykDPGAdpHQnsat/DXwZe23hWPTI9Vju7iKUiaeWd5FYqTwisMqMY4HGeeKl8Jxi21GRb1vOjn8yD7QHWMqCwK5Zf4lK43DHYmu4OgwwXu6G8m2vsaT94A8h4APXnO0E/3iCRzWGIq+zk1ffUTdmznb6xuNORVnhYSpMItkQ8wSEj5QvrnA4I5rpNW8HNfpo1xDfeRqem3TXSSlC8bb0KSRlSfuMpx1yMCsS+g+x+IfskxurucQHUrKd5z5DyoQBG5yW3dMEggDp0Ip/g34lweNLbUrPTLa4sNatbcM6zw+ZHHIy/KQwIDLuDDkjOK56rrSjGpT2W79dPPTe5M3zLU4/xdf6fPqviLSVj1CTVdPiW6ns4F2/aNgLxmE9fvAfd9GyKw/h/pUPjVra/8d6zdR+Lbu1l/sgXcSqYV3ZWaNcAMwBB2N6bh6i8iG01m08QeMY20rWv7Vt7HSruGTzjdFwQUlPHA3sW6KCCBkYB0fEHj/RtctpdVsdOupp9NnewmdrcpJaScqJACDtxknntnPQiu5OTSpw37q2j+fTZP0sVf7JR8MeF9STwT4j06x1x5dainlt7nVbqFwxSUIZzESQzbiinfnJKjnirlpqFr4lil0HQpnn1C0vobC+1OaERGKNFbzBk9GYI4BTBBYjIABMWh2fja/8ADl9q8+rTXirAU08LpyQkDcC8pAUlmKj5WCkE9uSKs/CrxGk09/4e1xtJW/u0+32upWMCra3bsWYu4AXEykDcHCscEfWarnFSkrOz18tvJX729Sb6XIrq1NtDY+bFct9jcyW1tbygQ3IDFGilJBA3KzYJHYcgjjsbPQUuvCtvHZyWh1GKPdkuCYn3EhSRyV7Vl3OiNbCTS7bUYZEiDW9zM7IjM0iktIuOFcNJkjgAAEA1yHgzwnq2h3Gs3nhi2urO9toWhjmvJBN9qIbG47fkwygEcZHfNOUlVjeM7Pf/ACv5a+f6D80ztHKNbK0bbbuMgyRg8Bhw2Pb+mKy3kzcPLG5SUoY5AOkiHHBHfnmotBbWtQ8OwanJY77/AHMJcSgowWQjcWBPGCeBk5A4rHtPGfgy/wDEaWB1DUrC8lO1op4GR4GPARxtZGycEEMAQR3ppcraWtu2ponbcvajfXVssMEDiKGRAknyqxz2AJB29OormdR1LX7GO3uLS2a+2BnvLfaiYQAHfGBzz0Awe2euRsSalYXOqzaVfyKS2fKuYm3RTIpIPI4DAgd8ds9M5+sasfDuoXtpqcslhbx2UclneyWzTrFOZACNq8sSGBU9OueldULLS2v9fP8Ar5G9rFnXn8SNbwzeHESWaVkDWrqA6Z7gHH0IPOT2xVbSNa1m0t7hfGlnFaywuE8+GJ0XcPvBtwwoGVG48c9a6fQHnfSLe6k1O31Ke5iWeK6Sy+ytLGw53R5Pzg9+MjqO5gfxLc2+oWFnHF9oj1CGcxC7jM1qpi4aJ3PMZ6AgDAyMg1mp3VrK33f19xnKo+iJZr60tZ0RZCI3GNzA7WOOxHTrnFDzWghEtpIkkqvsaKPk7McEjr+nb8aLPN5aJN9lV4XQSCIqAUB5+XpwPT/9VY2v6WLuW3uFmu4pIiVhaF8Kc9UkTpx604xTdmUrG9EYriESwSqB6nnB/ofrRLJ9mjLTMo2LuZgDjHrWG1vPC+TMUvYwBI/OW9mHf/PWpDrGoWywFdBg1gBma5t0u0t3aErw6F+GHUFQc9OnWlJW13HKNlzLVGjFcxzRLJG2UaTyg2PlD4+7kdD7GqtzCwklmjXewXZg8FTnr9Bzx1qVvDUIiN14ZvDc6M3JtJ4syQg8lVYfeAJ6HJHbipkRmcm55l6788Sc9fr6/SqjNbxZO6M0zvdSRzS5CE7QQBlTjnHr/jmnXrWcEctxIGHl/PhBlsk4AHqSelX7pBE37uzZ/wC9yMfketUr3Thdxp5EwhaN0kBYZ+brgj29fxq4yWl9C9CnFqa3bz2eoxzafdwsscsUzozxlwSgcITtLAHCnBqvb2d1BdDE6mKMuwRPleQH1UcZGO3btnNaup6ffanbwrqEkU7xMG81FCs4U7kzj7205wSe59ao6nDZ72m1GG9mWKPcfsqszCNTl9qjjODnk5wuByauEtLfkK/KuZli78+WEyafLAJkwSsyAqynnJPUcVh3EQ8QK1reRtZarbRsYXXIR1bgkLnlT0I/+tWlpd1Ff2XnWV2lxFEAUnQYEinpuAJw3XIHqKfbvFdzgXMUXnQN8kin5kJ4IB9DzVJuO26KaTV+hiQ2Ntt+z3c1zczXBy0CSkYYZJXA5JHJ/wD1Cireo6Onm+cZ52jViGRHCO2Rx82O3vxRW3NL7D/r70KzOkv/ALRdqqwyItzBfSG5BTJdGXcuw8YwcDPoMYxmujOnmTS4kQbgUJ5Ge/8AiDWFJbN59xAjSNDEgE8v3duT9wf3iQevQeldI+v2kWnM8f2eAxoqBdvOQMDqeWPA98V49TmSSgZ1G7qxhrpEBuYDNbWouEQQm8ZCZTEDkJuJ6Dp644q5caelxvn2oUUjc+7IHPHI9+mKZeXF3PDuldd7MUJReFHsO561CbMvYy2t1u3kblKPx9cr16j6GqTbs2w2EN6G028sraIRgBU83BJwXAJ2+mMjA6ZrI8O+HSZrO+v7j7UXnYedIgXZEMYjA7jO3rknb+FbWlRSvHMZgFnZQMFs9GxnP41reJbyx0aDSxdFEtFaG13zHKl5S2N/93JBGf8AaGeM0Oq6b5Ybv/L/ADJbtojj/s+razrOt6Z41s4n8Jyv5FlA7oVKDKh4dvSXAZ8kgjH59jd+GLGPRreK1ka+NrZKsrXEpbzlC43M2eCR1Irf1K00u48Lh7eBZriBSbVUx5pkQkAAjrzn2wT2rnb65+zRWksTFbG6LJclY1fYGXPLZyuW4JAOQ2RXNGs6rvD3baW72/V/mZ3u7oxdRF2fEWn2uiaZLNp8sPmNK/LW86Z2REE5KnAHodxORium0+D7LPNcWazi7BPmWtymGUEjgnjcMgYOOfU9a1NIu7C/0KIQoVu7ZNqyQoX2sO4I7eoP5Vxmrp4+14WutWEmn6bHbwzMtucSx3gDAp5hwrRjaXPG7BA6Glzym+SWiWju9/8AO/lsS30G+IfCN7BounyssEEFneo4WSRizRbiSGUcFgcYGSMDNUdC3Q6xqmntfRzSS2bXBk2Pm6tHcohlH3fPWQldy9sfQaOm+JdN1i91AT3N6l1p0ohu4bttjRK3EcsZOAYmzgPgEgjOMgV2vhDR7eSCW6vLe3lfc0UYKhti5BYfiQMgccDvV1MTKlTftP6v/V/6Q73VzirPT7az1e0hS/IuGdFjtpgvmMGBIKjIyDg8j0NafwcOv6xpGvRePbazedrx1S2VUKxxMMFCoz6HrknPNc98T/Bq3fjDw9d6fbQXc2k3cUsnmXPkvDZuzbk3ZGQrYZR1w5HOa0PEvgm71rwzef2X4nudGltnMu9MRMqbQRvcMG+4T1OOnYZqKk4VqfvSte2ttV93f+mN66lDxt4a1awSXRNFuJYdMR0ltneEy4i+YvbgtndjBwBztPGcHNfwnLeXd281zY2+k6yqNZLNIFlaeFNpDliPlJx0HQqM1Z8FeL7rWnuPDFxLey3/AIcCi6+02wtpZdhwsoYMwyCBxkbhyM5xWjf3NpZ2VvPf3MUTzS7F+2DEolc42DA+Yn/6/BrohUny8krN91rfz+fX/Me6tLSxROk6jpmtw6vd3CQ6HY6ZdNqMspG1JfNEiyKo4JYZHA52kHtW7LpGu6nq2n6xpTaVHo8G83FpHblWvsEYxnjHBweOvIPBEd/pGpaZbn7VHJDZu2fOjfd9mOMbsdAQTnkY963/AAD4etLHwklpaXupyeYpSY3V00xDn72MnABPPGBg1y1qyhH2id9fVa79f609SZLqYHinUZfE96dPgstW0+2l055ItTt2WMnkZRJFYt6cEAZWovCmnR6FNpFjq+qWo1GWMxw/a4xFNqDKTkkHDE8gc8nrisHxJr2p6Rp63EFu954ftpSLxbOQia3dJMOU74GNxHQjnkc1L4j1jRrVtK8W+JNOe5l89BZaqYpNsIcApIUUlcZx1781sqUowUI7O607/P8AH8PIcXbT+v6/rzxPiBYar4v8a6Ra6BeQ3HhOwn+0TTofPihuYz84LZHzKp+X9a0tU8R+JtehNloZt9H161uGma2Z4wutWhX93KruAGxgB16gE8g4FaXhfVb6703WvD+meGYdMt9PuneCSFmaC/Xd5jbWYAjcSDnkEcDtTrqyvrq40e5uotPhv7CV5JJIl8/yWfG6NMOpRWUFSpBGT1GKfNrFNJW2vr03fe/X/MaV46rY9BuNVNzpZs7gTWN5cQeWHgcYVyMHy5MHBBJwSOOOK4LwT4eHhBL/APsiVpbm4nmvZpr1iWYMAdkj9X27TliM854Oa0NOeW7HlvZT2l3DMy+R1wOqsCeCuBnPBGORWd49k1c2ci6Ja2t35rp9pa7mMQhO3cGRlADkj5jn1HXtz06Sg3BOyf8AX3fMcI68pW8P6HZacmqeINTYJBqk5vtRNsxa3jbHLKzZIALH69eOg1fC+t6HqAuLnwnrK6jottMIriGRmQIzDPGQGwccHG08j1xS8Rapb+HvDN3J4guIE05tkbTTRs4XnG3aMksd3cEHknpUGt22oab4esU8DjTo/tdzFcS3OlyxW5SIEsWAI2uWU+/UHHStNZr3nvp5flv5hNWbUXoc/wCNfDmt3fidtU+Hus6lpks+4zac5McW4HDOhDbCp6kDkDJHPAn0LRPHGlw3mprpulzXN3bCBheyI8UoVtwm/dASNwWwoVSuSTknjW8U+OJvDdtpFk9vO89zcm1s4Vt1ecKCV3J2YY4yOoPvxq6zd+EptQsLL7bFZeK1AWCLcSZTg8FuVwQDz/TitnUnyqLV16X0XfbTbXXzC7irHDXOl6R4Y0eOTVre6l0i3ty9tJCzS/Yl3DKogA3OTkkvuIU/exmtYa7aS6LZNeTyXGn20BltrkRNva1Zcjev3vlxwcZG0/jqm112DwrMkdpp914kM22K2jZlt5U3AfK7YDELkEjHPOOKxvDet6brmq6bYQ+IdM16WMNb6k9tE8UsZZgN0eRtMI3MhwcEsp5PNWpq3e1/+HXbt5mvOupb3hXt54il7aSxB47iJ9xZQeMOcjkc571Hd3Fjb/bJpJPIg2+bM8sY4AHWRTwWA/i6471zN/pdz4Ch1Xw1DbvNG7SSaa06F7ebdg+QeQVDZPGfvE4OCK53wF4jupb77Fd2N22gXEzWtxaXC+fNosxOON2Ge2OcFTyoyDyAz7XSSktU+3b+vIbjdXPWEvlitort7mOaCYb4nXo4xwRx0PrWbqN5aRwm5kuZIIyN7YiLoOnOR0xn2rE8Ny2qW9/4dDxLFpc0qPY7m87T3DH92M/6yBmOUccjeAe2cK28ZWOjz6nHqUd3pVxZrtuIgi3Mc8TttDou4BxnHzgqBuHB60RUY63/AK/r+rCsmrncW0ts9ss0Ie5BPl+ehaTccZA2jnGORxjFVdRv7WwtFkl+zwqNz73yNuMZYngrj1zVnQdQg0vSlewmaeO9hiuVezkMUkkbDeBHyGHowyDkVDqt/oviuFop/NWeRCG81Buc42j2YsBg84z71UXeV7Pl7l2fRaGJfXOoNaxm01h9K3lWimhlR0lPVTsbhhyDkc+4rQ8O3HiO61OHSdSTTrv7SW+zahb3CxbyATteInercYzgrkgZ5o00aMbePQ5bom1ijHEduzFEVgAcA5ABIBbGBu681l32oaUIHSPUFGmXJKW84i2xsVJXchIyrod2CM8qcZBrRw59EtfR/wBfIvd8vU662vokma1uZIJ8OyBkmRiGU4Ybk/iU5ypFWHdo2DwXKugIG1+MDuBXm1ppEPhzVLW7vdQ0SC3uxJGuq/Y9kkjqMjerOAC2SplGwZ6k5xXQprFha6i9pJLHf289uUuo7SVlkCMwCywuAD97aMHqTt5JxUezvqv6/T8fUSS26nSm4YuBGF85Tl1B4I7/AP66cyslzFcwO8NzA25XXjA9D7c1yOnaedLvw9lr8Op6O20xRPuWaA4wVKsSQBx3IOeO2NqTxFZpdJaPBdmV+EdF3KQex7kjnt3FDp/y6r+u4mtLosbCLya58u3juJm3yGGJU3k9WbH3iepJ5NZuo2UJlcJcC1WX5v7pBxjt6HHtW3+7dVXIPI3LjB55Bz9DWTdaey30V3jMa5WRSnzAYI6d8d8U6c7PsCXQVIAts43ea6NjexLZP6dqKq6SHtImY4SNyMq7lgDzn5jyR6H0OO1Fa3adkM7UmK2t1t2KmZmZmDbgxbklQCOcc9KzAunRhpnKSICJikuBH+JbgHPtwa3ILTwtYXd3PqGuxvcRy5SCa5V5Ii3Yp976ZHANYPi3xN4SutLj0HVtPubjSb+aOyknQKqWhdtoff8AwhTtIbkc4ry1J391N/h91znU1rbYkuLqSG3eeRRD56icrFIH2nHAIB9D1x9KpjxLYWscq6pC9raRBTdShlPlKz4G8feAJBGece3WuV+wXmljwtfvO9zA5l0y5dXAjk8qVl8zB5+dSvAPGfYV0Nx4U0LS/Fhn1bVJFTVI/shjDB98QAZht6AZIOQOuT611uFNKz132v00G2ranXh4Ltrq9sIliijjUyRI4ceWThgTxgg4468cVx3xIW9tLDxFq2qT2M2g2sum3UGn3Lnl45AHQ4HJc59ju5xjnr7WwtNIlmjtXC2CxljLI2xQmDyxPbjOTxWjdrZa2i3D21rf+TtuDBIu+O4UYYHv0OCDg9AeR14edQkmldf8FP79CWtPU2bq90680q6nEcEU6N5qkEFn24OQR1yB+IryxdV8SabH4jg1uxQ6dZSzW1hBEMzTbpd0M5PCrb+UwUsWPI5AINVvAL2GiPqFloeq3WsQK7Ott5qNJo6or5h8vf5koHqq446A8VrtJe6lqfgfxH4RuYptLlEi3s8b4jmg6bWRhuLIdwB4x0PPFKFFUZ23Xn/WmzX4rQlbCz+DW8V6RZiXUdR8PiEpdJDZN5LxsAocS4P735gx3qQRkYz30rzWPE2keJorzw8lvf6FdHOpWFzNte2kB+aaBupVuu0AjOTgbian0k2XhtX0p7x0jMm6FriUALuAwsbEAAHspPByOcCsTX9b8RaL4iTT9KsNNngnRZvOuUKzxLgl2HYnAOPXsc8VVnUk07NdL7W6/p/W4qTmbF1oh8RWVxOlu+h6qYTbwagIVdhGTu8tgfvxbhyjZHXGMmk+H2hSeFI5rb7RaadPc4uLwwFhbvOwwWjif7ucdAF4HTgAYXgDxnpuuy6jDpmp3OoRhTcQteq8ctu7n5ogSCpQNtwRk/Njpiuqns4brXre6klZo4LdreBRgeU0nLyHA+dsAKPQbsckmpnGUbweif8AXXz7/LzLN6GXL4iiTTNd1eG2k1kWoBmYMG3urorptAJHH8OMYrM8fJ4d1Pwlb3evapNoVhdGG3ZFlZTOjEsLaQorH5CMHjjGDitLT38M6jpeuJcX/wDZ6anu0+7h1C2NpLM7jy1KsThj0AZQ3TmuP022Xwgkfhe81PTpbLSLCabWreVfPdkIyrhCD8pUrkDuRmqik5cqumvyt93pp1Q7pt20/rzOlstX0fw7pGh6Ybq+vNPmkNrY6m3+kRxkjChmAwVYkKpxxwR7c14p8cpe+I4NF1HQ47pEuAJLi5YxRRsAuxg2CDhsjJyDjHpXUzCPWLbR7nwjqcVrpouEup1txtkmjXH7tcAbcHdkYGeOcVavJ9Il1m60qUW0l2yK01pJbAGROo3HHzYOD7Hoc1rHlUuZxbevqv6+70YXSOjufF0mlpcx6nZ3l28PEn2SLzHO7gHyx8w/lVdbq5lk1S00i0ls5AwEPnviGYEcqNvKkc/Tn0xT7zTyqjzbdYJZDklHzgDHBz27D0qLWJ9W0rTYTY6talAypGk+1jv7IDklhj054rgjGGnItX934XQly7WPPfBGjf8ACJapFpN3qcEuo6pcyNbRwhsjy1G5pGbnPbJ7Eetd3f30ttpTiK2gurQlopLaZQUBGOPQAdRjiuJ8Ka1qWr/EJrPU7aPU9MsJ5HjvrTT3s2tpDGymD95y+7Izyfug5I6dRc6vq/8Awm11pFz4Y1O20yUq9vqCIksMjhVBBAHyZJHXJ65HFdVeV5rn1dr/ANddv61G7t6oZqNh4Z8S+EoV8SaWw03ThJO4hkcCFQDuC+Xyy7eO5xzxisOzmubG3sZPAOq6RqtvBHjUi7oLiZSn7jMh43gAbgSM4J65xoWPjWz1K7m0zTJf+JvZl11CKKJgluE3bld+AG42gjjJA+sd7Y21pJH4q0jQbW6vLoG4mso5lha5aRTiXcw2lwQecYKyucCptq4SXot1+PfXVPzKjBqKmtiPStEGlay+uar4i1KC0ZWubyye6E1mi4+ZQcAjGM54AzjmtC3ubjVJY9e/dPCjDyDayHyGikwx6j58nqSP4jnpgUrR4tc0ma21TTp9IRZDb3Fhqa4WWJ0UEKysQ3JOCCOfTgVu6YNF0m0+xzWdwllbqkNsIQWKwAFQzHqQAASeTz35pSfMuaWr/T+vNmkZODfKt/v/AK+Rxuo+L/Dus3s+ix6tprykgC3aNmhJPHkyK/ysRxjbxkHJHFbtrZXGmeKmfTNCs7vTJ5i+sQtcAyQTKi+XIkedq7l2gqBkcdqo+I/DUPhvWYdf0LSLLW7WaVLiRRbh57eVujhgfusC3UHB65yCNe1tYbSwjfTGbBO+QtO7TAtyd7EnP3hnv6+tU+WydN3T7/rt/W3mXU42/rzMiDUPDtjfy6fCdVuw8zZe62oYhncFUY3N6b/1zzWkbOHVJLd3uZdNeEiMy+WJGAYg4WbG5lPvjGeauJqhfUBp80yC6KbwhGZAoBPX2H6c1znifV5bLToILKHV7q+wZFg0+2aVnj5J3YzsHIG8Z9q0jB3XLo/W/wA9Vb+vUJNzbcndmzqOl6uuqCHTtRlgtorg3M8jxArMCvyW1svYbhuL9zwT2rn/ABH4OsnjsLqFrnTNRsEMem39t+8gjLlnIZFGDkswJ6YHU4rY0LRZ0ti2s6nqNlK8sMqxxMJX2ggvGQyAgMSBkjgD1rP17XkvvCGtXWgxReKtL+fTX0YI8cjjzAm0jbvDLndnqBgjHWs6alTdua/9fNffp0M1JrbU6PQ9Vk1HT4k16CLUlWGNGuY4sGCXbn67SQSOuOma4Dx0mt3dlPbaLft9uiIkhSTDxTg8MikjhmGBknrwcZzUPwp1Dw9ZXOo2OiXOs2M9vci1m0y4vBcQ2snz5aBiB8hwQxYD0zyK1/FGrWfh7TLh9Rt31ExjYfsibix4BORnacn0xnH1rXDSjzPl/wCG/T+vmaJJSbSaTPKTHea9d2via2f+z/FOjyxWV9b3P7kXKj5UQ8AlyoK46lV6DGTFqviKK911bqWFrm0tXkt7+wuY1me2iJK+fADglcH5kHGRk9Qw9W8R6Lo3inwggvGmhingjuR9tJjUFQRuYkkwyKPlOCRyOMHjD1DwZvl00zMt3qcEe6G7nY+e8fQKSuBPHyFJPPPJHQ9cZQe2l/69P6sbU3zbaMzp9c0/T7HTbaDTbu/0+wXaLvT7wL5KMcRYiYEvkMvykBsnqc4rv9B0G18u3i1+SSC4nO2K4dI4mUuGK7kBPzYweDyOw5rkZ7QJcbrxBY6pbp5cdy8Y8tVBDeXvBCnBG4K2O+D2rT8SX+p6XoTWsGhPrE8SeZtjVpo3t8FY2Mq8smcgdCmBkjg06qdrRdr/ANaf5dXoTJ2dk9zmPFHgiaPWTa6zqQttRjvRaWckb+Q85ddwEbEBWBBHcYJ25Pe94p8XP4KtLMXttcyJMWWYArIYX6FMnI5AGRzkqelY+n2useOrO6b4lq1nGXt00zTiotmwqvhw7bnCdFJIYtv68ZGnFqsGq+FNa13UmbSp9LvZLW/twPNXDY2cN99Tz75H4khU9ol7Tr5W1/yDnbXv6GnrNout6FYXEXhTTNdeFjc2YST7LkPjLBR8hJIX5WX6ZxWb4d1S0uNV8QQNp91oGvahCjahY3+n5YnJO9OOFZjlsIoJ2nHeoLO7k1qxs9Qs9TleKOMLFdqBF5oB+aPaOcjHrn2PBNiDVH1C1V4GtNYsWyqFFRMHjguQAWH4HmrVK7TTVv6fXTz6Gipq90XDItrb78u9ntb7R9hmUJEuOZUEgYIRgk5BT/drn/D+p3VxdzW01xaeILJfnivrFk89cA/LNbKW5OMbl4H95hWvqt69lp0dsllDOLkbZpZ90qRjPzIVDLk4ZTywzjjuKpQ6RplpBKfD91pOnOEWTUvtW+CAf3WSQRsVyckBnI/unmrcXpIt2veWx1tneJeyws6XcckgCRsw3CT/AGeg56jsQaq6dq1rPey2kWoOscM4S6imUxzWwJwTIjgMoGepGPeuck1Ga3sJporyHVbGNwovrW7SYxluisc5IyOA4VhzjvmvqnjJZvEdpPr2jJdMu1YtZsyY7mNHGzZcZHzpz1I9MHtUuDS5lt/X9eRLjezjqjttF1KLVLzU9Nktbmw1zT2w9levlbiLdgSxPgccg8g5BBB5oqGLyIpUeaJpzGhjUoQSozyuD0Gedvr270VPK+n9fj+Zk4SjomXLCwhXx1cR6ZYwtbXKLdT3k7Eyzyu2DEWblVBVQVzgHsDT7uPUhrOt3N9Y6avhbTrLzfMiTfLv58yFk53AhXGCMYA9SKqxapp+mWn2kXUVzpV47GeJys9qzbMuyY+fBwe5B9M81uWPh+1n0CaZQL/TbyNiYby7d4yhwSVZ5d5AAAOWHcVzVU4K79F/wfP+vIwu07lHwIkOpeFodWtrX7Db38fmJaGXdGvlkqrLFnCnAAJQLnr71teIdOt7660643xy3tomYpGYhDIBgEHpkE/yrF8PWl3b6npun+LdVtrm8u5JP7Ia3skihjihQkxKYxgfJtIU4xyASc11zWrvqkSLvaLcxERAGFGPmUk8gqOpwf0rKdRKpdPv6ff+Hy9BK99TmvEmo3OmHSYtXsYZNA1PzLbUb93Ki0LLiMk9OTu4I54HGRnW8DzWmpeC7SSze8MLRfZjJLhS4X5dylWPynAxzxjHasvxN4yNr4hXw1qWkXFz4c1dPs1pdrb7gZG52lwTwuCCMBgBkZ61o+F9U0m7sJ49ABjsbEJEkEYwuwr8pHPIOD15z15qFzTpNtdb/wDD9nqVZkFh4c8Laf4rbUdOhz4hW2y7mQtIVzwzL03cKN2M45JPWr2q3OlWljcWEGvaZoN5FL92CS3idDIdxO1yFBbdkHHcnJzUFgrp4whvLZA9prdsEGVBaKaHlTn+6VY5yeCtYEWjadf6lqviDx7Lbh2vGtLeOZljtWtwNsYZQMyMwJJLZxwQBgUuX3ld309Xe+23e/5ha92dRFILmO3t7u4t7h3i8qTCKkcpx80irluG7ryMCs3QNBl0q6lntNWuWtJJZJINPZx5FqCeFhBBZPwYKc9AMVcuNI0gR2WlWtki6aubu0W2i3QqFYEEOB8rZII6E8kd6dHLcy6tq0M+lT2KW9ykFvPOT/pnyEtIvA+UcAMCeTjjBourWX9fL59NilaysXrLTneZriK03zsS2Q2di8HAf0JycdM9BWnpN2bLUzJdKVyCCwYMMY4ORj09qzdSujbWhaWeTy4Bl9rBSFPGWbIG3tk9PUVm6bqEV7vawh3vFIUnXdxEeeuAQTkHPTGDnmsnHmi29htOpo2QfFOy07Wo7e4/tpdLtrO7gvnlghJddrEHcoxkMSADzgjoe0V9Fos2qz3eraRZW1kixeTrMbxGS4V2BaHA5KHdtO7k7iMYqW1m0XxLZXE9lFb6lbXMf2KSZULBl3bxHIONvPzAMAQD6HmjDp3h7xT46j8SwX1vdXumxi1Plq222dejYY4DKM/d479a1hFRXK76fht2/X7jNwdtzffS7aG8tY4I/scXy7EW28tAvZgBxjtjpXl+lal4ns7qPT9T0e+vLv8AtWSSSa+tTuWz24EdtID/AHj/AAnjI4xmvRNB8QaPq15rEOhTfabmOfbfIhaN2ZflDsDyycYG0gdOKmi0Z4dSF3p95eWsJQ/adOd3ngkY9HXeTsIzzinGo4Pln+P9XX3fcS49WVLGTV008208H2eO4UpBfiQC5hB+75itna+ByAW/wq6X4Lggt2t9X1641ZSWktp/LzPZz/8APRZGLDcMY6BeOlbmrara6HZGbXr7T9MhYbY5Jpt24Y+6q4JY8joDjNQNI19pS6p4bin1rzFDQQ28ot2dTwxO8AgjrkZHtyKTnK19k+vS/q/8+4ly7HJ+INEudC0a6urKLXfEtlMEF1Fd3jG8iRgV32wRQFOMnjPbtWtNqTeFdU8N+HLa0166jkANvqd3ITu3AkRE7fvgcMvHH0Fbd3EZ9Kaxvklt4rq3ks5XVQxRXB5299rdDx1rFm0vWtK8RabpulWrX3hWTTDC2rtP5s8VxGGJZ0LYZxjoqgnceeCKbqJq0337/nfffQtWjJNoLLQ73StHa30RYL/VWkJmupIFiaYliSW8vG3G4gH5sDketVvE2uXHh5rHUbu1WTw3Dp073eoAb3WZHIjjGCF+diAOMHIxgDNRPqVvovhN9P8AiPqth9p1IS2Ie1Yo00LnAJ2DCyMrAM3QDGe4rebQ7Oz02HTrm301YdgiFnKFZBGjYVQrZBAI4PqM9eazad7/AKb/ANfgaqalHk2t95T8QabpfiHTYItSshJCFWaPe7RSR7kBVlOMqxDDIOR61rWVxtt4oLNZJFEaxIJRlsKMYJAG7p19u9MuLq7h0y9laOW4jtYnuZjtByi5PyseOducY445xWFovi3Rtc8KNr080Frpk8jwtNdvjdjgpgMSGIYHapJ6YqtWrb/j+A7RejLeg3nja216OC90GZdIlQv59sRIIyCPlYFjk9egHbHtU1TfpBufE1uNReVLf/StGScTws/G2UcfI4AG7apzz3yTnadd6f8ADLwtc67Zatq2oaXeyws09zM1zgMxClB8oAznd34wfSu2YXt03k6nd3lxE/yuu9V3ED0XA69+/am5Wm5NK3zTfqtfz9COV7aHP+AbwXFwviO6sbz+13MsUUAmJiCs20OF28EhQBvwRk8U/TrvVrrWNWvYbg6dLfQNawRF+Ig3y+ZEpwQ4YA8g5IPYgh2paU7P5NsJI4kUG1unSOUWc+xg0kcZOWIyMq4A64I4NTaVo9xbaWkOr3NtrNzDIGN5/ZwiDlWzGwGflYDHQ9eeepipNSlzJb/l2/rzOmMKVNNPXmW5keHPDWsPpzWmv6r9vnh3KtyDuaVAcKxLLw20jrk88k81B4c8OSad428QXkKzzTSqhadoVhQr/daJThyMr+8IBb5uvJro1XUDBMBHY/bUDFTbNN5R4wN4K5Azjjnvhu1V/Clx4mi0YWviTWYr29nkkY/Z7dEWKMgERxlUG85/iIH3sYwM1fNJNtdSZzlNJJaI4HxtFovhq707VBo32fkw3d1Y3KWx8jKna4dWSRv7q7QxC9SASOhtZLKfwH4T12+1vxLLPAJfJe3TdcTwszeWLuJUcyAKoXcMcHPUjPYJFIhdLeWRSc4w7GRskHGO3OOR7cVHBCJN5dbiRlOXKoHkJx1PzA8D0qLQWqViJw57cz2Obtbnwz410dU+yWOpWNxOQ8cG/AmUErvVgHjbkgDnIPGc88F4c8EeH9Vu31LVTq66fvuLaC0vFkhjhlfrJGB5TBVbgr0OSMkjn1S2ksnleWGawykv72SNopDuxggkfMD7nB+opLK1ghhZPsT7jN5yXqT4lV9uFcPhlJGeAVI4BPSteaaVv8/87fmX7OEk73PJvB11fWni++tdavNUvpdGY7Y7NRHYKz4/0dY5EDkhcsOQcqQFOMt64bF7/wAPxzaRZXejw3I8zNmptnd+7HGD5hIxjGeDyTWHqUvjDTG0q00GeK80SDIuI76ZBeS/Mc7ZWwhb5uBhTxg55NSj+yLGMQyQWtrIzfxS/ZismTjGXCscZ6ZIyQeAKKane7l+r+eq/XXYiUbvRf16HKjw3oXiC3uLcqmsGciUXKX7yXIlHBEuCSCM9TzzjAqtrOk65YWB8N3Vtr1/pGoSRLc6nFbrcxKm5dzSFCXjddqoxbkru4OBn0OO4tXuo9WxbJeLGIPtpMclwq9Qu9SWC9eOAfrVE211LrGqan5sOoW7Wrx2kRba3mgbhGzYwQGHysSGUud2QBjqdWcr3/z/AOAhTk2ea22nweGdjeHLK81JNKmnvHjD+ZDbSMgUZ6F1xngZYc7sdK5nwVc6a1vLb+ONZ0u3s5lM1tbSeek6M33XHkIVU85G7OP7uDx7n4Qa61K0u9U1zS7nSL1GZltfMW4nlUDk7VUHOcgKeTjPGav6xpFpcTWt+LCCedlSa3+0Q8r3EgV1PK5HHOCeemKPrC+GOnp+X4v0G5taJ/16HEnWbLTLhNG1Z7O/ucywWsruHeZ4jtZZGUgl89RgcdyazJ9Nt/Go1DXfBsTedcSW9lf6DcMi29tk/LdlcgSqVBCqeQzHrjAb42tI/CupWeof8IbBc+GbB2kuJk/eTxSSEB5YznaoPykbs8jgLnIk0b/hG/BOt69YafrNnJq99Ai28Mha3geParxjeSIyGyrZBDZyoPOKHJyVo6S09LdfLt8/K4OW0m9SbRNK8LnV9Q07whp9/b38Ttaz6lBC/wBjDKpyhyQGPYqVK5xzypFXUvAPiGzKXGj38VxZCM+db3Z3m3OfvRNtG5f9l+3GT1ruLWKG5s531u6gi1G2xOlpp0jM0Unl/NGxDZcljj5iEbI4GM1i+DbTUNc8aXfiLUraKy1KGBraO1eaWIRRkFf3kDqMOVABZCyZ5wDgmVUlBXXT1/q1vlfZaijWcdf6/r+rnEaZr0thrUlhqzmzvAD5n7/arHHXZJhv1bmiuq+LnhuXxdbixsfDE15d2+JYtQa8S18pScGMbwfMzg5GBtwDnnFFaTxeuy+//gM29tf7P9fcPh0S58PSWXhXwtbQ6grxPcvBfXRhV4weJI5CoViC53gYOMYAHNdPqOuWmleFxrus6f8A2bbaXBDBssyJsPvKr5bHG/fkHnHAOelW7GG+bWWkW8W60csXjtowG2+YDw3HGPu456/lY1fwkuoRJppuG07ybiOWOVQlwkLg5DBJAQCOzcEbuuOKwqVLWUn2/wCDp6W7+vQ5Guv9f1/XmboWzuPsM1tZBLzy93nBB5uGXkDjKN2I9OKw/GaeJLiDTIfDUm8rdb7kySpFI8J6qGOcMDnp1984rD03w9FrnjzW31QSX01vNG62MN7IUtnfcXK4xg5CMM4K7znIwa7jVdGu/sSWhlv9NglHlG5ieMyAc/LuKttYjGG4OTxziuZuFKUddd7P/h7v+rC0WhnadqAabULG6+1vJZFYrq4KsyzNJHuwnZsDAwMY49areGPDNp4ck1OaOJzHOkYHmrsZeuAw47EenAHXk1v2WnOWgEhlJhTbHK7tLkAd8kbj7/41hXOiamnjqx8RWmtziwFqbe60cgkXABYho9xwpztOeoK9SDij2u8Yu19/66fp6BrayMXWfGN7ceF7n/hFbJ18SWt3b2TaZNBu8qaVs4YfdKFAxDgkEEHIrsJrbTdQ0p59Us7eOW1WR0mmIjjhkYfMzfdABOMn/wCtVG0jbUJLxdV8Pw2Ulw4yzRI7SKvQNjrjIwCQR24qWHRrCw0q6094GutNupmeS2viZlYsQSo6lVHGBnA4x6kny7LR3vp8r6/f+oODTOQvryTwFH4attYe6u72+BhW3ilMiK+753kkzmQqrpgZHGTnpXYaleQ6LMJbi5nuWvZkiEEO6XfIRj5VboABuO30JNP0nw1o+madBZaVYCKKCQuYy5d1kJPzqzbs+g9BxVrUnlWZfIjDO0ipKN+Ci4J5HT065olUVR/ffpfXtrb7y4uxI0yK/mxF2kQ/KYkKluxAI/n9aijlV4ktrkosRfbgMkSb2OF4AAJJOMdz2OaJriK1CtcPHFlwu+WYRoXbsM4HbO3PWvMvG91beM9Il0u1TWLLT47pGXWyvk2MsqbixLlSxRArn5cAso5GRU0qbnr+IpW67nc6npV/NdWt3pMy2sUfLw/Z43JkxtYhwN3TPOT6dOK2Jr++lgiW4MgcD5i67Wdh/ugZA454/DiuOvPF7Wlt4ZHhKceIH8RSym1laRreSQqP3srnYQoQ/eHy4HRTiukIieea2j1CG91e3gSa7t45iGSMjG6FzyyDpnqMc80NNpcy0W2mvz7a9+pMZRfVamnIWCr5jyPFgMSy5BPfOcYPPGar32owaVaX2q390kNpaxiSRnhwQnAzuB5b0HfK5PNRwGPbFbQ+akj7VeVyd4QD+InALEg4PT9apzeIvD1rpVxqOpalHBp0WovpZlvslTOrEFVAUhlyCe4+U8jBrPl7a/L/AIcJtRV5FxLm31qzstRtZIJkeNZYZthLpuHZjnaegOCM+9SXECyFGubeWSbB3TBgTu2555+UdOe47iodTsLa4ngaTylucyRRiAMqSgqodgFwCcIMFgcbRjjrh6zruneEE0HTNWtr9/7Uuv7OtJFYySEAplpXzkZZwMDJxnApxS05d/666X/rsK6S12NtLm7QxRag1uJMeYGtATGSeBw3zMcHvx6Vla7rdvpGtWFhDBcX1/dFZcWcfzrHuwrAbTkggkr0AHXrWvY2C6akkFs2ryuzlgbic3Kqx6qjMcjnoFGMfU1k+MtZ1bStDkl07T4pZchZ/wC0bo20PkEHexkDDaR8oGcAZzz0qotXvb9P69EW4tr3USa7oGha5pkllrVja3NnbFmd5Ms0TZ/gZAMEt1HU96kglvIrwQpHZnTrRVghIhbzI2A+75jMc8g4VV4AyWOTXnHhS00a38VD+yfHF9/aUkIxpf8AaMdxb5Zd20SEDzVHY43cAnpXf39nqd7d2skfiWSLyEchIreKTIAyD+8U+3IBHTg1o6fLpf77/wDB/P8A4NJdWaP2tXmRvLmXy+SINqc+/wAu7bx0wR16Vy+s3WrWTQaf4Y8OaJNYonnwz3ciW9rby/MWXyQu7eeMOpBJbqBmumja8htpbK711Lq9lU/Zbi8hia4jbaTkxKY/MxjIwAcA1jRWWpzBNd8ReIPIkgs2tr2HfFHaxydFnTzBhGPD5bIJ46cVEUlq0v6/q353J50uhqR/ajY2czm2hv0jDy/ZsxxnA+bahZsKOBkE9M/TmL3xogvLeSx0+W+00XclnqWpTXSWUdiyFOSZQAQQ4YEkbug5rrPDHhg6ZHNNquoQ61PdK0f2qYKgnhcEENGp2DAIG7JDcnArgPhjH5vhfXdOudJ0qyigvbiJ9JYmWWBXbPl3CvnJO0ENgqV6FStOMoSdkN1ObSLOk1K7PiO0lsvCviy2gZHhknuFgDyLBIQVZMnapYdDg/gTxc1O7a0utORbC+kTULk2sRtI2ljtegHnyD/Vg5Xnpkk4xk1o23hzwzoJxptrBGs88AkbcV2QqoVULH+EAAY9z3zXFfC7V9U1Sx1aefWLK5vBePLqNjYykw2gOYwIpAcLvUFshmGVznJYUL3lzR28/wDgab9/JE+21stzsmF4D9nmMSuCIykk/lMrNtA2k55JYAD1OBnNcFLaat8QfD+o6Xcte6dqFndzW002nXjRusiqPlniOFePDKSVcH0A6VxHhPxp4i0/UNf0nxvcQapZ6criTQ9Rt5bq7ljySdsqp0x1Lkrhs7fTudZePX9C0jwjZ+HfFtlp+rW8ckOqCN5DaN/Asrh8yoBgEMwwu3A4FaKPKtUt9/6af9dXoKU5Pdf1/XctRaPrnhjSPD+nW/jrQb66e78sLq8P2ZruAKoWGLBZiQS2XAydyjcAuD291p0Tib920yhfniCsXjQnI3KFPHXr1rw/4daLp2k+KZ0sNUm8WalozyyQ6UmnLbG3lJVXuSZGwQrKowG3EgHgDJZ4b06fUfiBqerQfEuKXxyYHkQxwN5cYRBkPsVonXoNqkgAZ5PAXsZLZvTvv87a/MFKUdn95166cNJ1TUtTHw5nsSZ1hN8YfNWeMkkSsFOUXgFuPQsT0qzoVnp8mu3OqS3WoX73LyPGt3qDyJATncI8ERkAnowyvHzVxdt8aPHn9u6Ettq+n6vHfy+X5NlprPE21gGxwspcA5KgdCCM5wPTvEuq+Edb1vWdH05107xfDZf2h5nmmyRjtJBcsCvmBWDHchIUjJ4YK3zRdpLfs3+N7GqxMUrVo/MpSTWHiqwWPTF/tLR72J45b61niaOLqrRyK+2SM4OQQpPTrVqLQdMk0iHQ0015LOKKNEhaPezqgAVsjBPQHPX+VV/DHhm3sdJg1LXrfSNS1OKVmm1CxtVt5Qf4HYqMFipwTwD6tkGpb9zrY1W0urBdHtwYUiv7K/8AJnu2wRtCxEFQvAw+VzgAd6Sk+m39f10+4uNVpW3ffYZdeHPI0OSy8Om507ac2stspYW7btxwDgsM5BXkcnpWhA8sywXd3HC+qIoMpiyElHIzhgOMDIzyOMsetV9A06TTsWuqa1PqGqx3DNCupIUm8okbY/vAnAGfftmt6R2nuFib96SC6sr7iw7lccHB6gfl1puf9f13LbT3OI1vSJr6+0q20rxvdaRqEaSx2lrdN5IupSflYs25ZnG7btznGOmDnAbSPitrBudL8S6W0M9vCwstUtZDBHLIjKV80xHO0Dcy4VTuxnIyK9D8QabZ6vpE1jf2tvc2kuFkjkQEsOqsWXnp3+8CMjFZmzxHaQW9rpXi3UrK0t4gIkZI7plOTku8gZ5B6A4AAp3lJppr5/8AAX4W+ffL2M27x/H+tTio9B8Wa5PBY+K0lt9TtjKza3DLGkkqNlFtg2wmRSpLHdgjJzyAK3dI07ULCBtEuf7P1TQbPasNlc2z3L3CqhG2RpRthO85wuT2GAMt241TULq0S316XRNUXAPzWRgMvA5GZm57cL19Kkj0TwzsvIfsEunNqGWuRFK0isxGNzZ5BwRzj60pT5knO/y2+52f3LTuTGTiuVxsv67HB2mieH9J1nUrPRWtf7duLTdfx2UiLPHGwBCp91QEKoSwUEHBJ9NHVNOvr+zhiTxBdWSGQPKLW3RpQBGdhJZdxOehJHc1rWPgmXTNIhOkXVtrckMZjGpyurXEUW8kBXAJIC/KQDzg8c1zmr2VvYvBdN4gjtHVHijmeZ40Kt1DxMRvXIA28HB4I4NaUeVpxg/w19dtO66l39r719Tn2+IWm+GvDFqRJN4jurSRrS7huXZ7i1x08wALuGcKHzjnHUUU2/8ADMniW7sNTa50PSb633LJrfh+8n8y5RgQoKqrAP2Ylzxx6UUSSTtb8/00/rXW4KF9T0a34e80NdRhGu2kQkn+xkLcW8TqeAO4yQQSCRuGc7hU1nE+g6JPpOi2Oo3NrpMQjsfOcA3hK5wkhwAQcjnG3gcdKq28N/qx8QweNk0/TreOBr5bvTZWEvlRscrMyEN5sYA5VtvOACKn0e80OPwppM+j67qniDTLsMou5V825JjP3WbCEY3EYbnpXPKpzXUt393r+enmzFPmqKC3/wCGOAt7y90XxtrGlM2o2Woa5aJqENkt35alhGUeLzowcyYV/n4X5Rg5wa6vTfFXiO7js/B7xT2+pwafDepfXQFyl1GrDMcjHA34GC/GW/Xt44544Yp9RaB/k8vzLaAiOUEYyi8lemSpOFPc8Vm6vBrmoTG0XUJ9D0qExzte2rI0l3xzFyf3QGFy+MsDjAGcw5qo03/TW1uummgOzV7a/wBX/roSaXpzWL3pgvZPJubyS9Ecz7vJdjny8HGFXnA6c9KtwwSoSZxDuDgmQrsY45znk9cd+M+lNup3mfdDF5eGEjGDPAHTkjaBwO+fTNVL9taSK0bRU02MxPunivJJFUx4O7DoNyMPU5FGrWpSjZaEGl6tBq+pXsNnNFq9rHEFne2u45VikbdxJt+6RtyD7Y65rU063iWNPJQeWoOVfktwc5c9c8+nX3FRaS11a2EbTrbS6pKMTy2IEUSkng4J3McHqTk54FaEW+7uF8yRppQeVJCyE47ZIA/U0pO17bf1/V9CG3uc1/wklgvi0+HrGaQamIvMa3ubdvLKY3ZSQjA4+bqR6HORTrnULyfVbdo72xkMQ3PBy0gBUjLf8C24xgZB78Vg6nDe+HvGt35mj6/dxarcraWwtF86JIiodpd3OwBiFIGONx7VoatDoq+KvD2nXem2V9q0shZJHK+ZY28aljMrLhgN2MAnBJOPSui1PRx108u13/X49AT0ZwOqfDuW4tpU1GKy1CSWaQ3NxbWssl88YbckUXmErCCAFyF3DJwCCc+o+Hnez0aO11W2d3u0EQg3s8FvHt2rHg4XylUpH93cx3MR3q1eabMdNvb2zk8ppInIF9cu8bSH/VBXfIjXPLDaRnpgc1zfhaTWbjSLeDxPYW2nawrsk1pHcQyKz9pAqk7Awz36g8Y5pSmq1036/L8P6XyaUJaPQo6fr9lpmqt8P7Tw/tn0+aSK2t1zCRZsN0twrtu3LnLhN2WHBJNOsj4Q+Gmp6e95LfXmoTXTG3ubt2urna+I2MYUAIhJ5HO4kdcCuqkS+vda/tSHVdTh02C1k057F7fZHJKrcSq5Afr6Aq20DOARWHr3h/Tdd1W3fUn1FbpEXF/p1wI0m2uzGDarblJKgnAGclQynmlGUZr307dbPd/8Hf5/dnZu6+42/Eepva6LqkHhr7Lf65psmx4ZC6xJIykxpIx+U8EtgY7KcZzXN+ELDxfqdlqdn8RLDT5dOvLeDyoH8tpPMX7xWNBhE5PPDA4xyateHTqOo+PL/wARtaa7p1vqdvHbxaPetEYjjA88xhiYyoRTtYbssecHAg8dePpdI1bUNK0XRr/WbvT7iCK/aSVoVQSLvRlxyR1G7hQceoNKEW2oRWrs+l/k/X/LoxRT2e52lxe30Mrx20im7lBMnDNK2MjG/GABzwvT1zzXO3Wkahez3aXvjrWLWzv2BigsrBI5LdiACPN+bn3AB75NWtAtJ9Xkh1SxE0fh64RXK3WIntyoyVVW5Y7gFBbao6/NXR3UEIhtElspDdbdyr5m4Q4OR93HzZxk46ZGcVm7U3yrfrtdff2+9d9jRqLtFFK4LWd0I0kvZhcEf6xFDIyj7zkfcZj8wOAeegA4yPFmv2NrIljqdpDrF3dOv2KwniWaS4YcqVVhtAUjJkbAUDJPY9BcYtZRc3ZjjuFkMvl8BZNw/iAHJ9+uG681zWr6BZ+I9FFtqV7f6asL+Wxs5Cszx8fKJMcKQfunr74ogovWSv8A1/wxSjZXI9W8LaPrmnpD4isdOW4iH7mTToRHNZknI2P3HfJUA9RU2kS2yGz1WXUNI1632MdOv47dlmZekm6RG2k5wDgYJU55zjgLHWH8I6zeaFrfxC0o2Glqpia80qWedonb5QzKV4+YDILY9AK9Q06x0jRtOsLXT5LC006dR9ktElVoZ2b5j5atzyctwe/rxVzvH3b3T/rTTTzt8+4nON7Sf9feLNq8VlYahcafpdlFMYS7CCDZJOFPTccbsZJ5964fxR4n8Paj4TmvfEFzbrpss50knTDJKLlpI9xR4yi7XT73fB2kdcV1g1qOy8UQaY2n21pZby02p3NzHDHI+PlS3iV2aRvUMBjByOgrNu7Xx80F1LNZ+EpbxB/xL7OS4cvDkEeYJtoG4dgAp68joXDlhq9Ot7/1/wAD7jNzje0NLFrVJRqOs6VoGh+Iha6tp6m41GOL97LJbJGIyroqlQ290IVsZ5IFcU2h/ELSNU8XX0Vno0lzdwQ3sOoQkSxu0AVXtwrDzP3iAbVJ2hlwCMk1f+Hmn2XgrQY5Fhmv9c1XUjaXV5aNK637xFmaZwzfKiEy5b5dwUtg5FO8QeObzwt40t9L1a807/hHdRRJo5HWSKWzT5t+MArJ8ytwM8kDHSnTp1G3Ffd6f1sEU9TE0jxtbfESfxD4fVG067ntWj0/TdTtVkjaaPJ8wk5ZW3DBQg7QAwP3hXRaV8OJrCLw/faVeNo2vQCCXUrC2YRW2pOqnegiG2PfwQD90g8jvWR4H8J6np3izVLnULprDwobh7uyEYktZrhpAjYZnAlESZOQ5AZux7dw0elajqiXthcJPeWqyQDbOGiy5BZZVU5YjaTk9NxI56VN/wAm3p8v+H/zLavojnvCdxrPiC/1XVdc8MTaLd6UTa2klwuZJYCTvVf7jYHJDbDv4Awc8dqdhqt/Db6Rb6R4z0S/1qU3Ely0guIbGNJOJMpghchSU4I3ZG7IB2/hNH4n/tLW9Y8eWhR72W3ezXcpSJVDAmOIE7V2sgyOcDHXmu88O3kl6mpSX0L28BuXjtZTCUimAJ+ZSe5UfxAZzxmnzTgnyvT+trdtfzFGLWkkc1D4AttSWaTW5prfU77Sk06//s2VIgzl900ocL8zSMMvuHTIOeh09J0mz8O6lp2j+G9JtbfNi8r3QVTKTHgRRsdu+TOcsTjaPQEVe067g1aC4nsYrlbVMIlzLGqx3DtnIhYn5gGUg5xz7c1T8b+H9GvvC4TVtRuNPtIWM8moWVzHDKI24bdMwbCudvyjBYovpUO6dpavawOVloYekaXpnjHwbotrrGnaboGsWsT38djCBa3VtMJW3eUmfMQFlWQnody9etZ3jg6P4O1XR7m601Nc1jV7U2z32oQK5nt8qPLO1QjSgZGcbtu0Emus0bwvYWWn3l/4ct7GDULhAwkv3IuL1NoIMjSguN3GchOT0XrWReaVqviK1l8O674d1fTbAlbt52kQ2zNG4wu+MnaTnORjp14zVUpRTvLZPb+v0vrpcqCUtHL+vU6XQrq8trvUIdVku9RFzJIMvGiFUYACJSgHyqemRms3xl4T0vxHoz2f2+fS45SgkS4YyRzKDkKzDDDnHf8ADvWlpWmf2HpcVrZyyOkIPlTNc+e2CScEk5IGcc88D0qtr1hearp4iGt6np8wcnzrXam4ejKwO4e3GPU0oySleDt6f5ao0dJ3vEh8MeEtS0bwDLo2r6rpuo3ltdPLYyTwtdxQ2y7QkZLEMQDzwfl6A8Vg6foGslpG8RX+kXcNnO11aWtxhoy5yVSO4cLNb7W5G4ScYG4gHPReGbbU9E09IZ71bu1jURQS3ULCWTqT5pLFGPoQeR1xWff6/omtS3WmzXNobhR5dxDJmEk8fwv1Unjqc+9XSjJt2d16f1+fprqZcrjp/X3HRaL9l1qx8zSxcW15hmuLG9IaRCDyA2MEHdkMCVP51lxxjT4rk29nqGy2OBbRtk+uxBIduOwycc8Zxz5tcw3/AIP0rUrqPXnsZiVnsLq6kxHLI0n7xEKj5SY+cdMjtuJHq/gPxZpfjvSdRttKvFu7+xcJdKUyMNu2ENtCuDtbp6HrwSq6+ru97xb8/wCmtbd90bRqcmjZ5xBoeo+KLC21rxB4U0SDWGUxPp+qQvG08aHhoZQSYmwcbWU9M8Aiu71SeO00w3d8t1biLAlhiUzSIWxhdi/6w5IwcccnjtemZrV547ho7dUQPJDKCAMDlgxGNp56j8qh0jy9VsoNQsC6abJkpOsJhV+37vOGIzxuIwe3WlzW99/f/X/B+7Q1bUd2UbjU7OzvIG+221tqRAa3E37gyscgASEYJPTB5p9pPrWsSX3/AAk2iWMGCFhmgmE63ikHeGXaMY+UEEAHPTvVjxFYi68OXUUGltr0bDB02QA+YwOecnGR1Dc9OMEisDwt4e0aa0/daS2jPIu2S3S8nheHOMrgsNpz1HB60O0lzdvS/wB2jS/q4lytt9TTttPtLKDyrC1trWBSQYYY1VFJJJG0DAOc0VBp+s2pW3W9S606aZpLeOG+V2kJiJBDyDjOBkFiuQeM0VXM4aNGyV1c0vCH9u6Zq9tZXa3Gp2xhEcmrjEcrzjIIuYSc4PADjdkBQeSTXTLaWllZyWltY29ss9yZHaCLygHKnLNHgjsc9mPOMnNZ134GvoNQ8S3moeIb3UNG1QMyWHlBWsiTyY3BztC5G0AZ653AGqXgnRr7w7a/Yv7ZvtSsJd09lJezicCLC4TdgNjO35ecc+tcUpwrfvE9f6dv+Ba1kecl/X9fqN1rxpo3h/xFa6NL9qfU3j+1MlvDJIY0dxGpJwRyx5LdAPUgVoR3s9xOsGlJDdeQpe7MT79n3j5WMKQ2AOp6sOorhPE2teMrzRkvv7P1HQr+zSaO7a3RRE9w4IgZXkBE1uxC55+RnUk4HGp8MfBs2gajPruq6jI2sarbQJd2tyNr20gbc6o2TlcjAHQDoSMCtuSCp3dm/v8AT8PzXzm8vi/rzNmx0mdtfGr6jf3IKfu7XTZWCW1nkYck4/eSHnBPIGeOlWfFWq2ei6DcajfRzra27RO4t4/MeNCAVJB4OSScZx8veuB8fahc6o0MFjq9xouh6Dq0Ud9rEAUQSvkfcBbJaOU4KqCOQSflrqtVuPFGs6Bbap8PX06OGe6uDOuqIQsoQshcbSThypwvYOOlVKPLac9vw7pdd/S/cand2X9foRXGt634h02zm8EaYNTtm1IRHUXdVVbUbfNaPeVLfOzqCAeFOMjFZ/hvWJvEOua+Lnxd4bvLOGcraxW6SYijydoaRwFLbeMAnBHXrVjTNTs/DCW8HiLxPp9hrEqC523ky+YpJ2tGnl/Ikaldqquc4JIBJpNAla28Ua7Fp1hpKadE+8anYxp5M8xK5V4z0kAyGYfKflOVJAOllG6S06O3pu7NP5W9BL4vdlc1728F3q+lW+m63dmXSy11LZaYWEd5yoCvPgIQuclMcjoBya5/ULqFdV1V/D2lx6xrWmwpaz3LXkcbSSO29YvMcDcQfmbkBRgZY8Dr2TUk1d7gz2kFrcQIBpsxRSZEZt8yjAJDKVBHH3T7GrDac2oyh9RvpJLcD5ViBcKh7cADkDHfPHB5zjGoopdvv6+Vr9f60NIe47przOXs4tdvtKeC/Z9KkkIZTp06S7zghkbzYyu0fLyBz2PetTQNJ8R6IbKx0+4a/wBMleSW/n1K9VrgEjgRAKRtGAcfKMcepqC18U6Rf+O5/CWhWupXl1Zh2vJorhRDbbeCGJ6tkgEDgE4zwQKnjrwxpviK2SyuQziC5E0lpPLJFFKmPuGSLOCDyDhueCB1BJ8zs1ZPXa/4XKclUulv6G5qOl3erxzW1zeXWkxQ3AKzaa3lSyRoQNshZWOTnqB0A5wTWXIfHYstXf8A4Qqw32pC2dtHq6t9rO4AMQVChANzc7WJHQ5yKmrP4ysF06z8IaTo8VtFaiSZr27JTOdnlrgqXIUKS7A5z6iobyXXdNuG1Jbe51q+uVEFzpZ1UpbWpxjzY96ggjABBIAzkbjyDXo1bt/TX33M3Gb+E7bRYJrS9sNV1jUktLsWnkS6RDNH5KzthtoOBkjoOuc9T1MGk+HtL07UNQ1hbS0sr28iZL2dLYRXDF8EKrcZJPJ75x17cbqlhf6zqeuS3/iDUJdN1OOCI6baSBPI2LHuKS4OAzKw425DHqTWnaQ/Y7a2QJcSadbIIYi4klKqAO5bPtnB68+0Oi5ay0fovPRfe7f0i6eGm1eT3+8LeLVNb1NrzVdOuNPsoGeKLTGCzPIucrOJlYbMgAbPm6AjHJrag1LxKlzeG9s7bTrBGLJ5Tb5dmfvsxyAD/Sqj6nDc3GnaIbqWye6+aGGFhFcTog5VRjcBgfeG3AH3gM1zj2eg+CPEWva0b10XVZSdk3zqrLgyYPzSSqG6tgIo4x3rblc/dlHporX/AF3377ArJ2e50szpD4li0qa7SLU5ojcqNrSNsDBdzMPuZY8Z4bBA6Uy51e1jnWDTzrtysmS11boqWseCQ5aQjaMENxknjnHWuUa+8Mau/ijxjBaX99d2VqNG1ATMYoDEr4kdVU7xtHtk4GFXJasX4dXlp498NnTfBgutDs9DmtYvPkDKj23mtJNnDEb2xlgTznBODRGC5eap09P+He6IlVctjrPD1tdW2seJdL1myubpL+6ku0vruNDZ3COqAQqcs/IIOw9SMgCq2ta1oYhhb+zru8utHMz2OlW2mpLIPJ2jcMJ+6UHG04XIzlWwK3PEujaJq2uWWqPpH27UtKJksTNcvFBHIz703DoTnGPbA5wKr6XBpVlq8l3LaWlj4kvYjBdww3Bjeb5QzhchWY4yQ44wCRilCzXNbX5f57EtXWv9f1/wDLg1xNT/ALCuzp0Nvqusw3L/AGDUgVuIWQMSysFwIy23dnDAHI6VsaC+rf2Jb/8ACRTWEV20jfu9PdpYkiP3Ml+rdc7cDp3zXlniEN4a8PaLp/iK3SbV1urqwtNa3vFELZj8qzSchXlCEeyMScEsa9E8X+M7DwlceHLfXbKb7Pq0Uf8ApVrIskcWdpO0jhgrY6dVOR6Vs4Xsodb9unr5dN9AbS0b2HNpMzeO9Gexm8uw0uO5mkSO4ZDczzDaHeMDBAXcSSTuLYrrHgtbi5W6aK2uJ4UMUUqxKshjzu2sx6AMN3B7fWvLPG9547svEdxb6Nd+GoNPa8EVrPcXMUfBOcfNgljwCBz2FemX9q2oaNqGm3CSo1yqo80ACkDAyBnOAcdOlZ1YW5W5b/15d+g+uhw2qwJ418Sxv4W8WLatpUgi1S3ZZZoLlWICoyEhGUkPnP3gfar+j+EvA9n4hl1HRrJ9Hvo5WSZrK6bYvXKtEcjnIOCAOmO1bFvo2i+HrRksre2060nfnYQnm7RxuJ6t17nqaz/EaeF7H4oabALa6/4TDWUDbrVScQqhO5xuA2/JjkH7uccZock3o3azt5bXv/WnbUrmjGVuhf03QNK0zV9W1SS8vrh74h55jd7o0TOQoEnCkkZwOmduccVT8QxWM6RyaNe3Mt7GSIEeV3hQk5KvDFIgYEZA3dMjHSorrQftuuTweJPDdy+lQpugup5YTFISdxVYA24tkd1zwPujFQajab7FH8BJ4fnvLaYxvDeWKQLK643Kr5BDqOpGR2yMCiHK/e5m/Pp87X+7TsJuPr/XyLkOnape6GdFhe40pkiBgvrGGMQRHJIAhMj4HUFSeeuQekPijSb/AFC6s7zUdM0u4Onk3VrfC4MYgl3AZaFxt4Byoy3K9ec11Wnm+uLGGXVNOtNPu2G54FucleexHXseMdfrWF46S8vdMhhs5o7d7eUzNAbdroyZXaP3akHjJPP5UU581RXt+n4Pr9wXd/dMnR9Ki8N6RfW8d3e6wttJ58a3NoYhtk+YCNwNkkeQTlchQxGBxWn4a8SJc6DqU+mLqENzaZaexuEZXUZ6hc8j0YY461peF9Gg0/SJbHTo9Ruz8x33MUdtHFI/zHZGAMcknYc/Xmuj0jSjZjfNZ+ROTgzxRqcgqV5HPOT6Gpq14RTUtXf7/l/TJlNONijbwRX0FpNmMSyR+Y8sChAcHklGHT3B59OKPs0aOdt35yEZaGVCGBHI56en4VzfhLwd4q0jxXcXnirxdDq9rG6NZs0RWYrzvVgBhVwcYBYHGfl5rpLgbGij2mcMVOwIWZTkAHA7fdz9Kwcot+5K6/r+uhdOUtmwutCi1DT5YYrgBrhSu+BzHMh/vIxzyD0JBqvdR5Zo5EDCNQgWVdxI5A+Y5z057cdqwLzXJP7dutPk0jWS9qDKdTWMC0bhSqpJn5zlgDgfKQRyM139+q7YpLqWKEpEJLhUU7mPGeP0x7mplJwau7/0v66FOTp+9vc49bHTrqKa3ns7a8sJVG+3lQeWCDwOAeQenTmsXRfAvg7TNRiuotLv7XUIJxcpIdTuNok4wQA2DnpjuOPp1t+BvcCZQ0TgKwyN4znaAeh5PJJ6DPWqD3pkDRujuQM7k+8OOck9v8K21n3XzaNPZe0V7E2r+INMvrn7BdGOXUGjDmNI2k2qSV6qDgZyPmNZl9davFPfPp0dtdTEJHbQXbSRxRRhcH5lU55GflxnPUdK1LG7+0zzxJZGGVkLbiclmHX5sbvXg569qiuo1QGQyqsYHmO0hEflAY+9ntzjqfbninBKHupfqOEYr3ZGbp/26fZJK9rBqH+sK2TO0Ttkcjfz6cevrViS8eeWZ9QhluJJYyUQI2YnXPK5ycHuPxAzmo3uInRQZEZSwUMMlTknGR94Hj0wccUz7aybkuo1ktpG5Nwu8M/THzd+BzVat3sbzpXV0tjTt4bq6jeaBJbluA5kEaR47btzZyOR93r34oqGza010XcllLYyXMUhgd4vk2sp+ZGI5yp7HnnPfJKUWlpJpeq/4K/I5JOV/iPQorpbl5rRiI7tFy6qdwXI4IPGeoqo9sl7aW0MriKe3I3KVB5Ax09Oh/Kry2FqsjyeSpkY7izcnPqM9PwqaWJJBhh+IOD+deLzxi/dMHfoeDeKvAHiefx6NRW90zUNLaSSQ2UsEgXY64ETI77JVGCwywAYnoMLXoHhvSYtK022062mklXBYDzD0YbgvzM20HBxtOABxitvw5fNfmbzYIF2u4yqnnbsIzkn+9+grP1rRrdb8WoluPsNzaXCTWokwj733E8YYEbmAII4Jr0FiJ1F7KT2X5J/0gTT1sUNV0HQtRsLKyv9Njk020lWe3tmQJFHIGyGyh29Cc+vocmtOa5lea2VHupI7qZljltFQx2wVGIMhz8obHBwckgcZqlclYGRERQnmrEoGRtUY4BGCfociltr64l0mZ/MKCMEhFPHAOOufTtT5eZafj5mvsnJXuU9c8M6JqmtW19rSRXstvBIk0biOSKdHxzOrjBVdiFSCpUjqRzUfhXw+ultqsra3qGqWt5OslrazwMI7BecxoUIynOAAQqhR7mp5b6e20x5Y2QssKzDMa8MSue3+1+gp+m6NYRarc6qtrD/AGheLGtzN5agyqGAAbA7YGKpwlGO+n9dBODabvsQ/vdT1K5muNI0w2tum2G6vJlnnYActtQEoBkgfNuPfFT2cM8REjW3mojhX+cxR4zjKrk8YwctzwPWtLUNHsrbUdPSGNlS7nMMi+Y2APLd/lGeOVHt14rmfHfh5LbxP4P1Gy1LU7Vor37M1vFOPIlQhsh4yCpOCVyMHB9hhKrGVorr/XclLRpGprMa6fDdPDZIjTTKJJIoQGuPmwGfaMEEHrnO4twAcVmyeJtOuGkjhmt9auF6abYzW6yFTwN7M6gYPB5OSOM1s6JM1xfbJcMiHcoYbsbQccnJrz/xh4d0jwP4V1rVPCOnwaVqdw0EhuYV3NGZHGQivuVQA7AYHAPsKuDjH3ZLXp8/xXyHzWXKdtpU11qFusGr/ZdOKM8k0NlOXjixkjfKQMkDGccZz0rznw3eaho93rMvjDUbmHTdRv49L8PJqCozSuMgOIokCIjZVt2ACNvXgt7Tp2hQWFlFpb3N5eReQyPJdTbnk7EnGFGQTwAB7Vwl9t0mHTNHskRbO2SRI8jLgRYCfN14DEU6UvaTcY6f02/y8zNVJaWJrr7P4c0i81jxleXK28G1Wt7eL95IW+UcJk8kMODyFzkA4rzO0+IOta5DILLV9FOka8fsMXn6jHaNoseSGCRybDK6qyHzOTnAAx19Q1bQbTxrp8Oka41w1vMI5PMilKSI6ZKsreoyeueppmoNb63pqWuqadp9xbMq4ikgDKo3kYAOR2B5zzWkJ2dpK709Plp/XfoaTjKprNjLVLF9ZsJ7KyjS7aMWSa1eJuvJuzbXbnJHfnAP8OcVy+h+IPN8ReL7XVdP1G9GlobOTT4LLzoBAyMfs0Sjc0sjnJd2wCAMbVHOD8W5JtL8Y2GtWs8v2rQvDJvbKNiDEk/mlC5ToSQ2T2JVewxXpnhJLc6daSRWdtbm6SC4uBAnlieWWESu745Ylj37YFaTiow5uj/r+v0M01zKKXQ8yufAdtq97cPPdxeF9Hup8vY6KGh3QCMBVmwpUsDzyOrv1zkdzr76lp3g82XgKw0y2WIxpFFO0ccca/8ALS4ccLK4Azg4HU/MQAeeup38JfE/TPDel4k0rVoJLxku8ztbSLCXPlM2SFZlBKtuHXAGa7XxFdT2+gXmpWsrQXEE6wr5ZwpQxhsH8c9MdcVU48zhFdbW7fd/w5o+Vu1tf+AWYJ2MEpj86W3ClkP3zcEKTvPTJJzgHjLDFcvpF54mvEsNXN3DY+F76NVm0i/iCXNjlgBskXPmFnGSG24zjAIOLtj4asdX0xYS09nFqNsXkjt3/dRuSo3RxOGjRuTyF7561R8TwwaLqVh4bSBbmxvtPnnunmZlkmeGOPYSYyoHU52gVKjG/wDwO2/z7P8AzFUSQeJNF0T4veDIGuLl7G0F8Wt5odj7xGTG8aNkjDYyp5AwDz36HTNH0630eys57QyabpkaLZWkqlgGQkBizZJPzH8D6V88eOPiFr+haX4ftdLnSIPFNMZW3SSAGVlEYZifkVRgL0wT1r1fwFFLqVtpHiSS9vob65uZLe8iiuGEF2FXYjPESVDKOmzaM8kGtKmGcI819L2Xyv8A8HXcUFfbodb4i/s3V7KVfE1ja3tjkb7d4Q4jAOQyqRkEDPTBOfSs+bxZozeJNN8PWupImr3UafZ7VFkcMpUspZtmF4A/Cuk0uMXtysUzMFCnlevQ9/wFRxiJb1XFtB5kAlMTlcsgw2QG6gHAzjrXL7sLq2o2+xy+n37ab8RbfT9Rg1HU7m8nDKWhXbaBQeEAHKjklic8DGeKsfF3Q9Q8VW+LcHQ7233KmppGWdom52FgAwVsZIByCMEHkHS13xNc2PwwuPG8FrZ/25HZIVLKxjwZFBG3d/tHvXmfgzxXrurfDTW9VvdUuWuhq6oMEbQhjB24x0yfr05rpo03iJKrFJONo9d/LpYyjP2j0X9M6+08E2cfg9PD+uXd3rzwbZJby5ldOThx5XO5QM465PNauj6bpPh7T3a3e5dIyDHHNcyT+RxgJFvJKg8/rWjaBtR0tIrqR2B2pkHkAqO/1NeceHNVvb/S/HH78293pkkUNteQqPOQM4BbLAruAJAOOM5HODTipzhJyk9Gr+d3Y015bm7p2o3usfEG/wDDM0N9BJaWcd7JJCp2fOQQh4GThu5xkMMDFdD4t8CQanpEVvJ4h1TSvMkDE6WQslwD1DEgkjB46AZ5zXXWdjHo/hvyLJ59qqIQ8srSPjdtzuYk56nPqSa53SYhdpbmZ3Z5kZncnLEhiByfpXJ9YlVd4PlS0/D8BwTk7bHMxfD/AEhtf06ee81W703SNv8AZeltcKttZFT8rfJy7g85YknuTXWxWdtJKUETQwc+ZKbiTYox1Yk/4VNZxARqULJ8rEbT0welOuoka9e2KoYjB5h3IGyQxHcVN3e12X7KMdEZljrKyRxQwQErkqiMAhZRkA9emRjv0PtWvIJTaTW85MKSDDtC53DHUZHT9D79q1Fgii028uEjQTCM4YKBj5AOMdKwrSxgtbkKqlyF27mPUcHkDjqfSs+eM7tK1v8AhxxUZ3siulrYQ3PmSC8vXVTHGrMPKgXGOBkAngZb8sGpbt2vp3d8JIykELJgqCOTuyPzHtVm9kZSBwRgnn2NZWpytv8ALAULvxwo9OtawvJ36m0IJsg+zfYoBG0c4iGFjlubmSVmOc8yEsT04BPb8Kv7omuUaKAr+8clJY8dem05/XOOcVVhiVGdVLDGATnr9R0P5VSluWGsx2ypGiRAqCq4LBQxGfyq+Vy69zSVO1kbkZnHly2g3ckoChDAqPu4PJzz+APUcUTXLLb266pbCeCcOhRoxwB13nnJ4BGNuOvsKjId9/OHcNBJtUZyDweT789sUml3U0kdyXlkO2Ro/vHkDGKlw0v/AMOR7PqxbbS7S4aSOxRbWRxuj80M2GI7buD0FZT2rEo93HOtwkgTZNHvjAHzdM/KWBOOODk+1b1mouny+VZF3BlJB+n0qrPeyzK0EoRhHyrEfMMDGM+mD/Kmm0/IqM2mjX0q3s7uWeW2aXDHMjABST05xyTgDls8AY4orNtdQuLOdDE+VlALI3K5IJzj8KK5qkJp+69DmrRaluf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of an interface dermatitis with prominent suprabasilar lymphocytosis and dyskeratosis in mixed connective tissue disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin lesion in mixed connective tissue disease (MCTD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Indirect immunofluorescence microscopy for Cb5-9 from a skin lesion in mixed connective tissue disease, showing granular nuclear staining in the epidermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34266=[""].join("\n");
var outline_f33_29_34266=null;
var title_f33_29_34267="Morphologic terms vulvar lesion";
var content_f33_29_34267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Morphologic terminology for vulvar lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Term",
"      </td>",
"      <td class=\"subtitle1\">",
"       Definition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical example",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Macule",
"      </td>",
"      <td>",
"       Non-palpable lesion, &lt;5mm",
"      </td>",
"      <td>",
"       Junctional nevus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patch",
"      </td>",
"      <td>",
"       Non-palpable lesion, &gt;5mm",
"      </td>",
"      <td>",
"       Vitiligo",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Papule",
"      </td>",
"      <td>",
"       Palpable lesion, &lt;5mm",
"      </td>",
"      <td>",
"       Hemangioma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nodule",
"      </td>",
"      <td>",
"       Palpable lesion, &gt;5mm",
"      </td>",
"      <td>",
"       Basal cell carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Plaque",
"      </td>",
"      <td>",
"       Palpable lesion, wider than tall",
"      </td>",
"      <td>",
"       Psoriasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vesicle",
"      </td>",
"      <td>",
"       Clear fluid filled lesion, &lt;5mm",
"      </td>",
"      <td>",
"       Varicella",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bullae",
"      </td>",
"      <td>",
"       Clear fluid filled lesion, &gt;5mm",
"      </td>",
"      <td>",
"       Toxic epidermal necrolysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pustule",
"      </td>",
"      <td>",
"       Purulent fluid filled lesion",
"      </td>",
"      <td>",
"       Folliculitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyst",
"      </td>",
"      <td>",
"       Epithelial lined structure",
"      </td>",
"      <td>",
"       Epidermoid inclusion cyst",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     mm: millimeter.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34267=[""].join("\n");
var outline_f33_29_34267=null;
var title_f33_29_34268="Treating hypertension in acute ischemic stroke";
var content_f33_29_34268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to arterial hypertension in acute ischemic stroke",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Indication that patient is eligible for treatment with intravenous rtPA or other acute reperfusion intervention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Blood pressure level",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systolic &gt;185 mm Hg or diastolic &gt;110 mm Hg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Labetalol 10 to 20 mg IV over 1 to 2 minutes, may repeat x1;",
"       <strong>",
"        or",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Nitropaste 1 to 2 inches;",
"       <strong>",
"        or",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Nicardipine infusion, 5 mg/h, titrate up by 2.5 mg/h at 5- to 15-minute intervals, maximum dose 15 mg/h; when desired blood pressure attained, reduce to 3 mg/h",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       If blood pressure does not decline and remains &gt;185/110 mm Hg, do not administer rtPA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Management of blood pressure during and after treatment with rtPA or other acute reperfusion intervention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Monitor blood pressure every 15 minutes during treatment and then for another 2 hours, then every 30 minutes for 6 hours, and then every hour for 16 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Blood pressure level",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systolic 180 to 230 mm Hg or diastolic 105 to 120 mm Hg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Labetalol 10 mg IV over 1 to 2 minutes, may repeat every 10 to 20 minutes, maximum dose of 300 mg;",
"       <strong>",
"        or",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Labetalol 10 mg IV followed by an infusion at 2 to 8 mg/min",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systolic &gt;230 mm Hg or diastolic 121 to 140 mm Hg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Labetalol 10 mg IV over 1 to 2 minutes, may repeat every 10 to 20 minutes, maximum dose of 300 mg;",
"       <strong>",
"        or",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Labetalol 10 mg IV followed by an infusion at 2 to 8 mg/min;",
"       <strong>",
"        or",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Nicardipine infusion, 5 mg/h, titrate up to desired effect by increasing 2.5 mg/h every 5 minutes to maximum of 15 mg/h",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       If blood pressure not controlled, consider sodium nitroprusside",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34268=[""].join("\n");
var outline_f33_29_34268=null;
var title_f33_29_34269="Prostaglandin synthesis";
var content_f33_29_34269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prostaglandin and thromboxane synthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 318px; background-image: url(data:image/gif;base64,R0lGODlhpwE+AdUAAP///wAAAIiIiAAz/0RERCIiIt3d3ZmZmbu7uzMzMwBmM+7u7oig/0Rp/2ZmZhEREbvJ/1VVVczMzJmt/2aF/yJO/93r5N3k/3d3d4i4oDNc/0SPaSJ6ThFB/+718bvWyTOFXJnCre7x/8zW/6qqqmajhYCAgFV3/xFwQSAgIKCgoODg4PDw8GBgYLCwsHeS/8zg1lWZdxAQENDQ0MDAwJCQkFBQUDAwMKrMu6q7/3etkgAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACnAT4BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5RgMQZA0MVrxKDA1QxLrIexADFELLzVDCY7/BvUnH1EbZQsfJ3nbLAyIAFMxR0mLbU+hH3U7u3/Fwy78iHRrNEBUDAxMADfsGABzQ4QKAARr4+fsFsJzCfwnNXYgIbQjChw0oApjI7wWAERFPHIzo72K/jRE9YgNmciEwBvwEAngRc4S8m2mWTajAgEKD/2Yd/OXo8K/YBGE8D74kmtHgEAoaigJYduFEswsdbFpcKpXqCZEjOkBgEHUrAAZEB7ysAODrR7ErlZ5lymCEsGMDcuDci4bqvhE/L8Tkd4HaMiHUhFHNhpYfW2qCLwR8aLHXYmCRK/j7N6EqwpKWBwjutROAZsQT4ioW/av02WIM9lEYx7c2GKrYgG5GDOzwP5a9XjzGnHfm8I2irSIRJvw38qpg0cU+GJytsNJu7Y4tlrj6b7s2TxQbEtS2+S5Uh/ycGvC478SOe2Vr4Ph4ZI6EicSsIJ/4BfwqxVRSfNQBUBqArzm3X3/k8KNBA/Y4SNt5FELCjhQXnmNNhRx6kv9hNBuuE2KHJJZo4okopqgiIias6KI3AbwoYy4xzmgjLTXeqOMrOe7ooyo9/ihkKUEOaSQoRR6p5CZJLumkJU0+KWUkUU5pJSNVXqnlIVlu6aURASCgR5dflihBAgEEUIAARiBA5hFhuonHm2VWaMADDgghQARt0llEmGPWKaMACRThAAFCEIBBAWkWYACaAWAAwJlp8klAmgQsAECcMT5aqRx+CmqbAHkSYUAABpxqgJwARMCnBA8gQOgQAhSwwAIJsMlpq4jSEaqofNVqBAECYJAnqwUckOgBBkQQQAIHOFAqqZsiIGeydfwKLE538gnAngAgUMADEoQbgKauTgr/qJ5r2rrAmtXKGUGvc2i77U0IQJqrEAn0iquankb6bZoBKHtpAJnG2ymk3sJh7722LRArJQ9DzBcGhVJs8cZ3VMzxx114DHIy607BahLEgjpyiiVLcTISKbecBZoGCEFpAKWCuTKKMkPx8hEpe4HAA/sCcICkEgRQrs47n+cmmgWU+2yayg4dwAPKHvBAmgLUunUCCzx9dblWYw1AzNZOHTUAjKopwQIHPxBu28oS4UAEBxRQxAJKw9m0032nGwCbwj7AptZwS8rurWu6KSYBeRpu9ANw65p2uekOUQAGbmoqhNkkyD2ExCRILOYQiiIh8t+vsCosoHmrKgSq+SIs/4EAvULOqrSyb2oA2q7b6gDBeWJwtQCnEozqEAcoXyquOTPNOl+sJpAn7HpLLgDlQ0TgAO4A3HnA7pETTjnwNVrfvKbWD5G0+EAr3vnQdas+fW1upplAzdiHu7XZB4uaAAjGJ/L572oGs1z+npUqSBXAAQs8Vtv0JoRTLY1tpHKe3+63l59FAXxV8OAZVsdBVYjwCSCkwgnLQMISunBTL4zhFVoow+nRsIZ/uyEOd6bDHY6shz60mAqUF4AaBPGIQ1gBEWeAxCamgGAyaGITW0AwG0gRiS4gmAqueEQWEGwFXDziDQKQgjAe0QQBaIEZg0iDALhgjUEMAAvg6MMW0f/xjnjMox73yMc++vGPgGQEPI7woWkAI5CyEMEA2BIFePimMk1Qh4aIIElEtoIsYmnkeJJQyHQc0pKv4AkFoMGQCjjkJPrgBwNisw8NiOAw+BEGfQTyyotkxTkw4YdWkCOhtvAjLb04QUw+CUpWLOOVHRhHU4gAFQB04JOxuYA9JnAY8QiBF7ERgQg0wIBlyKcZv9BOEgSTg2hWxpyVLCYqTnkSxnTAMZEZQjc0c5jTUGeU3KCAb/DZGkYWATACwmdlBJpOdZbCHno5S1QgU5zmPFOe46HnANoSnbFUQJs82Sc465KhZioyNRVwCnWyKYKkGFQVEyCKEAQDmEPOsgL/bIHAO9UyT2pOdAStlCU/IKRRXNZkCDJdZDt/SZ1tEsSkJ02qUpfK1KY69alLsiNUBQXEqbLMqlTFap2qqtUScbWrHfoqWCsk1rGep6xmtQ1a08qXtbIVJ259qzziKldW1ICJT6BrXYEUABnYQAVgXIJe94oKIpKxBS6Y4wYJ2wjDOvaxkI2sZCdL2QBIlQiDZawYMlsFw97ABDRIAmc1+4XRTiFNKUCsYpVgWtJyobVRACwUSLjCSARtjbDdbBJuBi8l1BYPGKDXFG47KUhFb4e5DUOT7jSthiHht3bAlBWIezR1XRC5GjvCrOyWOwwELAJyCpikxHu2QoVOAvAi/524CBY+436rAIwCW/KetYCb8WmAbjNCCplHvPfGF10EY5MR+HZdHCYXDE2ilqlQpap5DUFer4pVumAlpgREYGJ5M1r2JCWvPN3pdo6SWP1ORYLtTopcAMCAc/Uk3CKsr1YGEDGMzybgIqTuiAcuLRKEZeNi5QlbQrhW3QiQtyEr61SKMx20ZHct5R0AhMmSwMEK1qxnHaB5BKMgEfYrhANAClVQjlapiAsA6DUxx15Y7gO8BS5xodjBQY7RhMM05wo763SEEp325By9MDugUHyrX61gVeAtt5htkiIBmHuVrFoxrsb+qx+Os3uE2j1LwP2qIMPCC6nxdvps90Ux3/8EjGVGtZdgBgiz1Rj1ZIIpC784+xOqt9yoRQshWf96QG+FMLz+xpHSTTBdF4bmOVpp2bVOQHPIoIAxLyRAcQO72umQnWxgU7sQyn7ttRGR7S10e9tN+HYWxA1u1lq73IAg9wzRTQh1W8Hd7MbsuePNB3hTwd70xrcU9M1ufs+W3oHwd14Bnu5IDFF5RiT4HgS+BCUqD68KzwPDl/DENEUx4oGKBBXTZEWM5+GyjshimrbocQ55MU2BLXmFxlhGlbNhgfub1JQdsAAeY1ARaFSjy9fgppoRIAIS81a+Uq3lXR+ijW/cuRp6/l6bG1tzkObSapV+hp5D71CzS1OqiRj/dUOAnOplgHnNtawqmxsd7LFgegUfkLD3mb3raHeF2m0287FDPe54z7ve9873vluCzH63RdAAX4dZqoUbM9WAP0RwyhOMQASzdGXgyTB4uNNhPcsYQWys8QJwasAgVekMhEpKzMk3wb6I+1ahplYwLBeMAO51fZ60xrVW6a/Y04BGUMpDBLuI1AjcND0UTMw2ZWFrcO+lcaIQNff13Vj17LO8F9ZzlNGchR8UOApiKKNQ4UOhytD6FgFIQMH+VT58qPIyqmtHAAn0Ok3HDYPh/cF7clDA90OwJ1Qm5H0U6k1iRWN+ipMyqrI5AKBoNSME3kMouFcG6zEEL8B7yqEB/xqgFUExERXRf00Aa3WDAdxTLRpmNFRDgGBWa7/TKJjjambwgPKUeIvXeCNwFPuhgcMlfTTYCorWgDdYC1/nCD24g1owcUwghNRGhOYGhDo2CUboWktoP0iYZvP2hOumhFK4bFRYhd4WhVh4Wlq4hVHQhIvlhe/WhWJYbVdYhp1FhmgoWGq4hqLVhm4YhpAAhoxFh38Sh1x4hng4cHq4h+EGh344O4AYiHYob4FohpJQiHWliIJ4iH/4B3e1b474iH5gcX+Vcmw4iZlYiUSUWol1hJooWpU1iqRYipP1gzAUiorgWaC1iarIJYf1iZT4ioYgW19Ii5zAiLjohLuICf+62It3CIyX8IvC2IjFOIjHiG3JiIzL+AcHRzAJ14yK4HAEA3HSmAgV11fXyAgbFwAdt42JIHIBQHLgiAgnFwCYWI6GwHLqiHNp1I6JgHTwmAhyNI8sYo/4mI/6uI/82I/++I8A2VWGd0iN8RkHsRnaBxLYF5AOmA8DoHn8IQSdd5BCoH0T4BHgoVWmuJEc2ZEe+ZEb+XUPuHu7YREIOVFDoEhagUYg2ZIu+ZIwOVktJwpNKHDUJxp3sZCDwQ+U5BF/oIjEiIiraAjz50y7gU8nYSAouU0Z2AdASQo1SZQZGIGboRxJqX0yVZKVmIhQ2VhSWQQFqXgUqZQNEhNNmXH/c9iVWDIkTzkKUSkJqDgIbUmTXsmVizCXofCWVLKWe+mWddmXQwmYefmXaXmXdkmXfCmY3HaYg5mYhRmYj9mYhsmYi6mYn6CXkVmZmWkGMFczUkY8C+B6vUV7BQOFTtCZMgearoczcHN7ZNBDqPmZ8FdzyiMApClpU2gFsVl3B3MArUlf2vZaRDRtRGA8dfObYBOcacB0Pxd0QbY/GfYtkoMBryY6yskEzAl0a/acBhCdFZQp72KDQfgF2emc4bI/Tked0pmFV1Ce23mePscmv/No17kFXEYEEkMAvTKf4VmfnLk8teJ0XaZlxBc6ptkETBegxzagSFA0uiU0ANou//q1oEJgoOPZnhEqoIkSdQ46bl8AQm5CAgDQPlrTO0PQoVigV1ZnPVi3KVrnnSdjAAUgolaIoKhydb2CaquZM8SnXOR5oyyao1oHazkiozTqoRgaY0GadctDXD2aoh9KL6EDZ6njpBnDnstJMGBjc6rindsFK7h5oTZ6e1yafhT6ZzqYhMOmpXZXQWC2oGDqny7DpmUan0OApjXKBfs1PJoyX2pyp8kpp2Qwd3fSdmaqJ2YzaAj2BITKdpryPt7ZXvHnoxCagOHjqOpCdFu2NoLqM8uzdoZqp48yqVDqBSlEfvqpekJAOqOqpmgwd6k5m6JZN21DNXm6BLAqm6y5o/+rSaEHygW5WndOV6uliaS6+al0B5q92audagUgqjTv4gC7djfMiqWSCZmbaQh4iSSE+QhLuK2X2a2O8K2UGa6O6a3nKq57QHhiiq1xwK735gbwmofvKp6SyAfnt6inKW6tla/tagb+aqxsELACmwcE26xyWa8birBfcLBjKK8CNq/0igaoxz2zwnpX5mqwB38iyLGkySbOQl/2JYe+FSMfezaYEjZqcjUh62kcizsDJHuTU3shCzYjG4xdULGacrGQkrEjGHv9dbI1m6Yio7OqirGudwAbG2syK7SuKT1aYLQ8SzVJu7SzF7Rbg3xDy4toQHzYcnyEozeDx3zI6nz/0MaAI9o1V0qySSAnz+douCIAjsM2iNI8reJh5FIrxGm2tJKcufKkQ9BDXmt8yoJ8wjK25mKpfKsnfgt3IjO4xbcpYat8Z0O2insub9u4bOusa/u1hTu5iNt8mHu2mru5YwB+rzZ+5ScmGXZ+Xfplq4Im7fd+OIO6ptsn52k70qInEFQjKdNkrgZC6qd17Od+zmO7OMsFtos75Dc7rCu2ESuf6Qe7xUu7kyoyy6u6zhuCrju96ye7xutryZsF2du8INi60Yt+3Um94Gu9XKsGwgKAAiaAC1uAiYasCxiom3q7RfAyC+gujeO7bNJhhnZr92up+auDGspV8Us08/u8/2czgNIrowfcPd+jv/w7fP/nwNvbuhKsvgaIgBaMtm/4oRscgBB8YyRIwQeIvxecpoaYBhwoBB7oOf2DZUo7wfjFKCeYXyFbMDMMtbgaIwFULgeTKazyuwuDaiC0w6hSxLZHNUEcw3qqgin2gTc8gjpsglD8w2Gais5qxTXcwXqDwyvsxD28Nl6cwR8kxlgMwWa8xSubxiloq2xcBhLLQurasPbqqluQx37Mx2zQWjnoMHvcBYWsBjqUyGnwVYzcyGo5mZapreXqCZiJrpKMyYiZyZpMj5XcCZc8ruk6yqB8yO7KJZ+ci6bsyZy8ypkQyq5ccJNcyqTcypQ8y6pcy/+nfMvZSsu2rMuCAK6WHMu8zMq9nAnPmCbRSAjJXESN0MzLLAjQzAjT3AnUmCbWOAjXHADZjAjb3M2A8M2MIM6ekI0Xdwjm/AjpjM5Q5Ajr7And+I2GEM+PQM+HYM/cWEWgII7kaAj8/Aj/fAgBzQgD3QnnmI6EcNCPoNCHwNCM4NCewI6KINGPQNGHYNGMgNGdkHOLwNGQ4NEs8o6PANKfII+KYNKPgNJH50aQoNKXOXXcBtONJdPYRtOraNObEJeDoNP32NFwyZBAHdRCPdREXdRGzRcfoABKDQIWAAAwsAFKrQAl4AEhENUckAFCEAIooNQhEAdJvdRN/dRRPdX/VT3WHgDVCgACHsAHX53WYY3WUu0BGRDVCpABWs3Vc9DWTO3UcD3VaB0CZ73Ua50HdK3UH3AEOqAAXQ0AgZ3Wg80ISd3UGxADHoACMSAEH8DUIcABQpABKIDVOtDVnu3VCiDZlG3ZmK3ZnD0EFrABHuABV83WpQ0Ak13Zlw0AmW0BGbDaQhDaADDachDZtH3at53btI3Vrf3asb0HGbABSVDZG+DcAJDcsI3VjSDcu73bRrDZQ5ABIEAEOIACpN3U2c3bQ8DdRwAC1q0H2H3V5t3Z7y0E4Z3Xs13eR7AB6y0E6s0HzY3ZCoADAAACJQAAWm0Bs00E+33dpe0BAl4C/9Id1RaA3ritAKzNAQAOB5HN4CXg4EIA4WWt1APe2d8t2xag4RwOABA+11Fd4Rc+3ib+4Eot2fnt3X3Q3/Jt2dK9ATpw3ERA446g13LN2wYe4bzt4zCAAouN4VGt1totBEMu4UNQAmrdB0De5NNd2lYuBEee5KQt2FY+5DwuBFL+2Hpg42KuAGtt4FYd5VP+4wc+3Sjg2k5d2ujt2aLNATBA303t5HG+1jBA5+ZtAQL+B8LN53L+57pt3rud53RQ6HB+6LON39M96H5g5jjAAdH92yNe2Tgg6CH+CI7O12b94Ryw2BxA11zOBqEu1iBO1XRdAh+uAPFtB6ve10FOBD6nHtWp3ga1btZ/HeuzXgc2ntQwANslsNwAUAIxAOxH3ezO/uzQHu3SPu3UXu3Wfu3Ynu3avu3c3u3e3gVBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of prostanoid synthetic pathways and the enzymes that catalyze the specific reactions.",
"    <div class=\"footnotes\">",
"     PG: prostaglandin; Tx: thromboxane.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34269=[""].join("\n");
var outline_f33_29_34269=null;
var title_f33_29_34270="Collar and cuff sling";
var content_f33_29_34270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Collar and cuff sling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 329px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFJAR0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5PWfiD4c0q4ktpL43NzGSrRWsbS7WHVSwG1T7Eik2lqxpN6I6yiuM0n4keHb+58iS4ksZCCVN4ojRgBk/OCVHAPBINc/qnxdiS5dNH0dry3VsCa4uPs4cf3lUIxx9cH2qXUgldstUpt2SPU6K800n4tafK4TWNOubHJ/wBbCftEY+uAH/JDXoOnX9pqdnHd6dcw3NtIMpLE4ZT+IpxnGWzJlCUNJItUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcv8R/ELeHfDE09u4W/uGFta5GcSMCd2Dwdqhmx32470m7K7Gk27I4b4peNZrm7uNB0eZoraE+XeXEbENI/eJSOgH8RHf5eMNnzZEWNFVFCqowABgAUkaCNFRSSAOpOSfcnufenV5VWo6juz2qNJUo2RVvw8qrBHH5jyEYTGdx3KAPxJqS0lEsCsG3cD5vXjg/iMGul+G+mvqfimGcLmC3YSu2OgXO38S3P0rG1+wbSPEOoWYUhYZW8tfWInKj3IBH5+9K3uhz+/YhrR8O63qHhzUftmkyBSxHn27n91cAdmHY46MOR7jIOapDAFTkHvS1MZOLui5RU1aR9JeFtfs/EmkR39gzBSSkkT8PC46ow9f0IIIyCDWvXzh4N8RyeFddS+yxsJcR3sQ5ynaQD+8mc+43DqRj6NjdJY1kjZXRgGVlOQQehBr1KVT2kbnj16TpSt0HUUUVqYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXiHxl1JrzxbDZK2YLC3GQP+eshy2fXCrHj/AHj617fXzd4zuDd+MtduCeWu2jx6eWBF/wCyVz4mVoep1YON6noY9WdN0u91m9Wx02JnlYZd+ixr6k9v898Az+HNKl13XodNhkWPKGaVzyVjUgMQPX5gB7noRmvZoV0bwnpqRtLBZQE43SuA0rfjyzewrgjC+p31ayjotxfC2g2/h/S0tYMNIcGWTGN7f0A7D/69cr8U/Dcl7Emr2CFriBdsyqOWTsce3OfbH92ulsvF2g3t1Db22pwPLNjyxyA+egBIwSfT/Ct6tWuhyRm0+Y+ZvMwvmxAkE/Onp7/54P61LHKkhwDhsZ2nr/8Aq9+lek+KT4KvNUuIpZpbbUoyyvLZ20j5YZJDBVIPI5PUnIByDjmV8H3F0ZW8PX1pfhOWt3DW8o9/LcfKPfOD1rN02dUa8XuYFez/AAX1lr3w7Lpc7Zl0t1jj9TAwJj/LDoPZB6147qNrd6XeC01W0ks7koJArlWBUkgEMpI6qe+a6z4RXxs/HEUJP7u+t5ICB3dcSKT9Asn/AH1WmHk4zs+pGKip0+ZdD3iiiivSPKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvmHxc7xa34hkjXdIt7dsoxnJEr4r6er5o8Tps8T60M5/064P5yMf61y4v4V6nZgvjfodp4N0PTbDWtI1DT3aSW5gnRpDMzFkz8pYZ2jO3PyhRweD26LxKNWs7a4k8O6Sl1dRxNIJZ5hubC52rkMxPouMHnlep5P4X3zXF1ZWBXD2CSr7GLOUI9h5uzH+xnoePVKyTSadtAknqm9Ty34ZXOu+IHW+8VaPY28/DjykkDxEM2Fcy5JI2Icq235hgHDY9SoqC8V2g/dZ3KytgHBIDAkD6gEUTkpSvFWQoppau5518Sl8V2d7ZHwdawxR3FwFupxbPKyISCXxGwJ5Lkggnjg84HV+HbbWZNPtB4iWwmZoVkbywweKQgZXDbumSM7if5DejdZEDocqafVOacVG2vcSi1K9zz7xpotjqfiC+nvVkLW2nwMpSZ0Kr5s24jBC8DnLBgMdOtcD4FujF4m8O3atuf7TEobGM+YPLJx24c12PxVvzbTXlpsDDULaC1+gb7Tvzx08vePXcV7Zrh9F/5GHQ/wDsJ2f/AKUR1le0onRTTdOXY+n6KKK9I80KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+dfiDEYfHuvJztM6MpP+1DGx/Umvoqvnz4mOrePtYVcZRog2PXyYz/IiubFfAdeD/iDfhjLFb+PbcuQHubOa3XnG4go4+uAj/nXtlfNMN7Pp2s2eoWal7izlSRFH8XXzE9iyZX/gQr6PsbqK9tIrm3YtFKu5SRg/Qg8gjoQehrlhsb11aY64jM1vLGsrws6lRJHjchI6jIIyOvIIrJfQpW0qKx/tvVwY23faBKgmPoC2zkfhz3zVzVILmZY/s00sagnzEjKguPYkdR25HXms8WufkzdsR0XyiHB9dxPl7v8AaAyfXJ5pGJtwRLDHsUkjcWJPqSSf1NSVS0u2ntomFxczTFj8qyMrbB6bgoJ9eapeLtfg8N6FcahcDzHUbYYQcNNIQdqD8sk9gCegNAHkvxFulvfiFqBBJFpbw2i85GRudiPfMgB/3cVl6a5i1jS5QM+VfW0mPXbMhx+lZcLyvP5lxIZbl5JXmcj7zO5Zmx25IOOwarEtwLeJrndxB+9yOcFTn9CKyv76Z3KNqfKfVtFAORkdKK9Y8UKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooApazqMWk6Vc39wsrxQIXKxIWZvYAf8A6vXA5r5gvr+XUNWu9RvMfabmV3KKc4ZjnYD3CgKoPovNfUl/btdWNxbxzyW7yoUEseNyZGMjPeuCm+GOi21lB515NHBblpriZ9oZwB/ePCqPmzxzk5PQ1hXpynZI6cPVjTbcjzDwda28eonVtWDHTdMJuJQiFmmmClkiQDliACx9FGTgHNeq6dpV9otlBJYBJZGQNeWjNtWWU8vJG38Lkkkj7rH+6SWq5Y+H47nQNQa3tPsf2qzktbK3dcGCFgeWB5DucM2efug8qSdHT7pb6wtruMFUniWVQeoDAH+tZTh7OKRXtPayciHTtVtb93ijZorqMZktphslTnGSp6jPRhlT2Jq/VS/sLW/RFu4EkKHcjHhoz6qw5U+4INVToNkwCu9+691e/nYH2IL4I9jWWgwvdZghne1tEe+v14Nvb4JT3duiDv8AMQTzgE8VzviDTnQLqOv3YxcI9jNsDNBZRyr8pRepIlWLMhGTk/dXgdjaWtvZwLDaQRQQr0jiQKo/AVQ8VRwy+GtUW53+SLaRmKHDLhScqRyGGMgjoQKcXZiaujwS80i+0qB7m5s50t4nMZmC7kYYHCnvxtwR1A471DbW0t7erb2kT3JuAdsUY3bwcZwB1xwfxNfQ4D+GohLdYbRZEzcjGRZvj5nAA/1THOeyHn7pO3WXRNMGpx6kllAt6gIEyLg8jHOOvHGTWrwqvoy1jXbVGT8NtU/tTwfYCVj9ts0Fndo3DLLGADuHUZGGAPZhXUUgABJAGT1PrS11I4nuFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVk+Itf0/w9ZrPqMpBc7YoUG6SZvRV7+56Ackgc0DjFydkrs1qr317a2Fs1xf3MFtbr96SaQIo+pPFeUav4+1vUNy2Cx6TAejACaf8SwKL7ja3s1crMpuLkXN3JLdXI4E1xIZXUegLE4HsMCg9zDZBiKutT3V97+49fj8a2WoXMlroEMuozouS5/cwjnGd7csvuiv1HrVLXF1W8t4P7QvY4rd7u2R7S1jG10aZAyO75LAgkfKEyDyK80tLmazuY7i2cxzIcqw/kfUV2TeLLW90xBeYtrmGaCcg52OI5Vc7T2yF6H1wM1lNzTVtgx2TSwq54e9H8j1CuT0FfIt7iyIwbK4kgC/3U3box/37aOulvru3sbWS5vJkhgjGWdzgDnA/EkgY7k1xuj6m994s12MWF1ZwiK2nX7QoVpWcSLvx/DlY0G04YY5AzilXV43PGpP3joKKKK5DpCszW1+0CysR1vLqOMg9CinzJAfYojj8a06xr/S7PV/FGkxX0CzLbQXFwobna37tAfY/OxB6jbxV01eSIm7RZ2RGRg9K4aDV5/DP9p2z2yXGjafcCKEpKFmjRkRxGFbCsq+ZtHzAhVAwSK15ftfhxPN825v9HX/AFiyEyz2y/3gx+aRB3By/Ugt0ryXV9RbVNX1K5E/mwPeSmLaQUKqfLVhjrlEXn0rtd+htluBeNrcl7Jas9Z0zxt4e1AokepRQTPwIboGByfQB8bvwzXR187uqupV1DKRggjINT6ZeX2kY/si/ubFR0jibMX/AH7bKfjjPvTPWr8OSWtGd/J/5n0DRXm/h74j4lW38TRwW6Nwt/DlYgf+mikkoP8AayR1ztr0gHIyOlB8/Xw9TDz5KqswooooMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMTxhr8XhzRJb1082diIreDdgzSnO1c9hwST2AJ7V4pPNc317Jf6nObm/mGHkIwFHZEH8KDsPxOSST0HxE1U6r4qkhRg1ppg8hMHhpSAZG/D5U9ir+tc/QfZ5FgY0qSrzXvS28l/wQooooPfCoL2E3FnPCG2mSNkB9MjFT0UCaTVmereCLh/FWn2niPU0Ksxb7LZMuBaFSyMSO8hIbk/dB2j+ItneNdam0DxXHKtqtxHe2SKN0pTHlO+ccEH/AFy1a+EU+/w3dW4+7a3siD/gQWU/rIaofGGDA0S7wTiWW16dN6b8/wDkHH40nFSVmfAYahCOOVCpqrtfoVR484507/yP/wDY0jePDt+XTcn3nx/7LXFUVn7GB9Z/Y2F7P7zqZ/HOoP8A6iztIP8AfZpc/ltrovhjcXmqT6xqd/IHffHaIAoUKFXzCR7HzQOc/drzM9K9g+G1mbPwVpm8YkuUN2w7gykuAfcBgv4VUYRjsjyc7w9DC0Yxpxs2/wAF/SL/AIxvW0/wpq91G22WO1k8o+shUhAPcsQPxrwmxtYrGygtLZdkEEaxRrnOFUYH6CvVPi7eeXoNpYg/NeXSbgOoSP8AeE/TcqD/AIFXmdWbcOUbU51X1dvu/wCHCiiig+kGkAghgCD1Brtfhj4iaxuofD965NrLkWDsclGAJMJ9sAlfTBX+6K4yop0d4/3UjRSqQ8ci9Y3Ugqw9wQD+FBw5hgo4yk4Pfo/M+i6KyfCurDXfD1jqO0I80f7xB0SRSVdfwYMPwrWoPzyScW0wooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUtb1CPSdHvtQmUtHawPMVBwW2qTge5xirtcX8Wrow+F47YHBvLuKHPoFzKfzEZH40GtGm6tSNNdWkeUQCQRg3D+ZcOTJK/9+RjuZvxYk/jUtFFB+mRiopRWyCiiigYUUUUAd18H58Xut2ucLtgnA9WO9WP5Ig/Ktz4q23neEJZlGZLa4hlUnsC4Rj/AN8O9cf8M5/I8ZIjEhLi0lj+rhkZR/3yJP1r0vxZZvqPhfV7OJd0s9pLGgxn5ihC/jnFB8Jmf+z5g5ro0/yZ4dRUcEqzQxyxnKOoZT7HmpKD7vcb9kbUJYbBM7ryVLbI6qHYKzfgCT+FfQ6qFUKoAUDAAGABXzTe6gLXUrBVNxGUlWWSeCQRtAozg7ywC7iCvJwQWH170+P9Q0mxea4lF3hQY4L6HypJ2PREnjzGSewCk+tB8bxDNzxMYLovxbIPiZffbfGBt15j06ARfSSTDuPptEP61zVI0k0809xdMGubiVppSOm5jkgew6D2ApaD6bAYf6th4Unut/XqFFFFB2BRRRQB3/wfvsDVtMYn93Il3HnoFcbWUfRkLH3evR68T8CXn2HxrpjfwXKyWjk9FDLvB+u6JV/4FXtlB8DnFD2OLlbZ6/f/AMEKKKKDywooooAKKKKACiiigAooooAKKKKACiiigArzT4wSn7bocBPylbiXH+0vlqD+Tt+del15V8X5M+I9EjyfltLlsfV4f8KD0sojzYyHqcdRRRQfoAUUVBJOEuoYNpLSKzZ9AuP6kUA3YnooooAv+G7kWfinRLhiNq3axkevmAxD9ZAa93r5yvJXt7Z7mIEy2+J48dd6Hcv6gV9FxusiK6MGVhkEdCKD47iOny14z7r8j53jg+yNLZ/8+kslr9fLcpn/AMdqStTxfbm08YazEARG0yzID6PGrE/TeXrGuWkWFvs6h52wkSH+OQnCr+LED8aD6bCVlLCwqPsr/dqdb4M8D22v6VcardXN5azzTGKF4GX/AFUZK4KspH+s8zng4xzXN+MvBf8Awj2oabC0thOtxK1wHjt/JkURlSeMtn5mTJyOp4r3TQtOj0jRrHT4juS1hSENjG7aACT7nr+NeR+Pb4aj4xvWVt0Voq2iY6ZHzOR77m2n/coPmMuxNfF4yzl7rbdt7L9DDooooPsgoqCS4WO7hgYEGVWKt2yMcfXBz+B9KZYTNPA7SYyJZU49FdlH6AUC5lexaooooGIs5tLi1ugcC2uIrhvdUkViPyU19D183asHbS7wR/fMLhfrtOK+jLWZbm2hnj+5KgdfoRmg+S4khapCflb+vvJaKKKD5oKKKKACiiigAooooAKKKKACiiigAooooAK8l+KxDeK7UDGY7IE/8CkbH/oJr1qvFfH90LzxtqJUnFskVoOeDhfMJ/OUj8KD18jg5YyLXS/5GHRRRQfdhWJqxmk1i0trUsjyW8oeVR/qkLR5IPqcED356CtuqMX/ACGrkntbxY/76k/+tQZ1FzJR7/8ADlxFCIqrnAGBzmnUUUGgh6V7N8Prn7T4K0Zjy8dusDn1aP8AdsfzU141XpfwguN/h+9tBwtreuFHs6rIT9Nzv+VB87xHTvRhU7P8/wDhjA+K1t5Piq0udvF3Z+XkesTknP8A3+H5VmeB7H+0vGOnRsuYbbdeSDsdmAg+u9kYf7hrrfjBbBrDSbxR88V0Ymb0R42J/NkjpvwgscWepaqw5uZhbxnsUiyCf+/jSD/gIoOKGM5MpcVvdx+/X8jttYv4tK0m91CcExWsLzMB1IUE4HucV4DD5pTfcsHuZCZJnH8UjEsx/FiT+NemfF7UfK0ux0pD899N5j/9coiGJ/77MQ+hNeb0HVw5h+WEqz66L5f1+AUUUUH0pU1K3e4tv3OBcRkSRE9A46Z9jyD7E1W8OXC3WliZAyh55ztYYZT5r5BHqDx+FalUNM+SS/iH3UuDj/gSq5/VjQZtWmpfIv0UUUGgh6V7D8NrxbvwTpSg5e1iFnJnrui+TP47Q30Irx+u7+EF5su9Y09jhW8u7QH+IkbHx7AJH/31QeBxDR58Oqi+y/wf9I9LooooPjAooooAKKKKACiiigAooooAKKKKACiiigAr51juftxkvTnN5I91g848xi+Pw3Y/CvdvFNy1n4Y1e6Q7Xgs5pQfQqhP9K8JhjWGJI0GFRQoHsKD6bhunedSfZJff/wAMSUUUUH1gVRsvmv8AUHPVZEj/AACK382NXqoaX85vJu0tw2P+AgR/zSgmW6L9FFFBQV2XwluRF4h1G1Y5NzapKo9PLchj+Pmr+VcbWt4MuvsXjLSJc7UldraRv9l0OB+Mgj/Sg83N6XtMHNdtfuPRvijA03gXU2jjMskAS5VF+83lyK+B7kKQPrWv4Z0waN4f0/T8hnghVZGH8cnV2/FiT+NQ6/8A6TdaXpy8ia4E8oHURxYfP03+Up9mqfxHqiaLoV9qMih/s8RdUzje3RU+pbA/Gg+C55OKpra/4nknjnUP7T8Y37r/AKmzAsoj2O3l2H/A2Kn/AK5isaobaNo4VWV/MlOWkfu7k5Zj7kkn8amoP0bB4f6vQjS7L8eoUUUUHSFUIv3eszrjCzQo6+7KWDH8ilX6y9TlW21TSpGzmaV7X2AZC/8AOID8aCJu1n5/8A1KKKKCwrc8AXP2TxvpvP8Ax9JNakduV8zP5xAfjWHT7S4+x6jp910WC7hlcjqEEi7/APx3dQceYUva4WpHyf4an0HRRRQfnIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzXxIlMfgbWADjzofs/18xgmPx3V49XrPxUbZ4HvCf+e9qPzuIxXk1B9fw2v3U35/oFFFNYhQSxAAGST2oPowYhQSxAAGST2qppVtcWdsbe9/4+lIlkGMYMqiYD8BIB+FQyXa30XlpaXc1nKQkkqBVzGSN+0OwJO3OD0JxzWv4p1yK/8RXV/Bp1/BazpGxLojMJANpG2NmONqpQcM60vrMFFPls7vp0t+RHRVJNTsmdUNwkch6Ry/u3P/AWwau0HapJ7MKIUu5b21j0u3kutRWVLiCCPALNGwcZJIAXIGSSBzjuK19J8K69q+mQ6jZW9n9knG6IS3DJK6Z4bbsIweo+bkEHvitqLw3q+heDvEF55LDWLgxxL9mcs8dqGXftI5DYaU/LycLjkCg8bHZrQ9k6dKScnp5a6X9DtfDs0mq6jf6pPbtAsbGxt43ZXKhGPmNlSQCX+UgE/wCqHWuV+L2qoZdN0NHG+Qm9mXPVEOEBHu53Z9Y/euA068ljtwunarqC2y5CpBqEwReeQAHwOfStnTYrjXfCviWdmuL42bw3tvOxaZ/NQMJURznJ8tdu0dPMPGWoPFWWSwE4Yiq04prZ/wDA6GTRVU31oJhEbqASngJ5g3H8KtUH2cZKSvF3CiiigYUz7D9vNwgTfJBaTXcS+skW11H44x+Jp9bvgBgvjTT9wDCVJYsH3Qt+P3P1oOHM5OOFnKO6/wAzABBAKkEHoRTqaLU2Ek9if+XOaS1BPUhGKg/iAD+NOoOulUVSCmtmrhUF7CbiznhB2mSNkz6ZGKnooKaurM960a9Go6RY3oGBcwRzY9Nyg/1q5XNfDiXzfBGkjtDEbYfSJjGP0WuloPzCceSTi+gUUUUEhRRRQAUUUUAFFFFABRRRQAUUUUAcj8V/+RGvP+vi1/8ASmKvJ69b+KKeZ4JvRtLYltm646Txn+leSUH2HDj/AHE15/oFFFFB9EFFFFADJESRGSRVdCMFWGQapLoVtcT29raI9s9zNHbj7PI0QXe4XcVUgHGc9O1aFa/gqD7R410UckRSSSsB6CJwCfozL+OKDjx81Tw86nVJntkMUcEMcUKLHFGoVEUYCgcAAelPoooPzkoXejaZeTGa806ynlIwXlgVmx9SKuxokaKkaqiKMKqjAA9hTqKAPPvjLMZ/DkmlIcefDNcy/wC5EuRg9j5hiP0Vq86ru/G9tqGqX+v/ANn2v2nZaLp6IJFVhIUMmfmIG0iZAec/L0rhbmK5tCfttje22OC0sDBAf98Db+RqeZXtc+n4eqwp+0U5JXta/wAxKKrQXtrcOUguYZWHVUcMR+VWao+qTTV0FaPhacWvi7Q52/1a3Wxv+2iPGP8Ax51rOqKe4+xqt4OtpIl0PcxsHA/8doOfGU/aYecO6f5HR/EGzFl42vmUfJexxXQP+1jy2A/79qf+BVg13nxgRPtGhTjl8zxA/wCyQjH9UH61wdBx5LVdTBxv0ugooooPVPWfhUxbwPZk4/190PyuJBXW1yPwo/5Eaz/6+Lr/ANKZa66g/NMV/Hn6v8wooooMAooooAKKKKACiiigAooooAKKKKAMvxTpzat4b1Swix5txbSRxknGHKnafwODXg9tMs8IdQynkMjDDIwOCrDsQQQR2Ir6MrA1jwfoWr3L3N7p6/aHxvlhkeB3xwNzIQW445zQetleZ/UXJSV0zxiivTLv4aaW6YtL7UrVh0xIsgP13qT+RFYtz8N9WiybXU7G59EkheDH/Agz5/IUH0VPP8JP4rx9V/lc42it248F+JbfOdOgufT7JdKf/RmyuZvLl7C+uLPULO8t7q3YJJH5Rl2kqrAZj3Doynr3+tB30cfh67tTmmWa6T4ZKG8cxhudunzuPY+ZCM/kx/OuM/tWyH+tnEHtODEf/HgK6P4c6vZReNrB0u7dxcxS2YKyAjLbXH5mIAe5A70HPmslLB1FF9P1PcqKKKD4AKKKKAOX0r95JqNwfvTXs2ec/cbyh+kYq/WfoxHkXQzyt7dAj0/fuf5EH8a0K4J/Ezrjsire2FnfJsvbS3uV9Jo1cfqKyZvB3h+UnbpcEGeT9mzBn67CM10FFSm1sXGTjqnY4678AacyN9gur6zbqB5vnLn38zJx9CPqK4bVbC60q8NhqyRh3z5Uqf6u4XuVz0OOq8kepGCfaqytXtbXUbWSz1m2R7VzkPn5Qexz1Rh69uxzWsKsovXU9DC5nWoS9580ezOI8TXb3/hfwZJI25xaSeaSefNQRo367656tLxNYyaCNH0iUy3EETXTWt24GWEriRo2I43KQfTIxjo2M2utNSV0e7klvq1o7XYUUUUz1z1j4Uf8iNZ/9fF1/wClMtddXJfCtdngizGc/v7k/ncSGutoPzTFa15+r/MKKKKDAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvANUn+1a3q1x18y9n+b+8Fcop/wC+VWvd9Ru47DT7q8m/1VvE0r/RQSf5V89WEUkdlbpNjzVjUPj+9jn9aD6PhyF6s59lb7/+GJ6gntoLjHnwxyY6b1BxVjaaTaaD65pNWZNb3+o22PI1XVEx0BvZWVfopYjHtjFX4fFHiOLga7dMvYPDAcfj5eT+JrKwfQ0mD70HLPAYWe9NfcjoE8aeI0BAv4ZB1zLbKT/47gfpT/8AhPPE2zZ5+mY/v/ZG3/n5mP0rncH3owfegxeU4N/8u1+INdanJqt5qD6vfpNcur+XDM0cMbAAZWPJXnGTkEH0rqNG8c3VriLXIPtMQ4+1WyfOB/tx9/qnXsorl8H0NGD6VEqcZbhVyrCzhyKNvT+vzPX9K1Ww1aAzabdw3KA4by2yUPow6qfY81erw17ZHlWbaVnQYSZGKSJ/uuMEfga1LPW9csuLfVZpEH3Y7pVmX8SQHP8A31WDoPozxq2R1Y/w5Jr7mepzyRsxhu49qEgKzfdY9sHsfrj2zQS9qD5jGS27s33kHue49+o756jiNP8AHU8cgj12yia2YYa5tAx2/wC9Ecnb7gsfbHNdfHfW0ESSxTrLYyRiVHQ7gqkZHI/hPb34HYDKUHHc8mth6lCXLUVmZvivSjqOjXVhGoadUNxYsf4JU6L9MnHurEV5lbyrPBHNGcxyKHU+xGRXoes67b6TbmGeQRz2jxmKFXTzpA5wFVScHCEgn1BOeCa86s0aK0gjYBWWNVIBzggetb0L2Z7uQOfvr7On3k9FFFdB9GevfDNdnguyGc/vJz+czmuornvh6mzwPoZ4HmWkc3H+2N35/NXQ0H5jWfNUk/NhRRRQZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBznxElMXgvVFH/AC8Ri1J9BKwjz/4/Xln2b2r1Hx9DJdaRb20aMySXUZkIBwqplwT7bkUfUiuV/s0/3aD6PJayo05N9Wcx9m9qPs3tXT/2af7tH9mn+7Qe19ej3OY+ze1H2b2rp/7NP92j+zT/AHaA+vR7nMfZvaj7N7V0/wDZp/u0f2af7tAfXo9zmPs3tR9m9q6f+zT/AHaP7NP92gPr0e5zH2b2o+ze1dP/AGaf7tH9mn+7QH16Pc5j7N7VB/ZzCF4I57mK1kbe8EchVGbO7PqvPJ2kAnk5rrv7NP8AdqWLRZ5v9VC7e4Xik1cyq4qlNfvEmvM8+1DTwl7p8g3vNJdMXlldpHc+S45ZiSeAByegHpV77I/oa7h/B17NdWErJGscMxkcFucGN14/FhWn/wAIu392mZRzajTvGLVjzT7I/oahvYza2c9wykrFG0hHqAM16j/wi7f3aju/Bz3Vs0O6NFchX3d0yNw4/wBnP/1qAnndNRbTOo0GyOnaHp1ixyba2jhJ/wB1QP6VeoooPjAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEYBhggEHsarPYWzf8sgD7cVaooKUnHZlA6XB2yKT+y4vX9K0KKC/bT7md/ZcftS/wBlx+1aFFAe3qdzP/suP2o/suP2rQooD29TuZ/9lx+1H9lx+taFFAe3qdygNLh7k09dNth1TP1NXKKBOtN9SJLaGP7kSD8KloooIbb3CiiigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The combination of a sling around the neck (collar) and a cuff around the wrist allows for some traction which may be useful in managing some proximal or midshaft fractures of the humerus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34270=[""].join("\n");
var outline_f33_29_34270=null;
var title_f33_29_34271="Langerhans histiocytosis CT I";
var content_f33_29_34271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic changes in Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Langerhans cell histiocytosis (eosinophilic granuloma) in an adolescent boy characterized by multiple cysts in the upper and lower lobes. The cysts are interspersed throughout the parenchyma and have a slightly thick wall. A posterior right upper lobe nodule and confluent bibasilar patchy lower lobe opacities are also part of the disease process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_29_34271=[""].join("\n");
var outline_f33_29_34271=null;
